<SEC-DOCUMENT>0001384101-23-000067.txt : 20230505
<SEC-HEADER>0001384101-23-000067.hdr.sgml : 20230505
<ACCEPTANCE-DATETIME>20230505080727
ACCESSION NUMBER:		0001384101-23-000067
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230505
DATE AS OF CHANGE:		20230505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VERACYTE, INC.
		CENTRAL INDEX KEY:			0001384101
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				205455398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36156
		FILM NUMBER:		23891371

	BUSINESS ADDRESS:	
		STREET 1:		6000 SHORELINE COURT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 243-6300

	MAIL ADDRESS:	
		STREET 1:		6000 SHORELINE COURT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALDEROME INC
		DATE OF NAME CHANGE:	20061219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vcyt-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:7dabdad4-bfd4-4b85-9e97-316e8975136b,g:d42a5b32-51ee-4157-98c8-837d0a6f976e,d:4f2ef3d807284fb8b2bf2284d857f08c--><html xmlns:vcyt="http://www.veracyte.com/20230331" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vcyt-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180L2ZyYWc6NzEyOTBjMTFiZmJiNDg3MDkzNzE4ODljOWNlMWU2OTEvdGFibGU6OTEzYjIxMjlkODcwNDY0OWFjOWQ3ZWRiMGFiNzEzNmUvdGFibGVyYW5nZTo5MTNiMjEyOWQ4NzA0NjQ5YWM5ZDdlZGIwYWI3MTM2ZV8zLTEtMS0xLTcyMTIz_813b4423-e3d9-4ffb-b92a-b111cd587d73">0001384101</ix:nonNumeric><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180L2ZyYWc6NzEyOTBjMTFiZmJiNDg3MDkzNzE4ODljOWNlMWU2OTEvdGFibGU6OTEzYjIxMjlkODcwNDY0OWFjOWQ3ZWRiMGFiNzEzNmUvdGFibGVyYW5nZTo5MTNiMjEyOWQ4NzA0NjQ5YWM5ZDdlZGIwYWI3MTM2ZV81LTEtMS0xLTcyMTIz_32962afa-c79e-4a24-be4d-adbb2d2c1936">false</ix:nonNumeric><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180L2ZyYWc6NzEyOTBjMTFiZmJiNDg3MDkzNzE4ODljOWNlMWU2OTEvdGFibGU6OTEzYjIxMjlkODcwNDY0OWFjOWQ3ZWRiMGFiNzEzNmUvdGFibGVyYW5nZTo5MTNiMjEyOWQ4NzA0NjQ5YWM5ZDdlZGIwYWI3MTM2ZV82LTEtMS0xLTcyMTIz_aea187cb-c8a6-44cd-aad7-5fd002ecdd50">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180L2ZyYWc6NzEyOTBjMTFiZmJiNDg3MDkzNzE4ODljOWNlMWU2OTEvdGFibGU6OTEzYjIxMjlkODcwNDY0OWFjOWQ3ZWRiMGFiNzEzNmUvdGFibGVyYW5nZTo5MTNiMjEyOWQ4NzA0NjQ5YWM5ZDdlZGIwYWI3MTM2ZV83LTEtMS0xLTcyMTIz_bbe675b9-bd70-4299-90b8-8a8d1e0e0d0a">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180L2ZyYWc6NzEyOTBjMTFiZmJiNDg3MDkzNzE4ODljOWNlMWU2OTEvdGFibGU6OTEzYjIxMjlkODcwNDY0OWFjOWQ3ZWRiMGFiNzEzNmUvdGFibGVyYW5nZTo5MTNiMjEyOWQ4NzA0NjQ5YWM5ZDdlZGIwYWI3MTM2ZV84LTEtMS0xLTcyMTIz_d2be12d3-14ba-418e-9650-9adf2887de0a">2023</ix:nonNumeric><ix:nonNumeric contextRef="i81d34a4128834b43aa56aba5f1ba758a_D20220101-20221231" name="us-gaap:DefinedBenefitPlanTypeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_c42f36f4-4860-4a82-9f52-48c65e91ae48">http://fasb.org/us-gaap/2022#PensionPlansDefinedBenefitMember</ix:nonNumeric><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:DefinedBenefitPlanTypeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_dbd24477-8f44-4199-93ad-3dfd106ab395">http://fasb.org/us-gaap/2022#PensionPlansDefinedBenefitMember</ix:nonNumeric><ix:nonNumeric contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MQ_8dcd2a74-c451-48ee-8234-99b6286ac891">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MQ_b8e18883-b7ca-498a-8118-1cbdf8c548c4">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1Mg_135ebc69-b606-42ce-b152-da2f2dbc668a">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1Mg_7fac536f-70a2-4239-a5bf-1ba0e01d202a">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vcyt-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7847b145543840bd99af437751321cf8_I20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i228462769a464129ba617b5c0e672ec2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i17d209f7b20f4172bb058631b2f4238e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i847532d1474b4753b04c345c4ed3d2bb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i872cd6a83fb94eeb96794042e25cae89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3084d7ec4bd64f8eaabed4981928a134_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i635aa95b5b3a4c40abecbcbe6550bef2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if31dd8bd6f8b4fb3b8a6f145af4d5d59_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie309aab35ae147468bed50274b964061_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95b8df0ff5f640d8a141c19c5bd881fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9dbd02e335643de8ce058f59321f616_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i924230acce20424dabe447ae137dbf83_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id752a28a43c4436681909d1cc3eed3b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1881985bc124c028c3c3dbad3abd14b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86fbf95cd4b5437dbec9986bc1144ec2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5753c1b61e2d42e58a2276f17d5fb19a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf29b5a393ba4124abdaee15f6859cb8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if523cf067c5f4dbebed00daf0386fb51_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55b285ff45524728a3082fa425970706_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0d48f67cf5c4722884b1138ecc775f2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87aca5bd093645dda8ac7488b345dc9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2f11f413da04f52830af895a72e45a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e26fa70903498190d2e5c48dd87a5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a4723b9349f4234b5edb4fc1dd4f8b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e2e9b82dc8546598d4d83b5a9b32dcd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64c8dbded3c748c0ac0a7f3125954a4f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc136e0ed6db40aa933f473850279a4c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5aea6fc5bfd40498c71f885f3a5b84c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906486b05220499884f0e0763ff0fcc5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida3550a7c5734f6d9ca5aaf01e299960_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibff0ccc6162b425f8af12108f388f189_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife0bc1a9501244b59b18b76ac93dbfb8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia60f7004a2544b82937e0bf55326ce59_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>vcyt:segment</xbrli:measure></xbrli:unit><xbrli:context id="ic43b0b3fe6664d3cbdb8a3f4f93ee2bd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i19f99811b32f40d18acdc45b83384992_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32cc63b081d34737b7c09f18254a0369_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if73c87216b7e431cbb1a5132319fc1ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc0d9d5bd4645f4a7aa6c4d79ddcca0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MajorCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdbdbc6fb5304aa6a286a799abfdc7c5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MajorCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icadd7189bc5c4c3385082591611320f5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if563c75164164060aab1e980fe9c7b0b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ca971045914a1a9146c9113b0b663d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35250c2e6deb44c4ac481dd4e6f612e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd3b24d188c147d0894ca33558f96f88_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i998dea8702a44f32b783fad66ceaef6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274a02acfdb5475dac6457d7c3ee154b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae14244c4fb41a999ccf232d576984d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2099bc12c8224f319528343bdffe545e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherContractManufacturingAndTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06548eac75174f9ca6d2b92d2d9f74ca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherContractManufacturingAndTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d34a4128834b43aa56aba5f1ba758a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d63ecdd09ee4ceeb3894542f9e9a7b1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc183be53114cd5ae6844b58582cac8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec98084255e1437ca83d101b89bdff0f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03e5c566c2b44d13b38e3125968a69bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ca496310a4471fab481bd7a0025487_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie962846780634c4abb77f3207cab491b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c2bbdf5d7e4d15a0928f584d49978a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf1cd50fe084f529b3b433569983a49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia23eed41b3e74c09a3af1063a3dfaaa4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36048a1bd9c5433d93652f6da7dcba37_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b268539086c467aab96e29940e65c30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic189876c9f5b49a491d19b401863e5c7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02c3ec7045e44e992b345c1c6f4e8db_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:ProsignaCustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45490cef3786448bb194a53c1a4925b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:ProsignaCustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf00f1922dfe4be3ac3b55ead1c6f375_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:ProsignaCustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4759963ae1646649f60d583de01125c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterDxLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a449a72bae04d50925d90a798163f1c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterDxLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c22e100729e4221b19089c051e020bd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterDxLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id96dd7074a874f3ab955a93c939fd0e2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:LymphmarkProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b06dd23ef3c466caa291f27746d9f0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:LymphmarkProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2dd2214b7954827af13bad315eaeef6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:LymphmarkProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465f5da059d4485493001b166d4b40d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBioSciencesProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbaa1203aac34a38a5d064b5630c2dbc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBioSciencesProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e1a841c902147639f42aaf1fc24846c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBioSciencesProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5af60edaf174d3dbf0da38ad4778d42_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBiosciencesTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id51f3fcca6344c0d8acf9827a75d098d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBiosciencesTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96b14c1a4f46482383ed19e470792768_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBiosciencesTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ea9d43677e4c86b1d71be599ac6865_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDXDevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cf1b2134c6848bc8109d15f1016674a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDXDevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43160a473e5b4aa6975f0c9b8f8a4911_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDXDevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac93bb77e6df4adebb1fce8ac3eb1425_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d58f9fdd9f24ea7beeb7a99ed47f1fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf4b5a8d9ac4269b9a4b8890c7ae167_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28f8ef0b3354ef5abe5718fad617afd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerBacklogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia17c0ca4207743efbafee0e3b75a8c67_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerBacklogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac056f15377a4e1a939745868f857e1d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerBacklogMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f2f83e07404b9d85ed5e0e5c227d9a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07f2d93ca49a414380853162fba3a86c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0afc28f37da46bb8ed8617d3e377f9d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e25dbe0d25644d0a01543012862a8ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id21ec14e64244f3c9d1c3685ce9e8719_D20191203-20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-03</xbrli:startDate><xbrli:endDate>2019-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie03a5b408d42420d880fd6b44b057d7b_D20191203-20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-03</xbrli:startDate><xbrli:endDate>2019-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65218b5801a4550bb42420dd8cece53_I20191203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9422a55af4419da61a04b81e81fff6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i155fac1703104d38b903faacc0c23041_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06680ff3bcf24e32836ef9479192a82f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339749b1f05542c299fce2f9a4340ccf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6732d99af20b4ace884710631c821dc1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56eb27109dad47bc902852a7e617ff8a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f89531611514010b1fddd2d6b74728c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe50f34924204d0f9cb24feac29d3c92_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b2066a3df0741c0a292648be37edb62_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4ebc4a8eea343589c8c8c3823833416_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56240dd72d974100bdcfa48ff0885b32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d7ee7173c0f4858a01e1d1da5a312b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3cca4fb364f4aa1a78fc4dbfe0f75ee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38b169efb35741c0a4e5cbe287a00d95_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vcyt:FacilitiesInMarseilleFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd87d5a6accd4b1fbbdd377429adeb05_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41c953ff703f4c40b8196a40233b0bea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i589fe7123b7241eea985d689b319d8bb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf67fe5c4e9c4625bf91b35cf11db759_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001384101</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:6.75pt"><span><br/></span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.140%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk4_d439d823-2918-4749-abb0-6a0258c4c3ff">10-Q</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.140%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6YjFkOWU0YzIzNDhhNGU4Y2E1YTdhZTMzZjc1MTdhOTMvdGFibGVyYW5nZTpiMWQ5ZTRjMjM0OGE0ZThjYTVhN2FlMzNmNzUxN2E5M18wLTAtMS0xLTcyMTIz_e1d85394-cb08-4f32-9245-cd367ea86a67">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8xNDA_6b21e259-3cae-41f4-9dd9-75da197e2006">March 31, 2023</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NTk1OTgxM2FhNDI2NDk1OWIyNmU2MTA1YzAwYzNkMDUvdGFibGVyYW5nZTo1OTU5ODEzYWE0MjY0OTU5YjI2ZTYxMDVjMDBjM2QwNV8wLTAtMS0xLTcyMTIz_0f0b49b9-ec62-4b28-9e38-23af46ffd08e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk0_c3c5fcd4-0d0c-4773-9b63-7d6877b37c6b">001-36156</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.140%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTA1_87d75c35-9e9d-44a2-9d3c-8ac101534c8b">VERACYTE, INC.</ix:nonNumeric></span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.140%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NDU3ZWJiYTAwMGZmNDFhM2JjOGMyYmI1MDUyNTkyNzAvdGFibGVyYW5nZTo0NTdlYmJhMDAwZmY0MWEzYmM4YzJiYjUwNTI1OTI3MF8wLTAtMS0xLTcyMTIz_cfe2a17e-d1f8-4504-b911-934d2cec6804">Delaware</ix:nonNumeric></span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NDU3ZWJiYTAwMGZmNDFhM2JjOGMyYmI1MDUyNTkyNzAvdGFibGVyYW5nZTo0NTdlYmJhMDAwZmY0MWEzYmM4YzJiYjUwNTI1OTI3MF8wLTYtMS0xLTcyMTIz_91337ea8-046a-4a60-a66f-86574d1869b9">20-5455398</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk1_964c1bd1-973a-40bd-9401-2886f87f47fb">6000 Shoreline Court</ix:nonNumeric>, <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk5_352d906a-fd3e-47d5-8b27-5576f170bcab">Suite 300</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTA2_b8625da5-4f0f-45bb-8db0-d4e1f8e1cad9">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTAy_245b2a6e-92f3-4260-8bc0-d33dbe347155">California</ix:nonNumeric> <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk2_f30d05fa-7871-4f1d-b972-2f1d326d049f">94080</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, zip code)</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTAw_502e3b19-c917-4392-94ff-9557c0edac7e">(650)</ix:nonNumeric> &#160;<ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTAz_5ad91def-8e9e-472e-84b1-cd53aa42f86e">243-6300</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.140%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.858%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6ODIzYjRiOGFiZmE3NGIwZDg2ZGZkNmRjODY1NjhkZmIvdGFibGVyYW5nZTo4MjNiNGI4YWJmYTc0YjBkODZkZmQ2ZGM4NjU2OGRmYl8xLTAtMS0xLTcyMTIz_a266e165-65f2-4370-8457-54ab3ae4802e">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6ODIzYjRiOGFiZmE3NGIwZDg2ZGZkNmRjODY1NjhkZmIvdGFibGVyYW5nZTo4MjNiNGI4YWJmYTc0YjBkODZkZmQ2ZGM4NjU2OGRmYl8xLTQtMS0xLTcyMTIz_ee67cc66-9606-4ef1-bde3-925e9791bab2">VCYT</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6ODIzYjRiOGFiZmE3NGIwZDg2ZGZkNmRjODY1NjhkZmIvdGFibGVyYW5nZTo4MjNiNGI4YWJmYTc0YjBkODZkZmQ2ZGM4NjU2OGRmYl8xLTgtMS0xLTcyMTIz_8b7a8db9-8b67-4868-9629-d9826c4502ea">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk3_c4585fa4-6014-4a2a-a62f-ec79af94d3b8">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTA3_49103be7-8893-4fe5-80f7-a106501c2b60">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NTY0MzQ2MmQzNDlhNGRiNGJkZGYyMjEzMDg3MGVlMmMvdGFibGVyYW5nZTo1NjQzNDYyZDM0OWE0ZGI0YmRkZjIyMTMwODcwZWUyY18wLTAtMS0xLTcyMTIz_8fa679f0-6276-4adb-84fb-c33cf4db0952">Large accelerated filer</ix:nonNumeric>&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#168;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NTY0MzQ2MmQzNDlhNGRiNGJkZGYyMjEzMDg3MGVlMmMvdGFibGVyYW5nZTo1NjQzNDYyZDM0OWE0ZGI0YmRkZjIyMTMwODcwZWUyY18xLTQtMS0xLTcyMTIz_a7d000f2-945d-4fac-9adf-bbde3b196b4c">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NTY0MzQ2MmQzNDlhNGRiNGJkZGYyMjEzMDg3MGVlMmMvdGFibGVyYW5nZTo1NjQzNDYyZDM0OWE0ZGI0YmRkZjIyMTMwODcwZWUyY18yLTQtMS0xLTcyMTIz_c7ee280d-123a-4361-ad54-9e4cfa57e085">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8xNjQ5MjY3NDQzNzgx_e85b03d6-2496-4fed-aa69-cb0ee207843a">x</ix:nonNumeric></span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;1, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i7847b145543840bd99af437751321cf8_I20230501" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDI2_4636ac88-455f-4ef5-853a-30b59ce2622f">72,417,156</ix:nonFraction> shares of common stock, par value $0.001 per share, outstanding.</span></div><div style="text-indent:20.25pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE,&#160;INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page<br/>No.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_10">PART&#160;I. &#8212; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_13">Item 1. Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_13">1</a></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_16">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_16">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_16">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_16">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_16"> and December&#160;31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_16">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_16">2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_16">1</a></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19">Condensed Consolidated Statements of Operations for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19">Month Period</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19"> Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19">2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_19">2</a></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_22">Condensed Consolidated Statements of Comprehensive Loss for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_22">Month Periods Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_22"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_22">2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_22">3</a></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_25">Condensed Consolidated Statements of Stockholders' Equity for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_25">Month Periods Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_25">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_25">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_25">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_25"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_25">2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_25">4</a></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28">Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28"> Month Periods Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28">March </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28">2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_28">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_31">6</a></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_64">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_64">16</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_97">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_97">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_100">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_100">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_103">PART&#160;II. &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_106">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_106">30</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_109">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_109">67</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_112">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_112">67</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_115">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_115">67</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_118">Item 5. Other Information </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_118">67</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_121">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_121">67</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_124">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_124">69</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE,&#160;INC.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements concerning our business strategy and plans, future operating results and financial position, as well as our objectives and expectations for our future operations, are forward-looking statements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In some cases, you can identify forward-looking statements by such terminology as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect&#8221; and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our expectations regarding total revenue and total test volume;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our expectations with respect to our future research and development, general and administrative and selling and marketing expenses and our anticipated uses of our funds;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the impact of inflation, rising interest rates and foreign exchange fluctuations, turmoil in the global banking and finance system, as well as the conflict in Ukraine, energy and supply chain disruptions, and market volatility resulting from the above, on our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business and the U.S. and global economy;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to continue to receive quality reagents from certain single source suppliers;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to continue to successfully integrate HalioDx, Decipher Biosciences, and the assets acquired from NanoString Technologies, Inc. into our business; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our ability to deploy the nCounter Analysis System successfully and run our tests on this platform worldwide;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our expectations regarding our biopharma partnerships and agreements; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our anticipated cash needs and our estimates regarding our capital requirements and profitability;  </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:13.8pt">our ability to obtain and maintain Medicare and commercial payer coverage for each of our tests;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our sales, marketing and distribution capabilities and strategy;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our intellectual property position;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">the impact of government laws and regulations; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:14.5pt">our competitive position.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, and financial needs. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements for any reason or to conform such statements to actual results or revised expectations, except as required by law.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I. &#8212; FINANCIAL INFORMATION</span></div><div style="text-align:center;text-indent:6.75pt"><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_13"></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Condensed Consolidated Financial Statements-(Unaudited)</span></div><div style="text-indent:6.75pt"><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_16"></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE,&#160;INC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and par value amounts)</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(See Note 1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNC0xLTEtMS03MjEyMw_0af09472-c39c-483e-b5ff-47f71a125753">177,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNC0zLTEtMS03MjEyMw_b5ac76e6-1a39-454a-9f0f-72fa38a81f49">154,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNS0xLTEtMS03MjEyMw_1ae90033-0d0d-4bde-b461-6d119aa2d74f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNS0zLTEtMS03MjEyMw_e057164c-02b8-4f1c-926e-e8f081bd16c8">24,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNi0xLTEtMS03MjEyMw_c298bb18-4acc-40a5-9cb1-e2040fc95f2f">45,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNi0zLTEtMS03MjEyMw_8b541bc9-a5a1-4b80-9b5a-3d08dce67a68">44,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies and inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNy0xLTEtMS03MjEyMw_3c57cc4b-8a64-4762-b4ee-ef933e3437b5">13,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNy0zLTEtMS03MjEyMw_0b75a240-ef5f-413d-81d0-d634b90dd67d">14,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfOC0xLTEtMS03MjEyMw_1505cc91-f67e-4cc3-b8a2-7c698d7f786d">14,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfOC0zLTEtMS03MjEyMw_0a6366f4-f5ce-4f21-982d-62b2c04d3398">11,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfOS0xLTEtMS03MjEyMw_3acfe216-4f28-4fa9-ab6c-a13d93f9256f">251,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfOS0zLTEtMS03MjEyMw_8aa71cec-b58d-4863-9985-cd283ff30c2e">248,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTAtMS0xLTEtNzIxMjM_dc62a0a8-90a6-4f86-aab6-91dc1606c3fb">18,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTAtMy0xLTEtNzIxMjM_d968474b-6279-4081-8557-0143ac2a7588">17,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTEtMS0xLTEtNzIxMjM_29b3d9bc-9648-4dfa-a71d-a9d9a93c6aab">11,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTEtMy0xLTEtNzIxMjM_a9553e15-c2f5-4e9b-91bd-47dec097f9b2">13,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTItMS0xLTEtNzIxMjM_4949e208-76ba-4075-bdaf-5a845c2296e0">170,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTItMy0xLTEtNzIxMjM_efa11fc6-e6bc-45bd-8307-80062f4f1aaf">174,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTMtMS0xLTEtNzIxMjM_b8c55ccf-3b4b-4865-ad4d-bdb1c5625469">699,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTMtMy0xLTEtNzIxMjM_a45bb413-99ad-4d59-875e-a5e0f3c2e312">695,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTQtMS0xLTEtNzIxMjM_f0add60b-f402-40c0-bd3f-45b4493f7116">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTQtMy0xLTEtNzIxMjM_dbbaf2b3-965b-4c0d-bd0c-9555a513e3a4">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTUtMS0xLTEtNzIxMjM_b0483da4-4395-4ef0-b598-b742ab071f48">5,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTUtMy0xLTEtNzIxMjM_7b088412-3bde-4923-855e-a0951f06020b">5,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTYtMS0xLTEtNzIxMjM_5053e811-906a-472b-a521-6e0f8436b252">1,157,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTYtMy0xLTEtNzIxMjM_8566ddf5-177b-45e7-a66e-4bccf6bc0b06">1,156,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTktMS0xLTEtNzIxMjM_38e3ca8c-cdab-4fda-984d-dc58ba7b1ef3">15,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTktMy0xLTEtNzIxMjM_8de4c7ea-bf48-4328-8b2e-0c19e0bc356c">11,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjAtMS0xLTEtNzIxMjM_09ecf94f-1d5b-48ba-a9f9-47a47f771420">30,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjAtMy0xLTEtNzIxMjM_39956a09-7bc6-4146-9020-74cbfc51bf66">37,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjItMS0xLTEtNzIxMjM_137cd930-5da3-4ddf-b34d-1669d6ffbe4c">2,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjItMy0xLTEtNzIxMjM_0d56c81b-a0e7-4501-b7ed-7b0567f3e5c0">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjMtMS0xLTEtNzIxMjM_4b845b61-4f6e-472d-9c84-7a6712480b43">3,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjMtMy0xLTEtNzIxMjM_0b1c0fed-0ddf-4594-955a-1e20b95e5a6a">6,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjQtMS0xLTEtNzIxMjM_f801684d-eeca-487d-ac38-dd2ea54e8dde">4,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjQtMy0xLTEtNzIxMjM_eda64230-454e-4d2d-8162-49a30cdc785c">4,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjUtMS0xLTEtNzIxMjM_7a267ed0-529f-41f7-a41e-29e42b1e6ea7">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjUtMy0xLTEtNzIxMjM_58cac4bd-4811-40df-96d0-78606fac6c3a">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjYtMS0xLTEtNzIxMjM_2b2411de-effc-4d7d-8b19-6ae5065b814c">55,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjYtMy0xLTEtNzIxMjM_244cd885-2def-4c2c-945d-2c4335cd0824">62,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjgtMS0xLTEtNzIxMjM_c0eaf193-fd72-4d1f-b95a-7be9a354cc01">4,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjgtMy0xLTEtNzIxMjM_88209dca-c840-4bbc-b792-33432bec7ee8">4,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjktMS0xLTEtNzIxMjM_2bb40bb6-da82-4580-907a-39e15f0b5005">4,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjktMy0xLTEtNzIxMjM_35366c10-4d4e-44f3-9ef9-0e70c244af96">2,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzAtMS0xLTEtNzIxMjM_4727ae42-e6c3-4c64-b5d1-63501d60829f">9,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzAtMy0xLTEtNzIxMjM_ee39c851-eae0-4356-8843-1e8a07b95c35">10,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzEtMS0xLTEtNzIxMjM_5165b7b4-500c-41ac-af14-52229e7d8ee0">791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzEtMy0xLTEtNzIxMjM_a716e531-dc4c-4693-a485-c370fbac2481">931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzItMS0xLTEtNzIxMjM_51988161-66db-40f9-bfca-eeed61f8366d">75,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzItMy0xLTEtNzIxMjM_71dcdae1-5de0-4db9-9a96-acfdf28302c3">81,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzMtMS0xLTEtNzIxMjM_272c367f-04ea-4de8-a211-95da2c9f4f94"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzMtMy0xLTEtNzIxMjM_a6d2f0f0-63f3-4db9-afc2-fdaf6bb18e8f"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY18yMQ_b50ecd68-0f4a-44b1-884f-c700f6351deb"><ix:nonFraction unitRef="usdPerShare" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY18yMQ_b6e9990d-38a7-4ae6-a358-5a4993571125">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY18zNQ_868fd9a1-f0eb-4c76-b1e7-4c0dde82e8e3"><ix:nonFraction unitRef="shares" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY18zNQ_91e07a06-2b03-428c-a3bb-3ff17ce944ea">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY181Nw_307e9742-ec71-473f-b011-d9d45ebf81dc"><ix:nonFraction unitRef="shares" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY181Nw_30b95715-f0c7-46e0-8f63-3b48ebeb6886"><ix:nonFraction unitRef="shares" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY181Nw_7f10c862-e947-4a57-99ce-e52b1cc07d9c"><ix:nonFraction unitRef="shares" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY181Nw_e9531449-50fb-408b-87f8-16a2c7e44306">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMS0xLTEtNzIxMjM_64fd44c9-dc06-4ba3-bfd9-5525cb8d5523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMy0xLTEtNzIxMjM_410aafbd-5f46-41cd-8682-52fa902831c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N18xOA_2e33a767-2634-401d-89f5-3655487ac6ef"><ix:nonFraction unitRef="usdPerShare" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N18xOA_395d0d1d-5a69-4a71-9e81-1b7a7be9b4b7">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N18zMg_3b14b437-2592-4285-aef3-c042e9022231"><ix:nonFraction unitRef="shares" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N18zMg_3d4ced90-238a-46a2-936c-3941291d16a8">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N181NA_0b145ee2-17da-4673-bc64-96e60618ce55"><ix:nonFraction unitRef="shares" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N181NA_4b5c50e1-09cd-4036-8388-8ecabb4da387">72,383,140</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N182MQ_baf72de7-cfb7-491c-a5c7-26ea35acdfdf"><ix:nonFraction unitRef="shares" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N182MQ_c3f639f5-6da3-4334-b605-775bfff2b457">71,959,454</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMS0xLTEtNzIxMjM_27af53e5-5d5b-4eb7-84dd-dcbf9bc034b3">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMy0xLTEtNzIxMjM_9d853f3e-df78-43da-86bb-5b4fc71a5359">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzctMS0xLTEtNzIxMjM_e620bbbf-9116-4b67-aba5-38c9aea4b7a9">1,509,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzctMy0xLTEtNzIxMjM_0ddb7d23-4f32-44db-b332-7ca4dd5888ae">1,500,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzgtMS0xLTEtNzIxMjM_3d316a43-fd8e-4ecb-8205-d6e6100ddfbf">401,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzgtMy0xLTEtNzIxMjM_178cf70e-f418-463e-89bc-e39e132a4bd5">393,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzktMS0xLTEtNzIxMjM_f1014249-b29c-4219-9b4b-93ab94e13897">26,866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzktMy0xLTEtNzIxMjM_8f64d7cf-0c25-4210-a7c8-2afeef1589d4">31,346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNDAtMS0xLTEtNzIxMjM_c9037085-7e20-4ac5-a4d7-a5bb667c780d">1,081,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNDAtMy0xLTEtNzIxMjM_d635bbb7-68ba-4901-93e1-05b93d1ecb88">1,075,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNDEtMS0xLTEtNzIxMjM_e1eda4d6-d5f6-4dbd-a76a-754f1e653894">1,157,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNDEtMy0xLTEtNzIxMjM_c8335a61-6d43-4e7f-80bc-309cc39d758d">1,156,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE,&#160;INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.298%"><tr><td style="width:1.0%"></td><td style="width:55.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Testing revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847532d1474b4753b04c345c4ed3d2bb_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMy01LTEtMS03MjEyMw_f722fd99-86b5-4c56-903a-4dda50268f84">72,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872cd6a83fb94eeb96794042e25cae89_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMy03LTEtMS03MjEyMw_c5241d26-fb16-43d2-9a2b-a9370ce9f6a7">55,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3084d7ec4bd64f8eaabed4981928a134_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNC01LTEtMS03MjEyMw_257eaf5d-870e-4df6-86a7-f922800669ee">3,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i635aa95b5b3a4c40abecbcbe6550bef2_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNC03LTEtMS03MjEyMw_0108b800-58df-4968-a776-f769de0e801c">2,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biopharmaceutical and other revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31dd8bd6f8b4fb3b8a6f145af4d5d59_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNS01LTEtMS03MjEyMw_a098fe13-adca-4eee-aceb-1e9aba68b3d0">6,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie309aab35ae147468bed50274b964061_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNS03LTEtMS03MjEyMw_019639da-d0a5-47ba-9f73-368be80e5568">8,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNi01LTEtMS03MjEyMw_f9a7a63e-6084-4936-9ce6-d59fd491adf9">82,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNi03LTEtMS03MjEyMw_a3f8ca13-90ae-48fb-bacd-cf4781a0bb14">67,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of testing revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847532d1474b4753b04c345c4ed3d2bb_D20230101-20230331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfOC01LTEtMS03MjEyMw_26cbb4cb-4fcf-4011-9030-b32786d9c10e">19,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872cd6a83fb94eeb96794042e25cae89_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfOC03LTEtMS03MjEyMw_5c970b23-addb-448a-871a-de270a1d36a6">17,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3084d7ec4bd64f8eaabed4981928a134_D20230101-20230331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfOS01LTEtMS03MjEyMw_efed608f-a9c3-4ef4-9c11-fc07d4e73407">2,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i635aa95b5b3a4c40abecbcbe6550bef2_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfOS03LTEtMS03MjEyMw_3d21e1a4-bad5-4d72-9d2d-60c3d3b12220">1,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of biopharmaceutical and other revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31dd8bd6f8b4fb3b8a6f145af4d5d59_D20230101-20230331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTAtNS0xLTEtNzIxMjM_fdf4464f-b016-44ed-bbad-3cf7067da9d3">4,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie309aab35ae147468bed50274b964061_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTAtNy0xLTEtNzIxMjM_1c5f5a03-a01d-43db-abc2-655bcccadb7a">4,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTEtNS0xLTEtNzIxMjM_17d2b9e7-3652-4f04-9809-f15688d17139">12,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTEtNy0xLTEtNzIxMjM_3734fb3d-9038-449d-81c8-39de9d147623">9,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTItNS0xLTEtNzIxMjM_0542a0dd-a1af-4d64-b14f-6e6f9bfaae61">26,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTItNy0xLTEtNzIxMjM_6d6d87ee-c921-4ff7-8c99-8150e01e39ba">23,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTMtNS0xLTEtNzIxMjM_2c52c6bc-856d-4abc-96d7-368029c8e315">22,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTMtNy0xLTEtNzIxMjM_bb3ef2d4-fef8-4197-b490-cb2212f09299">20,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTQtNS0xLTEtNzIxMjM_653b5235-b90b-4349-8246-f829803292d5">5,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTQtNy0xLTEtNzIxMjM_50254451-e117-439a-831f-efa34128fe68">5,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTUtNS0xLTEtNzIxMjM_7b31d0c5-5357-4a55-8554-8c37ae23ca01">92,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTUtNy0xLTEtNzIxMjM_46e90251-63c5-402c-97fe-12ff429ac2f6">83,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTYtNS0xLTEtNzIxMjM_2fd3eb17-edc3-481b-ad3b-38330e078792">10,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTYtNy0xLTEtNzIxMjM_9cb1e05b-dd10-4319-8063-c9f2f7832e0e">15,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTctNS0xLTEtNzIxMjM_757485e6-fdf4-4330-9c25-cefd3e54d9ff">2,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTctNy0xLTEtNzIxMjM_fe8126ad-1b22-4c14-b06e-8b8ce635eb89">784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTgtNS0xLTEtNzIxMjM_b5606177-9cfb-4fa7-97b3-5baacc2b4d61">8,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTgtNy0xLTEtNzIxMjM_e59331c1-ed4d-41c9-a19b-67e70706881d">14,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTktNS0xLTEtNzIxMjM_0cd2f45d-d481-45e4-bb62-df78340ea0aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTktNy0xLTEtNzIxMjM_c4cdc3f7-82c7-4eb8-9535-ff778270ba43">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjAtNS0xLTEtNzIxMjM_6a9c5d47-536f-4b0a-b5aa-703c471fe57b">8,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjAtNy0xLTEtNzIxMjM_1375711f-1691-494b-9e0a-c3e21adb9f86">14,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjEtNS0xLTEtNzIxMjM_3cb52f6d-147d-487e-a7cc-fd4cb43ccb47"><ix:nonFraction unitRef="usdPerShare" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjEtNS0xLTEtNzIxMjM_54738b51-6878-4a87-bb14-3a3ef9db4cfb">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjEtNy0xLTEtNzIxMjM_0aea3854-9985-4366-bbbc-2d26c0a09803"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjEtNy0xLTEtNzIxMjM_b7747972-9551-496f-bfdc-684c4ddf1dd7">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares used to compute net loss per common share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjItNS0xLTEtNzIxMjM_0043e872-ff36-4ab2-aeca-f48490d9f50f"><ix:nonFraction unitRef="shares" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjItNS0xLTEtNzIxMjM_41027c96-5166-4589-9f09-677a4db74813">72,175,457</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjItNy0xLTEtNzIxMjM_013bd912-61aa-4fc3-933e-d7d2b91ba052"><ix:nonFraction unitRef="shares" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjItNy0xLTEtNzIxMjM_d498e6d6-dd00-4589-8d25-a0124dce9148">71,229,672</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE,&#160;INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.298%"><tr><td style="width:1.0%"></td><td style="width:55.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfMi01LTEtMS03MjEyMw_955a9343-3373-49fc-8d09-a301bc2ca2c7">8,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfMi03LTEtMS03MjEyMw_aac607bb-3926-42c4-a95f-e6fa2dadcacc">14,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in currency translation adjustments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfNC01LTEtMS03MjEyMw_c0f4f68a-0234-4e29-8ef2-6f16f24fccfa">4,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfNC03LTEtMS03MjEyMw_f8016e27-fbd8-4ad9-ad77-16c678e9a331">5,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfMTMtNS0xLTEtNzIxMjM_3d852e73-55de-409a-91a1-b680a6a43ba2">3,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfMTMtNy0xLTEtNzIxMjM_5b6c11a1-1332-411a-9e04-e9410330a68c">20,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE,&#160;INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95b8df0ff5f640d8a141c19c5bd881fa_I20221231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi0xLTEtMS03MjEyMw_c5e53a76-1492-4ce4-a059-a490c553ea7e">71,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b8df0ff5f640d8a141c19c5bd881fa_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi0zLTEtMS03MjEyMw_e06d3a57-b8f4-408e-ad42-001ff891a566">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9dbd02e335643de8ce058f59321f616_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi01LTEtMS03MjEyMw_701373c4-82ef-4fcc-8ea1-ab781a05eb08">1,500,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i924230acce20424dabe447ae137dbf83_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi03LTEtMS03MjEyMw_576cbf11-89c1-4c9e-a478-5db8ecae0744">393,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id752a28a43c4436681909d1cc3eed3b6_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi05LTEtMS03MjEyMw_111a3dd5-5d74-474e-966a-d6ad21b15780">31,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi0xMS0xLTEtNzIxMjM_d9a75cb3-e769-49dc-bb3c-1fe18096a749">1,075,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock on exercise of stock options and vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1881985bc124c028c3c3dbad3abd14b_D20230101-20230331" decimals="-3" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMy0xLTEtMS03MjEyMw_0f0fb91f-0e06-494a-a47e-56ca4a6478a8">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331" decimals="-3" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMy01LTEtMS03MjEyMw_f122401a-f209-4641-82d9-2f3bee801d13">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMy0xMS0xLTEtNzIxMjM_26945744-56a4-429a-921e-d6c693b35c26">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan (ESPP)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1881985bc124c028c3c3dbad3abd14b_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNC0xLTEtMS03MjEyMw_fdc09717-196d-4eed-a9de-db64fe1faea9">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNC01LTEtMS03MjEyMw_2855477b-0873-425b-a262-63f4f74f562c">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNC0xMS0xLTEtNzIxMjM_cdf147a8-4d80-47ab-be97-e824773fe4ee">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax portion of vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNS01LTEtMS03MjEyMw_8d14ddea-8f8a-4b41-b592-32faf0165029">2,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNS0xMS0xLTEtNzIxMjM_cb2191ed-ca00-4cee-b5ac-619fdf8deeeb">2,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense (employee)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNi01LTEtMS03MjEyMw_8aac44ac-8c0e-45a9-b409-7bc48bd8cfef">7,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNi0xMS0xLTEtNzIxMjM_cf9876ea-3590-49a7-b3a4-e8d06969e0ae">7,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense (ESPP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfOC01LTEtMS03MjEyMw_2c85bd90-0055-4c92-beda-e2fe887d6717">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfOC0xMS0xLTEtNzIxMjM_e7062e3b-a199-4c87-8ffc-fe805831c7d8">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86fbf95cd4b5437dbec9986bc1144ec2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfOS03LTEtMS03MjEyMw_31a48bf8-4d3e-4ca3-a3fd-4705907b02a1">8,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfOS0xMS0xLTEtNzIxMjM_1e528ff8-7f74-4ed6-a6d3-b1d2bffef7cb">8,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5753c1b61e2d42e58a2276f17d5fb19a_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTAtOS0xLTEtNzIxMjM_4cc72460-6ccf-42e0-acc2-1c174ae7711d">4,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTAtMTEtMS0xLTcyMTIz_105db9ec-191d-4252-ab83-65cb4e79710e">4,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf29b5a393ba4124abdaee15f6859cb8_I20230331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtMS0xLTEtNzIxMjM_fa90cc53-1bc8-4cbf-9ef4-b7f05b320ae3">72,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf29b5a393ba4124abdaee15f6859cb8_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtMy0xLTEtNzIxMjM_5fa11d99-5010-48b0-9bca-b48eb61d32f3">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if523cf067c5f4dbebed00daf0386fb51_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtNS0xLTEtNzIxMjM_339c3c52-57b9-41fb-98e7-c1a902b0ddc8">1,509,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55b285ff45524728a3082fa425970706_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtNy0xLTEtNzIxMjM_83e8d322-573e-4f2d-8a3c-558cdaa6ad02">401,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0d48f67cf5c4722884b1138ecc775f2_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtOS0xLTEtNzIxMjM_2b203843-4fa3-455f-bb7d-d22a3e04429d">26,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtMTEtMS0xLTcyMTIz_4bd79324-09b4-41bf-b2eb-8cd1bd030a3e">1,081,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:6.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:6.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:28.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.366%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87aca5bd093645dda8ac7488b345dc9f_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi0xLTEtMS03MjEyMw_bb5bc304-dcc6-4baf-83b0-5a1d90a84e40">71,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87aca5bd093645dda8ac7488b345dc9f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi0zLTEtMS03MjEyMw_a54e9546-5985-409e-b5d7-cfa1334154cc">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f11f413da04f52830af895a72e45a5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi01LTEtMS03MjEyMw_c8acb343-545a-42db-a8c9-4a826888a211">1,468,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4e26fa70903498190d2e5c48dd87a5c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi03LTEtMS03MjEyMw_cb5b38c8-3a2a-4c9f-b48b-7d16ae818af8">357,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a4723b9349f4234b5edb4fc1dd4f8b2_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi05LTEtMS03MjEyMw_ba154676-9ab2-4b37-a2c4-e47e9b4f0995">15,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2e9b82dc8546598d4d83b5a9b32dcd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi0xMS0xLTEtNzIxMjM_ef36e939-da70-41e8-8458-2c7243eb499a">1,096,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock on exercise of stock options and vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64c8dbded3c748c0ac0a7f3125954a4f_D20220101-20220331" decimals="-3" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNC0xLTEtMS03MjEyMw_f6e78e4a-ab11-4a0d-b7be-8bc16b25654a">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331" decimals="-3" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNC01LTEtMS03MjEyMw_bc332ae3-10b5-45e7-969c-7537e8b1e180">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNC0xMS0xLTEtNzIxMjM_4fd8594f-6019-4466-b968-a3d6fe885f1c">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64c8dbded3c748c0ac0a7f3125954a4f_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNS0xLTEtMS03MjEyMw_b344378c-9e71-47ed-8ea3-d23b79e5b92b">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNS01LTEtMS03MjEyMw_72e4e70c-2da2-4d9b-9575-4ac81ebed653">2,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNS0xMS0xLTEtNzIxMjM_438d50ef-bbe5-4de4-a509-09037aed396c">2,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax portion of vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNi01LTEtMS03MjEyMw_fc693685-9d6b-40aa-a871-a3c113bd7742">1,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNi0xMS0xLTEtNzIxMjM_7398d40c-0562-4fc5-8efc-36d5f959bf94">1,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense (employee)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNy01LTEtMS03MjEyMw_d4d7e57b-f01e-4264-95ee-f6ff1f31e10b">6,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNy0xMS0xLTEtNzIxMjM_4f85c6bd-840b-4531-925c-813e379c9b86">6,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense (non-employee)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfOC01LTEtMS03MjEyMw_2cbb2043-c486-426d-9d60-aa55efb1b994">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfOC0xMS0xLTEtNzIxMjM_3acb530f-f8d7-4f0c-b0db-7c2042dc8135">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense (ESPP)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfOS01LTEtMS03MjEyMw_e6ca7184-a6e8-4490-a464-c0b926f615fa">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfOS0xMS0xLTEtNzIxMjM_c6e2067b-109f-4fa6-8cae-8cc6d5af4494">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc136e0ed6db40aa933f473850279a4c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTAtNy0xLTEtNzIxMjM_8bbd4075-413e-4662-bd88-5320d4db3ece">14,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTAtMTEtMS0xLTcyMTIz_b832a6c0-1344-4ecf-ab4e-e5e27970dc81">14,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5aea6fc5bfd40498c71f885f3a5b84c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTEtOS0xLTEtNzIxMjM_baa066a6-ef64-4477-a76e-e26602ea7f29">5,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTEtMTEtMS0xLTcyMTIz_288f653e-0cf1-4f0b-9c42-00781cf05890">5,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i906486b05220499884f0e0763ff0fcc5_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItMS0xLTEtNzIxMjM_2a0cd007-eb58-4c02-b53a-6a3a9ade8f87">71,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906486b05220499884f0e0763ff0fcc5_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItMy0xLTEtNzIxMjM_5910fac1-281f-4ac5-9652-aee56963ef99">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3550a7c5734f6d9ca5aaf01e299960_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItNS0xLTEtNzIxMjM_bd98594c-9104-4486-a246-e0eebb17060b">1,477,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibff0ccc6162b425f8af12108f388f189_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItNy0xLTEtNzIxMjM_51f02e90-92d7-44dc-ad3e-2d15e8abe362">371,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife0bc1a9501244b59b18b76ac93dbfb8_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItOS0xLTEtNzIxMjM_b0f6ce59-7906-47dd-a60e-4d38fb479f35">20,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60f7004a2544b82937e0bf55326ce59_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItMTEtMS0xLTcyMTIz_f7ee08a1-53b5-48ed-a198-3d08a35bf79d">1,085,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:6.75pt"><span><br/></span></div><div style="text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-indent:6.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE,&#160;INC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:6.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMy0xLTEtMS03MjEyMw_e4fa74b7-2d7d-4a74-a970-173b7d8a362f">8,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMy0zLTEtMS03MjEyMw_8197a9c4-7dba-47f9-9f85-56b4a08f7031">14,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNS0xLTEtMS03MjEyMw_9a538204-fd4b-49cf-83af-fe2e1c20158c">6,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNS0zLTEtMS03MjEyMw_ce30d9f2-3b82-496f-8613-a9cafe50a273">6,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNi0xLTEtMS03MjEyMw_a587d4eb-767c-4bb3-9d59-37d75ad2da69">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNi0zLTEtMS03MjEyMw_70873d1f-a613-4cbe-ae90-b7860eb53722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNy0xLTEtMS03MjEyMw_988a2b61-fd25-425a-8cca-1b71ea8eb7b5">7,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNy0zLTEtMS03MjEyMw_e3343a0d-d7ba-4ce8-af35-06491775ac34">6,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfOC0xLTEtMS03MjEyMw_e0f1f5cb-a114-4045-b038-fe9d6705b1d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfOC0zLTEtMS03MjEyMw_60a8a1a5-7d34-4840-86c4-68870daf7383">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on end-of-term debt obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="vcyt:DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfOS0xLTEtMS03MjEyMw_13ba3b4f-43d4-4ebb-ad7c-ce05ca1edda7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="vcyt:DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfOS0zLTEtMS03MjEyMw_ff9d6cce-e7f9-49ef-832b-649f77e9b0a9">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="vcyt:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTAtMS0xLTEtNzIxMjM_a4f385a2-f48f-4dd6-9ecc-c9b6264b8134">903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="vcyt:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTAtMy0xLTEtNzIxMjM_0be43d5e-2cac-49bb-b62d-c064f9aa3e04">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revaluation of acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTEtMS0xLTEtNzIxMjM_e17277e9-bc77-418b-877d-2e33a08f051f">485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTEtMy0xLTEtNzIxMjM_fd75b786-f793-4096-a77e-37401fceca45">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of foreign currency on operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTItMS0xLTEtNzIxMjM_ad1e2820-a1c7-4eef-846f-2b4a7a62ef39">224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTItMy0xLTEtNzIxMjM_8a927eaa-c2c9-4e75-b1d3-f99191059363">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTMtMS0xLTEtNzIxMjM_f6fff5ba-c245-498a-ac92-1d9be45de868">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTMtMy0xLTEtNzIxMjM_c26bfaff-c614-4983-a1bc-aad65ffe4a26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTUtMS0xLTEtNzIxMjM_8b7e0f84-ce5f-40cf-89df-f37b89da3fc6">1,302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTUtMy0xLTEtNzIxMjM_3d33a84d-0c09-497c-9533-a3446f5c96be">3,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Supplies and inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTYtMS0xLTEtNzIxMjM_2621f272-273c-4d56-80ac-ecfa703df939">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTYtMy0xLTEtNzIxMjM_0dfbb07a-5d0b-4ae6-8c03-98e81301f232">1,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTctMS0xLTEtNzIxMjM_f25832d4-d06d-4164-9fff-c233d2be66c2">3,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTctMy0xLTEtNzIxMjM_798fa0f5-5b89-4fd1-83ea-81d70ee3ab2a">2,139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTgtMS0xLTEtNzIxMjM_00b24894-1adb-45c9-a0ee-d262dedc50fc">491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTgtMy0xLTEtNzIxMjM_d6b530e6-ffee-4df7-9c2e-aa7293cbe570">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTktMS0xLTEtNzIxMjM_ff86325d-b82a-43ca-bf9d-5d6e2fc61dc6">950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTktMy0xLTEtNzIxMjM_4ff278df-9244-43ed-b60a-15d778da90d6">597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjAtMS0xLTEtNzIxMjM_1d5e9392-1026-409c-af29-0c6b7fc331d4">2,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjAtMy0xLTEtNzIxMjM_8f8780b1-2579-4c04-8f3d-e23c6f0ccaf4">960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities and deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjEtMS0xLTEtNzIxMjM_8f48cece-b527-46fe-bcf6-8338ca203a7c">7,721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjEtMy0xLTEtNzIxMjM_eb9b6283-0112-4470-9f7e-68099c96ddde">390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjItMS0xLTEtNzIxMjM_beef1b7a-8f0f-409e-93b6-8619886b0795">2,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjItMy0xLTEtNzIxMjM_031b7600-870d-4d83-a44a-df7ed2eabc73">8,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjYtMS0xLTEtNzIxMjM_59670a8e-04bf-4d7f-932d-bbf99819c6fe">19,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjYtMy0xLTEtNzIxMjM_f68043f4-4ae5-4113-8ead-f92910aaf4f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjctMS0xLTEtNzIxMjM_f722c773-f071-4d96-b049-98f451db7e18">39,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjctMy0xLTEtNzIxMjM_3b2dfc6b-2cb6-4320-b433-e5e61df12d78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturity of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjgtMS0xLTEtNzIxMjM_cc000e24-25de-48db-adad-4bab22261c0f">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjgtMy0xLTEtNzIxMjM_498542f0-50da-49eb-979c-40d2cd1a035b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzAtMS0xLTEtNzIxMjM_18b76372-6da7-4ff5-8e5a-c899feceeeb7">993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzAtMy0xLTEtNzIxMjM_c1d63b8a-fb54-4ecb-8c60-4d8f23daf28d">2,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzEtMS0xLTEtNzIxMjM_abd61eb5-95c2-4ba5-8a27-192f3260a810">24,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzEtMy0xLTEtNzIxMjM_50cc9de7-aacd-4ae2-ba75-30ce18e30038">2,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzQtMS0xLTEtNzIxMjM_6da8c725-3fa9-4f6f-a1e9-b6998904f162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzQtMy0xLTEtNzIxMjM_dbf2c281-a9f7-44e2-9e18-e464fbca8d8d">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of taxes on vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzUtMS0xLTEtNzIxMjM_be31e1e9-2a29-4b63-adb6-a5a1ef5a8f20">2,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzUtMy0xLTEtNzIxMjM_1e274a0e-1f27-4801-af10-a397876e4a8c">1,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the exercise of common stock options and employee stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzYtMS0xLTEtNzIxMjM_f81dce3d-837c-497b-86b4-3dcd88295907">3,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzYtMy0xLTEtNzIxMjM_de0be713-0b39-41c4-a94e-5bbe991d77e8">3,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzctMS0xLTEtNzIxMjM_253fc396-d625-4c06-b0a9-ad97e8314a05">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzctMy0xLTEtNzIxMjM_dbee56c6-6706-4692-8898-8def4f797f8b">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzgtMS0xLTEtNzIxMjM_81bb48b6-9aee-40fb-9221-1791b7a62499">23,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzgtMy0xLTEtNzIxMjM_9bdf7c1b-61f4-4978-a9b6-e6ff8f5885f5">9,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of foreign currency on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzktMS0xLTEtNzIxMjM_c423fccb-18ac-4714-b265-1b5d3d185909">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzktMy0xLTEtNzIxMjM_a5aa0a92-6d15-45b0-b768-b48ff0743358">247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDAtMS0xLTEtNzIxMjM_99c14cf2-682e-4ade-8f9d-c5ea5cf8931a">23,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDAtMy0xLTEtNzIxMjM_634d2047-2628-486e-b763-4753f64902d5">9,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDEtMS0xLTEtNzIxMjM_19533cde-86a6-4c98-a0a5-f6ddb9be7f93">154,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2e9b82dc8546598d4d83b5a9b32dcd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDEtMy0xLTEtNzIxMjM_0c8ce6bb-4dc4-4163-b16a-600ae1ac21d0">173,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDItMS0xLTEtNzIxMjM_cbc2b2e3-d3f3-43a3-bf3d-a79224c26e9b">178,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60f7004a2544b82937e0bf55326ce59_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDItMy0xLTEtNzIxMjM_2d016552-d26c-496f-94da-18c0b498f239">164,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplementary cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDQtMS0xLTEtNzIxMjM_999ab3be-9230-43a9-8596-7ca8acffca38">1,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDQtMy0xLTEtNzIxMjM_3e5d6c04-3e03-4592-b070-8e7f437d728c">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:center;text-indent:6.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMS0xLTEtMS03MjEyMw_389316a3-7cec-4657-8859-f12383b6fd32">177,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMS0zLTEtMS03MjEyMw_569a74a9-a8c9-4ead-bc71-f1a9d11112df">154,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMi0xLTEtMS03MjEyMw_7b29eecf-d74a-49d0-bb46-f208fba5548d">749</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMi0zLTEtMS03MjEyMw_bbf0a461-aabb-4ba8-81e1-5c35bb8a41fd">749</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMy0xLTEtMS03MjEyMw_59f17f1f-d112-4793-961e-e593ff9eec2b">178,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMy0zLTEtMS03MjEyMw_54702027-6518-43c5-9317-996ee3fb690b">154,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE, INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDI_1f4d7ebd-d901-44fb-9f00-25fef6f0b686" continuedAt="ia59b07ce2c75437e8a3b037cef11feec" escape="true">Organization, Description of Business and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia59b07ce2c75437e8a3b037cef11feec" continuedAt="ib04579d9dde04a4d81d9539ce20ff673"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veracyte, Inc., or Veracyte, or the Company, is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Veracyte's high-performing tests enable clinicians to make more confident diagnostic, prognostic and treatment decisions, helping patients avoid unnecessary procedures and interventions, and speed time to appropriate treatment, thereby improving outcomes for patients all over the world. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veracyte was incorporated in the state of Delaware on August 15, 2006, as Calderome, Inc. Calderome operated as an incubator until early 2008. On March 4, 2008, the Company changed its name to Veracyte, Inc. The Company&#8217;s headquarters are in South San Francisco, California, and it also has operations in San Diego, California; Austin, Texas; and Marseille, France. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently offers tests in thyroid cancer (Afirma); prostate cancer (Decipher Prostate); breast cancer (Prosigna); interstitial lung diseases (Envisia); and bladder cancer (Decipher Bladder). The Company&#8217;s Percepta Nasal Swab test is being run in its CLIA lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company serves global markets with two complementary models. In the United States, it offers laboratory developed tests, or LDTs, through its centralized, Clinical Laboratory Improvement Amendments of 1988, or CLIA, certified laboratories in South San Francisco and San Diego, California, supported by its cytopathology expertise in Austin, Texas. Additionally, primarily outside of the United States, the Company provides its Prosigna test to patients through distribution to laboratories and hospitals that can perform the tests locally as an in vitro diagnostic, or IVD, test that runs on the nCounter Analysis System.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTc_f9963afc-14bf-4fb8-9df1-5d877494e89f" escape="true"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of March&#160;31, 2023, the condensed consolidated statements of operations for the three months ended March&#160;31, 2023 and 2022, the condensed consolidated statements of comprehensive loss for the three months ended March&#160;31, 2023 and 2022, the condensed consolidated statements of stockholders' equity for the three months ended March&#160;31, 2023 and 2022, and the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results, stockholders' equity and cash flows for the periods presented. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from audited financial statements. The results for the three months ended March&#160;31, 2023 are not indicative of the results expected for the full year or any other period. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.  The Company operates in <ix:nonFraction unitRef="segment" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfNTM5Mw_05b815b0-b784-40b5-bdca-c7b42e027e91">one</ix:nonFraction> segment.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim period condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDc_8f9a8e78-d745-48d8-bf5f-44453d7c69d0" continuedAt="ia4f5cb3620cf4cd7bf9ca3fb9b742c99" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property, plant and equipment; the recoverability of long-lived assets; the incremental borrowing rates for leases; accounting for acquisitions; the estimation of the fair value of intangible assets and contingent consideration; stock based compensation; income tax uncertainties, including a valuation allowance for deferred tax assets; credit related losses on investments; and allowance for credit losses and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE, INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="ib04579d9dde04a4d81d9539ce20ff673" continuedAt="i2c5c2b352dc649589ba1f9d334b27b01"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia4f5cb3620cf4cd7bf9ca3fb9b742c99">that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDQ_29ff4fd0-292d-44bc-b226-cc4462cdba8a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have. As a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company&#8217;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict. If the financial markets or the overall economy are impacted for an extended period, the Company&#8217;s liquidity, revenue, supplies, goodwill and intangibles may be adversely affected. The Company considers the effects, to the extent knowable, of the COVID-19 pandemic in developing its estimates.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s cash and cash equivalents are deposited with two major financial institutions in the United States. Deposits in these institutions may exceed the amount of insurance provided on such deposits. The Company has not realized any losses on its deposits of cash and cash equivalents other than exchange rate losses related to foreign currency denominated accounts.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of the components of the Company&#8217;s sample collection kits and test reagents, and the nCounter system and related diagnostic kits, are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company&#8217;s requirements on a timely basis, or are unable to provide the Company with reagents that perform to specifications, the Company could suffer delays in being able to deliver its diagnostic solutions, suffer a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March&#160;31, 2023, the Company has derived most of its revenue from the sale of Decipher and Afirma testing. To date, Decipher and Afirma testing have been delivered primarily to physicians in the United States. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect. The Company generally does not perform evaluations of customers&#8217; financial condition for testing revenue and generally does not require collateral. The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and other revenue based on collection history, current developments and credit worthiness of the customer. The estimate of credit losses is not material at March&#160;31, 2023.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDU_28f3d9e4-eef1-4e75-8d93-ec5adcded1fe" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic43b0b3fe6664d3cbdb8a3f4f93ee2bd_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfMi01LTEtMS03MjEyMw_0a54dcc1-d7ea-45ea-8300-e699654ed620">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i19f99811b32f40d18acdc45b83384992_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfMi03LTEtMS03MjEyMw_d9537926-a88d-4199-aefb-b9f1cbfb92c5">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UnitedHealthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32cc63b081d34737b7c09f18254a0369_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfMy01LTEtMS03MjEyMw_deaf5b51-5580-4010-8b21-f4d6b2b388bb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if73c87216b7e431cbb1a5132319fc1ba_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfMy03LTEtMS03MjEyMw_ecdf936e-bbf1-4e8e-8fff-01fd981ddcba">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iecc0d9d5bd4645f4a7aa6c4d79ddcca0_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfNC01LTEtMS03MjEyMw_b93e4eab-345c-45b4-bf2b-f65f9d31fdff">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdbdbc6fb5304aa6a286a799abfdc7c5_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfNC03LTEtMS03MjEyMw_ab840a55-ef69-4570-b4d3-870c7bc51e75">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's significant third-party payers in excess of 10% of total accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icadd7189bc5c4c3385082591611320f5_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOmJkOTI5MTI3Zjk2NTRkMjg5ODk4NGNhYmI0MGViYWVmL3RhYmxlcmFuZ2U6YmQ5MjkxMjdmOTY1NGQyODk4OTg0Y2FiYjQwZWJhZWZfMS0xLTEtMS03MjEyMw_c6771cb2-707d-4690-be06-788bcc95950c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if563c75164164060aab1e980fe9c7b0b_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOmJkOTI5MTI3Zjk2NTRkMjg5ODk4NGNhYmI0MGViYWVmL3RhYmxlcmFuZ2U6YmQ5MjkxMjdmOTY1NGQyODk4OTg0Y2FiYjQwZWJhZWZfMS0zLTEtMS03MjEyMw_94d845c3-328d-4a07-9d56-f3857e0e2350">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UnitedHealthcare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8ca971045914a1a9146c9113b0b663d_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOmJkOTI5MTI3Zjk2NTRkMjg5ODk4NGNhYmI0MGViYWVmL3RhYmxlcmFuZ2U6YmQ5MjkxMjdmOTY1NGQyODk4OTg0Y2FiYjQwZWJhZWZfMi0xLTEtMS03MjEyMw_c5fa961d-317a-4774-bea3-a89a1b8b06b7">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35250c2e6deb44c4ac481dd4e6f612e9_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOmJkOTI5MTI3Zjk2NTRkMjg5ODk4NGNhYmI0MGViYWVmL3RhYmxlcmFuZ2U6YmQ5MjkxMjdmOTY1NGQyODk4OTg0Y2FiYjQwZWJhZWZfMi0zLTEtMS03MjEyMw_b32b62e1-7bca-42c9-b2b4-ad989739d658">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE, INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i2c5c2b352dc649589ba1f9d334b27b01" continuedAt="i834ecb133e7941209e727b8183a9d735"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDY_6b579b1a-4f35-4d21-8876-2544c9649335" continuedAt="i5b78349917184bf9879a7c32cb85a106" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash&#160;and&#160;Cash&#160;Equivalents</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5b78349917184bf9879a7c32cb85a106">The Company considers demand deposits in a bank, money market funds and highly liquid investments with an original maturity of 90 days or less to be cash equivalents.</ix:continuation> </span></div><div style="text-indent:42.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDg_b7b66b8a-bfa3-45b2-83c9-f60871f268fe" continuedAt="ie9f23a8634da4ad4b480b82dc2bab537" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie9f23a8634da4ad4b480b82dc2bab537">The Company's short-term investments consist of U.S. treasury securities with maturities at the time of purchase that were between 90 days and one year. The Company classifies these investments as held-to-maturity debt securities, which are reported at amortized cost. The amortization of discounts or premiums from the purchase of the securities are recognized as a component of interest income in other income (loss), net in the condensed consolidated statements of operations. Investments are initially recorded net of an allowance for expected credit losses, if any, which are remeasured each period and any impairments are recognized as an expense. Unrealized gains and losses are not recognized in income.</ix:continuation> As of both March&#160;31, 2023 and December&#160;31, 2022, <ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTE3NTk_4fbc8853-822c-4be1-928d-71dc3228afa7"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTE3NTk_f1d20560-4f46-45de-b18e-0644142744f9">no</ix:nonFraction></ix:nonFraction> allowances for expected credit losses had been recorded and there have been no impairment or credit losses on the Company's short term investments.</span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had deposits of $<ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTE5NTc_b9b99076-ecf6-4944-900c-1092116730fc"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTE5NTc_c9c77fa5-19bf-4698-b945-ca474e87df49">0.7</ix:nonFraction></ix:nonFraction> million included in long-term assets as of both March&#160;31, 2023 and December&#160;31, 2022, restricted from withdrawal and held by banks in the form of collateral for irrevocable standby letters of credit held as security for the Company's leases. </span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDA_5cd87ede-a3cb-404c-a148-d27f1164908e" continuedAt="i96796eda826849669c2cd86f0cea0bde" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with the provisions of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has completed a service or transferred control of a product to the customer. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one service or good, each required service or good is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the service or good either on its own or together with other resources that are readily available and (ii) the service or good is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred which may be at a point in time or over time.</span></div><div><span><br/></span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Testing Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bills for testing services at the time of test completion as defined by the delivery of test results. The Company recognizes revenue based on estimates of the amount that will ultimately be realized. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management. Actual results could differ from those estimates and assumptions.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Product Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products consist of the Prosigna breast cancer assay, the nCounter Analysis System and related diagnostic kits. Product revenue from diagnostic kits is generally recognized upon shipment. Product revenue from instruments is </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE, INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i834ecb133e7941209e727b8183a9d735" continuedAt="ic0aabaa51f29403fb719419a31cee623"><ix:continuation id="i96796eda826849669c2cd86f0cea0bde" continuedAt="i732fd95362884cc0aee564c4470e1777"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally recognized when the instrument is ready for use by the end customer. Shipping and handling costs incurred for product shipments are included in product revenue. Revenue is presented net of the taxes that are collected from customers and remitted to governmental authorities. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Biopharmaceutical and Other Revenue</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into arrangements for biopharmaceutical research and development, commercialization, contract manufacturing and development, and testing services, which are classified under biopharmaceutical and other revenue. Such arrangements may require the Company to deliver various rights, manufactured diagnostic test kits, services and/or samples, including intellectual property rights/licenses, biopharmaceutical research and development services, and/or commercialization services. The Company receives consideration in the form of upfront license fees; payments on delivery of data, test results or manufactured products; costs of service plus margin; and development and commercial performance milestone payments. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price may include independent evidence of market price, forecasted revenue or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if the obligation can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. Milestone payments that are not within either party&#8217;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within either party&#8217;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative revenue and earnings in the period of adjustment. One collaboration arrangement with milestone payments falls under the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 808. These milestone payments are recognized in the same manner as milestone payments from customers and are classified under biopharmaceutical and other revenue.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable from biopharmaceutical and other revenue was $<ix:nonFraction unitRef="usd" contextRef="ifd3b24d188c147d0894ca33558f96f88_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTkwNzk_91c4e61f-fcb7-452b-9432-ec7d9a1246d2">8.8</ix:nonFraction>&#160;million&#160;at March&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="i998dea8702a44f32b783fad66ceaef6f_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTkwOTI_de0989db-13dd-4acf-be36-c8fbe266c761">9.3</ix:nonFraction>&#160;million at December&#160;31, 2022. There was $<ix:nonFraction unitRef="usd" contextRef="ifd3b24d188c147d0894ca33558f96f88_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTkxMTI_6450951b-1334-4435-8386-6e69be87a405">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i998dea8702a44f32b783fad66ceaef6f_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTkxMTk_2f23213d-1097-4f5a-b9cc-21437964e0fc">2.6</ix:nonFraction>&#160;million of deferred revenue related to these agreements at March&#160;31, 2023 and December&#160;31, 2022, respectively. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDE_61755a89-98af-4e87-98ec-95a18cc1082d" continuedAt="ifccdc865205244368f76d42baa51f8e5" escape="true">Revenue included in biopharmaceutical and other revenue for the three months ended March&#160;31, 2023 and 2022 was as follows (in thousands of dollars):</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:42.75pt"><ix:continuation id="ifccdc865205244368f76d42baa51f8e5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biopharmaceutical revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274a02acfdb5475dac6457d7c3ee154b_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfMi01LTEtMS03MjEyMw_c0dec4e2-567e-47de-8633-307831fe28d0">4,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae14244c4fb41a999ccf232d576984d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfMi03LTEtMS03MjEyMw_0cdc55d8-b3d1-4248-bb59-fb5e4f807c31">7,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing and testing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2099bc12c8224f319528343bdffe545e_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfMy01LTEtMS03MjEyMw_bf33ce37-893e-4002-99e0-1f429b07367d">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06548eac75174f9ca6d2b92d2d9f74ca_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfMy03LTEtMS03MjEyMw_24ee331c-7ed5-40e1-9246-5dcaefeb9373">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31dd8bd6f8b4fb3b8a6f145af4d5d59_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfNC01LTEtMS03MjEyMw_5f3e1495-db1a-46e4-987a-02de27a46567">6,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie309aab35ae147468bed50274b964061_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfNC03LTEtMS03MjEyMw_ff7446b7-0490-4308-bd2b-396d6e22f4fe">8,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Testing Revenue</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE, INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="ic0aabaa51f29403fb719419a31cee623"><ix:continuation id="i732fd95362884cc0aee564c4470e1777" continuedAt="id796db8fe06a4c4b9aacaba6b55e4bef"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue consists primarily of costs of purchasing instruments and diagnostic kits from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">third</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-party contract manufacturers, installation, service and packaging and delivery costs, and the Company's internal labor expenses. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#8217;s products. Cost of product revenue for instruments and diagnostic kits&#160;is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the condensed consolidated statements of operations.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Biopharmaceutical and Other Revenue</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id796db8fe06a4c4b9aacaba6b55e4bef">Cost of biopharmaceutical and other revenue consists of costs of performing activities under arrangements that require the Company to perform biopharmaceutical research and development, commercialization, contract manufacturing and contract testing services on behalf of a customer.</ix:continuation>&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTg_899ee160-2029-4e8c-95da-f1566d3484d2" continuedAt="ie2860f45ba624939a1265cb82f6392ad" escape="true">Pension Liability</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie2860f45ba624939a1265cb82f6392ad">The Company offers a defined benefit <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_c42f36f4-4860-4a82-9f52-48c65e91ae48"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_dbd24477-8f44-4199-93ad-3dfd106ab395">pension plan</span></span> to certain non-U.S. employees of its Veracyte SAS subsidiary.</ix:continuation>  As of both March&#160;31, 2023 and December&#160;31, 2022, the total pension obligation was $<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjA5NTk_11af291c-1806-4e16-ae80-1b1934ccb9b7"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-5" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjA5NTk_ddd0aa6b-d8b1-43f2-9a30-3fd4f1c2255d">0.7</ix:nonFraction></ix:nonFraction>&#160;million and is included in other liabilities on the condensed consolidated balance sheets. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTY_55e97823-070d-426b-9464-99c0a1e8ccdd" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 2014-09, Revenue from Contracts with Customers (Topic 606). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. The new standard is effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance in 2023 and such adoption had no material impact on its consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RleHRyZWdpb246MjFlN2FiNTg2MTEyNDdkZmIxMTAwNDM0Y2I4M2FiMzhfNjYy_be989436-d610-4572-9dfe-1e36a01e3f6e" continuedAt="i3a0e685c716b4a59a40ef48207da561a" escape="true">Net Loss Per Common Share</ix:nonNumeric></span></div><ix:continuation id="i3a0e685c716b4a59a40ef48207da561a"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RleHRyZWdpb246MjFlN2FiNTg2MTEyNDdkZmIxMTAwNDM0Y2I4M2FiMzhfNjYz_eafb51e7-9f47-43f8-8f3d-7530118d2e7e" continuedAt="ic814f2f4099b44acb441b026987b029b" escape="true">The following outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive:</ix:nonNumeric></span></div><ix:continuation id="ic814f2f4099b44acb441b026987b029b"><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.225%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of common stock subject to outstanding options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d63ecdd09ee4ceeb3894542f9e9a7b1_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfMi01LTEtMS03MjEyMw_25de6431-5e49-4483-bde3-f253e7df3f15">3,767,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cc183be53114cd5ae6844b58582cac8_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfMi03LTEtMS03MjEyMw_c91282cb-0f0d-4c39-9a7a-cc7965656502">3,703,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec98084255e1437ca83d101b89bdff0f_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfMy01LTEtMS03MjEyMw_3eb24f52-1923-4cf5-a68b-b7c75104bf61">33,998</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03e5c566c2b44d13b38e3125968a69bf_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfMy03LTEtMS03MjEyMw_2bd83f1d-5e5b-4e99-b0da-750ddd0d8d4b">30,622</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87ca496310a4471fab481bd7a0025487_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfNC01LTEtMS03MjEyMw_471f2132-be9d-4291-b649-87517cfddf24">2,349,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie962846780634c4abb77f3207cab491b_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfNC03LTEtMS03MjEyMw_3f270d79-be68-453e-ad1d-0e415b481d3d">1,559,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfNS01LTEtMS03MjEyMw_d57e71e1-bed7-4fc1-97fc-fd2ba4691b3b">6,150,235</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfNS03LTEtMS03MjEyMw_0105613c-dc2a-4b10-a4bf-224bf23d61c5">5,293,818</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMjI4Mg_0455c787-9130-43b7-87c0-c1c866185cd6" continuedAt="ibd37853fc1b844cca55e222265a99353" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ibd37853fc1b844cca55e222265a99353" continuedAt="i244a36ce90c54fe58791bfcf4c5774c8"><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify;text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was $<ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNTc_a0b4ac08-84f6-4b80-929b-7e88807157b8">699.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNjQ_01e4cffd-08dc-4057-81e0-39556c8fe49f">695.9</ix:nonFraction>&#160;million as of March&#160;31, 2023 and December&#160;31, 2022, respectively. The changes in the carrying amounts of goodwill during the three months ended March 31, 2023 were due to foreign currency translation.  The Company has not recorded any impairment related to goodwill.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i244a36ce90c54fe58791bfcf4c5774c8" continuedAt="ic925c9bcb1cd43658cbe49296c9a1e14"><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include finite-lived product technology, customer relationships, licenses and trade names and indefinite-lived in-process research and development. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMjI4NA_7013c671-b633-4a7d-86c5-4dd4875e0d6a" continuedAt="i3bb13af73be648f9b8e0c30be518167c" escape="true">Intangible assets consisted of the following (in thousands of dollars):</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><ix:continuation id="i3bb13af73be648f9b8e0c30be518167c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:29.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.099%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Amortization Period (Years)</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Percepta product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c2bbdf5d7e4d15a0928f584d49978a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi0xLTEtMS03MjEyMw_297d3102-348a-4fe7-95a8-64a687878987">16,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1c2bbdf5d7e4d15a0928f584d49978a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi0zLTEtMS03MjEyMw_d7eb15c5-b9af-4821-8e06-31b7bb122c64">8,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c2bbdf5d7e4d15a0928f584d49978a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi01LTEtMS03MjEyMw_5e932304-d67a-4a9a-8c03-1e6e6832a992">7,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf1cd50fe084f529b3b433569983a49_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi03LTEtMS03MjEyMw_bb7ac323-05c2-4d51-b7c8-ee3b29a8b601">16,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdf1cd50fe084f529b3b433569983a49_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi05LTEtMS03MjEyMw_4b5cf30f-1909-4082-9793-a8725675aec2">8,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf1cd50fe084f529b3b433569983a49_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi0xMS0xLTEtNzIxMjM_dc8e71f5-cb47-41ac-9fb8-7bb11cd43bd4">7,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia23eed41b3e74c09a3af1063a3dfaaa4_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi0xMy0xLTEtNzIxMjM_07503673-e2c3-4a25-898d-242b6971ebd1">7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prosigna product technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36048a1bd9c5433d93652f6da7dcba37_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy0xLTEtMS03MjEyMw_f44bca9c-d2b7-4098-b33b-f021e70c3819">4,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36048a1bd9c5433d93652f6da7dcba37_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy0zLTEtMS03MjEyMw_3caf0bbc-78a1-4531-ae78-9c6fde568db9">915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36048a1bd9c5433d93652f6da7dcba37_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy01LTEtMS03MjEyMw_8496befb-3c8a-4f31-a0be-d9ff56c30df8">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b268539086c467aab96e29940e65c30_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy03LTEtMS03MjEyMw_1bbe81c6-a4ba-4162-9fa7-e06bbb2f480e">4,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b268539086c467aab96e29940e65c30_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy05LTEtMS03MjEyMw_d64105c9-6f3e-42df-9307-3c7f421da736">847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b268539086c467aab96e29940e65c30_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy0xMS0xLTEtNzIxMjM_dd0ae676-914d-45fd-a8b3-ebb3d55f1f50">3,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic189876c9f5b49a491d19b401863e5c7_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy0xMy0xLTEtNzIxMjM_fbd1d07f-6f2e-4f39-8f46-99de8a3e078e">11</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prosigna customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02c3ec7045e44e992b345c1c6f4e8db_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC0xLTEtMS03MjEyMw_dcdee01a-a9c4-46ac-8b8d-ce45f4ec3ae7">2,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if02c3ec7045e44e992b345c1c6f4e8db_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC0zLTEtMS03MjEyMw_559550ed-eacf-40ee-8e50-027288b076b1">1,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02c3ec7045e44e992b345c1c6f4e8db_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC01LTEtMS03MjEyMw_40708b62-f373-40e3-9f33-d736c8039a0f">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45490cef3786448bb194a53c1a4925b9_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC03LTEtMS03MjEyMw_2986c58e-89a8-4af3-946c-d9b9944cc2d6">2,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45490cef3786448bb194a53c1a4925b9_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC05LTEtMS03MjEyMw_b52e0e2a-3c74-48d0-b66e-05aab6593435">1,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45490cef3786448bb194a53c1a4925b9_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC0xMS0xLTEtNzIxMjM_01e283f5-f12f-4bdb-bc45-8fca5031d49a">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf00f1922dfe4be3ac3b55ead1c6f375_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC0xMy0xLTEtNzIxMjM_7c831ca7-87bf-42d0-a5c5-f2a7926de20e">1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">nCounter Dx license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4759963ae1646649f60d583de01125c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS0xLTEtMS03MjEyMw_0bddbab6-2a67-4dc4-b883-e2627c932e13">46,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4759963ae1646649f60d583de01125c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS0zLTEtMS03MjEyMw_77054772-8fbd-4673-9f2e-3673bebc8f40">10,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4759963ae1646649f60d583de01125c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS01LTEtMS03MjEyMw_9d90929c-57ce-4c68-a4c2-7a7bfa57ae4f">36,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a449a72bae04d50925d90a798163f1c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS03LTEtMS03MjEyMw_c9def112-8f78-43b8-9f94-fbdf84cda548">46,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a449a72bae04d50925d90a798163f1c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS05LTEtMS03MjEyMw_c344c826-eb9b-4086-81e8-9a30db769ab0">9,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a449a72bae04d50925d90a798163f1c_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS0xMS0xLTEtNzIxMjM_493da314-30aa-4182-8105-efcb0ea3a976">37,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c22e100729e4221b19089c051e020bd_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS0xMy0xLTEtNzIxMjM_77dabb2e-333f-4abf-b568-544342fa3ebd">11</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LymphMark product technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96dd7074a874f3ab955a93c939fd0e2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi0xLTEtMS03MjEyMw_7748d95d-1900-4256-94c2-041b29c00965">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id96dd7074a874f3ab955a93c939fd0e2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi0zLTEtMS03MjEyMw_25565d8a-8e7a-4f4a-a8b3-6814998b95ff">471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96dd7074a874f3ab955a93c939fd0e2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi01LTEtMS03MjEyMw_a57f65f7-94dd-4da4-bcbe-7ca065e1217b">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b06dd23ef3c466caa291f27746d9f0f_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi03LTEtMS03MjEyMw_b8f8bdeb-4545-41a3-b3d2-00b068d874b9">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b06dd23ef3c466caa291f27746d9f0f_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi05LTEtMS03MjEyMw_f1f18ee7-9ef8-4dec-8a18-f13585c689c6">436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b06dd23ef3c466caa291f27746d9f0f_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi0xMS0xLTEtNzIxMjM_37d4c87d-413d-4c8c-a4c9-412f3a95246d">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2dd2214b7954827af13bad315eaeef6_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi0xMy0xLTEtNzIxMjM_802e210d-16d3-486f-9e9f-c953809e84b1">4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decipher product technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i465f5da059d4485493001b166d4b40d9_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy0xLTEtMS03MjEyMw_0924ff04-bc8a-4a9b-86ed-d737f538e6b8">90,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i465f5da059d4485493001b166d4b40d9_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy0zLTEtMS03MjEyMw_277e9711-417d-4911-ac00-c770385d7f24">18,484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i465f5da059d4485493001b166d4b40d9_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy01LTEtMS03MjEyMw_18809489-5129-485f-8aa4-68541e39b1fc">71,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbaa1203aac34a38a5d064b5630c2dbc_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy03LTEtMS03MjEyMw_d4896844-9e28-4f3b-ac56-77152fceb43c">90,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbaa1203aac34a38a5d064b5630c2dbc_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy05LTEtMS03MjEyMw_1a7b8f63-6dd5-4d09-9a84-3315c3ebf626">16,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbaa1203aac34a38a5d064b5630c2dbc_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy0xMS0xLTEtNzIxMjM_cfbfe713-3435-4f09-b62c-856917d6c5a0">73,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e1a841c902147639f42aaf1fc24846c_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy0xMy0xLTEtNzIxMjM_3ec9bfd6-bf1d-4ed2-ba5c-c1b98c2effb3">8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decipher trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5af60edaf174d3dbf0da38ad4778d42_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC0xLTEtMS03MjEyMw_265365ef-d32a-4991-9ca1-4942803d170e">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5af60edaf174d3dbf0da38ad4778d42_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC0zLTEtMS03MjEyMw_ca02a5c0-583c-4931-a94c-a41fce9626fa">1,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5af60edaf174d3dbf0da38ad4778d42_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC01LTEtMS03MjEyMw_fcb3c5b5-fd45-4fcf-88c6-989746944516">2,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51f3fcca6344c0d8acf9827a75d098d_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC03LTEtMS03MjEyMw_b199eefc-4da5-4296-bdce-96c66480a160">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id51f3fcca6344c0d8acf9827a75d098d_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC05LTEtMS03MjEyMw_98e9b822-7215-4077-8f08-f16f53fbe7b3">1,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51f3fcca6344c0d8acf9827a75d098d_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC0xMS0xLTEtNzIxMjM_a62273c4-4535-442f-9571-710c3ed18b7a">2,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i96b14c1a4f46482383ed19e470792768_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC0xMy0xLTEtNzIxMjM_d7b22786-033c-4831-9ee4-be438bb5105e">3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HalioDx developed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ea9d43677e4c86b1d71be599ac6865_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS0xLTEtMS03MjEyMw_b7a0c383-0966-45d3-960f-fafd7de88f91">40,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1ea9d43677e4c86b1d71be599ac6865_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS0zLTEtMS03MjEyMw_fce4c1ad-6314-4588-9f9b-5eaffff2490b">7,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ea9d43677e4c86b1d71be599ac6865_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS01LTEtMS03MjEyMw_5e32fb90-4046-4d5a-b5dc-4efbdb9e8143">33,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf1b2134c6848bc8109d15f1016674a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS03LTEtMS03MjEyMw_58f3e52a-350d-47c4-95e3-9fb3509ded6f">39,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cf1b2134c6848bc8109d15f1016674a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS05LTEtMS03MjEyMw_73cd4591-9e43-4c60-9e9d-3e9ec9cb6708">5,899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf1b2134c6848bc8109d15f1016674a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS0xMS0xLTEtNzIxMjM_2f381738-a87a-4188-a3dc-e53b0b295a4b">33,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i43160a473e5b4aa6975f0c9b8f8a4911_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS0xMy0xLTEtNzIxMjM_3b2acd0c-0369-4372-a911-e2337dc2fe2f">8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HalioDx customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac93bb77e6df4adebb1fce8ac3eb1425_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtMS0xLTEtNzIxMjM_fc313b65-0cbb-44d6-bfa7-0e3a07d0e5af">4,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac93bb77e6df4adebb1fce8ac3eb1425_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtMy0xLTEtNzIxMjM_ba465b1d-4db7-457b-8791-4cbba2c78b37">1,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac93bb77e6df4adebb1fce8ac3eb1425_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtNS0xLTEtNzIxMjM_a27960e3-dab9-48e8-86df-e68d85a4fac6">3,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d58f9fdd9f24ea7beeb7a99ed47f1fb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtNy0xLTEtNzIxMjM_8c6848ec-cfb6-4828-8d0a-371d1475f787">4,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d58f9fdd9f24ea7beeb7a99ed47f1fb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtOS0xLTEtNzIxMjM_4718186f-6faf-47f3-ad70-9e282a71e70a">1,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d58f9fdd9f24ea7beeb7a99ed47f1fb_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtMTEtMS0xLTcyMTIz_ec0e822a-36e0-49eb-a365-19c28f2b507a">3,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibcf4b5a8d9ac4269b9a4b8890c7ae167_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtMTMtMS0xLTcyMTIz_bfe38673-d553-46b5-bb45-e1f02439dd1e">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HalioDx customer backlog</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28f8ef0b3354ef5abe5718fad617afd_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtMS0xLTEtNzIxMjM_f1fcbafb-13d5-46cf-9448-fba31e828ad6">6,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if28f8ef0b3354ef5abe5718fad617afd_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtMy0xLTEtNzIxMjM_32e623fd-9f96-45e2-840b-771cadfdc6a1">2,759</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28f8ef0b3354ef5abe5718fad617afd_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtNS0xLTEtNzIxMjM_1fdad9cb-a409-4562-b1db-ba2fb7d890f2">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17c0ca4207743efbafee0e3b75a8c67_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtNy0xLTEtNzIxMjM_201d47a8-5bd2-4642-ba2e-31091b067764">6,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia17c0ca4207743efbafee0e3b75a8c67_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtOS0xLTEtNzIxMjM_922e0bc2-0672-4127-b117-02beb69dfb33">2,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17c0ca4207743efbafee0e3b75a8c67_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtMTEtMS0xLTcyMTIz_11210323-0f05-4a62-8521-737912b84c5a">4,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac056f15377a4e1a939745868f857e1d_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtMTMtMS0xLTcyMTIz_797a7585-f9c7-498c-a412-d6a8bfb2e786">2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItMS0xLTEtNzIxMjM_7db42cfd-21dd-405b-93c3-f32137f61980">216,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItMy0xLTEtNzIxMjM_9944c58b-bea4-4980-aa07-3a050691727c">53,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItNS0xLTEtNzIxMjM_8e7b59e7-2ceb-4171-9f2f-f39556b63db4">162,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItNy0xLTEtNzIxMjM_f7b23112-f06c-48ba-9014-5e55203c484a">215,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItOS0xLTEtNzIxMjM_3130a2f3-9fed-4468-bac1-9234810ae192">47,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItMTEtMS0xLTcyMTIz_f4706e9f-819a-4e3e-affe-703ef5a35935">167,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItMTMtMS0xLTcyMTIz_3ec3a622-122d-40ac-bce0-66f6617c842b">8.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTMtMS0xLTEtNzIxMjM_09fdc90f-6115-4e9d-9e31-70608d61d284">7,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTMtNS0xLTEtNzIxMjM_13e7dcdb-6b5d-483c-b1f9-1941499d48d0">7,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTMtNy0xLTEtNzIxMjM_d9f5b9fa-1a03-49b5-9c97-e7cd27a99377">7,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTMtMTEtMS0xLTcyMTIz_22880b6b-6325-4307-9da8-f51d4df1be3e">7,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtMS0xLTEtNzIxMjM_841cda22-b869-420b-9949-e0762ef9c4cd">223,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtMy0xLTEtNzIxMjM_a8b7e8d8-6518-4a64-b640-b89cf7b4fe4f">53,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtNS0xLTEtNzIxMjM_aa8d5ca9-c4ef-4611-a132-0d1e3ba39779">170,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtNy0xLTEtNzIxMjM_aea29b87-ffad-41f7-9958-d879262389ed">222,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtOS0xLTEtNzIxMjM_0c68bd3e-9965-4cdc-8077-b6d572e1b5bc">47,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtMTEtMS0xLTcyMTIz_7d5ecb9e-a091-4ce0-b74c-a684bcd8a3d5">174,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the finite-lived intangible assets is recognized on a straight-line basis. Amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMTU2NA_1d628d4c-f29f-4537-893e-772a34e78df5">5.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMTU3MQ_00f98377-c845-4883-b0db-2d1b91a25256">5.5</ix:nonFraction>&#160;million was recognized for the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMjI4NQ_d1ea9271-8ddc-4bcc-8310-3478466bc901" continuedAt="i3f11943e40554649acc5000391e1ad9f" escape="true">The estimated future aggregate amortization expense as of March&#160;31, 2023 is as follows (in thousands of dollars):</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="i3f11943e40554649acc5000391e1ad9f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:86.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December&#160;31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 remainder of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfMS0xLTEtMS03MjEyMw_3f670298-e76e-4ca3-b68d-3df3ed27e181">16,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfMi0xLTEtMS03MjEyMw_ae62cd9b-fca0-451e-840f-68754828f595">21,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfMy0xLTEtMS03MjEyMw_54d017ed-6506-49d5-abb9-554747d37428">20,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfNC0xLTEtMS03MjEyMw_912f61db-a7b3-4889-b586-1e3d52accc7d">18,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfNS0xLTEtMS03MjEyMw_0fae8979-163a-4b20-bbfb-416f6d56aab2">17,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="vcyt:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfNi0xLTEtMS03MjEyMw_ae1229d7-3458-4676-9de0-d5c0a07e8fdc">69,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfNy0xLTEtMS03MjEyMw_fccfa553-9fd3-4e82-a89a-b38b81f52cfd">162,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplies and Inventory</span></div><div style="text-align:justify;text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, supplies and inventory consisted of $<ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-5" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNTQ5NzU1ODE2ODI0_5870a6a8-9415-49b4-9831-cad7750f2d0d">10.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-5" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNTQ5NzU1ODE2ODEw_c4b7df84-6e40-41bf-92e9-9bf53caa0da1">10.2</ix:nonFraction>&#160;million, respectively, of lab supplies and reagents consumed in the performance of testing services, and $<ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-5" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNTQ5NzU1ODE2ODI4_d79f51e6-0e9c-47e3-b83e-4838d3a4e568">3.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-5" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNTQ5NzU1ODE2ODE0_d597050d-ab7a-4141-a8dd-46bb391ef80d">4.1</ix:nonFraction>&#160;million, respectively, of inventory related to raw materials consumed in the contract manufacturing process, as well as finished and semi-finished components used in the assembly of diagnostic kits related to product sales.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><ix:continuation id="ic925c9bcb1cd43658cbe49296c9a1e14"><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="text-indent:6.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMjI4Ng_7e16da47-24f6-476b-b7e0-da3487902e88" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands of dollars):</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMS0xLTEtMS03MjEyMw_294e0ed5-628d-4366-9889-1c1dbcd39469">21,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMS0zLTEtMS03MjEyMw_32c0e7f9-70d2-4c21-8c59-62b9acff0ab6">30,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMi0xLTEtMS03MjEyMw_d5a2d252-b6ba-45d5-ae34-f1e540f74e70">8,688</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMi0zLTEtMS03MjEyMw_2b3e20d9-a7f1-44b6-9c22-dd898a282e92">7,137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMy0xLTEtMS03MjEyMw_f0b08e11-eb60-4529-8efe-7018c5f02e8d">30,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMy0zLTEtMS03MjEyMw_aaea4310-6ef2-44db-9a74-ce38600a38c1">37,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:6.75pt"><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_43"></div><div style="text-align:justify;text-indent:6.75pt"><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfNDkxNQ_219c695b-f45c-4c2f-a3d8-e68cdb93c861" continuedAt="i043fc2915d934aa298bf35bfd17d151c" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div style="text-indent:6.75pt"><span><br/></span></div><ix:continuation id="i043fc2915d934aa298bf35bfd17d151c" continuedAt="iea7bfd80d3e54445a7b9b5508e209736"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records certain of its financial assets and liabilities at fair value. The accounting guidance for fair value provides a framework for measuring fair value and clarifies the definition of fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level I: Inputs which include quoted prices in active markets for identical assets and liabilities;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level II: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The fair value of the Company&#8217;s financial assets includes money market funds and deposits for leases of the Company's facilities. Money market funds, included in cash and cash equivalents in the accompanying condensed consolidated balance sheets, were $<ix:nonFraction unitRef="usd" contextRef="i34f2f83e07404b9d85ed5e0e5c227d9a_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTcxOQ_979fcddc-2637-46d4-af67-6df2851dfca2">42.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i07f2d93ca49a414380853162fba3a86c_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTcyNg_25393448-caaf-4a74-a089-63799c260e17">131.2</ix:nonFraction> million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and are Level&#160;I assets as described above. The deposits for the leases, included in restricted cash, were $<ix:nonFraction unitRef="usd" contextRef="ia0afc28f37da46bb8ed8617d3e377f9d_I20230331" decimals="-5" name="us-gaap:SecurityDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTg2Ng_79f95626-ba30-4ea9-b7f6-f2274e00f306"><ix:nonFraction unitRef="usd" contextRef="i3e25dbe0d25644d0a01543012862a8ba_I20221231" decimals="-5" name="us-gaap:SecurityDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTg2Ng_f825ee1e-039a-4547-ba15-ec9bca5fe659">0.7</ix:nonFraction></ix:nonFraction> million as of both March&#160;31, 2023 and December&#160;31, 2022 and are a Level I assets as described above. There were no transfers between Levels 1, 2 or 3 for the three months ended March 31, 2023 and 2022.</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2019, the Company acquired from NanoString the exclusive global diagnostics license to the nCounter Analysis System, the Prosigna breast cancer prognostic gene signature assay, and the LymphMark lymphoma subtyping assay. Pursuant to the terms of the agreement, Veracyte paid NanoString $<ix:nonFraction unitRef="usd" contextRef="id21ec14e64244f3c9d1c3685ce9e8719_D20191203-20191203" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjMxNg_ee888c44-796a-4734-b54b-e2947e2a8066">40.0</ix:nonFraction> million in cash and $<ix:nonFraction unitRef="usd" contextRef="ie03a5b408d42420d880fd6b44b057d7b_D20191203-20191203" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjMzMQ_2b7d6bc2-8e86-4d4a-8ff8-d5c99b77f4d7">10.0</ix:nonFraction> million in Veracyte common stock, and may pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="id21ec14e64244f3c9d1c3685ce9e8719_D20191203-20191203" decimals="-5" name="vcyt:BusinessCombinationContingentConsiderationCashToBePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjM5Mg_439fe7bb-8ea2-4818-a7ea-e51aec0e5d57">10.0</ix:nonFraction> million in cash, contingent upon first achievement or occurrence, by or on behalf of Veracyte, of the commercial launch of the first, second and third diagnostic tests for use on the nCounter multiplex analysis system. This contingency was valued at $<ix:nonFraction unitRef="usd" contextRef="ia65218b5801a4550bb42420dd8cece53_I20191203" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjYzNw_9fd3170d-224a-4be6-b3e3-66258022526c">6.1</ix:nonFraction>&#160;million as of the acquisition date and is remeasured to fair value at each reporting date until the contingent consideration is settled. As of March&#160;31, 2023 and December&#160;31, 2022, this contingency was remeasured to $<ix:nonFraction unitRef="usd" contextRef="i3c9422a55af4419da61a04b81e81fff6_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjgyMQ_82e72afc-d171-45af-81f7-6386cf00e10b">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i155fac1703104d38b903faacc0c23041_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjgyOA_f140c827-d950-441b-8348-148f3085f3ce">8.6</ix:nonFraction> million, respectively, with the corresponding changes included in general and administrative expense in the Company's condensed consolidated statements of operations. For the three months ended March 31, 2023, a reversal of expense of $<ix:nonFraction unitRef="usd" contextRef="i06680ff3bcf24e32836ef9479192a82f_D20230101-20230331" decimals="-5" sign="-" name="vcyt:BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMzAyMQ_b377770a-6344-4d9d-bc42-47e609dde6e5">0.5</ix:nonFraction> million was recorded in general and administrative expense for the changes in carrying value and, for the three months ended March 31, 2022, <ix:nonFraction unitRef="usd" contextRef="i339749b1f05542c299fce2f9a4340ccf_D20220101-20220331" decimals="INF" name="vcyt:BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMzAyOA_4dfe0be2-7f67-4633-a4d3-ec02ba330880">no</ix:nonFraction> expense was recorded. As of March&#160;31, 2023, the achievement of one of the milestones is forecasted to occur within the next 12 months. As a result, $<ix:nonFraction unitRef="usd" contextRef="i3c9422a55af4419da61a04b81e81fff6_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMzM0NQ_20a9945c-37f3-44c3-9fa2-0954f6cd04af">3.3</ix:nonFraction> million of the contingent consideration is included in short term liabilities at March&#160;31, 2023. The fair value of the contingent consideration includes inputs that are not observable in the market and thus represents a Level III financial liability. The estimation of the fair value of the contingent consideration is based on the present value of the expected payments calculated by assessing the likelihood of when the related milestones would be achieved and estimating the Company's borrowing rate. These estimates form the basis for making judgments about the carrying value of the contingent consideration that are not readily apparent from other sources. Changes to the forecasts for the achievement of the milestones and the borrowing rate can significantly affect the estimated fair value of the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE, INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="iea7bfd80d3e54445a7b9b5508e209736"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingent consideration. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfNDkxNA_ea7d4a06-135e-4aba-8627-6a2fc5c7d0c4" continuedAt="ibaffd0ec838540db9c547bee7125d5df" escape="true">As of March&#160;31, 2023 and December&#160;31, 2022, the Company calculated the estimated fair value of the milestones using the following significant unobservable inputs:</ix:nonNumeric></span></div><ix:continuation id="ibaffd0ec838540db9c547bee7125d5df"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value or Range (Weighted-Average)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6732d99af20b4ace884710631c821dc1_I20230331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMi0yLTEtMS03MjEyMw_814191c9-96bb-4b9b-b3f3-2bef6a2f7b9a">7.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56eb27109dad47bc902852a7e617ff8a_I20221231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMi00LTEtMS03MjEyMw_32836233-82d5-422a-8dd7-a5616ef179cb">8.3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f89531611514010b1fddd2d6b74728c_I20230331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy0yLTEtMS03MjEyMy90ZXh0cmVnaW9uOmFjM2M0ZDRmMDgyMDRhMTZiMGM1Nzg0ZjAwNjAzMDM1XzQ_dd4474ba-5f58-4745-a050-cb9bfcaa1fef">80</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ibe50f34924204d0f9cb24feac29d3c92_I20230331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy0yLTEtMS03MjEyMy90ZXh0cmVnaW9uOmFjM2M0ZDRmMDgyMDRhMTZiMGM1Nzg0ZjAwNjAzMDM1Xzk_e39db3f1-c404-432c-ad9c-d2b301b46c40">100</ix:nonFraction>% (<ix:nonFraction unitRef="number" contextRef="i5b2066a3df0741c0a292648be37edb62_I20230331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy0yLTEtMS03MjEyMy90ZXh0cmVnaW9uOmFjM2M0ZDRmMDgyMDRhMTZiMGM1Nzg0ZjAwNjAzMDM1XzEz_af53b722-56ca-4490-92bd-5f891a4d30dc">92</ix:nonFraction>%)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4ebc4a8eea343589c8c8c3823833416_I20221231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy00LTEtMS03MjEyMy90ZXh0cmVnaW9uOjNiMGZlYzljMDRmZDQyMTJhNDYxODM4Y2JmMDkxMzRhXzQ_0102960c-9b86-417c-85e1-e61b27a93063">80</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i56240dd72d974100bdcfa48ff0885b32_I20221231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy00LTEtMS03MjEyMy90ZXh0cmVnaW9uOjNiMGZlYzljMDRmZDQyMTJhNDYxODM4Y2JmMDkxMzRhXzk_1c3f8858-269a-4b9a-b0c2-cc476b041fef">100</ix:nonFraction>% (<ix:nonFraction unitRef="number" contextRef="i3d7ee7173c0f4858a01e1d1da5a312b6_I20221231" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy00LTEtMS03MjEyMy90ZXh0cmVnaW9uOjNiMGZlYzljMDRmZDQyMTJhNDYxODM4Y2JmMDkxMzRhXzEz_c7247033-dc99-4dad-86df-147eb1e5f205">94</ix:nonFraction>%)</span></div></td></tr></table></div></ix:continuation><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments Held-to-Maturity</span></div><div style="text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's short-term investments consist of U.S. treasury securities with maturities at the time of purchase that were between 90 days and one year. The Company classifies these investments as held-to-maturity debt securities, which are reported at amortized cost, and are Level&#160;I assets as described above. As of March&#160;31, 2023, the Company held <ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODYzNQ_d4650f9b-6b44-4559-90d3-fdba4b769328">no</ix:nonFraction> short-term investments and, as of December&#160;31, 2022, short-term investments comprised U.S. treasury bills recorded at amortized cost of $<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfNDc4Mw_e94c6afc-69c3-4b3e-8e70-4e4f6646d5a1">24.6</ix:nonFraction> million with a fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-5" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfNDgyNA_aca50851-4271-4e86-86f8-e0679403a960">24.6</ix:nonFraction> million. As of December&#160;31, 2022, gross unrealized losses on short-term investments were insignificant. As part of its banking partner diversification efforts, the Company sold $<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-5" name="us-gaap:HeldtomaturitySecuritiesSoldAtPar" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODU2NA_3bb24c1a-b498-47c7-b2e5-4523100e2c18">40.0</ix:nonFraction>&#160;million U.S. treasury bills with an amortized cost of $<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-5" name="us-gaap:DebtSecuritiesHeldToMaturitySoldAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODU3OQ_67f5d328-867b-4485-abcb-3d6d18b47526">39.8</ix:nonFraction>&#160;million for $<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODU5NA_b0ee12b8-309b-4b20-bb13-c3b3bc6239b2">39.8</ix:nonFraction>&#160;million and realized a gross gain of $<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODYwOQ_6350eb55-a52a-473a-8cb4-986b0f2d2a8e">13</ix:nonFraction>&#160;thousand during the three months ended March 31, 2023. <ix:nonFraction unitRef="usd" contextRef="i81d34a4128834b43aa56aba5f1ba758a_D20220101-20221231" decimals="INF" name="us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODYyNg_43b7e825-ecfc-45f2-a226-69e9dbbc7c39">No</ix:nonFraction> realized gains or losses on short-term investments were recognized in 2022.</span></div></ix:continuation><div style="text-indent:6.75pt"><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc0OA_cbb69d92-82f9-496b-9c58-f62adaefa585" continuedAt="i77da36b1348548bf9f9d6339f786d0f2" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i77da36b1348548bf9f9d6339f786d0f2" continuedAt="i89cb310292474993acf283884a79a841"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office and laboratory facilities in South San Francisco and San Diego, California; Austin, Texas; Marseille, France; and Richmond, Virginia, and leases certain equipment under various non-cancelable lease agreements. The lease terms extend to October 2030 and contain extension of lease terms and expansion options. The leases have a weighted average remaining lease term of <ix:nonNumeric contextRef="ib3cca4fb364f4aa1a78fc4dbfe0f75ee_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfNDUz_9950179b-89d0-4e6f-ab50-66741a818b7a">3.6</ix:nonNumeric> years as of March&#160;31, 2023. The Company had deposits of $<ix:nonFraction unitRef="usd" contextRef="ia0afc28f37da46bb8ed8617d3e377f9d_I20230331" decimals="-5" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfNDk0_79f95626-ba30-4ea9-b7f6-f2274e00f306"><ix:nonFraction unitRef="usd" contextRef="i3e25dbe0d25644d0a01543012862a8ba_I20221231" decimals="-5" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfNDk0_f825ee1e-039a-4547-ba15-ec9bca5fe659">0.7</ix:nonFraction></ix:nonFraction>&#160;million included in long-term assets as of both March&#160;31, 2023 and December&#160;31, 2022 restricted from withdrawal and held by banks in the form of collateral for irrevocable standby letters of credit held as security for the leases.</span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its operating lease liabilities using payments through their current expiration dates and a weighted average discount rate of <ix:nonFraction unitRef="number" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfODQ0_1efde12b-ab39-4c82-8563-3076e1cdc2ba">6.4</ix:nonFraction>% based on the rate that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments in a similar economic environment. Operating lease liabilities along with the associated right-of-use assets are disclosed in the accompanying condensed consolidated balance sheets.  After the adoption of ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 842, the Company classified its deferred rent for tenant improvements with its operating lease right-of-use assets on the consolidated balance sheets.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VERACYTE, INC.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><ix:continuation id="i89cb310292474993acf283884a79a841"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc0OQ_422f1ef7-a2ec-4670-ba4b-93dbe34be12e" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable operating leases as of March&#160;31, 2023 are as follows (in thousands of dollars):</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfMS0xLTEtMS03MjEyMw_1da39706-fbc4-4bd4-a94b-13dbe74d7ff1">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfMi0xLTEtMS03MjEyMw_6614a22c-fb44-4529-b0e3-d66870cc1303">4,449</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfMy0xLTEtMS03MjEyMw_c9170777-09fe-4288-bd19-3d3f1c5a49b8">4,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfNC0xLTEtMS03MjEyMw_93012c6c-1d90-465e-a2ec-c518d64bf2f5">1,405</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfNS0xLTEtMS03MjEyMw_707fce1f-5c8c-4dce-ade7-88136507e7ad">699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="vcyt:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfNi0xLTEtMS03MjEyMw_0d1dd97c-40d6-4c11-a40e-5ec861f4bd96">885</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfNy0xLTEtMS03MjEyMw_28ecda9e-1b5d-4d41-b9cf-b6d076ba9515">15,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfOC0xLTEtMS03MjEyMw_318af399-6b3c-4588-975a-53471037f43b">1,695</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfOS0xLTEtMS03MjEyMw_d16c86ca-d8a2-4b03-b62e-537e2571e185">13,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: short-term lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfMTAtMS0xLTEtNzIxMjM_4a2626e3-3288-4b6e-a84b-747a8e75520d">4,076</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfMTEtMS0xLTEtNzIxMjM_b6cdcb2c-d7bc-49c7-b516-fae7cfcbeacc">9,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes operating lease expense on a straight-line basis over the non-cancelable lease period. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MA_337f08c0-be87-42bf-9816-9668ed79eec1" continuedAt="id4fe0c57ae96445981a0ac1b8e92cf48" escape="true">The following table summarizes operating lease expense and cash paid for amounts included in the measurement of lease liabilities (in thousands of dollars): </ix:nonNumeric></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><ix:continuation id="id4fe0c57ae96445981a0ac1b8e92cf48"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"><tr><td style="width:1.0%"></td><td style="width:64.086%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjA5ZDAxNGY1YzQ2NjQwMTJhZDAxNGI3YTdhZDU2ZTA2L3RhYmxlcmFuZ2U6MDlkMDE0ZjVjNDY2NDAxMmFkMDE0YjdhN2FkNTZlMDZfMi01LTEtMS03MjEyMw_293a3d37-9ac8-4699-bbf5-4dac8c371e26">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjA5ZDAxNGY1YzQ2NjQwMTJhZDAxNGI3YTdhZDU2ZTA2L3RhYmxlcmFuZ2U6MDlkMDE0ZjVjNDY2NDAxMmFkMDE0YjdhN2FkNTZlMDZfMi03LTEtMS03MjEyMw_1f8b66a8-5516-4a6e-9654-39279b7f5e1e">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjA5ZDAxNGY1YzQ2NjQwMTJhZDAxNGI3YTdhZDU2ZTA2L3RhYmxlcmFuZ2U6MDlkMDE0ZjVjNDY2NDAxMmFkMDE0YjdhN2FkNTZlMDZfMy01LTEtMS03MjEyMw_ab6db79e-ec93-4aef-b82d-b75a2b3b6af5">1,177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjA5ZDAxNGY1YzQ2NjQwMTJhZDAxNGI3YTdhZDU2ZTA2L3RhYmxlcmFuZ2U6MDlkMDE0ZjVjNDY2NDAxMmFkMDE0YjdhN2FkNTZlMDZfMy03LTEtMS03MjEyMw_f92e6c71-2a5b-40f6-af47-10301989e4dc">1,068</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has leased laboratory equipment under various financing leases. The total right-of-use assets and total financing lease liabilities for these financing leases were $<ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjE4OA_97ab0153-ed5a-4b9d-ac2f-7ddfa3b83578">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="-5" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjE5NQ_667fbf76-744e-46fe-be22-d4cc58e3aa57">0.2</ix:nonFraction>&#160;million, respectively, as of March&#160;31, 2023, and are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MQ_8dcd2a74-c451-48ee-8234-99b6286ac891"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MQ_b8e18883-b7ca-498a-8118-1cbdf8c548c4">property, plant and equipment, net</span></span> and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1Mg_135ebc69-b606-42ce-b152-da2f2dbc668a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1Mg_7fac536f-70a2-4239-a5bf-1ba0e01d202a">other liabilities</span></span> in the accompanying condensed consolidated balance sheets. As of December&#160;31, 2022, the total right-of-use assets and total financing lease liabilities for these financing leases were $<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjQ2Mg_d73d5fd9-0aee-4796-80ac-811abe743328">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjQ2OQ_8f6e4d85-dae8-44a7-b704-6e540ad2b728">0.4</ix:nonFraction>&#160;million, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s wholly-owned foreign subsidiary has entered into an arrangement under which it expects to sign a lease agreement for facilities which will be constructed in Marseille, France. The lease will commence upon completion of the construction of the office building which the Company currently expects to occur in the third quarter of 2023 at which time the Company will record a lease liability and a corresponding ROU asset. The initial term of the lease will be <ix:nonNumeric contextRef="i38b169efb35741c0a4e5cbe287a00d95_I20230331" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjk2Mg_5151b7f6-f0ca-4038-928e-9007e323561f">twelve years</ix:nonNumeric> with annual rent of approximately $<ix:nonFraction unitRef="usd" contextRef="i38b169efb35741c0a4e5cbe287a00d95_I20230331" decimals="-5" name="vcyt:LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjk5OQ_29cfb0b1-4414-4f41-85c0-1c774683e653">1.3</ix:nonFraction>&#160;million, which is subject to change based on final construction.</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no litigation pending that could have, either individually or in the aggregate, a material impact on the Company's consolidated financial statements.</span></div></ix:continuation><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_52"></div><div><span><br/></span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RleHRyZWdpb246MmUzNjVlZDQ0M2EwNGQ4MmExZjNkOWNiOTQzY2I5ZmVfMTIy_db626b5a-9e11-4627-97f3-f12fb6fd6e44" continuedAt="ibd1d7d2b8273467fba8d86be6215407f" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="ibd1d7d2b8273467fba8d86be6215407f"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RleHRyZWdpb246MmUzNjVlZDQ0M2EwNGQ4MmExZjNkOWNiOTQzY2I5ZmVfMTIz_c058c70a-f5d8-4fad-95f3-5a2f7b19a940" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows:</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock units issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd87d5a6accd4b1fbbdd377429adeb05_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMS0xLTEtMS03MjEyMw_c2d130da-0246-4b40-aa96-fb04d5e6da60">7,054,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41c953ff703f4c40b8196a40233b0bea_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMS0zLTEtMS03MjEyMw_eab06743-65cb-42d3-86b1-68df90ab9fbf">5,881,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock units available for grant under stock option plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd87d5a6accd4b1fbbdd377429adeb05_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMi0xLTEtMS03MjEyMw_943900e5-9690-49bc-a076-1947f3f599f5">5,322,628</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41c953ff703f4c40b8196a40233b0bea_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMi0zLTEtMS03MjEyMw_e719dcb4-2eb1-4a58-b5e6-cb895ad54357">5,591,977</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock available for the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i589fe7123b7241eea985d689b319d8bb_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMy0xLTEtMS03MjEyMw_94f4331e-4171-4458-9cf5-8ca8e4e64e77">1,242,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf67fe5c4e9c4625bf91b35cf11db759_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMy0zLTEtMS03MjEyMw_4dd70600-276d-4b3c-a677-b2e5d1c61e5c">1,335,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i228462769a464129ba617b5c0e672ec2_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfNC0xLTEtMS03MjEyMw_1b570690-370c-45e0-851d-698fab0f0226">13,620,056</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfNC0zLTEtMS03MjEyMw_45d00b7d-5093-4068-800b-dc2be1925ae7">12,809,236</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RleHRyZWdpb246MjBjODczMGRkMGUyNDhlY2IyYWFlZDkyNTY5MmJlNmZfMTI0_db96c4bc-257a-43be-a282-388579425f81" continuedAt="i64fb9de592104256a828e45ed56cec66" escape="true">Components of Other Income</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i64fb9de592104256a828e45ed56cec66"><ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RleHRyZWdpb246MjBjODczMGRkMGUyNDhlY2IyYWFlZDkyNTY5MmJlNmZfMTI1_d4b02c4d-9132-456a-9316-7b0e87d2c0a4" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Other income, net consists of the following (in thousands of dollars):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">French research tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="vcyt:OtherNonoperatingIncomeExpenseForeignTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfMi01LTEtMS03MjEyMw_2b722e7d-58e8-4684-ac75-d6c59ec89f3e">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="vcyt:OtherNonoperatingIncomeExpenseForeignTaxCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfMi03LTEtMS03MjEyMw_394e4b5a-0625-40b7-ad99-142c73839e62">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="vcyt:OtherNonoperatingIncomeExpenseInterestIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfMy01LTEtMS03MjEyMw_557ac925-49bc-43d7-bdbf-307130e1fc27">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="vcyt:OtherNonoperatingIncomeExpenseInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfMy03LTEtMS03MjEyMw_731fbc68-88d5-4eaf-b629-3fe231f49f3e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="vcyt:OtherNonoperatingIncomeExpenseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNC01LTEtMS03MjEyMw_984c17e6-b7a8-4ff9-b6c4-c680ebb44635">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="vcyt:OtherNonoperatingIncomeExpenseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNC03LTEtMS03MjEyMw_e2fadaf6-cb21-431b-981f-e8c4bad363e3">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on currency revaluation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="vcyt:OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNS01LTEtMS03MjEyMw_9bde3649-556b-49d0-87fd-0399db26c33a">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" sign="-" name="vcyt:OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNS03LTEtMS03MjEyMw_5c5d9546-66a3-4d80-889b-8104f4b0c8df">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" sign="-" name="vcyt:OtherNonoperatingIncomeExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNi01LTEtMS03MjEyMw_fc8915a6-22b5-40df-85df-f35d61634e7e">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="vcyt:OtherNonoperatingIncomeExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNi03LTEtMS03MjEyMw_c33c4617-0cab-4c04-a625-9f518a735fee">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNy01LTEtMS03MjEyMw_d6fa45b3-0a02-4970-9865-99abfdbca988">2,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNy03LTEtMS03MjEyMw_873f12e9-d13e-426c-9d5c-c2f0775364c5">784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y182MS9mcmFnOjc2MmRkM2VlYjk4OTQ4ZGViODZlMGI0YjNjZWE0N2FlL3RleHRyZWdpb246NzYyZGQzZWViOTg5NDhkZWI4NmUwYjRiM2NlYTQ3YWVfODYy_2591558c-19c9-4181-9f77-ca39a5143193" continuedAt="i010d92fb5b4346aaa1d33283be682d6b" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i010d92fb5b4346aaa1d33283be682d6b"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded <ix:nonFraction unitRef="usd" contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y182MS9mcmFnOjc2MmRkM2VlYjk4OTQ4ZGViODZlMGI0YjNjZWE0N2FlL3RleHRyZWdpb246NzYyZGQzZWViOTg5NDhkZWI4NmUwYjRiM2NlYTQ3YWVfMTY0OTI2NzQ0NDAyOQ_1ff8a178-d544-4be1-b48a-f87f037fadd4">no</ix:nonFraction> income tax expense for the three months ended March 31, 2023 and an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331" decimals="-2" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y182MS9mcmFnOjc2MmRkM2VlYjk4OTQ4ZGViODZlMGI0YjNjZWE0N2FlL3RleHRyZWdpb246NzYyZGQzZWViOTg5NDhkZWI4NmUwYjRiM2NlYTQ3YWVfNTQ5NzU1ODE1OTAw_808fbac0-7fa5-4522-80fe-36539b196495">3.0</ix:nonFraction>&#160;thousand for the three months ended March 31, 2022. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022 was signed into law August 16, 2022, and includes significant legislation addressing taxes, inflation, climate change and renewable energy incentives, and healthcare.  Key tax provisions include a 15% corporate minimum tax, clean energy incentives, and a 1% excise tax on stock buybacks. The Company does not expect the provisions of such legislation to have any impact on the effective tax rate of the Company but will continue to evaluate the tax effects should any provisions become applicable to the Company.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As discussed in the section titled &#8220;Special Note Regarding Forward Looking Statements,&#8221; the following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth in the section titled &#8220;Risk Factors&#8221; under Part II, Item 1A.  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When used in this report, all references to "Veracyte," the "company," "we," "our" and "us" refer to Veracyte, Inc., together with its consolidated subsidiaries, unless otherwise noted. </span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veracyte, Afirma, Percepta, Envisia, Prosigna, Lymphmark, Decipher, GRID, HalioDx, Brightplex, Immunosign, and the Veracyte logo are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc., or NanoString, in the U.S. and selected countries and used by Veracyte under license. Immunoscore is the registered trademark of Institut National de la Sant&#233; et de la Recherche M&#233;dicale, or Inserm, in the U.S. and selected countries and used by Veracyte under license.</span></div><div style="text-align:justify;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and treatment decisions, helping patients avoid unnecessary procedures and interventions, and speed time to appropriate treatment, thereby improving outcomes for patients all over the world. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently offer tests in thyroid cancer (Afirma); prostate cancer (Decipher Prostate); breast cancer (Prosigna); interstitial lung diseases (Envisia); and bladder cancer (Decipher Bladder). Our Percepta Nasal Swab test is being run in our CLIA lab in support of clinical studies and our tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We serve global markets with two complementary models. In the United States, we offer LDTs through our centralized CLIA certified laboratories in South San Francisco and San Diego, California, supported by our cytopathology expertise in Austin, Texas. Additionally, primarily outside of the United States, we provide tests to patients through distribution to laboratories and hospitals that can perform the tests locally. Today, this includes our Prosigna test, and in the future, we intend to offer the Envisia, Decipher Prostate and Percepta Nasal Swab tests as in IVD tests that run on the nCounter Analysis System. We believe our broad menu of advanced diagnostic tests, combined with our ability to deliver them globally, uniquely positions us in the diagnostics industry. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_70"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 and Macroeconomic Factors</span></div><div style="text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the COVID-19 outbreak, including its numerous variants, impacted our total test volumes primarily during 2020 and 2021. Our customers, third-party contract manufacturers, carriers, suppliers and collaboration partners have been affected by the closure of hospitals, doctors' offices, manufacturing sites, or country borders, among other measures put in place around the world. Layoffs, furloughs and unplanned loss of staff in the medical industry and otherwise during the pandemic have had, and will continue to have, negative impacts on the demand for and supply of medical care and diagnostic tests, which affects the frequency with which tests are ordered, and the ability of doctors and hospitals to administer such tests. Further the inability to travel and conduct face-to-face meetings can also make it more difficult to expand utilization of our products into new geographies and to drive awareness of our products. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Decipher Prostate test has been least impacted by the pandemic because our customers are mostly community-based urology practices, which generally remained more accessible to patients and our sales reps. Our Afirma thyroid cancer test was impacted by COVID-19 in 2020 and portions of 2021 as a majority of our samples come from large institutions which are less accessible to patients and our reps. We believe our pulmonology business was the most impacted since the bronchoscopy procedures used to collect samples for our Envisia test are considered elective procedures and are performed in hospital settings, which have been more restrictive. Further these tests are ordered by pulmonologists who may have been largely preoccupied with caring for COVID-19 patients. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, ongoing interest rate increases and inflation in the U.S. and other markets globally and turmoil in the global banking and finance system may heighten the risk of an economic downturn or recession and volatility and dislocation in the capital or credit markets in the U.S. or globally. Moreover, the continued strengthening of the U.S. dollar compared to other currencies, has impacted and may continue to impact our results of operations. We intend to continue to monitor macroeconomic conditions closely and may determine to take certain financial or operational actions in response to such conditions as appropriate. Finally, the military conflict between Russia and Ukraine has increased the risk of disruptions to energy supplies in Europe, which may impact our ability to manufacture tests from our facility in Marseille, France.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent of the impact of COVID-19 and other macroeconomic factors on our future liquidity and operational performance will depend on certain developments, including the deployment and long-term efficacy of vaccines; the duration and spread of the outbreak particularly in the form of more transmissible variants; the impact on our customers' operations; the impact to our sales and renewal cycles; changes in central bank policies and interest rates; rates of inflation; and changes in foreign currency exchange rates. See Risk Factors for further discussion. </span></div><div style="text-indent:6.75pt"><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Our Performance</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reported Total Test Volume</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance depends on the number of tests that we perform and report as completed in our CLIA-certified laboratories and Prosigna tests processed on the nCounter Analysis System. Factors impacting the number of tests that we report as completed include, but are not limited to:</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of COVID-19 on patients seeking to have tests performed;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of hospital staff to perform and support procedures needed to collect samples for our tests; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of samples that we receive that meet the medical indication for each test performed;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the quantity and quality of the sample received;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of the necessary documentation, such as physician order and patient consent, required to perform, bill and collect for our tests;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient's ability to pay or provide necessary insurance coverage for the tests performed;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time it takes us to perform our tests and report the results, including as a result of supply chain challenges;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality inherent in our business, such as the impact of work-days per period, timing of industry conferences and timing of when patient deductibles are exceeded, which also impacts the reimbursement we receive from insurers; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain prior authorization or meet other requirements instituted by payers, benefit managers, or regulators necessary to be paid for our tests.</span></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continued Adoption of and Reimbursement for our Products</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue growth depends on our ability to secure coverage decisions, achieve broader reimbursement at increased levels from third-party payers, expand our base of prescribing physicians and increase our penetration in existing accounts. Because some payers consider our products experimental and investigational, we may not receive payment for tests and payments we receive may not be at acceptable levels. We expect our revenue growth to increase if more payers make a positive coverage decision and as payers enter into contracts with us, which should enhance our revenue and cash collections. Our sales teams are aligned under our general manager-based structure to focus on specific products and global markets. If we are unable to expand the base of prescribing physicians and penetration within these accounts at an acceptable rate, or if we are not able to execute our strategy for increasing reimbursement and associated collections, we may not be able to effectively increase our revenue. We expect to continue to see pressure from payers to limit the utilization of tests, generally, and we believe more payers are deploying cost containment tactics, such as pre-authorization, reduction of the payer portion of reimbursement and employing laboratory benefit managers to reduce utilization rates. Revenue growth also depends on our ability to secure reimbursement from government payers at a reimbursement rate that is consistent with past reimbursement rates.</span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">How We Recognize Revenue</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with the provisions of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. &#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Testing Revenue</span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bill for testing services at the time of test completion as defined by the delivery of test results. We recognize revenue based on estimates of the amount that will ultimately be realized. In determining the amount to accrue for a delivered test, we consider factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and us, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management. Actual results could differ from those estimates and assumptions.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, cash we receive is collected within 12&#160;months of the date the test is billed. We cannot provide any assurance as to when, if ever, or to what extent any of these amounts will be collected. Notwithstanding our efforts to obtain payment for these tests, payers may deny our claims, in whole or in part, and we may never receive payment for these tests.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bill list price regardless of contract rate, but only recognize revenue from amounts that we estimate are collectible and meet our revenue recognition criteria.&#160;Revenue may not be equal to the billed amount due to a number of factors that we consider when determining revenue accrual rates, including differences in reimbursement rates, the amounts of patient co-payments and co-insurance, the existence of secondary payers, claims denials and the amount we expect to ultimately collect. Finally, when we increase our list price, it will increase the cumulative amounts billed but may not positively impact accrued revenue. In addition, payer contracts generally include the right of offset and payers may offset payments prior to resolving disputes over tests performed.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we determine accrual rates by calculating an average of reimbursement from all payers for tests performed over a four-quarter period as it reduces the effects of temporary volatility and seasonality. The periods selected to determine accrual rates typically are at least six months old because it takes a significant period of time to collect from some payers. We may also determine accrual rates based on other factors such as coverage decisions, contracts, or more recent reimbursement data as appropriate. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average test reimbursement rates will change over time due to a number of factors, including medical coverage decisions by payers, the effects of contracts signed with payers, changes in allowed amounts by payers, our ability to successfully win appeals for payment, and our ability to collect cash payments from third-party payers and individual patients. Historical average reimbursement is not necessarily indicative of future average reimbursement. </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur expense for tests in the period in which the test is conducted and recognize revenue for tests in the period in which our revenue recognition criteria are met.</span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenue</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products consist of the Prosigna breast cancer assay, the nCounter Analysis System and related diagnostic kits. We recognize product revenue when control of the promised goods is transferred to our customers, in an amount that reflects the consideration expected to be received in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer, either on its own or together with other resources that are readily available to the customer, and is separately identified in the contract. Performance obligations are considered satisfied once we have transferred control of a product to the customer, meaning the customer has the ability to use and obtain the benefit of the product. We recognize product revenue for satisfied performance obligations only when there are no uncertainties regarding payment terms or transfer of control. Shipping and handling costs incurred for product shipments are charged to our customers and included in product revenue. Revenue is presented net of the taxes that are collected from customers and remitted to governmental authorities.</span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biopharmaceutical and Other Revenue</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into arrangements to license or provide access to our assets or services, including testing services, clinical services, research and development, contract manufacturing and development, as well as other services. Such arrangements may require us to deliver various rights, data, services, manufactured diagnostic test kits, access and/or testing services to partner biopharmaceutical companies. One such arrangement is a collaborative arrangement that falls under the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or ASC 808. The underlying terms of these arrangements generally provide for consideration paid to us in the form of nonrefundable fees; payments on delivery of data, test results or manufactured products; costs of service plus margin; performance milestone payments; expense reimbursements and possibly royalty and/or other payments.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales of data or other services to our customers are recognized in accordance with ASC 606 and are classified under biopharmaceutical and other revenue. Milestone payments which fall under the scope of ASC 808, are recognized in the same manner as milestone payments from customers and are considered to be collaboration revenue. Payments received that are not related to sales or services to a customer or collaboration revenue are recorded as offsets against research and development expense or cost of biopharmaceutical and other revenue in our consolidated statements of operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one good or service delivered to a customer, each good or service is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if the selling price on a stand-alone basis is not available.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred which may be at a point in time or over time. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, we utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenue generated from royalties or profit sharing as the underlying sales occur.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Timing of Our Research and Development Expenses</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deploy state-of-the-art and costly genomic technologies in our biomarker discovery experiments, and our spending on these technologies may vary substantially from quarter to quarter. We also spend a significant amount on activities to secure clinical trial results in support of our testing and product development portfolio and on-market tests, as well as clinical validation and utilization studies. The timing of these research and development activities is difficult to predict, as is the timing of clinical trial enrollments and sample acquisitions. If a substantial number of clinical samples are acquired in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the&#160;timing of these expenses can affect our financial results. We conduct clinical studies to validate our new products, as well as on-going clinical studies to further the published evidence to support our commercialized tests. As these studies are initiated, start-up costs for each site can be significant and concentrated in a specific quarter. Spending on research and development, for both experiments and studies, may vary significantly by quarter depending on the timing of these various expenses.</span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March&#160;31, 2023, we had derived most of our revenue from the sale of Decipher and Afirma tests, delivered primarily to physicians in the United States. We generally invoice third-party payers upon delivery of a patient report to the prescribing physician. As such, we take the assignment of benefits and the risk of cash collection from the third-party payer and individual patients. Third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"></td><td style="width:55.467%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:20.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UnitedHealthcare</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For tests performed, we recognize the related revenue upon delivery of a patient report to the prescribing physician based on the amount that we expect to ultimately receive. In determining the amount to accrue for a delivered test, we consider factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and us, payment as a percentage of agreed upon reimbursement rate (if applicable), amount paid per test and any current development or changes that could impact reimbursement. Upon ultimate collection, the amount received is compared to previous estimates and the amount accrued is adjusted accordingly. Our ability to increase our revenue will depend on our ability to penetrate the market, obtain positive coverage policies from additional third-party payers, obtain reimbursement and/or enter into contracts with additional third-party payers for our current and new tests, and increase reimbursement rates for tests performed. Finally, should the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgments underlying our estimated reimbursement change, our accrued revenue and financial results could be negatively impacted in future periods.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Testing Revenue</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our cost of testing revenue are laboratory expenses, sample collection kit costs, sample collection expenses, compensation expense, license fees and royalties, depreciation, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are recorded as the test is processed regardless of whether and when revenue is recognized with respect to that test. As a result, our cost of testing revenue as a percentage of testing revenue may vary significantly from period to period because we may not recognize all revenue in the period in which the associated costs are incurred. We expect cost of testing revenue in absolute dollars to increase as the number of tests we perform increases. However, we expect that the cost per test will decrease over time due to leveraging fixed costs, efficiencies we may gain as test volume increases and from automation, process efficiencies and other cost reductions. As we introduce new tests, initially our cost of testing revenue will be high as we expect to run suboptimal batch sizes, run quality control batches, test batches, registry samples and generally incur costs that may suppress or reduce gross margins. This will disproportionately increase our aggregate cost of testing revenue until we achieve efficiencies in processing these new tests.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of product revenue consists primarily of costs of purchasing instruments and diagnostic kits&#160;from third-party contract manufacturers, installation, warranty, service and packaging and delivery costs. In addition, cost of product revenue includes royalty costs for licensed technologies included in our products and labor expenses. As our Prosigna test kits are sold in various configurations with different number of tests, our product cost per test will vary based on the specific kit configuration purchased by customers.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Biopharmaceutical and Other Revenue</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of biopharmaceutical and other revenue are the costs of performing activities under arrangements that require us to perform research and development, commercialization, contract manufacturing and development, and contract testing services on behalf of a customer. This cost is mainly composed of compensation expense, laboratory supplies and pass-through costs.</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include expenses incurred to develop our technology, collect clinical samples and conduct clinical studies to develop and support our products and pipeline. These expenses consist of compensation expenses, direct research and development expenses such as laboratory supplies and costs associated with setting up and conducting clinical studies at domestic and international sites, professional fees, depreciation and amortization, other miscellaneous expenses and allocation of facility and information technology expenses. We expense all research and development costs in the periods in which they are incurred. We incurred a majority of our research and development expenses in 2022 and in the three months ended March 31, 2023 in support of our early-stage products, including Percepta Nasal Swab. Going forward, we expect to incur significant expense as we invest in the development of our innovation engine, early-stage products, including required clinical studies, the development of current tests for the nCounter instrument and the transition of manufacturing to our Veracyte Marseille facility.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expenses consist of compensation expenses, direct marketing expenses, professional fees, other expenses such as travel and communications costs, as well as allocation of facility and information technology expenses. Our sales team of approximately 120 representatives is organized by business unit, with separate teams calling on thyroid cancer, urologic cancers, and pulmonology physicians. The business units have dedicated marketing support, as well as a marketing operations team that serves the commercial organization broadly. Prosigna sales outside of the U.S. are led by country managers that call on laboratories and breast cancer oncologists and have dedicated marketing support. </span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses include compensation expenses for executive officers and administrative, billing and client service personnel, professional fees for legal and audit services, occupancy costs, depreciation and amortization, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other expenses such as information technology and miscellaneous expenses, offset by allocation of facility and information technology expenses to other functions. General and administrative expenses include costs related to the acquisitions of Decipher Biosciences and HalioDx, which were included in general and administrative compensation expense and professional fees. We expect general and administrative expenses to continue to increase as we build our infrastructure to scale revenue growth, and to stabilize thereafter.</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset Amortization</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our finite-lived intangible assets, acquired in business combinations, are being amortized over 4 to 15 years, using the straight-line method. Amortization expense is expected to be approximately $21.3&#160;million per year through 2024 and decrease thereafter.</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense is attributable to our borrowings under debt agreements and costs associated with the prepayment of debt.</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Loss), Net</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (loss), net consists primarily of realized and unrealized gains and losses on foreign currency transactions, French research tax credits, interest expense on our debt and interest income from our cash held in interest bearing accounts. The French research tax credits (cr&#233;dit d&#8217;imp&#244;t recherche or CIR) are generated by our wholly-owned subsidiary, Veracyte SAS, in connection with its research efforts performed in Marseille, France. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of our foreign subsidiary, Veracyte SAS, is the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of accumulated other comprehensive income (loss) within stockholders&#8217; equity. Revenue and expenses from our foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur.  Foreign currency transaction gains and losses are recorded in other income (loss), net, on the condensed consolidated statements of operations.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comparison of the three months ended March 31, 2023 and 2022 (in thousands of dollars, except percentages and test volume):</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.298%"><tr><td style="width:1.0%"></td><td style="width:50.165%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Testing revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biopharmaceutical and other revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expense:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of testing revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of biopharmaceutical and other revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,920&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,031&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,889&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,498)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,248)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,091)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,464)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,091)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,461)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Operating Data:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic tests reported</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product tests sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total test volume</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18%</span></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $14.6&#160;million for the three months ended March 31, 2023 compared to the same period in 2022. This was primarily due to a $16.4&#160;million increase in testing revenue driven by a 23% volume increase, partially offset by a $2.7&#160;million decrease in our Biopharmaceutical and other revenue. The increase in testing revenue and tests reported for the three months ended March 31, 2023 was due to Afirma and Decipher Prostate tests, which contributed $16.8&#160;million of the increase. The remaining testing business decreased by $0.4 million primarily due to our decision to discontinue our Immunoscore test and to stop actively marketing our Percepta GSC tests.  Product revenue increased $0.9&#160;million for the three months ended March 31, 2023 compared to the same period in 2022, driven primarily by an increase in product test kits sold. This growth was partially offset by a decline in currency exchange rates, which negatively impacted product revenue by $0.1 million. Biopharmaceutical and other revenue primarily decreased by $2.7&#160;million for the three months ended March 31, 2023 driven primarily by the reduction of customer projects given overall spending constraints across the industry. Currency exchange rates negatively impacted our total revenue by $0.3 million for the three months ended March 31, 2023 when compared to rates for the same period in 2022, primarily related to our Biopharmaceutical and other revenue.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of revenue</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comparison of the three months ended March 31, 2023 and 2022 is as follows (in thousands of dollars, except percentages):</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.467%"><tr><td style="width:1.0%"></td><td style="width:50.974%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of testing revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laboratory costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sample collection costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees and royalties</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of product revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees and royalties</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of biopharmaceutical and other revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License fees and royalties</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of testing revenue increased $2.1&#160;million, or 12%, for the three months ended March 31, 2023 compared to the same period in 2022. The increase in cost of testing revenue was due to increased volume in testing, primarily related to Afirma and Decipher Prostate.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue is related to sales of Prosigna and nCounter Analysis Systems. Cost of product revenue increased $0.6&#160;million, or 37%, for the three months ended March 31, 2023 compared to the same period in 2022, driven by increased test volume. This was partially offset by a $0.1 million currency exchange impact.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of biopharmaceutical and other revenue includes labor costs incurred by our employees working on customer projects, laboratory supplies and pass-through expenses incurred on these projects. Cost of biopharmaceutical and other revenue decreased by $0.2&#160;million driven by reduction of variable expenses related to projects, including a $0.1&#160;million favorable currency exchange impact when compared to rates for the three months ended March 31, 2022.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comparison of the three months ended March 31, 2023 and 2022 is as follows (in thousands of dollars, except percentages):</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.274%"><tr><td style="width:1.0%"></td><td style="width:49.435%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Direct research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense&#160;increased $3.6&#160;million, or 39%, for the three months ended March 31, 2023 compared to the same period in 2022. The increase in compensation expense was primarily due to annual merit increases. The increase in direct research and development expense was primarily related to our on-going clinical studies including, but not limited to, furthering the support and evidence of our Percepta Nasal Swab test. The increase in other expenses was primarily driven by increased support in developing our IVD platform. We recognized a $0.1 million favorable impact from foreign currency exchange when compared to the rates for the three months ended March 31, 2022. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling and marketing</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comparison of the three months ended March 31, 2023 and 2022 is as follows (in thousands of dollars, except percentages):</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.766%"><tr><td style="width:1.0%"></td><td style="width:46.755%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling and marketing expense:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Direct marketing expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,754&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense increased $2.4&#160;million, or 10%, for the three months ended March 31, 2023 compared to the same period in 2022. The increase in compensation expense was primarily due to additional employees hired and increased commissions to support the growth of Afirma and Decipher test volume. Other expenses increased primarily due to increased travel and entertainment to also support the growth of Afirma and Decipher test volume. The increase was partially offset by reduced expenses related to Immunoscore and Percepta support. We recognized a $0.1 million favorable impact from foreign currency exchange rates when compared to the rates for the three months ended March 31, 2022.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comparison of the three months ended March 31, 2023 and 2022 is as follows (in thousands of dollars, except percentages):</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.766%"><tr><td style="width:1.0%"></td><td style="width:46.755%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Occupancy expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(812)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,463&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased by $1.6&#160;million for the three months ended March 31, 2023, compared to the same period in 2022. This increase is driven by $1.4&#160;million of impairment of right-of-use and fixed assets in relation to exiting our Richmond facility. General and administrative expenses related to occupancy costs and information technology costs are allocated to general and administrative expense, selling and marketing expense, research and development expense, and cost of revenue based on the headcount and employee location. We recognized a $0.1 million favorable impact from foreign currency exchange rates when compared to the rates for the three months ended March 31, 2022.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income, net</span></div><div style="text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, increased $1.6&#160;million for the three months ended March 31, 2023 compared to the same period in 2022, due to an increase of $1.2&#160;million from interest and dividend income, an increase of $0.3&#160;million of unrealized foreign currency gain and an increase of $0.1&#160;million from operations in France related to the CIR during the period. We recognize other income from the CIR over time based on when the research and development expenses are incurred.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March&#160;31, 2023, we have been financed primarily through net proceeds from the sale of our equity securities. We have incurred net losses since our inception. For the three months ended March 31, 2023, we had a net loss of $8.1&#160;million, and we expect to incur additional losses for the remainder of 2023 and potentially in future years. As of March&#160;31, 2023, we had an accumulated deficit of $401.8&#160;million. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 10, 2023, Silicon Valley Bank, or SVB, one of our banking partners, was closed by the California Department of Financial Protection &amp; Innovation, and the Federal Deposit Insurance Corporation, or FDIC, was named as Receiver. At the time of closing on March 10, 2023, we had cash and cash equivalents and short-term investments at SVB or under SVB management, however the majority of these assets were not restricted by the FDIC action to take control of SVB as most of our cash and cash equivalents and short-term investments resided in a custodial account with a third-party bank for which SVB acted as advisor. The FDIC subsequently transferred SVB&#8217;s deposits to a newly created bridge bank, named Silicon Valley Bridge Bank, N.A. and, on March 26, 2023, the FDIC announced that First Citizens Bank &amp; Trust Company had agreed to purchase and assume all deposits and loans of Silicon Valley Bridge Bank. As a result, the closure of SVB did not impact our ability to satisfy our operations and obligations and we have full access to funds that were previously held at SVB. Our ongoing cash management strategy is to maintain diversity in our deposit accounts across financial institutions, but deposits in these institutions may exceed the amount of insurance provided on such deposits. We have not realized any losses on our deposits of cash and cash equivalents other than exchange rate losses related to foreign currency denominated accounts.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing cash and cash equivalents of $177.9&#160;million as of March&#160;31, 2023, and cash flows generated by our revenue during the next 12 months will be sufficient to meet our anticipated cash requirements for at least the next 12 months from the filing date of this report. We expect that our near- and longer-term liquidity requirements will continue to consist of costs to run our laboratories, research and development expenses, selling and marketing expenses, general and administrative expenses, working capital, capital expenditures, lease obligations and general corporate expenses associated with the growth of our business. However, we may also use cash to acquire or invest in complementary businesses, technologies, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services or products that would change our cash requirements. If we are not able to generate cash flows from our revenue to finance our cash requirements, we will need to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations or licensing arrangements. If we raise funds by issuing equity securities, dilution to stockholders could result. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings could impose significant restrictions on our operations. The incurrence of indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, restrictions on our cash and other operating restrictions that could adversely affect our ability to conduct our business. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third-party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives, or forgo potential acquisitions or investments. In addition, we may have to work with a partner on one or more of our products or development programs, which could lower the economic value of those programs to us. Moreover, any instability in the global banking system may impact liquidity both in the short term and long term and may result in adverse impacts to our or our customers&#8217; business, including in our customers&#8217; ability to pay for our products.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office and laboratory facilities in South San Francisco and San Diego, California; Austin, Texas; Marseille, France; and Richmond, Virginia, and lease certain equipment under various non-cancelable lease agreements. The lease terms extend to October 2030 and contain extension of lease term and expansion options. As of March&#160;31, 2023, the leases have a weighted average remaining lease term of 3.6 years and total future minimum lease payments of $15.5&#160;million. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veracyte SAS has signed a lease agreement for facilities which will be constructed in Marseille, France. The lease will commence upon completion of the construction of the office building which we currently expect to occur in the third quarter of 2023 at which time we will record a lease liability and a corresponding ROU asset. The initial term of the lease will be twelve years with annual rent of approximately $1.3&#160;million, which is subject to change based on final construction. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we acquired from NanoString the exclusive global diagnostics license to the nCounter Analysis System, the Prosigna breast cancer prognostic gene signature assay, and the LymphMark lymphoma subtyping assay. Pursuant to the terms of the agreement, we paid NanoString $40.0&#160;million in cash and $10.0&#160;million in Veracyte common stock, and may pay up to an additional $10.0&#160;million in cash, contingent upon first achievement or occurrence, by or on behalf of Veracyte, of the commercial launch of the first, second and third diagnostic tests for use on the nCounter multiplex analysis system.  As of March&#160;31, 2023, the achievement of one of the milestones is forecasted to occur within the next 12 months, requiring payments totaling $3.5&#160;million. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HalioDx Acquisition-Related Payments</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the HalioDx Acquisition, 11,031 unvested HalioDx free ordinary share awards, or free shares, were modified to provide us the right to purchase the vested free shares (call option) from the holders and the holders the right to sell the vested free shares to us (put option) from time to time through late 2023. As a result of the call and put options, the free shares are liability classified. Additionally, in connection with the HalioDx Acquisition, all of HalioDx's equity-classified options that were outstanding prior to the HalioDx Acquisition were terminated and cancelled at the acquisition date. We committed to pay cash consideration of $1.5&#160;million to holders of unvested options on the date the employee satisfies the original service requirement. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, we held back $16.8&#160;million of the cash consideration, or the holdback, which will be payable to the founders of HalioDx based on their continuous employment with us. Fifty percent of the holdback was placed in escrow on the founders' behalf on the first anniversary of the closing date and the remainder will be paid directly to the founders on the second anniversary. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the remaining amount to be paid for all HalioDx related items was $7.4&#160;million subject to holders continued service, excluding any potential associated social charges.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the three months ended March 31, 2023 and 2022 (in thousands of dollars):&#160;</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,172)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,872)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,080&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,453)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the three months ended March 31, 2023 was $2.2&#160;million. The net loss of $8.1&#160;million includes non-cash charges of $8.0&#160;million of stock-based compensation expense, $6.7&#160;million of depreciation and amortization, which includes $5.3&#160;million of intangible asset amortization, $1.4&#160;million of impairment of right-of-use and fixed assets and non-cash lease expense of $0.9&#160;million. Cash used as a result of changes in operating assets and liabilities was $10.5&#160;million, primarily comprising a decrease in accrued liabilities and deferred revenue of $7.7&#160;million, an increase in prepaids and other current assets of $3.1&#160;million, an increase in accounts payable of $2.0&#160;million, an increase in accounts receivable of $1.3&#160;million, a decrease in supplies and inventory of $1.1&#160;million, a decrease in operating lease liability of $1.0&#160;million and a $0.5 million impact from other working capital accounts. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the three months ended March 31, 2022 was $8.9&#160;million. The net loss of $14.5&#160;million includes non-cash charges of $6.6&#160;million of stock-based compensation expense, $6.6&#160;million of depreciation and amortization, which includes $5.5&#160;million of intangible asset amortization, and non-cash lease expense of $0.6&#160;million. Cash used as a result of changes in operating assets and liabilities was $8.4&#160;million, primarily comprised of an increase in accounts receivable of $3.6&#160;million, an increase in prepaid expense and other current assets of $2.1&#160;million, an increase in supplies and inventory of $1.2&#160;million, a decrease in accounts payable of $1.0&#160;million, and a $0.5 million impact from other working capital accounts. </span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities, for the three months ended March 31, 2023, was $24.1&#160;million, consisting of $44.8&#160;million generated from the sale and maturity of short-term investments, partially offset by $19.7&#160;million used in the purchase of short-term investments and $1.0&#160;million used in the purchase of property, plant and equipment.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities, for the three months ended March 31, 2022, was $2.5&#160;million for the purchase of property, plant and equipment.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the three months ended March 31, 2023, was $1.7&#160;million, consisting of $4.0&#160;million in proceeds from the exercise of options to purchase our common stock and the purchase of stock under our Employee Stock Purchase Plan, or ESPP, partially offset by $2.3&#160;million in tax payments during the period related to the vesting of restricted stock units granted to employees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the three months ended March 31, 2022, was $2.0&#160;million, consisting of $3.5&#160;million in proceeds from the exercise of options to purchase our common stock and the purchase of stock under our ESPP, partially offset by $1.4&#160;million in tax payments during the period related to the vesting of restricted stock units granted to employees.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 2014-09, Revenue from Contracts with Customers (Topic 606). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. The new standard is effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. We adopted this guidance in 2023 with no material impact on our consolidated financial statements and related disclosures.</span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates. We had cash and cash equivalents of $177.9 million as of March&#160;31, 2023 which consisted of bank deposits, money market funds and U.S. treasury securities. Such interest-bearing instruments carry a degree of risk; however, a hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our condensed consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 we held $5.0 million of bank deposits denominated in Euros. Such Euro denominated deposits carry a degree of risk from changes in currency exchange rates as the gains or losses from changes in exchange rates are included in our net loss and comprehensive loss. As of March&#160;31, 2023 a hypothetical 10% appreciation or depreciation of the U.S. dollar relative to the Euro would not have had a material impact on our condensed consolidated financial statements. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation Risk</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are facing inflation headwinds in compensation, travel, supply and inventory costs, however we do not believe that inflation has had a material effect on our business, financial condition, or operating results to date.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160; CONTROLS AND PROCEDURES</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, or Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout our Company. There were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act)&#160;identified in connection with the evaluation identified above that occurred during the quarter ended March&#160;31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#8212; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160; RISK FACTORS</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary of Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investing in our common stock involves a high degree of risk. You should carefully review the &#8220;Risk Factors&#8221; section before you invest in shares of our common stock. Listed below are some of the more significant risks relating to an investment in our common stock.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses, and we expect to incur net losses for the foreseeable future and may never achieve or sustain profitability.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our financial results currently depend mainly on sales of our Afirma and Decipher Prostate tests, and we will need to generate sufficient revenue from these and our other diagnostic tests to grow our business.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to grow sales of our portfolio of tests including Prosigna, Envisia, and Decipher Bladder, or we are unable to launch or commercialize our new tests, our business may suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on a few payers for a significant portion of our revenue and if one or more significant payers stops providing reimbursement or decreases the amount of reimbursement for our tests, our revenue could decline.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If payers do not provide reimbursement, rescind or modify their reimbursement policies, delay payments for our tests, recoup past payments, or if we are unable to successfully negotiate additional reimbursement contracts, our commercial success could be compromised.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may experience limits on our revenue if physicians decide not to order our tests or if patients decide not to use our tests as a result of increased costs, fees or changing insurer policies.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with federal, state and foreign licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts for various reasons, including in response to the way we recognize revenue and/or the amount of cash we generate, which may cause our stock price to fluctuate or decline.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our general strategy of seeking growth through acquisitions and collaborations is not successful, or if we do not successfully integrate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies or assets that we acquire into our business, our prospects and financial condition will suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success and international growth depends, in part, on our ability to adapt and manufacture select tests to be performed on the nCounter Analysis System. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The growth that we are expecting in our biopharma services business may not transpire</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic has had, and may continue to have, an adverse effect on certain of our business, results of operations and financial condition.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on sole suppliers for some of the reagents, equipment, and other materials used to perform our tests, and we may not be able to find replacements or transition to alternative suppliers, which may materially impact our ability to generate revenue.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on a specialized cytopathology practice to perform the cytopathology component of our Afirma test, and our ability to perform our diagnostic solution would be harmed if we were unexpectedly unable to secure a replacement.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to support demand for our commercial tests, services or products, our business could suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in healthcare policy, including legislation reforming the U.S. healthcare system, may have a material adverse effect on our financial condition and operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because of Medicare billing rules, we may not receive reimbursement for all tests provided to Medicare patients.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the FDA or foreign authorities were to begin regulating those of our tests that they do not currently regulate, we could incur substantial costs and delays associated with trying to obtain premarket clearance, approval or certification.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtaining marketing authorization or certification by the FDA and foreign regulatory authorities or notified regulatory bodies for our diagnostic tests will take significant time and require significant research, development and clinical study expenditures and ultimately may not succeed.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our senior management team, and the loss of one or more of our executive officers, or the inability to attract and retain highly-skilled employees or other key personnel could adversely affect our business.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Billing for our diagnostic tests is complex, and we must dedicate substantial time and resources to the billing process to be paid.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our internal sales force is less successful than anticipated, our business expansion plans could suffer and our ability to generate revenue could be diminished. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing new products involves a lengthy and complex process, and if we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, our business will suffer and our stock price may decline.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must successfully integrate the HalioDx and Decipher Biosciences businesses to realize the financial goals that we currently ant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">icipate.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Aspects of our international business expose us to business, personnel, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may be adversely affected by unfavorable macroeconomic and market conditions.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Security breaches, loss of data and other disruptions to our or our third-party service providers' data systems could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property effectively, our business would be harmed. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be involved in litigation related to intellectual property, which could be time-intensive and costly and may adversely affect our business, operating results or financial condition.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Being a Public Compa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ny</span></div><div><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risks Related to Our Common Stock</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of losses, and we expect to incur net losses for the foreseeable future and may never achieve or sustain profitability.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception. For the three months ended March 31, 2023 and 2022, we had net losses of $8&#160;million and $14&#160;million, respectively. As of March&#160;31, 2023, we had an accumulated deficit of $402 million. We expect to incur additional losses in the future, and we may never achieve revenue sufficient to offset our expenses. We have experienced and may continue to experience decreases in total test volume due to the impact of COVID-19, including as a result of additional COVID-19 variants. Additionally, ongoing widespread inflationary pressures in the U.S. and across global economies have resulted in higher costs for our raw materials, non-material costs, labor and other business costs, and significant increases in the future could adversely affect our results of operations. We expect to continue to devote substantially all of our resources to increase adoption of and reimbursement for our molecular diagnostic portfolio of tests, and the development of additional tests. We may never achieve or sustain profitability, and our failure to achieve and sustain profitability in the future could cause the market price of our common stock to decline.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial results currently depend mainly on sales of our Afirma and Decipher Prostate tests, and we will need to generate sufficient revenue from these and our other diagnostic tests to grow our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our revenue to date has been derived from the sale of our Afirma tests, which are used in the diagnosis of thyroid cancer. We also derive significant revenue from our Decipher urological tests. Over the next few years, we expect to continue to derive a substantial portion of our revenue from sales of our Afirma and Decipher tests. Once tests are clinically validated and commercially available for patient testing, we must continue to develop and publish evidence that our tests are informing clinical decisions in order for them to receive positive coverage decisions by payers. Without coverage policies, our tests may not be reimbursed and we will not be able to recognize revenue. We cannot guarantee that tests we commercialize will gain and maintain positive coverage decisions and therefore, we may never realize revenue from tests we commercialize. In addition, we are in various stages of research and development for other diagnostic tests that we may offer, but there can be no assurance that we will be able to identify other diseases that can be effectively addressed or, if we are able to identify such diseases, whether or when we will be able to successfully commercialize solutions for these diseases and obtain the evidence and coverage decisions from payers. If we are unable to increase sales and expand reimbursement for our Afirma and Decipher Prostate tests, or develop and commercialize other tests, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to grow sales of our portfolio of tests including Prosigna, Envisia, and Decipher Bladder, or we are unable to launch or commercialize our new tests, our business may suffer.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Prosigna, Envisia, and Decipher Bladder have not contributed significant revenue to date, we expect them to grow and become an increasingly important component of our strategic focus, as well as our results of operations. We plan to introduce new tests going forward as well. There can be no assurance that we will be successful in our launch or commercialization of new tests, nor that physicians will request our new tests be performed in sufficient volumes for our revenue to meet our projections. Additionally, we anticipate expanding the reach of our tests to international markets through the distribution of the nCounter Analysis System; if our distribution of this platform is unsuccessful, or if our products are not widely adopted internationally, our business and results of operations may be adversely affected. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on a few payers for a significant portion of our revenue and if one or more significant payers stops providing reimbursement or decreases the amount of reimbursement for our tests, our revenue could decline.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal Medicare funding and state budgets are limited and have been placed under tremendous strain in recent years, which is likely to be further exacerbated as a result of reduced tax receipts and greater deficit spending as a result of the COVID-19 pandemic. Such budgetary pressures may force Medicare or state agencies to reduce payment rates or change coverage policies. If there is a decrease in Medicare or other payers&#8217; payment rates for our tests, our revenue from Medicare and such payers will decrease and the payment rates for some of our commercial payers may also decrease if they tie their allowable rates to the Medicare rates. These changes could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for tests performed on patients covered by Medicare and UnitedHealthcare Group was 31% and 10%, respectively, of our revenue for the three months ended March 31, 2023, compared with 30% and 9%, respectively, for the three months ended March 31, 2022. The percentage of our revenue derived from significant payers is expected to fluctuate from period to period as our revenue fluctuates, as additional payers provide reimbursement for our tests or if one or more payers were to stop reimbursing for our tests or change their reimbursed amounts. Effective January 2012, Palmetto GBA, the regional Medicare Administrative Contractor, or MAC, that handled claims processing for Medicare services over our jurisdiction at that time, issued coverage and payment determinations for our Afirma Classifiers now covered by Noridian Healthcare Solutions, the current MAC for our jurisdiction, through the MolDX program, administered by Palmetto GBA, under an LCD.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2015, CPT code 81545 for the Afirma GEC was issued. On January 1, 2018, the Medicare Clinical Laboratory Fee Schedule payment rate for the Afirma classifier increased from $3,220 to $3,600. This rate is based on the volume-weighted median of private payer payment rates made between January 1 and June 30, 2016, which we reported to the Centers for Medicare &amp; Medicaid Services in 2017 as required under the Protecting Access to Medicare Act of 2014, or PAMA. In December 2019, through the Further Consolidated Appropriations Act of 2020, Congress delayed the next data reporting period from 2020 to 2021 for final payments made between January 1 and June 30, 2019, extending the applicability of the payment rates based on 2017 reporting by one year through December 31, 2021. In March 2020, through the CARES Act, Congress further delayed the next reporting period to 2022 for final payments made between January 1 and June 30, 2019, extending the applicability for the payment rates based on 2017 reporting through December 31, 2022. In December 2021, through the Protecting Medicare and American Farmers from Sequester Cuts Act, Congress further delayed the next reporting period to 2023. In December 2022, through the Consolidated Appropriations Act of 2023, Congress further delayed the next </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting period to 2024. As a result of the transition from Afirma GEC to Afirma GSC, a new CPT Category I code (81546) was established for the Afirma classifier, effective January 1, 2021. This code went through the national payment determination process for Medicare in 2020, through which CMS priced 81546 at the same rate of $3,600 as 81545. Since the Afirma GSC CPT code 81546 was newly issued in 2021, the first PAMA data reporting period for 81546 under the current triennial data reporting process is expected to be January 2027 through March 2027, resulting in a new potential reimbursement rate effective January 1st, 2028. There is no guarantee that the Afirma GSC Medicare rate will not be negatively impacted in future PAMA reporting cycles based on the reported weighted median of private commercial payers. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decipher Prostate Biopsy and Decipher Prostate RP are currently reimbursed by Medicare pursuant to LCDs issued by Palmetto GBA and adopted by Noridian Healthcare Solutions, each acting as a MAC, as well as by a number of commercial payers.  However, there are many commercial payers who currently do not provide reimbursement for our prostate genomic tests, or provide only limited reimbursement, and we have contracts for reimbursement with only a limited number of commercial payers for our prostate tests. Our Decipher Prostate tests were assigned a new American Medical Association Current Procedural Terminology code, or CPT code, 81542, for 2020. CPT code changes can result in a risk of an error being made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payer. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment we receive.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submit claims to Medicare for Decipher Prostate Biopsy and Decipher Prostate RP using CPT code 81542. CMS assigned 81542 to the gapfilling process in 2020, under which the individual MACs set the payment rate for the test based on the following four factors: 1) charges for the test and routine discounts to charges; 2) resources required to perform the test; 3) payment amounts determined by other payers; and 4) charges, payment amounts, and resources required for other tests that may be comparable or otherwise relevant. 81542 has been priced at $3,873 since January 1, 2021, based on CMS&#8217; revision of the median of payment rates set by the MACs through the gapfilling process. Since the CPT code was issued in 2020, we expect the next PAMA reporting period to take place between January 2027 and March 2027, resulting in a potential new reimbursement rate effective January 1, 2028. There can be no assurance that the Medicare payment rates for Decipher Prostate Biopsy and Decipher Prostate RP will not decrease during a future reporting cycle under PAMA.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An LCD was issued for Prosigna by Palmetto GBA in August 2015, which has been in effect since October 1, 2015. There can be no assurance that the Prosigna payment rate will not decrease during subsequent reporting cycles under PAMA.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noridian Healthcare Solutions provided Medicare coverage for the Envisia Genomic Classifier on April 11, 2019.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submit claims to Medicare for Envisia using CPT code 81554, which became effective January 1, 2021. We applied for New ADLT designation for Envisia, and the test was approved as a New ADLT on September 17, 2020. Effective October 1, 2020 through June 30, 2021, the Medicare payment rate for Envisia was set at $5,500, the actual list charge as defined under the ADLT regulations for the test. Veracyte reported private payer rates for Envisia in March 2021, reflecting final payments between October 1, 2020 and February 28, 2021. The volume-weighted median of these reported rates, which was $5,500, set the payment rate for Envisia from July 1, 2021 through December 31, 2022, after which Envisia will be priced based on private payer rates collected and reported annually. Effective January 1, 2023, the Medicare payment rate for 81554 is $5,520. There can be no assurance that the Medicare payment rate for Envisia will not be reduced when it is set based on the volume-weighted median of private payer rates. Current ADLT PAMA regulations require us to report these private payer rates for Envisia, 81554, annually.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 18, 2021, Decipher Bladder is reimbursed by Medicare pursuant to LCDs issued by three MACs and Decipher Bladder is covered by a fourth MAC, Noridian Healthcare Solutions, effective as of July 25, 2021.  We have not yet contracted with any commercial payers for reimbursement of Decipher Bladder.  Our Decipher Bladder test was assigned a new CPT code, 0016M, for 2020. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will submit claims to Medicare for Decipher Bladder using CPT code 0016M. CMS assigned 0016M to the gapfilling process in 2021. Since January 1, 2022, the payment rate for 0016M has been $3,489.63, based on the median of payment rates set by the MACs through the gapfilling process. There is no assurance that the Medicare payment rate for Decipher Bladder will not decrease during a future reporting cycle under PAMA.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have entered into contracts with certain third-party payers that establish in-network allowable rates of reimbursement for many of our tests, payers may suspend or discontinue reimbursement at any time, with or without notice, for technical or other reasons, may require or increase co-payments from patients, or may reduce the reimbursement rates paid to us. Reductions in private payer amounts could decrease the Medicare payment rates for our tests under PAMA. In addition, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private payers have begun requiring prior authorization for molecular diagnostic tests. Potential reductions in reimbursement rates or increases in the difficulty of achieving payment could have a negative effect on our revenue.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If payers do not provide reimbursement, rescind or modify their reimbursement policies, delay payments for our tests, recoup past payments, or if we are unable to successfully negotiate additional reimbursement contracts, our commercial success could be compromised.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians might not order our tests unless payers reimburse a substantial portion of the test price. There is significant uncertainty concerning third-party reimbursement of any test incorporating new technology, including our tests. Reimbursement by a payer may depend on a number of factors, including a payer&#8217;s determination that these tests are:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not experimental or investigational;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-authorized and appropriate for the specific patient;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supported by peer-reviewed publications; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">included in clinical practice guidelines.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since each payer makes its own decision as to whether to establish a coverage policy or enter into a contract to reimburse our tests, seeking these approvals is a time-consuming and costly process.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an out-of-network provider with some commercial payers in the U.S. and thus, we do not have control over rates or terms of reimbursement. Without contracted rates for reimbursement, our claims are often denied upon submission, and we must appeal the claims. The appeals process is time consuming and expensive and may not result in payment. In cases where we are out-of-network, there is typically a greater patient cost-share responsibility which may result in further delays and/or decreased likelihood of collection. Payers may attempt to recoup prior payments after review, sometimes after significant time has passed, which would impact future revenue.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to focus substantial resources on increasing adoption, coverage and reimbursement for the Afirma, Decipher Prostate, Prosigna, Envisia and Decipher Bladder and any other future tests we may develop. We believe it will take several years to achieve coverage and contracted reimbursement with a majority of third-party payers. We cannot predict whether, under what circumstances, or at what payment levels payers will reimburse for our tests. Also, payer consolidation is underway and creates uncertainty as to whether coverage and contracts with existing payers will remain in effect. Finally, if there is a decrease in the Medicare payment rates for our tests, the payment rates for some of our commercial payers may also decrease if they tie their allowable rates to the Medicare rates. Reductions in private payer amounts could decrease the Medicare payment rates for our tests under PAMA. Our failure to establish broad adoption of and reimbursement for our tests, or our inability to maintain existing reimbursement from payers, will negatively impact our ability to generate revenue and achieve profitability, as well as our future prospects and our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience limits on our revenue if physicians decide not to order our tests.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to create or maintain demand for our tests in sufficient volume, we may not become profitable. To generate demand, we will need to continue to educate physicians about the clinical utility and cost-effectiveness of our tests through published papers, presentations at scientific conferences, marketing campaigns and one-on-one education by our sales force. In addition, our ability to obtain and maintain adequate reimbursement from third-party payers will be critical to generating revenue. Moreover, certain patients have been deferring elective procedures and medical visits as a result of the COVID-19 pandemic, and we have experienced, and expect to continue to experience, a reduction in patient demand or physician recommendations, which has and may continue to adversely affect our business.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Afirma genomic classifier is included in most physician practice guidelines in the United States for the assessment of patients with thyroid nodules. However, historical practice recommended a full or partial thyroidectomy in cases where cytopathology results were indeterminate to confirm a diagnosis. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of the clinical data supporting the use of the Decipher Prostate Biopsy and Decipher Prostate RP tests have led to the tests&#8217; inclusion in national guidelines. For example, in the 2020 NCCN Practice Guidelines for Prostate Cancer, the Decipher Prostate RP test is &#8220;recommended&#8221; for use to improve therapy decision making. It is the only test to achieve this designation for post-surgery patients with localized prostate cancer. Further, in September 2021, the 2022 NCCN guidelines were released and recommend specific treatment decisions for patients based on their Decipher Prostate RP score. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequently, Decipher also received a &#8220;Level 1&#8221; evidence designation in the NCCN&#8217;s update to the 2023 prostate cancer guidelines. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Decipher Prostate Biopsy and Decipher Prostate RP have been integrated into the NCCN guidelines, if we are unsuccessful in maintaining and increasing the level of recommendation of our genomic tests within these guidelines, are unable to cause any new genomic tests we develop to be included in these guidelines, are unable to cause our genomic tests to be included in other influential guidelines, or if our competitors are successful at achieving similar or more extensive guidelines for their tests, we may be at a disadvantage in gaining market acceptance and market share relative to our competitors.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lung products are not yet integrated into practice guidelines and physicians may be reluctant to order tests that are not recommended in these guidelines. The Prosigna test is included in practice guidelines in the United States and internationally but faces competition from other products globally.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our Afirma, Decipher Prostate Biopsy, Decipher Prostate RP, Envisia, and Decipher Bladder testing services are performed by our certified laboratories under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, rather than by the local laboratory or pathology practice, pathologists may be reluctant to support our testing services as well. Guidelines that include our tests currently may subsequently be revised to recommend another testing protocol, and these changes may result in physicians deciding not to use our tests. Lack of guideline inclusion could limit the adoption of our tests and our ability to generate revenue and achieve profitability. To the extent international markets have existing practices and standards of care that are different than those in the United States, we may face challenges with the adoption of our tests in international markets.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience limits on our revenue if patients decide not to use our tests as a result of increased costs, fees or changing insurer policies.</span></div><div style="text-align:justify;text-indent:7.2pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some patients may decide not to use our tests because of price, all or part of which may be payable directly by the patient if the patient&#8217;s insurer denies reimbursement in full or in part. There is a growing trend among insurers to shift more of the cost of healthcare to patients in the form of higher co-payments or premiums, and this trend is accelerating which puts patients in the position of having to pay more for our tests. In addition, rising interest rates and ongoing inflation in the U.S. and globally may put further pressure on insurers and other providers to raise prices or reduce reimbursement, increasing the cost to the patient. We expect to continue to see pressure from payers to limit the utilization of tests, generally, and we believe more payers are deploying costs containment tactics, such as pre-authorization and employing laboratory benefit managers to reduce utilization rates. Implementation of provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively the ACA, has also resulted in increases in premiums and reductions in coverage for some patients. These events may result in patients delaying or forgoing medical checkups or treatment due to their inability to pay for our tests, which could have an adverse effect on our revenue. Many patients have been deferring elective procedures and medical visits as a result of the COVID-19 pandemic, and we have experienced, and may continue to experience, a significant reduction in patient demand, which has and may continue to adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with federal and state licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific personnel qualifications, facilities administration, quality systems, inspections, and proficiency testing. CLIA certification is also required for us to be eligible to bill state and federal healthcare programs, as well as many private third-party payers. To renew these certifications, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may conduct random inspections of our clinical reference laboratories. If we fail to maintain CLIA certificates in our South San Francisco, California; San Diego, California; or Austin, Texas laboratory locations, we would be unable to bill for services provided by state and federal healthcare programs, as well as many private third-party payers, which may have an adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also required to maintain state licenses to conduct testing in our laboratories. California, New York, and Texas, among other states&#8217; laws, require that we maintain a license and comply with state regulation as a clinical laboratory. Other states may have similar requirements or may adopt similar requirements in the future. In addition, all of our clinical laboratories are required to be licensed on a test-specific basis by New York. We have received approval for the Afirma, Decipher Prostate, Envisia and Decipher Bladder tests. We will be required to obtain approval for other tests we may offer in the future. If we were to lose our CLIA certificate or California license for our South San Francisco or San Diego laboratories, whether as a result of revocation, suspension, limitation or otherwise, we would no longer be able to perform our molecular tests, which would eliminate our primary source of revenue and harm our business. If we fail to meet the state licensing requirements for our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Austin laboratory, whether as a result of revocation, suspension, limitation or otherwise, it could result in a delay in processing tests during that transition and increased costs. If we were to lose our licenses issued by New York or by other states where we are required to hold licenses, we would not be able to test specimens from those states. New tests we may develop may be subject to new approvals by regulatory bodies such as the New York State Department of Health, and we may not be able to offer our new tests until such approvals are received.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts for various reasons, including in response to the way we recognize revenue and/or the amount of cash we generate, which may cause our stock price to fluctuate or decline.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly financial and operating results depend on sales of our products in the markets we operate and are sensitive to a number of factors, including patient and clinician demand, market conditions in the US and globally, and the prevalence of the indications we seek to address.  In addition, we cannot be sure that we will be able to successfully complete development of or commercialize any of our planned future products, or that they will prove to be capable of reliably being used. Before we can successfully develop and commercialize any of our currently planned or other new diagnostic solutions, we will need to:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">conduct substantial research and development;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">obtain the necessary testing samples and related data;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">conduct analytical and clinical validation studies, as well as clinical utility studies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">expend significant funds;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">expand and scale-up our laboratory processes;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">expand and train our sales force;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">gain acceptance from a large number of ordering clinicians;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">gain acceptance from ordering laboratories; and</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">seek and obtain regulatory clearances, approvals or certifications of our new solutions, as required by applicable regulatory bodies.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This process involves a high degree of risk and may take up to several years or more. Our test development and commercialization efforts may be delayed or fail for many reasons, including:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">failure of the test at the research or development stage;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">difficulty in accessing suitable testing samples, especially testing samples with known clinical results;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">lack of analytical and clinical validation data to support the effectiveness of the test, or lack of clinical utility data to support the value of the test;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">delays resulting from the failure of third-party suppliers or contractors to meet their obligations in a timely and cost-effective manner;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">failure to obtain or maintain necessary clearances, approvals or certifications to market the test;</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">manufacturing constraints due to limited energy supply in Europe or other supply constraints; or</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28pt">lack of commercial acceptance by patients, clinicians or third-party payers.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of new diagnostic tests, or we may be required to expend considerable resources repeating clinical studies, which would adversely impact the timing for generating potential revenue from those new diagnostic tests. In addition, as we develop diagnostic tests, we will have to make additional investments in our laboratory operations as well as sales and marketing operations, which may be prematurely or unnecessarily incurred if the commercial launch of a test is abandoned or delayed. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we would likely abandon the development of the test or test feature that was the subject of the clinical study, which could harm our business. If a clinical utility study fails to demonstrate the value of a particular test, we may not be able to obtain reimbursement for the test. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we recognize test revenue upon delivery of the patient report to the prescribing physician based on the amount we expect to ultimately realize. We determine the amount we expect to ultimately realize based on payer reimbursement history, contracts, and coverage. Upon ultimate collection, the amount received is compared to the estimates and the amount accrued is adjusted accordingly. We cannot be certain as to when we will receive payment for our diagnostic tests, and we must appeal negative payment decisions, which delays collections. Should judgments underlying estimated reimbursement change or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be incorrect at the time we accrued such revenue, our financial results could be negatively impacted in future quarters. Furthermore, most of our European sales are denominated in Euros, and if the U.S. dollar strengthens relative to the Euro, our results of operations may be adversely affected even where our underlying business is performing as anticipated. As a result, comparing our operating results on a period-to-period basis may not be meaningful. You should not rely on our past results as an indication of our future performance. In addition, these fluctuations in revenue may make it difficult for us, for securities analysts and for investors to accurately forecast our revenue and operating results. If our revenue or operating results fall below expectations, the price of our common stock would likely decline.</span></div><div style="text-align:justify;text-indent:7.2pt"><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our general strategy of seeking growth through acquisitions and collaborations is not successful, or if we do not successfully integrate companies or assets that we acquire into our business, our prospects and financial condition will suffer.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an element of our growth strategy, we may pursue opportunities to license assets or purchase companies or assets that we believe would complement our current business or help us expand into new markets.  For example, we acquired the nCounter Analysis System and Prosigna test from NanoString; we also acquired Decipher Biosciences and HalioDx. We may pursue additional acquisitions of complementary businesses or assets as part of our business strategy. There can be no assurance that we will successfully integrate the assets acquired from such acquisitions into our existing business, in general, or that our exclusive worldwide license to the nCounter Analysis System for in vitro diagnostic use granted by NanoString will allow us to expand our international reach as anticipated. This and any future acquisitions made by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. Integration of acquired companies or businesses we may acquire in the future also may require management resources that otherwise would be available for ongoing development of our existing business. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance any acquisitions or investments, we have previously issued, and may choose in the future, to issue shares of our stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all. If these funds are raised through the sale of equity or convertible debt securities, dilution to our stockholders could result. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success and international growth depends, in part, on our ability to adapt and manufacture select tests to be performed on the nCounter Analysis System.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy to expand into international markets depends on our ability to successfully acquire and distribute the nCounter Analysis System, adapt our menu of diagnostic tests for the platform, and secure necessary regulatory approvals. Currently, the Prosigna breast cancer assay is the only commercially-available test on the platform. If we are not able to adapt our other current or future genetic tests to be performed on the nCounter Analysis System, or if the nCounter Analysis System fails to be competitive against other diagnostic platforms, our prospects for growth could suffer. In addition, to the extent international markets have existing practices and standards of care that are different than those in the United States, we may face challenges with the adoption of the nCounter Analysis System in international markets.</span></div><div><span><br/></span></div><div style="text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The growth that we are expecting in our biopharma services business may not transpire.</span></div><div style="text-align:justify;text-indent:7.2pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have previously entered into technology licensing and collaboration arrangements, such as our collaborations with Johnson &amp; Johnson in December 2018, with Acerta Pharma, the hematology research and development arm of AstraZeneca, in December 2019 and with CareDx in May 2020, which reflect an important element of our business strategy. With the acquisition of Decipher Biosciences and HalioDx, we continue to seek to expand the range of our biopharma services offerings to pharmaceutical partners with services such as clinically relevant biomarker identification, patient stratification for clinical trials, and development of companion diagnostics. The success of our biopharma services business depends in part on our ability to identify and successfully negotiate with appropriate pharma partners. We cannot guarantee that we will be successful in the identification of appropriate pharma partners or the successful and timely negotiation with such partners.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has had, and may continue to have, an adverse effect on certain of our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and the ongoing emergence of new variants has caused significant volatility in global financial markets. Public health problems resulting from COVID-19 and precautionary measures instituted by governments and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">businesses to mitigate its spread, including travel restrictions and quarantines, have contributed to a general slowdown in the global economy, adversely impacted patients, physicians, customers, suppliers, third-party contract manufacturers, and collaboration partners, and disrupted our operations. The global COVID-19 pandemic continues to evolve. While many countries have re-opened, the uncertainty of COVID-19 (and other public health concerns) may require a return to restrictions. Changes in our operations in response to COVID-19 or employee illnesses resulting from the pandemic may result in inefficiencies or delays, including in sales and product development efforts, timing to receive patient sample shipments and additional costs related to business continuity initiatives, that cannot be fully mitigated through succession planning, employees working remotely or teleconferencing technologies. To date, the FDA has approved several vaccines. Although vaccines are increasingly available in the United States and Europe, and certain countries in South America, Asia and Oceania, there can be no guarantee that the vaccines will be effective against new strains of the virus or that the vaccines will be broadly accepted. Also there can be no guarantee that federal, state, local and foreign agencies will not continue to take other cautionary steps to combat the virus to reduce the incidence of new cases or variants, which could negatively impact our volumes and revenue and limit our ability to reliably forecast our test volumes and levels of revenue.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 and related governmental reactions have had and may continue to have a negative impact on our business, liquidity, results of operations, and stock price due to the occurrence of some or all of the following events or circumstances among others:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability of healthcare providers to deliver anticipated total test volumes due to temporary or permanent staff attrition.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to manage our business effectively due to key employees becoming ill, working from home inefficiently and being unable to travel to our facilities.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our customers, suppliers, third-party contract manufacturers, and collaboration partners may be prevented from operating worksites, including manufacturing facilities, due to employee illness, reluctance to appear at work or &#8220;stay-at-home&#8221; regulations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interruptions in manufacturing (including the sourcing of reagents or supplies) and timely shipment of our products due to challenges in receiving reagents and supplies may impact our ability to perform our tests.  When not limited by the expiration date of products and when we feel it reasonable and feasible to do so, we are taking steps to increase our level of supplies and inventory reserves, to develop alternative sources of supply and to implement procedures to mitigate the impact on our supply chain or our ability to process samples in our laboratories.  Though we are in regular contact with our key suppliers, we do not have, nor expect to have, the necessary insight into our vendors&#8217; supply chain issues that we may need to know to effectively mitigate the impact to our business. Though we attempt to mitigate the impact to our business, these interruptions in manufacturing (including the sourcing of reagents or supplies) may negatively impact our total test volumes or levels of revenue.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduced patient demand for, or provider capacity to deliver, diagnostic testing and elective procedures generally (which may impact our ability to deliver to our revenue estimates).</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions of the operations of our third-party contract manufacturers and suppliers, which could impact our ability to purchase components at efficient prices and in sufficient amounts.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to raise capital, and if we raise capital by issuing equity securities, our common stock may be diluted.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock may drop or remain volatile.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may incur significant employee health care costs under our insurance programs.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability or delay of regulatory bodies to conduct inspections/surveys, review or clear/approve our regulatory filings and submissions, and perform other activities necessary for us to conduct our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent of the impact of COVID-19 on our business and financial results will depend largely on future developments, including the deployment, efficacy, availability and utilization of vaccines, the emergence of new variant strains of COVID-19, the impact on capital and financial markets and the related impact on the financial circumstances of patients, physicians, suppliers, third-party contract manufacturers, and collaboration partners, all of which are highly uncertain and cannot be predicted. This situation is changing rapidly, and additional impacts may arise that we are not aware of at this time.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on sole suppliers for some of the reagents, equipment and other materials used to perform our tests, and we may not be able to find replacements or transition to alternative suppliers, which may materially impact our ability to generate revenue.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on sole suppliers for critical supply of reagents, equipment and other materials and services that we use to perform our tests, and to manufacture the nCounter Analysis System for diagnostic use and Prosigna test kits sold to customers. We also purchase components used in our sample collection kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors and their inability to provide us with reagents that perform to specifications, could negatively </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact our ability to provide timely response and reports to our customers and, as a result, may materially impact our ability to generate revenue.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If suppliers can no longer provide us with the materials we need to perform the tests and for our sample collection kits, if the materials do not meet our quality specifications or are otherwise unusable, if we cannot obtain acceptable substitute materials, or if we elect to change suppliers, an interruption in test processing or system and test kit deliveries could occur, we may not be able to deliver tests to physicians or deliver patient reports and we may incur higher one-time switching costs. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on NanoString for the supply of the nCounter Analysis System for diagnostic use and Prosigna test kits. As part of the HalioDx Acquisition we intended to, and have begun to, migrate manufacture of the test kits for the nCounter from NanoString to HalioDx. In the future, we may need to transition the manufacture of the nCounter Analysis System for diagnostic use from NanoString to Veracyte. While we are preparing for such transition, we cannot be certain that we will be successful in effectively manufacturing the system or acquiring or retaining the talent, skillset, or suppliers required to manufacture the system.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have developed alternate sourcing strategies for these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. Moreover, the supply of key reagents and testing materials has been severely challenged by the COVID-19 pandemic. Periodically, as a result of the COVID-19 pandemic and other challenges to global supply chains, we experienced supply chain disruptions in the supply of plastic materials used in the processing of samples, although this has not resulted in delays in our ability to timely return test results. Carriers responsible for transporting samples to us are currently operating at lower than usual capacity because of COVID-19, causing delays in the timeliness of our receipt of samples. Any such interruption may significantly affect our future revenue, cause us to incur higher costs, and harm our customer relationships and reputation. In addition, in order to mitigate these risks, we maintain inventories of these supplies at higher levels than would be the case if multiple sources of supplies were available. If our total test volume decreases or we switch suppliers, we may hold excess supplies with expiration dates that occur before use which would adversely affect our losses and cash flow position. As we introduce any new test, we may experience supply issues as we ramp test volume. Moreover, the COVID-19 pandemic has disrupted supply chains globally, and could adversely affect our ability to source essential reagents, equipment and other materials in a timely manner or at all.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on a specialized cytopathology practice to perform the cytopathology component of our Afirma test, and our ability to perform our diagnostic solution would be harmed if we were unexpectedly unable to secure a replacement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on TCP to provide cytopathology professional diagnoses on thyroid FNA samples pursuant to a pathology services agreement. Pursuant to this agreement, as amended, TCP has the exclusive right to provide our cytopathology diagnoses on FNA samples at a fixed price per test. Until February 2019, TCP also previously subleased a portion of our facility in Austin, Texas. Our agreement with TCP is effective through October 31, 2023, and automatically renews every year unless either party provides notice of intent not to renew at least 12 months prior to the end of the then-current term.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If TCP were unexpectedly unable to support our current test volume or future increases in total test volume or to provide the quality of services we require, or if we were unable to agree on commercial terms and our relationship with TCP were to terminate, our business could be harmed until we were able to secure the services of another cytopathology provider. There can be no assurance that we would be successful in finding a replacement that would be able to conduct cytopathology diagnoses at the same volume or with the same high-quality results as TCP. Locating another suitable cytopathology provider could be time consuming and would result in delays in processing Afirma tests until a replacement was fully integrated with our test processing operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the need to scale our testing capacity, future growth, including our transition to a multi-product company with international operations, will impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees with the necessary skills to support the growing complexities of our business. Rapid and significant growth may place strain on our administrative, financial and operational infrastructure. Our ability to manage our business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We have implemented an internally-developed data warehouse, which is critical to our ability to track our diagnostic services and patient reports delivered to physicians, as well as to support our financial reporting systems. The time and resources required to optimize these systems is uncertain, and failure to complete optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to support demand for our commercial tests, services or products, our business could suffer.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As demand for our tests, services and products grow, we will need to continue to scale our capacity, processing technology, expand customer service, billing and systems processes, enhance our internal quality assurance program and expand our manufacturing capacity. We will also need additional certified laboratory scientists as well as other scientific and technical personnel to process higher volumes. We cannot assure you that any increases in scale, related improvements, supply of reagents to perform testing, and quality assurance measures will be successfully implemented or that appropriate personnel will be available and able to be hired. Failure to implement necessary procedures, transition to new processes or hire the necessary personnel could result in higher costs of processing tests, quality control issues or inability to meet demand. There can be no assurance that we will be able to perform our testing or fulfill our product, testing, or service commitments on a timely basis at a level consistent with demand, or that our efforts to scale our operations will not negatively affect the quality of test results. If we encounter difficulty meeting market demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in healthcare policy, including legislation reforming the U.S. healthcare system, may have a material adverse effect on our financial condition and operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA, enacted in March 2010, made changes that significantly affected the pharmaceutical and medical device industries and clinical laboratories. Along with the now-repealed 2.3% excise tax on the sale of certain medical devices sold outside of the retail setting, other significant measures contained in the ACA include, for example, coordination and promotion of research on comparative clinical effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in payment methodologies. The ACA also includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physician customers, lower thresholds for violations and increasing potential penalties for such violations. In addition, various efforts to amend the ACA are ongoing. We cannot predict if, or when, the ACA will be amended, and cannot predict the impact that an amendment of the ACA will have on our business.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the ACA, various healthcare reform proposals have also periodically emerged from federal and state governments. For example, in February 2012, Congress passed the Middle Class Tax Relief and Job Creation Act of 2012, which in part reset the clinical laboratory payment rates on the Medicare Clinical Laboratory Fee Schedule, or CLFS, by 2% in 2013. In addition, under the Budget Control Act of 2011, which is effective for dates of service on or after April 1, 2013, Medicare payments, including payments to clinical laboratories, are subject to a reduction of 2% due to the automatic expense reductions (sequester) until fiscal year 2024. In March 2020, Congress passed the CARES Act, which suspended the 2% reduction in Medicare fee-for-service payments from May 1, 2020 through December 31, 2020.  To account for this temporary suspension, the legislation also extends the effect of sequestration by a year (now through fiscal year 2031). Reductions resulting from the Congressional sequester are applied to total claims payment made; however, they do not currently result in a rebasing of the negotiated or established Medicare or Medicaid reimbursement rates. In December 2020, Congress passed the Consolidated Appropriations Act of 2021, or CAA, which extended the suspension through March 31, 2021. Legislation enacted April 14, 2021 further extended the suspension through December 31, 2021.  The Protecting Medicare and American Farmers from Sequester Cuts Act, enacted on December 10, 2021, extends the suspension through March 31, 2022, after which a 1.0% sequestration would apply for Medicare payments made between April 1, 2022 and June 30, 2022. The legislation also applies a 2.25% sequestration to Medicare payments made during the first six months of fiscal year 2030, and a 3% reduction to payments made during the last six months of fiscal year 2030. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State legislation on reimbursement applies to Medicaid reimbursement and managed Medicaid reimbursement rates within that state. Some states have passed or proposed legislation that would revise the reimbursement methodology for clinical laboratory payment rates under those Medicaid programs. For example, effective July 2015, California&#8217;s Department of Health Care Services implemented a new rate methodology for clinical laboratories and laboratory services. This methodology involved the use of a range of rates that fell between zero and 80% of the calculated California-specific Medicare rate and the calculation of a weighted average (based on units billed) of such rates. Effective for dates of service on or after July 1, 2022, the cap at 80% of the Medicare rate has been replaced with a cap at 100% of the lowest maximum allowance established by the federal Medicare program for the same or similar services.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the United States in which we do or may do business, or the effect any future legislation or regulation will have on us. The taxes imposed by the new federal legislation, cost reduction measures and the expansion in the role of the U.S. government in the healthcare industry may result in decreased revenue, lower reimbursement by payers for our tests or reduced medical procedure volumes, all of which may adversely affect our business, financial condition and results of operations. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, sales of our tests outside the United States subject our business to foreign regulatory requirements and cost-reduction measures, which may also change over time.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing calls for deficit reduction at the federal government level and reforms to programs such as the Medicare program to pay for such reductions may affect the pharmaceutical, medical device and clinical laboratory industries. Currently, clinical laboratory services are excluded from the Medicare Part B co-insurance and co-payment as preventative services. Any requirement for clinical laboratories to collect co-payments from patients may increase our costs and reduce the amount ultimately collected.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS bundles payments for clinical laboratory diagnostic tests together with other services performed during hospital outpatient visits under the Hospital Outpatient Prospective Payment System. CMS currently maintains an exemption for molecular pathology tests and &#8220;Criterion A&#8221; ADLTs from this bundling provision. It is possible that this exemption could be removed by CMS in future rule making, which might result in lower reimbursement for tests performed in this setting.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PAMA includes a substantial new payment system for clinical laboratory tests under the CLFS. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the CLFS and the Physician Fee Schedule would report on a triennial basis (or annually for ADLTs), private payer rates and volumes for their tests with specific CPT codes based on final payments made during a set data collection period (the first of which was January 1 through June 30, 2016). We believe that PAMA and its implementing regulations are generally favorable to us. We reported to CMS the data required under PAMA before the March 31, 2017 deadline. The new payment rate for the Afirma genomic classifier based on the volume-weighted median of private payer rates took effect January 1, 2018, increasing from $3,220 to $3,600 through December 31, 2020. In December 2019, through the Further Consolidated Appropriations Act of 2020, Congress delayed the next data reporting period from 2020 to 2021 for final payments made between January 1 and June 30, 2019, extending the applicability of the current rate for Afirma through December 31, 2021. In March 2020, through the CARES Act, Congress further delayed the next reporting period to 2022 for final payments made between January 1 and June 30, 2019, extending the applicability of the payment rates based on 2017 reporting through December 31, 2022. In December 2021, through the Protecting Medicare and American Farmers from Sequester Cuts Act, Congress further delayed the next reporting period to 2023. In December 2022, through the Consolidated Appropriations Act of 2023, Congress further delayed the next reporting period to 2024. There can be no assurance that the payment rate for Afirma or Prosigna will not decrease in the future or that the payment rates for Decipher Prostate Biopsy, Decipher Prostate RP or Decipher Bladder will not be adversely affected by the PAMA law and regulations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Envisia classifier was approved by CMS as a New ADLT on September 17, 2020. The initial payment rate (for a period not to exceed nine months) under PAMA for a New ADLT (an ADLT for which payment has not been made under the CLFS prior to January 1, 2018) will be set at the &#8220;actual list charge&#8221; for the test as reported by the laboratory. Effective July 1, 2021, Envisia is priced based on private payer rates collected and reported annually.  We can determine whether to seek ADLT status for our tests, but there can be no assurance that our tests will be designated ADLTs or that the payment rates for our tests, including Envisia, will not be adversely affected by such designation.   </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have also been substantial changes to the payment structure for physicians, including those passed as part of the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which was signed into law on April 16, 2015. MACRA created the Merit-Based Incentive Payment System which, beginning in 2019, more closely aligns physician payments with composite performance on performance metrics similar to three existing incentive programs (i.e., the Physician Quality Reporting System, the Value-based modifier program and the Electronic Health Record Meaningful Use program) and incentivizes physicians to enroll in alternative payment methods. At this time, we do not know whether these changes to the physician payment systems will have any impact on orders or payments for our tests.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, Congress passed the 21st Century Cures Act, which, among other things, revised the process for LCDs. Additionally, effective June 11, 2017, a MAC is required to, among other things, publish a summary of the evidence that it considered when developing an LCD, including a list of sources, and an explanation of the rationale that supports the MAC&#8217;s determinations. In October 2018, CMS issued additional guidance revising the requirements for the development of LCDs. We cannot predict whether these revisions will delay future LCDs and result in impeded coverage for our test products, which could have a material negative impact on revenue.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, in its enactment of the CAA, Congress enacted the No Surprises Act. This law, which takes effect January 1, 2022, prohibits an out-of-network provider from billing a patient at an amount in excess of the in-network cost sharing for services furnished with respect to a visit at certain in-network health-care facilities. The law establishes an independent dispute resolution process between the provider and the payer to determine the appropriate payment rate to the provider. As written, the No Surprises Act may apply to laboratory tests furnished by an independent laboratory with respect to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a hospital visit. The law establishes a notice and consent exception that generally does not apply to laboratory tests, although it allows for the Secretary of the Department of Health and Human Services, or HHS, to apply the exception to certain advanced tests. HHS, the Department of Labor, and the Department of the Treasury have implemented the No Surprises Act through rulemakings issued on July 1, 2021, September 30, 2021, and August 19, 2022. The No Surprises Act, and regulations and subregulatory guidance promulgated thereunder, could limit our ability to achieve payment in full for our testing services.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because of Medicare billing rules, we may not receive reimbursement for all tests provided to Medicare patients. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under previous Medicare billing rules, hospitals were required to bill for our molecular pathology tests when performed on Medicare beneficiaries who were hospital outpatients at the time of tissue specimen collection when these tests were ordered less than 14 days following the date of the patient's discharge.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, CMS revised its billing rules to allow the performing laboratory to bill Medicare directly for molecular pathology tests and Criterion A ADLTs performed on specimens collected from hospital outpatients, even when those tests are ordered less than 14 days after the date of discharge, if certain conditions are met. We believe that our Afirma, Decipher Prostate Biopsy, Decipher Prostate RP, Envisia, and Decipher Bladder classifiers, along with Prosigna, should be covered by this policy. Accordingly, we bill Medicare for these tests when we perform them on specimens collected from hospital outpatients and meet the conditions set forth in CMS's revised billing rules.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This change does not apply to tests performed on specimens collected from hospital inpatients. We will continue to bill hospitals for tests performed on specimens collected from hospital inpatients when the test was ordered less than 14 days after the date of discharge.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the CY 2020 Hospital Outpatient Prospective Payment System Proposed Rule, CMS solicited comments on potential revisions to these billing rules that could have impacted our ability to bill Medicare directly for our Afirma, Decipher Prostate Biopsy, Decipher Prostate RP, Envisia, and Decipher Bladder classifiers, as well as for Prosigna, when performed on specimens collected from hospital outpatients. Although these changes were not finalized, if CMS makes similar changes in the future, it could negatively impact our business.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we must maintain CLIA compliance and certification to sell our tests and be eligible to bill for diagnostic services provided to Medicare beneficiaries.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA or foreign authorities were to begin regulating those of our tests that they do not currently regulate, we could incur substantial costs and delays associated with trying to obtain premarket clearance, approval or certification.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical laboratory tests have long been subject to comprehensive regulations under CLIA, as well as by applicable state laws. Most clinical diagnostic tests developed and run within a single CLIA-certified clinical laboratory (known as &#8220;laboratory developed tests&#8221; or &#8220;LDTs&#8221;), are not currently subject to regulation under the FDA's enforcement discretion policy concerning LDTs. While the FDA maintains its authority to regulate LDTs, it continues to exercise enforcement discretion not to enforce the premarket review, quality system/current Good Manufacturing Practices regulations, and other applicable medical device requirements against most LDT developers and users. Certain reagents, instruments, software or components manufactured and sold by third parties and used by their customers to manufacture or perform diagnostic tests may be subject to regulation under certain circumstances. We believe that the Afirma, Decipher Prostate Biopsy, Decipher Prostate RP, Envisia, and Decipher Bladder classifiers, have been developed and are performed in a manner consistent with FDA&#8217;s enforcement discretion policy concerning LDTs. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, the FDA issued two draft guidance documents stating that the FDA intended to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the existing classification of medical devices. Although the FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight approach to LDTs and to give Congressional authorizing committees the opportunity to develop a legislative solution, it is unclear if Congress or the FDA will modify the current approach to the regulation of LDTs in a way that would subject our current or future services marketed as LDTs to FDA regulatory requirements. The FDA Commissioner and the Director of the Center for Devices and Radiological Health, or CDRH, have expressed significant concerns regarding disparities between some LDTs and in vitro diagnostics that have been reviewed, cleared, authorized or approved by the FDA. If the FDA were to determine that Afirma, Decipher Prostate Biopsy, Decipher Prostate RP, Envisia and Decipher Bladder classifiers are not within the scope of FDA's enforcement discretion policy for LDTs for any reason, including new rules, policies or guidance, or due to changes in statute, our tests may become subject to extensive FDA requirements, or our business may otherwise be adversely affected. If the FDA were to disagree with our LDT status or modify its approach to regulating </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LDTs, we could experience reduced revenue or increased costs, which could adversely affect our business, prospects, results of operations and financial condition.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, a draft bill on the regulation of LDTs, entitled "The Diagnostics Accuracy and Innovation Act", or DAIA, was released for discussion. In December 2018, the sponsors of DAIA released a new version of the legislation called the &#8220;Verifying Accurate, Leading-edge IVCT Development Act", or VALID Act. The VALID Act proposes a risk-based approach to regulate LDTs and creates a new in vitro clinical test category, which includes LDTs, and a new regulatory structure under the FDA. Similar versions of the VALID Act have since been introduced. The most recent version was included in the Food and Drug Administration (FDA) Safety and Landmark Advancements Act (FDASLA) reported to the Senate on July 13, 2022. As proposed, the bill would create a precertification program for lower risk tests not otherwise required to go through premarket review. It would grandfather certain existing tests from some requirements but would allow the FDA to subject otherwise grandfathered tests to premarket review under certain conditions. Similarly, the Verified Innovative Testing in American Laboratories (VITAL) Act was introduced in December 2020 and re-introduced in May 2021.  In contrast with the VALID Act, the VITAL Act would prevent FDA from regulating LDTs and would instead assign regulatory authority over LDTs entirely to CMS.  We cannot predict whether either of these or other draft bills governing LDTs will become legislation and cannot quantify the effect of such draft bills on our business. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changes in the way the European Union, or EU, regulates LDTs could result in additional expenses for offering our current and any future tests or possibly delay or suspend development, or commercialization of such tests. The EU Regulation (EU) 2017/746 of April 5, 2017, repealing the IVDD, referred to as the IVD Medical Devices Regulation, or IVDR, became applicable on May 26, 2022 (subject to certain transition provisions). Under the IVDR, the general safety and performance requirements set out in Annex I are also applicable to devices that are not placed on the market but used in the context of a commercial activity. If our tests do not qualify for an exemption, we may be subject to the full application of the IVDR with respect to some or all of our existing, as well as future, tests, and we would be required to expend additional time and resources to complying with the requirements of the IVDR. Following Brexit, the IVDR will not be applicable in Great Britain (although it will apply in Northern Ireland), but the UK government is currently undertaking a consultation on the regime applicable to in vitro diagnostics in the UK, and it is anticipated that similar provisions will be introduced as under the IVDR.  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or foreign authorities were to require us to seek clearance, approval or certification for our existing tests that are not currently cleared, approved, or certified or any of our future products for clinical use, we may not be able to obtain such clearances, approvals or certifications on a timely basis, or at all. While it is possible that our Afirma, Decipher Prostate Biopsy, Decipher Prostate RP, Envisia, and Decipher Bladder classifiers, would be &#8220;grandfathered&#8221; and therefore exempted from some new regulatory requirements, there can be no assurance of what the FDA might ultimately require if it issues a rule or if legislative reforms are enacted. If premarket reviews or certifications are required, our business could be negatively impacted if we are required to stop selling our products pending their clearance, approval or certification. In addition, the launch of any new products that we develop or modifications we make to existing products could be delayed by the implementation of future FDA or foreign regulations. The cost of complying with premarket review or certification requirements, including obtaining clinical data, could be significant. In addition, any future regulation by the FDA or foreign authorities could subject our business to further regulatory risks and costs. For example, our sample collection kits are listed as Class I devices with the FDA. If the FDA were to determine that they are not Class I devices or otherwise not exempt from 510(k) clearance requirements, we would be required to file 510(k) premarket notifications and obtain FDA clearance to use the containers, which could be time consuming and expensive. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has raised potential concerns where companies manufacture and label finished clinical test kits or clinical testing components as &#8220;research use only&#8221;, or RUO, or &#8220;investigational use only&#8221;, or IUO, and either knowingly use them or sell them for use in patient care. The FDA has taken the position that if evidence demonstrates that a product which otherwise meets the definition of a regulated medical device is inappropriately labeled as RUO or IUO, the distribution, sale, or use of the product could violate the misbranding or adulteration provisions of the Federal Food, Drug, and Cosmetic Act, or the FDC Act. In the EU, under the IVDD, RUO products which are intended to be used for research purposes, without any medical objective, are not regarded as devices for performance evaluation used in diagnostic procedures. More importantly, the IVDR expressly provides that products intended for RUO are excluded from the scope of the regulation. A material intended for RUO, without any medical purpose or objective, is therefore not considered as an IVD MD and is not subject to compliance with the IVD MDs requirements. Depending on the product in question, other regulations may be applicable to the RUO products. Some of the reagents, instruments, software or components obtained by us from suppliers for use in our products are currently labeled by those suppliers as &#8220;RUO&#8221; or &#8220;IUO&#8221;. If the FDA or foreign bodies were to determine that any of these reagents, instruments, software or components are improperly labeled as RUO or IUO and undertake enforcement actions, some of our suppliers might cease selling these reagents, instruments, software or components to us or be forced to recall them, and any failure to obtain an acceptable substitute could significantly and adversely affect our business, financial condition and results of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations, including increasing the cost of testing or delaying, limiting or prohibiting the purchase of reagents, instruments, software or components necessary to perform testing.  Such actions could also lead FDA to investigate our purchase and use of supplier products and for the Agency to question whether or not Veracyte has violated the FDC Act.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulatory requirements of the FDA or foreign authorities could result in enforcement action, including receiving untitled or warning letters, fines, injunctions, or civil or criminal penalties. Any such enforcement action would have a material adverse effect on our business, financial condition and operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining marketing authorization or certification by the FDA and foreign regulatory authorities or notified regulatory bodies for our diagnostic tests will take significant time and require significant research, development and clinical study expenditures and ultimately may not succeed.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we begin to label and market some of our products for use as clinical diagnostics in the United States, unless an exemption applies, we are required to obtain clearance from the FDA by submitting a premarket notification under section 510(k) of the FDC Act or 510(k), or approval from the FDA by submitting a premarket approval, or PMA. Alternatively, we may be able to obtain marketing authorization through a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De Novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification process rather than through a PMA for class I or class II devices if the 510(k) pathway is not available. In September 2013, Prosigna was granted FDA 510(k) clearance as a prognostic indicator for distant recurrence-free survival at ten years in post-menopausal women with Stage I/II lymph node-negative or Stage II lymph node-positive (1-3 positive nodes), hormone receptor-positive breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors after they have undergone surgery in conjunction with locoregional treatment and consistent with the standard of care. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA issued guidance titled "In Vitro Companion Diagnostic Devices" that defined an IVD companion diagnostic device as an in vitro diagnostic device that provides information that is essential for the safe and effective use of a corresponding therapeutic product. The use of an IVD companion diagnostic device with a therapeutic product is stipulated in the instructions for use in the labeling of both the diagnostic device and the corresponding therapeutic product, including the labeling of any generic equivalents of the therapeutic product. The FDA stated that an IVD companion diagnostic should be submitted for review and cleared or approved through an appropriate device submission contemporaneously with the review and approval of the therapeutic product to facilitate concurrent review. The FDA guidance also stated that while there may be cases when a companion diagnostic could come to market through the 510(k) pathway, the FDA expects that most companion diagnostics will be Class III devices. An IVD diagnostic device that is not a companion diagnostic device, because it is not essential for the safe and effective use of a corresponding therapeutic product, may still be beneficial for use with a therapeutic product, but may not be identified in the labeling of the therapeutic product. It is possible that revenue from a cleared or approved beneficial or complementary IVD diagnostic device may be less than revenue from a cleared or approved IVD companion diagnostic device.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA issued another draft guidance in December 2018 specific to oncology companion diagnostic tests, which it finalized in April 2020.  The guidance explained that some oncology companion diagnostic tests can be developed in a way that results in labeling for a specific group of oncology therapeutic products, rather than a single therapeutic product. However, there is no assurance that we would be able to obtain clearance or approval for any of our diagnostic devices in development as a companion diagnostic device or that any such clearance or approval will occur without significant delay.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any marketing authorization we obtain for any future device product would be subject to regulatory requirements that would affect how we are able to market and sell the device. The FDC Act and FDA regulations place considerable requirements on medical devices, including, but not limited to, compliance with the quality system regulation, or QSR, establishment registration and product listing with the FDA, and compliance with labeling, marketing, complaint handling, medical device reporting requirements, and reporting certain corrections and removals. Obtaining FDA clearance or approval for diagnostics can be expensive and uncertain, generally may take several months to several years, and generally requires detailed and comprehensive scientific and clinical data, as well as compliance with FDA regulations for investigational devices. In addition, we have limited experience in obtaining PMA, 510(k) clearance, or De Novo authorization approval from the FDA and are therefore supplementing our operational capabilities to manage the more complex processes needed to obtain and maintain marketing authorization. Notwithstanding the expense, these efforts may never result in FDA clearance or approval. Even if we were to obtain marketing authorization, it may not be for the uses we believe are important or commercially attractive, in which case we would not market our product for those uses.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our diagnostic tests outside the United States are subject to foreign regulatory requirements governing clinical studies, vigilance reporting, marketing approval, manufacturing, regulatory inspections, product licensing, pricing and reimbursement. These regulatory requirements vary greatly from country to country. As a result, the time required to obtain approvals or certifications outside the United States may differ from that required to obtain FDA marketing authorization, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may not be able to obtain foreign regulatory approvals on a timely basis or at all. Marketing authorization from the FDA does not ensure approval or certification by regulatory authorities in other countries, and approval or certification by any foreign regulatory authority does not ensure marketing authorization or certifications by regulatory authorities in other countries or by the FDA. Foreign regulatory authorities could require additional testing beyond what the FDA requires. In addition, the FDC Act imposes requirements on the export of medical devices, such as labeling requirements, and foreign governments impose requirements on the import of medical devices from the United States. Failure to comply with these regulatory requirements or to obtain required approvals, clearances, and export certifications could impair our ability to commercialize our diagnostic products outside of the United States.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, in order to sell some of our products in the EU, those products must comply with the General Safety and Performance Requirements of the IVDR. Compliance with these requirements is a prerequisite to place IVD products on the EU market. All medical devices placed on the market in the EU must meet the General Safety and Performance Requirements laid down in Annex I to the IVDR, including the requirement that an IVD MD must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performances intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. To demonstrate compliance with the General Safety and Performance Requirements we must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. As a general rule, demonstration of conformity of IVD MDs and their manufacturers with the essential requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU regulatory landscape concerning medical devices has significantly changed, and the new IVDR governing IVD MDs became applicable on May 26, 2022 (subject to certain transitional provisions meaning that were such transitional provisions apply, the products can continue to be placed on the market under the IVDD for a certain period of time). The new requirements in the IVDR have a significant effect on the way we conduct our business in the EU and the EEA. In particularly, substantially more IVDs require the involvement of a notified body to be able to affix a CE Mark to the product, which may lead to delay in being able to place such products on the market.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2017, the IVDR was adopted to establish a modernized and more robust EU legislative framework, with the aim of ensuring better protection of public health and patient safety. Unlike directives, the IVDR does not need to be transposed into national law and therefore reduces the risk of discrepancies in interpretation across the different European markets. The IVDR increases the regulatory requirements applicable to IVD MDs in the EU and would require that we re-classify and obtain new certificates of conformity for our existing CE-marked IVD MDs by May 25, 2022, unless a transitional provision applies to the product, meaning that where such transitional provisions apply, the products can continue to be placed on the market under the IVDD for a certain period of time. For most IVD MDs, the manufacturer used to self-declare the conformity of its products with the essential requirements of the IVDD. Under the IVDR, the majority of IVD MDs require now the intervention of a notified body for conformity assessment. Notified bodies are independent organizations designated by EU member states to assess the conformity of devices before being placed on the market. The notified body audits and examines the product&#8217;s technical documentation and the manufacturer&#8217;s quality system. If satisfied that the relevant product conforms to the General Safety and Performance Requirements, the notified body issues a certificate of conformity. The manufacturer may then apply the CE Mark to the device, which allows the device to be placed on the market throughout the EU. If we fail to remain in compliance with applicable EU laws and directives, we would be unable to continue to affix the CE mark to our products, which would prevent us from selling them within the EU and European Economic Area, or EEA (which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland). </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IVDR will not be implemented in Great Britain, and since January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, has become the sovereign regulatory authority responsible for the Great Britain (i.e., England, Wales and Scotland) medical device market according to the requirements provided in the&#8239;Medical Devices Regulations 2002&#8239;(SI 2002 No 618, as amended). The UK regulation implemented the three pre-existing EU directives, including the IVDD. Following the end of the Brexit transitional period on January 1, 2021, new regulations require medical devices to be registered with the MHRA before being placed on the Great Britain market. The MHRA only registers devices where the manufacturer or their United Kingdom, or UK, Responsible Person has a registered place of business in the UK. Manufacturers based outside the UK need to appoint a UK Responsible Person that has a registered place of business in the UK to register devices with the MHRA. By July 1, 2023, in Great Britain, all medical devices will require a UK Conformity Assessed, or UKCA, mark but CE marks issued by EU notified regulatory bodies will remain valid until this time. Manufacturers may choose to use the UKCA mark on a voluntary basis until June 30, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the time being, the regulatory regime for medical devices and IVD MDs in Great Britain (England, Scotland and Wales) continues to be based on the requirements derived from current EU legislation. An MHRA public consultation was opened until end of November 2021 on the post-Brexit regulatory framework for medical devices and diagnostics. The MHRA seeks to amend the UK Medical Devices Regulations 2002, in particular to create a new access pathway to support innovation, create an innovative framework for regulating software and artificial intelligence as medical devices, reform IVD MD regulation, and foster sustainability through the reuse and remanufacture of medical devices. The regime is expected to come into force in July 2023, coinciding with the end of the acceptance period for EU CE marks in Great Britain, subject to appropriate transitional arrangements. The consultation indicated that the MHRA will publish guidance in relation to the changes to the regulatory framework and may rely more heavily on guidance to add flexibility to the regime.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the outcome of the MHRA public consultation on the post-Brexit regulatory framework for medical devices and diagnostics, the UK may choose to retain regulatory flexibility or align with the EU Medical Devices Regulation and the IVDR going forward. EU CE markings will continue to be recognized in the UK, and certificates issued by EU-registered notified regulatory bodies will be valid in the UK, until June 30, 2023. For medical devices, including IVD MDs, placed on the market in Great Britain after this period, the UKCA marking will be mandatory. In contrast, UKCA marking and certificates issued by UK notified regulatory bodies are not recognized on the EU market.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules for placing medical devices on the Northern Ireland market differ from those in Great Britain, and the IVDR will apply in Northern Ireland. Under the terms of the Northern Ireland Protocol of the Withdrawal Agreement between the EU and UK, Northern Ireland follows EU rules on medical devices, including the IVDR when applicable. Therefore, devices marketed in Northern Ireland will require assessment according to the EU regulatory regime. Such assessment may be conducted by an EU notified body, in which case a CE mark is required before placing the device on the market in the EU or Northern Ireland. Alternatively, if a UK notified body conducts such assessment, a &#8216;UKNI&#8217; mark is applied and the device may only be placed on the market in Northern Ireland and not the EU.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A mutual recognition agreement (MRA) aligning in vitro diagnostic (IVD) regulations between the European Union and Switzerland has officially expired following the In Vitro Diagnostic Medical Devices Regulation&#8217;s (IVDR) May 26, 2022 date of application, impacting certification and authorized representation requirements for manufacturers. The Swiss government has issued its own Ordinance on In Vitro Diagnostic Medical Devices (IvDO). The Swiss regulation aligns closely with the IVDR in terms of requirements for manufacturers, and follows the IVDR&#8217;s transitional timelines regarding compliance deadlines according to IVD risk classifications as well as designations of Swiss Authorized Representatives.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These modifications may have an effect on the way we intend to conduct our business in these countries.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain marketing authorizations or certifications, approvals, clearances or certifications to market Prosigna or our other assays on the nCounter Analysis System in additional countries or if regulatory limitations are placed on our diagnostic kit products, our business and growth will be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA cleared the Prosigna test for marketing in the United States. Prosigna is CE marked which permits us to market the test in the EU and Prosigna received marketing authorizations in selected other jurisdictions. We intend to seek regulatory authorizations or certifications for Prosigna in other jurisdictions and, potentially, for other indications. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to our collaborations with pharmaceutical companies for the development of companion diagnostic tests for use with their drugs, we are responsible for obtaining regulatory authorizations or certifications to use the companion diagnostic tests in clinical studies as well as the authorizations or certifications to sell the companion diagnostic tests following completion of such studies. Some of the compensation we expect to receive pursuant to these collaborations is based on the receipt of authorizations or certifications. Any failure to obtain authorizations or certifications for our diagnostic kits in a particular jurisdiction may also reduce sales of the nCounter Analysis System for clinical use in that jurisdiction, as the lack of a robust menu of available diagnostic tests would make those systems less attractive to testing laboratories.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the IVDR has introduced a new classification system for companion diagnostics which are now specifically defined as a device which is essential for the safe and effective use of a corresponding medicinal product to: (a) identify, before and/or during treatment, patients who are most likely to benefit from the corresponding medicinal product; or (b) identify, before and/or during treatment, patients likely to be at increased risk of serious adverse reactions as a result of treatment with the corresponding medicinal product. Companion diagnostics have to undergo a conformity assessment by a notified body. Before it can issue a certificate of conformity, the notified body will have to seek a scientific opinion from the European Medicines Agency or the relevant national competent authority on the suitability of the companion diagnostic to the medicinal product concerned.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure investors that we will be successful in obtaining or maintaining regulatory clearances, certifications, approvals, or marketing authorizations. If we do not obtain or maintain regulatory clearances, certifications, approvals, or marketing authorizations for future diagnostic kit products or expand future indications for diagnostic purposes, if additional regulatory limitations are placed on our diagnostic kit products or if we fail to successfully commercialize such products, the market potential for our diagnostic kit products would be constrained, and our business and growth prospects would be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing and increasingly extensive regulatory requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are regulated as IVD MDs, including Prosigna and the nCounter Analysis System. Accordingly, we and certain of our contract manufacturers are subject to ongoing International Organization for Standardization, or ISO, obligations as well as requirements under CLIA and state laboratory quality statutes and regulations, the FDC Act and related FDA regulations, and other statutory and regulatory requirements enforced by other government authorities. These may include routine inspections by notified bodies, FDA, CMS, and other health authorities, of our manufacturing facilities and our records for compliance with standards such as ISO 13485 and the QSR, which establish extensive requirements for quality assurance and control as well as manufacturing and change control procedures, among other things. These inspections may include the manufacturing facilities of any suppliers.  In the event that a supplier fails to maintain compliance with regulatory or our quality requirements, we may have to qualify a new supplier and could experience manufacturing delays as a result.  We are also subject to other regulatory obligations, such as registration of our company offices and facilities and the listing of our devices with the FDA (and similar listings and certifications in certain other countries); continued adverse event and malfunction reporting; reporting certain corrections and removals; and labeling and promotional requirements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IVDR increases the regulatory requirements applicable to in vitro diagnostics in the EU and would require that we re-classify and obtain new certificates of conformity for our existing CE-marked IVD products by May 25, 2022, unless a transitional provision applies to the product. Failure to secure these re-certifications in time will halt our ability to commercialize our products in relevant countries. Currently Prosigna is our only test that will require recertification. Moreover, complying with the stricter regulatory requirements of the IVDR, including with respect to clinical evaluation requirements, quality systems, and post-market surveillance, may require us to incur significant expenditures.  Failure to meet these requirements could adversely impact our business in the EU and EEA and other regions that tie their product registrations or regulations to the EU requirements.  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IVDR became applicable five years after publication on May 26, 2022 and once applicable to a particular product, the IVDR will among other things:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthen the rules on placing devices on the market and reinforce surveillance once they are available;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish explicit provisions on importers&#8217; and distributors&#8217; obligations and responsibilities; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose an obligation to identify a responsible person who is ultimately responsible for all aspects of compliance with the requirements of the new regulation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improve the traceability of medical devices throughout the supply chain to the end-user or patient through the introduction of a unique identification number, to increase the ability of manufacturers and regulatory authorities to trace specific devices through the supply chain and to facilitate the prompt and efficient recall of medical devices that have been found to present a safety risk;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">set up a central database (Eudamed) to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish recourse for damage caused by a defective device; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthen rules for the assessment of certain high-risk devices that may have to undergo an additional check by experts before they are placed on the market.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other regulatory bodies may also issue guidelines and regulations that could impact the development of our products, including companion diagnostic tests. For example, the European Medicines Agency recently launched an initiative to determine guidelines for the use of genomic biomarkers in the development and lifecycle of drugs. The guidelines may impose greater requirements for demonstrating the clinical validity and utility of our biomarker-based tests and may interfere with our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to develop companion diagnostics or otherwise obtain or maintain marketing authorization or certifications for our diagnostic tests.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to additional FDA or foreign regulatory authority post-marketing obligations or requirements by the FDA or foreign regulatory authority to change our current product classifications which would impose additional regulatory obligations on us. For example, FDA has issued a proposed rule to revise the QSR to more closely align with ISO 13485:2016 but that also includes proposed clarifications and additional definitions and requirements. The promotional claims we can make for Prosigna in the United States are limited to the indications for use as cleared by the FDA or outside the United States as authorized or certified by the applicable regulatory authority. If we are not able to maintain regulatory compliance, we may not be permitted to market our medical device products and/or may be subject to enforcement actions by the FDA or other governmental authorities such as the issuance of warning or untitled letters, fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution. In addition, we may be subject to similar regulatory regimes of foreign jurisdictions as we continue to commercialize our products in new markets outside of the United States and Europe. Adverse notified body, EU competent authority or FDA or global regulatory authority action in any of these areas could significantly increase our expenses and limit our revenue and profitability.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our Afirma genomic classifier we face competition from companies and academic institutions that use next generation sequencing technology or other methods to measure mutational markers such as BRAF and KRAS, along with numerous other mutations. These organizations include, Interpace Diagnostics Group, Inc., CBLPath, Inc./University of Pittsburgh Medical Center and others who are developing new products or technologies that may compete with our tests. In the future, we may also face competition from companies developing new products or technologies.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Decipher Prostate test faces competition from Myriad Genetics and MDx Health, which offer genomic testing for prognostic purposes within localized prostate cancer. New, advanced machine learning and AI technologies may become competitors to our product base, including Decipher. Additionally, traditional methods used by pathologists and clinicians to estimate risk of disease progression pose competitive threats to our business in addition to new technologies such as artificial intelligence and digital pathology. In bladder cancer, we are not currently aware of a direct competitor offering genomic testing for prognostic purposes that match the intended use population for the Decipher Bladder test. However, DNA mutational analysis and traditional clinical methods and nomograms are currently in use by physicians for similar purposes.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our primary competition in pulmonology with our Envisia classifiers will similarly come from traditional methods used by physicians to diagnose the related diseases. For the Percepta Nasal Swab test, we expect competition from companies focused on lung cancer such as Biodesix, Inc. We believe our principal competitor in the breast cancer diagnostics market is Exact Sciences, Inc., which currently commands a substantial majority of the market. Other competitors in the breast cancer diagnostics market include Myriad Genetics, Inc. and Agendia, Inc. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our portfolio of tests, we may also face competition from companies informing treatment decisions such as Guardant Health or Foundation Medicine, Inc. Competition could also emerge using alternative samples, such as blood, urine or sputum. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, we also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics, and Sonic Healthcare USA, with strong infrastructure to support the commercialization of diagnostic services. We face potential competition from companies such as Illumina, Inc. and Thermo Fisher Scientific Inc., both of which have entered the clinical diagnostics market. Other potential competitors include companies that develop diagnostic products, such as Roche Diagnostics, a division of Roche Holding Ltd, Siemens AG and Qiagen N.V., and we also may face competition from competitors of our biopharma services such as Neogenomics, Adapative, Tempus and Akoya.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors may develop their own versions of our solutions in countries we may seek to enter where we do not have patents or where our intellectual property rights are not recognized, and compete with us in those countries, including encouraging the use of their solutions by physicians in other countries.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To compete successfully, we must be able to demonstrate, among other things, that our diagnostic test results are accurate and cost effective, and we must secure a meaningful level of reimbursement for our products.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources, and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by physicians and payers as functionally equivalent to our solutions or offer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solutions at prices designed to promote market penetration, which could force us to lower the list price of our solutions and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. As we add new tests, products and services, we will face many of these same competitive risks.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We depend on our senior management team, and the loss of one or more of our executive officers, or any inability to attract and retain highly-skilled employees and other key personnel could adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on the skills, experience and performance of members of our executive management team and others in key management positions. We have in the past and may in the future experience changes in our executive management, which may be disruptive to our business. Executive transitions may impact our ability to implement our business strategy and could have a material adverse effect on our business. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life science businesses. Our success in the development and commercialization of advanced diagnostics requires a significant medical and clinical staff to conduct studies and educate physicians and payers on the merits of our tests in order to achieve adoption and reimbursement. We are in a highly competitive industry to attract and retain this talent, and the labor market in our industry is becoming increasingly competitive. Additionally, our success depends on our ability to attract and retain qualified salespeople. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be successful in maintaining and growing our business. Additionally, as we increase our sales channels for new tests we commercialize, we may have difficulties recruiting and training additional sales personnel or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our tests. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business requires specialized capabilities in reimbursement, billing, and other areas and there may be a shortage of qualified individuals. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory, sales and reimbursement, billing and finance efforts. All of our U.S. employees are at will, which means that either we or the employee may terminate their employment at any time. We do not carry key person insurance for any of our employees. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we rely, in part, on equity awards to compensate and incentivize our employees to drive our further growth. As the equity capital markets have been highly volatile in recent periods and the price of our common stock has declined, certain of our employees&#8217; equity awards have lost some or all of their value, which may limit their effectiveness as retention tools and, in the event we fail to retain such employees, may adversely affect our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Billing for our diagnostic tests is complex, and we must dedicate substantial time and resources to the billing process to be paid.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billing for clinical laboratory testing services is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, including Medicare, commercial insurance companies and patients, all of which have different billing requirements. We generally bill third-party payers for our diagnostic tests and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. To the extent laws or contracts require us to bill patient co-payments or co-insurance, we must also comply with these requirements. We may also face increased risk in our collection efforts, including potential write-offs of accounts receivable and long collection cycles, which could adversely affect our business, results of operations and financial condition including cash collections. Furthermore, third-party payers may reduce or refuse to pay for our tests, with or without notice. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several factors make the billing process complex, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences between the list price for our tests and the reimbursement rates of payers;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with complex federal and state regulations related to billing government payers, such as Medicare and Medicaid, including requirements to have an active CLIA certificate;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk of government audits related to billing Medicare and other government payers;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes among payers as to which party is responsible for payment;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in coverage and in information and billing requirements among payers, including the need for prior authorization and/or advanced notification;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of patient co-payments or co-insurance;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">individual payers may argue technical contract noncompliance and withhold payment; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to billing codes used for our tests;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incorrect or missing billing information; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resources required to manage the billing and claims appeals process.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use standard industry billing codes, known as CPT codes, to bill for our tests, including cytopathology. Through December 31, 2020, we used the CPT code 81545 to bill for our Afirma classifier. Effective January 1, 2021, we began using the new CPT code 81546 to bill for our Afirma classifier, and code 81545 was retired. Effective January 1, 2020, we began using CPT code 81542 to bill for Decipher Prostate Biopsy and Decipher Prostate RP tests. Effective January 1, 2021, we began using the new CPT code 81554 to bill for our Envisia classifier. Effective October 1, 2020, we began using CPT code 0016M to bill for our Decipher Bladder test. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CPT codes can change over time. When codes change, there is a risk of an error being made in the claim adjudication process. These errors can occur with claims submission, third-party transmission or in the processing of the claim by the payer. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment received. Coding changes, therefore, may have an adverse effect on our total revenue. Even when we receive a designated CPT code specific to our tests, there can be no assurance that payers will recognize these codes in a timely manner or that the process of transitioning to such a code and updating their billing systems and ours will not result in errors, delays in payments and a related increase in accounts receivable balances.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we introduce new tests, we will need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Correct coding is subject to the coding policies of the American Medical Association CPT Editorial Panel, or AMA CPT. With respect to claims submitted to Medicare and Medicaid, it is also subject to coding policies developed through the National Correct Coding Initiative, or NCCI. Other payers may develop their own payer-specific coding policies. The broader coding policies of the AMA CPT, NCCI, and other payers are subject to change. For instance, the NCCI adopted an update to its Coding Policy Manual effective January 1, 2019, to limit instances when multiple codes may be billed for molecular pathology testing. Although the NCCI appears to have moderated this change in its updates effective January 1, 2020, such coding policy changes may negatively affect our total revenue and cash flow.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, challenge coverage and payment denials, assist patients in appealing claims, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. Payers also conduct external audits to evaluate payments, which adds further complexity to the billing process. If the payer makes an overpayment determination, there is a risk that we may be required to return some portion of prior payments we have received. Additionally, the ACA established a requirement for providers and suppliers to report and return any overpayments received from government payers under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws. These billing complexities, and the related uncertainty in obtaining payment for our tests, could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a third-party provider to transmit claims to payers, and any delay in transmitting claims could have an adverse effect on our revenue.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we manage the overall processing of claims, we rely on a third-party provider to transmit the actual claims to payers based on the specific payer billing format. We have previously experienced delays in claims processing when our third-party provider made changes to its invoicing system, and again when it did not submit claims to payers within the timeframe we require. Additionally, coding for diagnostic tests may change, and such changes may cause short-term billing errors that may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take significant time to resolve. If claims are not submitted to payers on a timely basis or are erroneously submitted, or if we are required to switch to a different provider to handle claim submissions, we may experience delays in our ability to process these claims and receipt of payments from payers, or possibly denial of claims for lack of timely submission, which would have an adverse effect on our revenue and our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our internal sales force is less successful than anticipated, our business expansion plans could suffer and our ability to generate revenue could be diminished. In addition, we have limited history selling our molecular diagnostics tests on a direct basis and our limited history makes forecasting difficult.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.68pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our internal sales force is not successful or new additions to our sales team fail to gain traction among our customers, we may not be able to increase market awareness and sales of our molecular diagnostic tests and products. If we fail to establish our molecular diagnostic tests and products in the marketplace, it could have a negative effect on our ability to sell subsequent molecular diagnostic tests and products, thereby hindering the desired expansion of our business. We have growing, however limited, historical experience forecasting the direct sales of our molecular diagnostics tests and products. Our ability to produce total test volumes that meet customer demand is dependent upon our ability to forecast accurately and plan production capacities accordingly.</span></div><div><span><br/></span></div><div style="text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Developing new products involves a lengthy and complex process, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">if we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, our business will suffer and our stock price may decline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we expect to estimate and publicly announce the anticipated timing of the accomplishment of various clinical and other product development goals. The actual timing of accomplishment of these targets could vary dramatically compared to our estimates, in some cases for reasons beyond our control, including the impact of the COVID-19 pandemic. We cannot be certain that we will meet our projected targets and if we do not meet these as publicly announced, the commercialization of our tests may be delayed or may not occur at all and, as a result, our business will suffer and our stock price may decline.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually seek to develop enhancements to our test offerings and additional diagnostic tests that requires us to devote considerable resources to research and development. We may face challenges obtaining sufficient numbers of samples to validate a genomic signature for our products. We must provide sufficient clinical and analytical validity, as well as clinical utility studies that meet individual payer evidence requirements to obtain reimbursement. Even after launching new products, we must complete additional studies that meet the clinical evidence required by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">individual</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payers to obtain reimbursement. Moreover, we may experience delays in the development and introduction of new products due to the effects of the current COVID-19 pandemic.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to develop and commercialize diagnostic tests to be run in our CLIA lab, we need to:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expend significant funds to conduct substantial research and development;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct successful analytical and clinical studies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scale our laboratory processes to accommodate new tests; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">build the commercial, regulatory, and compliance infrastructure to market and sell new products.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development process involves a high degree of risk and may take several years. Our test and product development efforts may fail for many reasons, including:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to identify a genomic signature in biomarker discovery;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to secure sufficient numbers of samples at an acceptable cost and on an acceptable timeframe to conduct analytical and clinical studies; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of clinical validation studies to support the effectiveness of the test.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a product candidate, or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new product and our ability to invest in other products in our pipeline. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study or if we fail to sufficiently demonstrate analytical validity, we might choose to abandon the development of the product, which could harm our business. If a clinical utility study fails to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demonstrate the value of a particular test, we may not be able to obtain reimbursement for the test. In addition, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to develop products to keep pace with rapid technological, medical and scientific change, our operating results and competitive position could be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, there have been numerous advances in technologies relating to diagnostics, particularly diagnostics that are based on genomic information. These advances require us to continuously develop our technology and to work to develop new solutions to keep pace with evolving standards of care. Our solutions could become obsolete unless we continually innovate and expand our product offerings to include new clinical applications. If we are unable to develop new products or to demonstrate the applicability of our products for other diseases, our sales could decline, and our competitive position could be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Complying with numerous statutes and regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to other extensive federal, state, local, and foreign laws and regulations, all of which are subject to change. These laws and regulations currently include, among others:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which established comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions, and amendments made to those standards in 2013 pursuant to the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, which strengthened and expanded HIPAA privacy and security compliance requirements, increased penalties for violators, extended enforcement authority to state attorneys general, and imposed new requirements for breach notification;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare billing and payment regulations applicable to clinical laboratories, including requirements to have an active CLIA certificate;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Anti-kickback Statute (and state equivalents), which prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal healthcare program;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Eliminating Kickbacks in Recovery Act of 2018, which prohibits the solicitation, receipt, payment or offering of any remuneration in return for referring a patient or patronage to a recovery home, clinical treatment facility, or laboratory for services covered by both government and private payers;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Stark physician self-referral law (and state equivalents), which prohibits a physician from making a referral for certain designated health services covered by the Medicare program, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity providing the designated health services, unless the financial relationship falls within an applicable exception to the prohibition;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health-care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health-care program, unless an exception applies;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal False Claims Act, which imposes liability on any person or entity who knowingly presents, or causes to be presented, a false, fictitious, or fraudulent claim for payment to the federal government;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, enacted as part of the ACA, which imposes annual reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to covered recipients, including physicians, as defined by such law, teaching hospitals, and certain healthcare providers as well as ownership or investment interests that physicians or physicians&#8217; immediate family members hold with the reporting entity;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, fee-splitting restrictions, prohibitions on the provision of products at no or discounted cost to induce physician or patient adoption, and false claims acts, which may extend to services reimbursable by any third-party payer, including private insurers;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other party;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Protecting Access to Medicare Act of 2014, which requires us to report private payer rates and test volumes for specific CPT codes on a triennial basis and imposes penalties for failures to report, omissions, or misrepresentations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the No Surprises Act and its implementing regulations (effective January 1, 2022), which prohibit an out-of-network provider from billing a patient at an amount in excess of the in-network cost sharing for services furnished with respect to a visit at certain in-network health-care facilities, as well as various state laws restricting balance billing of patients; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rules regarding billing for diagnostic tests reimbursable by the Medicare program, which prohibit a physician or other supplier from marking up the price of the technical component or professional component of a diagnostic test ordered by the physician or other supplier and supervised or performed by a physician who does not &#8220;share a practice&#8221; with the billing physician or supplier;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that prohibit other specified practices related to billing such as billing physicians for testing that they order, waiving co-insurance, co-payments, deductibles, and other amounts owed by patients, and billing a state Medicaid program at a price that is higher than what is charged to other payers;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act of 1977, and other similar laws, which apply to our international activities;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unclaimed property (escheat) laws and regulations, which may require us to turn over to governmental authorities the property of others held by us that has been unclaimed for a specified period of time; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enforcing our intellectual property rights; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign laws and regulations equivalent to the above.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted policies and procedures designed to comply with applicable laws and regulations. In the ordinary course of our business, we conduct internal reviews of our compliance with these laws. Our compliance with some of these laws and regulations is also subject to governmental review. The growth of our business, sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years U.S. Attorneys&#8217; Offices have increased scrutiny of the healthcare industry, as have Congress, the Department of Justice, the Department of Health and Human Services&#8217; Office of the Inspector General and the Department of Defense. These bodies have all issued subpoenas and other requests for information to conduct investigations of, and commenced civil and criminal litigation against, healthcare companies based on financial arrangements with health-care providers, regulatory compliance, product promotional practices and documentation, and coding and billing practices. Whistleblowers have filed numerous qui tam lawsuits against healthcare companies under the federal and state False Claims Acts in recent years, in part because the whistleblower can receive a portion of the government&#8217;s recovery under such suits.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many member states in the EU have adopted specific anti-gift statutes that further limit commercial practices for medical devices (including IVD MDs), in particular vis-&#224;-vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities and many EU member states have adopted national &#8220;Sunshine Acts&#8221; which impose reporting and transparency requirements (often on an annual basis), similar to the requirements in the United States, on medical device manufacturers.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. If one or more such agencies alleges that we may be in violation of any of these requirements, regardless of the outcome, it could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations and other commercial third-party payers. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of these laws </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regulations, we may be subject to any applicable penalty associated with the violation, including civil and criminal penalties, damages and fines, we could be required to refund payments received by us, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal, state and local laws, rules and regulations governing the use, discharge, storage, handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, and either could negatively affect our operating results.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must successfully integrate the HalioDx and Decipher Biosciences businesses to realize the financial goals that we currently anticipate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks we face in connection with the ongoing integration of HalioDx and Decipher Biosciences include:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may have difficulties managing acquired products and tests or retaining key personnel from the acquired businesses;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not successfully integrate the acquired businesses as planned (including, for example, systems integration), there could be unanticipated adverse impacts on the acquired businesses, or we may otherwise not realize the expected return on our investments, which could adversely affect our business or operating results and potentially cause impairment to assets that we record as a part of an acquisition including intangible assets and goodwill;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results or financial condition may be adversely impacted by (i) claims or liabilities related to the acquired businesses including, among others, claims from U.S. or international regulatory or other governmental agencies, terminated employees, current or former customers or business partners, or other third parties; (ii) pre-existing contractual relationships of the acquired businesses that we would not have otherwise entered into, the termination or modification of which may be costly or disruptive to our business; (iii) unfavorable accounting treatment as a result of the acquired businesses' practices; and (iv) intellectual property claims or disputes;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prior to the acquisitions, neither HalioDx nor Decipher Biosciences were required to maintain an internal control infrastructure that would meet the standards of a public company, including the requirements of the Sarbanes-Oxley Act of 2002. During 2022, we integrated the operations of HalioDx and Decipher Biosciences into our internal control structure and implemented additional internal controls where needed. As we continue to integrate and improve the operations of HalioDx and Decipher Biosciences we may need to implement additional controls. The costs that we may incur to implement such controls and procedures may be substantial and we could encounter unexpected delays and challenges in this implementation. In addition, we may discover significant deficiencies or material weaknesses in the quality of HalioDx's or Decipher Biosciences' respective financial and disclosure controls and procedures;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may experience a failure of development activities on behalf of a HalioDx customer where HalioDx bears development risk resulting in a refund of development fees;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may fail to transition manufacturing of the test kits for the nCounter, currently produced by NanoString, to HalioDx&#8217;s manufacturing facility in Marseille, France in a timely manner or at all, or we may experience manufacturing irregularities or challenges in connection with the transition, including rolling blackouts due to energy shortages in Europe; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not realize the anticipated accretion to our gross margins as a result of transitioning manufacturing of test kits to HalioDx;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may experience disagreements with the French employee work council; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may have failed to identify or assess the magnitude of certain liabilities, shortcomings or other circumstances prior to acquiring either of the acquired businesses, which could result in unexpected litigation or regulatory exposure, unfavorable accounting treatment, a diversion of management&#8217;s attention and resources, and other adverse effects on our business, financial condition, and operating results.</span></div><div style="text-align:justify;text-indent:7.2pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are exposed to risks associated with transactions denominated in foreign currency.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the value of the relevant currencies may affect the cost of certain items required in our operations and contractual agreements. Changes in currency exchange rates may also affect the relative prices at which we are able to sell products in the same market. Our revenue from international customers may be negatively impacted as increases in the U.S. dollar relative to our international customers local currency could make our products more expensive, impacting our ability to compete. Our costs of materials from international suppliers may increase if, in order to continue doing business with us, they raise their prices as the value of the U.S. dollar decreases relative to their local currency. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. Recent global financial conditions have led to a high level of volatility in foreign currency exchange rates and that level of volatility may continue, which could adversely affect our business, financial condition, or results of operations.</span></div><div style="text-align:justify;text-indent:7.2pt"><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aspects of our international business expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy currently includes international presence and expansion in select countries and may include developing and maintaining physician outreach and education capabilities outside of the United States, establishing agreements with laboratories, and expanding our relationships with international payers. In 2021, we acquired HalioDx, an immuno-oncology diagnostics company that is based in Marseille, France, and operates globally. Doing business internationally involves a number of risks, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple, conflicting and changing laws and regulations such as tax laws, privacy laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in maintaining the manufacturing output we anticipate at the Marseille, France facility as a result of rolling blackouts due to energy shortages in Europe resulting from the Russian invasion of Ukraine;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us to obtain regulatory approvals or certifications where required for the use of our solutions in various countries;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems, including payers mandating additional evidence requirements for reimbursement consideration;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">logistics and regulations associated with shipping tissue samples, including infrastructure conditions and transportation delays;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges associated with establishing laboratory partners, including proper sample collection techniques, management of supplies, sample logistics, billing and promotional activities;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limits on our ability to penetrate international markets if we are not able to process tests locally;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial risks, such as longer payment cycles, difficulty in collecting from payers, the effect of local and regional financial crises, and exposure to foreign currency exchange rate fluctuations;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, including COVID-19, boycotts, curtailment of trade and other business restrictions (including as a direct or indirect result of the conflict in Ukraine); and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over activities that may fall within the purview of the Foreign Corrupt Practices Act of 1977, including both its books and records provisions and its anti-bribery provisions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may be adversely affected by unfavorable macroeconomic and market conditions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business or financial results may be adversely impacted by uncertain economic conditions, including: the impact of the COVID-19 pandemic, turmoil in the global banking and finance system, adverse changes in interest rates, foreign currency </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exchange rates, tax laws or tax rates; inflation; a recession; contraction in the availability of credit in the marketplace due to legislation or other economic conditions, which may potentially impair our ability to access the capital markets on terms acceptable to us or at all; and the effects of government initiatives to manage economic conditions. Many of the countries in which we operate, including the U.S. and those in Europe, have experienced and continue to experience uncertain economic conditions, including increased inflation and interest rates, resulting from global as well as local factors. For example, the short and long-term implications of the military conflict between Russia and Ukraine are difficult to predict at this time, including as it relates to our site in Marseille, France. The impact to Ukraine as well as actions taken by other countries, including new and stricter sanctions imposed by the U.S. and the European Union, and other countries and companies and organizations, could adversely affect the global economy and financial markets and thus could affect our business and results of operations, as well as the price of our common stock and our ability to raise additional capital when needed on acceptable terms.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we cannot predict how future economic conditions will affect our customers, suppliers and distributors and any negative impact on our critical customers, suppliers or distributors may also have an adverse impact on our results of operations or financial condition. A severe or prolonged economic downturn, as result of a global pandemic such as the COVID-19 pandemic or otherwise, could result in a variety of risks to our business, including weakened demand for our products and services and our ability to raise additional capital when needed on favorable terms, if at all. A weak or declining economy could strain our collaborators, possibly resulting in supply disruption, or cause delays in their payments to us. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on distributors for sales of our products outside of the United States, and on clinical laboratories for delivery of Prosigna testing services, could limit or prevent us from selling our products and impact our revenue.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established distribution agreements for the nCounter Analysis System for diagnostic use and related diagnostic kit products in certain countries where we do not sell directly. We intend to continue to grow our business internationally, and to do so we must attract additional distributors and retain existing distributors to maximize the commercial opportunity for our products. There is no guarantee that we will be successful in attracting or retaining desirable sales and distribution partners or that we will be able to enter into such arrangements on favorable terms. Distributors may not commit the necessary resources to market and sell our products to the level of our expectations or may choose to favor marketing the products of our competitors. If current or future distributors do not perform adequately, or we are unable to enter into effective arrangements with distributors in particular geographic areas, we may not realize long-term international revenue growth.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, we or our distributors have entered into agreements with clinical laboratories globally to provide Prosigna testing services. We do not provide testing services directly and, thus, we are reliant on these clinical laboratories to actively promote and sell Prosigna testing services. These clinical laboratories may take longer than anticipated to begin offering Prosigna testing services and may not commit the necessary resources to market and sell Prosigna testing services to the level of our expectations. Furthermore, we intend to contract with additional clinical laboratories to offer Prosigna testing services, including physician-owned laboratories, and we may be unsuccessful in attracting and contracting with new clinical laboratory providers. If current or future Prosigna testing service providers do not perform adequately, or we are unable to enter into contracts with additional clinical laboratories to provide Prosigna testing services, we may not be successful selling Prosigna and our future revenue prospects may be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Errors or defects in our products or services could harm our reputation, decrease market acceptance of our products or services or expose us to product liability claims, and we could face substantial liabilities that exceed our resources.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are creating new tests, products and services, many of which are initially based on novel technologies. Our new tests and products may contain undetected errors or defects that are not identified until after they are first introduced to the market. As all of our tests, products and services progress, we or others may determine that we made unintended scientific or technological mistakes or omissions. Furthermore, the testing processes utilize a number of complex and sophisticated biochemical, informatics, optical and mechanical processes, many of which are highly sensitive to external factors and variation between testing runs. Refinements to our processes may initially result in unanticipated issues that reduce efficiency or increase variability. In particular, sequencing, which is a key component of these processes, could be inefficient with higher-than-expected variability. This could increase total sequencing costs and reduce the number of samples we can process in a given time period, which may negatively impact customer turnaround time. Additionally, our laboratory operations could result in any number of errors or defects. Our quality assurance system or product development processes may fail to prevent us from inadvertent problems with samples, sample quality, lab processes including sequencing, software, data upload or analysis, raw materials, reagent manufacturing, assay quality or design, or other components or processes. Moreover, our assays may have quality or design errors, and we may have inadequate procedures or instrumentation to process samples, assemble our proprietary primer mixes and commercial materials, upload and analyze data, or otherwise conduct our laboratory operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the marketing, sale and use of our current or future tests could lead to product liability claims if someone were to allege that the tests failed to perform as they were designed. We may also be subject to liability for errors in the results we provide to physicians or for a misunderstanding of, or inappropriate reliance upon, the information we provide. Our Afirma classifiers are performed on FNA samples that are diagnosed as indeterminate by standard cytopathology review. We report results as benign or suspicious to the prescribing physician. Under certain circumstances, we might report a result as benign that later proves to have been malignant. This could be the result of the physician having poor nodule sampling in collecting the FNA, performing the FNA on a different nodule than the one that is malignant or failure of the classifier to perform as intended. We may also be subject to similar types of claims related to our Decipher Prostate, Prosigna, Envisia, and Decipher Bladder tests, as well as tests we may develop or acquire in the future. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing defects or errors could harm our reputation, decrease market acceptance of our products or services or expose us to product liability claims.  A product liability or errors and omissions liability claim could further result in substantial damages and be costly and time consuming for us to defend. Although we maintain product liability and errors and omissions insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any product liability or errors and omissions liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future.  Additionally, any product liability lawsuit could cause injury to our reputation, decrease market acceptance of our products or cause us to recall or suspend sales of our products and solutions. The occurrence of any of these events could have an adverse effect on our business and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and the operations of our laboratories are subject to the risk of disruptions caused by pandemics, political events, war, terrorism, earthquakes, fire, power outages, severe weather, floods, and other catastrophic events.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">War, terrorism, geopolitical uncertainties, including any developments or consequences of the conflict in Ukraine or related sanctions, trade restrictions, public health issues, natural disasters and other catastrophic events may cause damage or disruption to the economy and commerce on a global, regional or country-specific basis, and could disrupt supply or delivery of, or demand for, our products. For example, the COVID-19 outbreak has had, and may continue to have, a negative effect on consumer confidence and spending, and other impacts, which could adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we perform all of the Afirma and Envisia genomic classifier testing at our laboratory in South San Francisco, California, near major earthquake faults known for seismic activity and in a region affected by wildfires. We perform our urology tests in our laboratory in San Diego, California. Our laboratory in Austin, Texas accepts and stores the majority of our Afirma FNA samples pending transfer to our California laboratory for genomic test processing. Our manufacturing facility in Marseille, France, produces many of our Prosigna tests, as well as products for our IVD manufacturing business, and is subject to the risk of power outages resulting from constrained European energy supply.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laboratories and equipment we use to perform our tests would be costly to replace and could require substantial lead time to replace and qualify for use if they became inoperable. Either of our facilities may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, flooding and power outages, which may render it difficult or impossible for us to perform our testing services for some period of time or to receive and store samples. The inability to perform our tests for even a short period of time may result in the loss of customers or harm our reputation, and we may be unable to regain those customers in the future. Although we maintain insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at all. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize new solutions and technologies and expand our operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect continued capital expenditures and operating losses over the next few years as we expand our infrastructure, commercial operations and research and development activities. We may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements. Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, dilution to our stockholders could result. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings could impose significant restrictions on our operations. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants, such as limitations on our ability to incur debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline. In the event that we enter into collaborations or licensing arrangements </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third-party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. The trading prices for our common stock and other companies have been highly volatile as a result of the COVID-19 pandemic, which may reduce our ability to access capital on favorable terms or at all. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our products or development programs, which could lower the economic value of those programs to our company.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, on March 10, 2023, SVB was closed by the California Department of Financial Protection &amp; Innovation, and the FDIC was named as Receiver. At the time of closing on March 10, 2023, we had cash and cash equivalents and short-term investments at SVB or under SVB management. While the majority of these assets were not restricted by the FDIC action to take control of SVB as most of our cash and cash equivalents and short-term investments resided in a custodial account with a third-party bank for which SVB acted as advisor and the FDIC has taken steps to make whole all depositors of SVB, there is no assurance that similar guarantees will be made in the event of further bank closures and continued instability in the global banking system. Our ongoing cash management strategy is to maintain diversity in our deposit accounts across financial institutions, but deposits in these institutions may exceed the amount of insurance provided on such deposits and there can be no assurance that this strategy will be successful. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, then our ability to access our cash and cash equivalents and short-term investments may be threatened, which could have a material adverse effect on our business and financial condition. Moreover, events such as the closure of SVB, in addition to other global macroeconomic conditions, may cause further turbulence and uncertainty in the capital markets.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches, loss of data and other disruptions to our or our third-party service providers' data systems could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party service providers collect and store sensitive data, including legally protected health information, other personally identifiable information, credit card information, intellectual property, and our proprietary business and financial information. We manage and maintain our applications and data utilizing a combination of on-site systems, managed data center systems and cloud-based data center systems. We face a number of risks related to our protection of, and our service providers&#8217; protection of, this critical information, including loss of access, inappropriate disclosure and inappropriate access, as well as risks associated with our ability to identify and audit such events. System failures or outages, including any potential disruptions due to significantly increased global demand on certain cloud-based systems during the COVID-19 pandemic, could compromise our ability to protect sensitive information and prevent business interference, which could harm our ability to conduct business and/or delay our financial reporting. Such failures could materially adversely affect our operating results and financial condition.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance or other activities. While we are not currently aware of any such attack or breach having occurred, if such an event were to occur and cause interruptions in our operations, our networks would be compromised and the information we store on those networks could potentially be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability, and penalties under federal, state, and international laws and regulations that protect the privacy and security of personal information, such as the HIPAA regulations and the EU General Data Protection Regulation, or GDPR. Unauthorized access, loss or dissemination of such data also could disrupt our operations, including our ability to process tests, provide test results, bill payers or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process, and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business, any of which could adversely affect our business, including by materially damaging our reputation.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the interpretation and application of consumer, health-related and data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory, and in flux. It is possible that these laws may be interpreted and enforced in a manner that we have not anticipated in designing our practices and compliance policies. If so, this could result in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. Certain health-related and data protection requirements have been modified under section 319 of the Public Health Service Act during the Public Health Emergency, or PHE, first declared January 31, 2020, which was most recently extended effective January 11, 2023. The Biden Administration has announced that it intends to lift the PHE declaration on May 11, 2023. In addition, we are subject to various state laws, including the California Consumer Privacy Act, or CCPA, which, among other things, requires covered companies to provide disclosures to California consumers concerning the collection and sale of personal information, and gives such consumers the right to opt out of certain sales of personal information. Amendments to the CCPA have been made since its enactment in 2018, most significantly in the form of amendments and expansions pursuant to the California Privacy Rights Act adopted by ballot measure in November 2020, and it remains unclear what, if any, further amendments will be made to this legislation or how it will be interpreted. We cannot yet predict the impact of the CCPA or similar laws on our business or operations, but they may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks associated with data privacy issues, including evolving laws, regulations and associated compliance efforts, may adversely impact our business and financial results.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation in various countries around the world with regard to cybersecurity, privacy and data protection is rapidly expanding and creating a complex compliance environment. We are subject to many federal, state, and foreign laws and regulations, including those related to privacy, rights of publicity, data protection, content regulation, intellectual property, health and safety, competition, protection of minors, consumer protection, employment, and taxation. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent developments in Europe have created compliance uncertainty regarding the processing of personal data from Europe. For example, the GDPR, which became effective in the EU on May 25, 2018, applies to our activities conducted from an establishment in the EU or related to products and services that we offer to EU users. The GDPR imposed new compliance obligations applicable to our business, including accountability obligations requiring data controllers and processors to maintain a record of their data processing and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and to disclose to data subjects how their personal data is to be used, protected, and shared; imposes limitations on retention of personal data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. Continued compliance with these obligations could cause us to change our business practices, and we risk financial penalties for noncompliance (including possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million (whichever is higher) for the most serious infringements). In addition, the GDPR prohibits the transfer of personal data from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws unless a data-protective transfer mechanism has been put in place. On July 16, 2020, the Court of Justice of the European Union, or CJEU, issued a decision undermining the validity of the data-protective transfer mechanisms previously relied on, creating widespread uncertainty about compliance with the GDPR rules on data transfers to non-&#8220;adequate&#8221; jurisdictions. The EU Commission announced in December 2022 that it had begun the process of adopting an adequacy decision that would apply to the United States based on an executive order issued by President Biden in October 2022; even if the EU Commission approves the adequacy decisions, however, it is widely expected that the new data transfer framework may be challenged before the CJEU.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the CJEU generally confirmed the validity of the European Commission-approved &#8220;Standard Contractual Clauses&#8221;, or SCCs, as a personal data-protective transfer mechanism, it made clear that reliance on the SCCs alone may not necessarily be sufficient in all circumstances. Use of the SCCs must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. In response to the CJEU decision, the European Commission has published revised SCCs; existing SCC arrangements were required to be migrated to the revised SCCs by December 27, 2022. We were required to implement the revised SCCs, in relation to relevant existing contracts and certain additional contracts and arrangements, by that date. In addition, the revised SCCs are not to be relied on for data transfers to non-EEA entities subject to the GDPR, and we are waiting for further guidance on valid mechanisms for data transfers from the EEA to such entities.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the United Kingdom&#8217;s withdrawal from the EEA and the EU, and the expiry of the transition period, companies processing the information of EU data subjects have to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover.  The European Commission has adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from EU member states to the United Kingdom without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews/ extends that decision, and remains under review by the Commission during this period. The relationship between the United Kingdom and the EU in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. These developments may lead to additional costs and increase our overall risk exposure.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to civil and criminal penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CCPA established individual privacy rights for California consumers and places increased privacy and data security obligations on entities handling personal information of consumers or households. The CCPA was amended several times after its enactment, most recently by the California Privacy Rights Act, or the CPRA, which, as of its effective date of January 1, 2023, gives California residents expanded privacy rights, including the right to opt out of certain personal information sharing, the use of &#8220;sensitive personal information,&#8221; and the use of personal information for automated decision-making or targeted advertising.  The CCPA and CPRA provide for civil penalties and a private right of action for data breaches that is expected to increase data breach litigation. The CCPA and CPRA may increase our compliance costs and potential liability. Following the lead of California, several other states, including Colorado, Utah, Virginia and Connecticut have each enacted laws similar to the CCPA/CPRA and other states are considering enacting privacy laws as well. The multiple layers of privacy law within the United States could increase our potential liability, increase our compliance costs, and adversely affect our business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other countries outside of the United States and Europe have enacted or are considering enacting similar crossborder data transfer restrictions and laws requiring local data residency and restricting crossborder data transfer, which could increase the cost and complexity of delivering our services and operating our business. For example, Brazil recently enacted the General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais or LGPD) (Law No. 13,709/2018), and effective November 1, 2021 was China&#8217;s Personal Information Protection Law (&#20010;&#20154;&#20449;&#24687;&#20445;&#25252;&#27861;, PIPL), both of which broadly regulate the processing of personal information and impose compliance obligations and penalties comparable to those of the GDPR.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These recent developments are likely to require us to review and amend the legal mechanisms by which we make and/ or receive personal data transfers to/in the United States and other countries outside of the EEA. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or commence enforcement actions, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services and/or the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot license rights to use technologies on reasonable terms, we may not be able to commercialize new products in the future.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may license third-party technology to develop or commercialize new products. In return for the use of a third-party&#8217;s technology, we may agree to pay the licensor royalties based on sales of our solutions. Royalties are a component of cost of revenue and affect the margins on our solutions. We may also need to negotiate licenses to patents and patent applications after introducing a commercial product. Our business may suffer if we are unable to enter into the necessary licenses on acceptable terms, or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the license or fail to prevent infringement by third parties, or if the licensed patents or other rights are found to be invalid or unenforceable.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property effectively, our business would be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply for and in-license patents covering our products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our current or future patented technologies. We may not be successful in defending any challenges made against our patents or patent applications. Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents and increased competition to our business. The outcome of patent litigation can be uncertain and any attempt by us to enforce our patent rights against others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies&#8217; patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of methods for analyzing or comparing nucleic acids.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, the patent positions of companies engaged in the development and commercialization of genomic diagnostic tests are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to certain diagnostic tests and related methods. These decisions state, among other things, that patent claims that recite laws of nature (for example, the relationship between blood levels of certain metabolites and the likelihood that a dosage of a specific drug will be ineffective or cause harm) are not themselves patentable. What constitutes a law of nature is uncertain, and it is possible that certain aspects of genomic diagnostics tests would be considered natural laws. Accordingly, the evolving case law in the United States may adversely affect our ability to obtain patents and may facilitate third-party challenges to any owned and licensed patents.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties protecting and defending such rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or in interpretations of patent laws in the United States or other countries may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third-party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that our employees have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and face increased competition to our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential products, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, competitors could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. Others may independently develop similar or alternative products and technologies or replicate any of our products and technologies. If our intellectual property does not adequately protect us against competitors&#8217; products and methods, our competitive position could be adversely affected, as could our business.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not registered certain of our trademarks in all of our potential geographic markets. If we apply to register these trademarks, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. If some other business in one of these markets already owns a trademark that is confusingly similar to one of our trademarks, we may be prohibited from entering that market under our trademark unless we re-brand our product in that location. Similarly, if we develop a new product line, there is no guarantee that one of our existing trademarks will be available as the brand for that new product line.  Under those circumstances, we may incur the cost of developing a new trademark for this new product line.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage of our competitors&#8217; products, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time consuming and expensive.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in litigation related to intellectual property, which could be time-intensive and costly and may adversely affect our business, operating results or financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may receive notices of claims of direct or indirect infringement or misappropriation or misuse of other parties&#8217; proprietary rights from time to time. Some of these claims may lead to litigation. We cannot assure you that we will prevail in such actions, or that other actions alleging misappropriation or misuse by us of third-party trade secrets, infringement by us of third-party patents and trademarks or other rights, or the validity of our patents, trademarks or other rights, will not be asserted or prosecuted against us.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings, or other post-grant proceedings declared by the U.S. Patent and Trademark Office that could result in substantial cost to us. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, the patent laws of the United States allow for various post-grant opposition proceedings, and their outcome can be difficult to predict. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary for us to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any litigation or other proceeding is inherently uncertain and might not be favorable to us, and we might not be able to obtain licenses to technology that we require on acceptable terms or at all. Further, we could encounter delays in product introductions, or interruptions in product sales, as we develop alternative methods or products. In addition, if we resort to legal proceedings to enforce our intellectual property rights or to determine the validity, scope and coverage of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we move into new markets and applications for our products, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and, in the future, have significantly larger and more mature patent portfolios than we currently have. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial success may depend in part on our non-infringement of the patents or proprietary rights of third parties. Numerous significant intellectual property issues have been litigated, and will likely continue to be litigated, between existing and new participants in our existing and targeted markets and competitors may assert that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into or growth in those markets. Third parties may assert that we are employing their proprietary technology without authorization. In addition, our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our products infringes these patents. We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products, and could result in the award of substantial damages against us. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, and obtain one or more licenses from third parties, or be prohibited from selling certain products. We may not be able to obtain these licenses on acceptable terms, if at all. We could incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our financial results. In addition, we could encounter delays in product introductions while we attempt to develop alternative methods or products to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products, and the prohibition of sale of any of our products could materially affect our business and our ability to gain market acceptance for our products. With respect to trademarks, infringement litigation or threats of infringement litigation may require us to re-brand our product in order to enter into the new mark.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards may be limited and may result in increased future tax liability to us.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception and may never achieve profitability. As of December 31, 2022, we had net operating loss, or NOL, carryforwards of approximately $402.0 million, $78.8 million and $126.1 million available to reduce future taxable income, if any, for federal, California and other state income tax purposes, respectively. The U.S. federal NOL carryforwards will begin to expire in 2031 while for state purposes, the NOL carryforwards begin to expire in 2023. In addition, as of December 31, 2022, we had foreign net operating loss carryforwards of approximately $69.9 million and $44.2&#160;million available to reduce future taxable income, if any, for Canadian and French income tax purposes, respectively. The Canada net operating loss carryforwards will begin to expire in 2034, while for French purposes, the net operating losses will carryforward indefinitely. These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Cuts and Jobs Acts, or Tax Act, which was enacted in December 2017, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. We may be limited in the portion of NOL carryforwards that we can use in the future to offset taxable income for U.S. federal and state income tax purposes, and federal tax credits to offset federal tax liabilities. Sections 382 and 383 of Internal Revenue Code limit the use of NOLs and tax credits after a cumulative change in corporate ownership of more than 50% occurs within a three-year period. The limitation could prevent a corporation from using some or all its NOL and tax credits before they expire within their normal 20-year lifespan, as it places a formula limit of how much NOL and tax credits a loss corporation can use in a tax year. In the event we have undergone an ownership change under Section 382 of the Internal Revenue Code, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability to us.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into law. The CARES Act changes certain provisions of the 2017 Tax Act. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminates the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021, and increases the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of interest expense that may be deducted to 50% of adjusted taxable income for taxable years beginning in 2019 or 2020. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act, as modified by the CARES Act, is uncertain and our business, financial conditions, results of operations and growth prospects could be materially and adversely affected.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to Internal Revenue Code Section 174 under the 2017 Tax Cuts and Jobs Act went into effect in 2022. The revised code no longer permits a deduction for research and development expenditures in the tax year that such costs are incurred. Instead, such costs must be capitalized and amortized over five or 15 years for U.S. and foreign costs, respectively. The new rules will change the utilization of our NOLs and it is uncertain whether the new rules will be repealed or modified in the future.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment in the value of our goodwill or other intangible assets could have a material adverse effect on our operating results and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record goodwill and intangible assets at fair value upon the acquisition of a business. Goodwill represents the excess of amounts paid for acquiring businesses over the fair value of the net assets acquired. Goodwill and indefinite-lived intangible assets are evaluated for impairment annually, or more frequently if conditions warrant, by comparing the carrying value of a reporting unit to its estimated fair value. Intangible assets with definite lives are reviewed for impairment when events or circumstances indicate that their carrying value may not be recoverable. Declines in operating results, divestitures, sustained market declines and other factors that impact the fair value of our reporting unit could result in an impairment of goodwill or intangible assets and, in turn, a charge to net income. Any such charges could have a material adverse effect on our results of operations or financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of amounts that have been accrued.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the United States and various foreign jurisdictions. Our effective tax rate may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our revenue from country to country, the establishment or release of valuation allowances against our deferred tax assets, and changes in tax laws. In addition, we have recorded gross unrecognized tax benefits in our consolidated financial statements that, if recognized, would impact our effective tax rate. We are subject to tax audits in various jurisdictions, including the United States, and tax authorities may disagree with certain positions we have taken and assess additional taxes. There can be no assurance that we will accurately predict the outcomes of these audits, and the actual outcomes could have a material impact on our net income or financial condition. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business and results of operations. The recognition of deferred tax assets is reduced by a valuation allowance if it is more likely than not that the tax benefits will not be realized. We regularly review our deferred tax assets for recoverability and establish a valuation allowance based on historical income, projected future income, the expected timing of the reversals of existing temporary differences, and the implementation of tax-planning strategies.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported operating results.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. GAAP is subject to interpretation by the Financial Accounting Standards Board, the Securities and Exchange Commission, or the SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in accounting standards or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before the change is effective. New accounting pronouncements and varying interpretations of accounting pronouncements have occurred and may occur in the future. Changes to existing rules or the questioning of current practices may adversely affect our reported financial results or the way we conduct our business.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our condensed consolidated financial statements are subject to change and if our estimates or judgments relating to our critical accounting policies prove to be incorrect, our operating results could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and related notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, as provided in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Quarterly Report on Form 10-Q. The results of these estimates form the basis for making judgments about the carrying values of assets, liabilities, and equity, and the amount of revenue and expenses that are not readily apparent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from other sources. In addition, when we acquire businesses, we make judgments about how best to account for their revenue, assets and liabilities in our condensed consolidated financial statements. These judgments may be based on limited information, estimates and various assumptions, which we may revisit as we more fully integrate such businesses into our company. Critical accounting policies and estimates used in preparing our consolidated financial statements include those related to: revenue recognition; write-down of supplies; the useful lives of property, plant and equipment; the recoverability of long-lived assets; the incremental borrowing rate for leases; the estimation of the fair value of intangible assets and contingent consideration; variable interest entity assessment; impairment of equity investment, at cost; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; reserve on accounts receivable and contingencies. Our operating results may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the price of our common stock.</span></div><div style="text-align:justify;text-indent:43.2pt"><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Being a Public Company</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating results.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we will continue to incur significant legal, accounting, consulting and other expenses that we did not incur as a private company, including costs associated with public company accounting and reporting requirements. In addition, the Sarbanes-Oxley Act of 2002 and the Dodd-Frank Act of 2010, as well as rules implemented by the SEC, and The Nasdaq Stock Market LLC, impose a number of requirements on public companies, including with respect to corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance and disclosure obligations. Moreover, these rules and regulations have and will continue to increase our legal, accounting and financial compliance costs and make some activities more complex, time-consuming and costly. We also expect that it will continue to be expensive for us to maintain director and officer liability insurance.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section 404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal controls on an annual basis. If we have material weaknesses in our internal control over financial reporting, we may not detect errors on a timely basis and our consolidated financial statements may be materially misstated. We will need to maintain and enhance the systems, processes and documentation necessary to comply with Section 404 of the Sarbanes-Oxley Act as we grow, and we will require additional management and staff resources to do so. Additionally, even if we conclude our internal controls are effective for a given period, we may in the future identify one or more material weaknesses in our internal controls, in which case our management will be unable to conclude that our internal control over financial reporting is effective. We are also required to include an attestation report from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting annually. Further, our recent acquisitions of Decipher Biosciences and HalioDx, both of which were previously private companies and were not subject to audits of internal controls, require or will require us to incorporate additional controls to such businesses, which may be difficult, costly and time-consuming. Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented or reviewed.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to conclude that our internal control over financial reporting is effective, or if our auditors were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material weaknesses, investors could lose confidence in the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Irrespective of compliance with Section 404, any failure of our internal control over financial reporting could have a material adverse effect on our reported operating results and harm our reputation. Internal control deficiencies could also result in a restatement of our financial results.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investors&#8217; expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks.</span></div><div style="text-align:justify;text-indent:7.2pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increasing focus from certain investors, employees, regulators and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance, or ESG, matters. Some investors may use these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-financial performance factors to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our policies and actions relating to corporate responsibility are inadequate. We may face reputational damage in the event that we do not meet the ESG standards set by various constituencies.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if our competitors&#8217; corporate social responsibility performance is perceived to be better than ours, potential or current investors may elect to invest with our competitors instead. In addition, in the event that we communicate certain initiatives and goals regarding environmental, social and governance matters, we could fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could be criticized for the scope of such initiatives or goals. If we fail to satisfy the expectations of investors, employees and other stakeholders or our initiatives are not executed as planned, our reputation and business, results of operations, and financial condition could be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in our and our competitors&#8217; results of operations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the global macroeconomic impact of the current COVID-19 outbreak, rising interest rates or inflationary pressures;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of new products, commercial relationships or capital commitments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in reimbursement by current or potential payers, including governmental payers;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of new securities analysts&#8217; reports or changed recommendations for our stock;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our revenue, due in part to the way in which we recognize revenue;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in regulatory oversight of our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning our intellectual property or other proprietary rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement of, or our involvement in, litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announced or completed acquisitions of businesses or technologies by us or our competitors, including the effect of additional equity we or our competitors issue as consideration for such acquisitions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">instability in the global banking system;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any major change in our management; and</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic conditions, including inflation and changes in interest rates, and slow or negative growth of our markets.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for stock of life sciences companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may cause the trading volume of our stock to decrease. In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could discourage, delay or prevent a change in control and may affect the trading price of our common stock.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our restated certificate of incorporation and our amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our restated certificate of incorporation and amended and restated bylaws include provisions that:</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue, without further action by the stockholders, up to 5.0 million shares of undesignated preferred stock;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that special meetings of our stockholders can be called only by our board of directors, our chairman of the board, or our chief executive officer;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that our directors may be removed only for cause;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that vacancies on our board of directors may, except as otherwise required by law, be filled only by a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that no stockholder is permitted to cumulate votes at any election of directors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require a super-majority of votes to amend certain of the above-mentioned provisions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers. Section 203 generally prohibits us from engaging in a business combination with an interested stockholder subject to certain exceptions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:7.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid dividends on any of our capital stock and currently intend to retain any future earnings to fund the growth of our business. We may enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future.</span></div><div style="text-align:justify;text-indent:7.2pt"><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 4. Mine Safety Disclosures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Not applicable.</span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5. Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div><span><br/></span></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_121"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ITEM 6.&#160; EXHIBITS</span></div><div style="text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filed <br/>Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1384101/000138410123000007/ex31veracyte-amendedandres.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1384101/000138410123000007/ex31veracyte-amendedandres.htm">Amended and Restated Bylaws of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36156</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/10/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31103-31x2023.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31103-31x2023.htm">Certification of Principal Executive Officer pursuant to Rules 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31203-31x2023.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31203-31x2023.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32103-31x2023.htm">32.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32103-31x2023.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. &#167; 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32203-31x2023.htm">32.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32203-31x2023.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167; 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item&#160;601(b)(32)(ii)&#160;of Regulation&#160;S-K and SEC Release No.&#160;34-47986, the certifications furnished in Exhibits&#160;32.1 and 32.2 hereto are deemed to accompany this Form&#160;10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except to the extent that the registrant specifically incorporates it by reference.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i4f2ef3d807284fb8b2bf2284d857f08c_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4f2ef3d807284fb8b2bf2284d857f08c_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:6.75pt"><span><br/></span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;5, 2023 </span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:111.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VERACYTE,&#160;INC.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rebecca Chambers</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebecca Chambers</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31103-31x2023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i76a2a435162641489996fecf4b5e2042_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL EXECUTIVE OFFICER&#8217;S CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Marc Stapley, certify that&#58;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Veracyte,&#160;Inc. for the quarter ended March&#160;31, 2023&#59;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160; &#160; &#160; &#160; &#160; &#160; Based&#160;on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2023</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Marc Stapley</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Stapley</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31203-31x2023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i50b6fa0becb74f0bb31c6b1a7054fc73_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL FINANCIAL OFFICER&#8217;S CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Rebecca Chambers, certify that&#58;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160; I have reviewed this quarterly report on Form&#160;10-Q of Veracyte,&#160;Inc. for the quarter ended March&#160;31, 2023&#59;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2023</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Rebecca Chambers</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebecca Chambers</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32103-31x2023.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8b1fc14ddca74c54a90f176af60a8fe9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Veracyte,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to such officer&#8217;s knowledge&#58;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:81pt"><font><br></font></div><div style="padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2023</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Marc Stapley</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Stapley</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:center;text-indent:6.75pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32203-31x2023.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibdf3d2cd462e43909c5d65fd187fc768_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.2</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Veracyte,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to such officer&#8217;s knowledge&#58;</font></div><div style="text-indent:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:81pt"><font><br></font></div><div style="padding-left:81pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2023</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Rebecca Chambers</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebecca Chambers</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:center;text-indent:6.75pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vcyt-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7dabdad4-bfd4-4b85-9e97-316e8975136b,g:d42a5b32-51ee-4157-98c8-837d0a6f976e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vcyt="http://www.veracyte.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.veracyte.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vcyt-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.veracyte.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShare" roleURI="http://www.veracyte.com/role/NetLossPerCommonShare">
        <link:definition>0000009 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.veracyte.com/role/BalanceSheetComponents">
        <link:definition>0000010 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.veracyte.com/role/FairValueMeasurements">
        <link:definition>0000011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.veracyte.com/role/CommitmentsandContingencies">
        <link:definition>0000012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.veracyte.com/role/StockholdersEquity">
        <link:definition>0000013 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofOtherIncome" roleURI="http://www.veracyte.com/role/ComponentsofOtherIncome">
        <link:definition>0000014 - Disclosure - Components of Other Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.veracyte.com/role/IncomeTaxes">
        <link:definition>0000015 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000016 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000017 - Disclosure - Organization , Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareTables" roleURI="http://www.veracyte.com/role/NetLossPerCommonShareTables">
        <link:definition>0000018 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsTables">
        <link:definition>0000019 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.veracyte.com/role/FairValueMeasurementsTables">
        <link:definition>0000020 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000021 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.veracyte.com/role/StockholdersEquityTables">
        <link:definition>0000022 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofOtherIncomeTables" roleURI="http://www.veracyte.com/role/ComponentsofOtherIncomeTables">
        <link:definition>0000023 - Disclosure - Components of Other Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000024 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails" roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails">
        <link:definition>0000025 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Third-party Payers And Other Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails" roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails">
        <link:definition>0000026 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareDetails" roleURI="http://www.veracyte.com/role/NetLossPerCommonShareDetails">
        <link:definition>0000027 - Disclosure - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsNarrativeDetails" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsNarrativeDetails">
        <link:definition>0000028 - Disclosure - Balance Sheet Components - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofIntangibleAssetsDetails" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails">
        <link:definition>0000029 - Disclosure - Balance Sheet Components - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1">
        <link:definition>0000029 - Disclosure - Balance Sheet Components - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails">
        <link:definition>0000030 - Disclosure - Balance Sheet Components - Schedule of Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails">
        <link:definition>0000031 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>0000032 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementInputDetails" roleURI="http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails">
        <link:definition>0000033 - Disclosure - Fair Value Measurements - Fair Value Measurement Input (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>0000034 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails" roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails">
        <link:definition>0000035 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1">
        <link:definition>0000035 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofOperatingLeaseExpenseDetails" roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseExpenseDetails">
        <link:definition>0000036 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.veracyte.com/role/StockholdersEquityDetails">
        <link:definition>0000037 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofOtherIncomeDetails" roleURI="http://www.veracyte.com/role/ComponentsofOtherIncomeDetails">
        <link:definition>0000038 - Disclosure - Components of Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.veracyte.com/role/IncomeTaxesDetails">
        <link:definition>0000039 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember" abstract="true" name="BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_PerceptaProductTechnologyMember" abstract="true" name="PerceptaProductTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_FacilitiesInMarseilleFranceMember" abstract="true" name="FacilitiesInMarseilleFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_NCounterDxLicenseMember" abstract="true" name="NCounterDxLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_OtherNonoperatingIncomeExpenseOther" abstract="false" name="OtherNonoperatingIncomeExpenseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_HalioDXDevelopedTechnologyMember" abstract="true" name="HalioDXDevelopedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember" abstract="true" name="BiopharmaceuticalAndOtherContractManufacturingAndTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit" abstract="false" name="OtherNonoperatingIncomeExpenseForeignTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_TestingMember" abstract="true" name="TestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss" abstract="false" name="OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_EmployeeAndNonEmployeeStockOptionMember" abstract="true" name="EmployeeAndNonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_UnitedHealthcareMember" abstract="true" name="UnitedHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_HalioDxCustomerRelationshipsMember" abstract="true" name="HalioDxCustomerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty" abstract="false" name="DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_NanostringMember" abstract="true" name="NanostringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" abstract="false" name="ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vcyt_DevelopedProductTechnologyMember" abstract="true" name="DevelopedProductTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_LymphmarkProductTechnologyMember" abstract="true" name="LymphmarkProductTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember" abstract="true" name="HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_DecipherBioSciencesProductTechnologyMember" abstract="true" name="DecipherBioSciencesProductTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_OtherNonoperatingIncomeExpenseInterestExpense" abstract="false" name="OtherNonoperatingIncomeExpenseInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_ProsignaCustomerRelationshipsMember" abstract="true" name="ProsignaCustomerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_HalioDxCustomerBacklogMember" abstract="true" name="HalioDxCustomerBacklogMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_BusinessCombinationContingentConsiderationCashToBePaid" abstract="false" name="BusinessCombinationContingentConsiderationCashToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember" abstract="true" name="HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_DecipherBiosciencesTradeNamesMember" abstract="true" name="DecipherBiosciencesTradeNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_MeasurementInputProbabilityOfAchievementMember" abstract="true" name="MeasurementInputProbabilityOfAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_BiopharmaceuticalAndOtherMember" abstract="true" name="BiopharmaceuticalAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_MajorCustomersMember" abstract="true" name="MajorCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue" abstract="false" name="IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_OtherNonoperatingIncomeExpenseInterestIncome" abstract="false" name="OtherNonoperatingIncomeExpenseInterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vcyt_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>vcyt-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7dabdad4-bfd4-4b85-9e97-316e8975136b,g:d42a5b32-51ee-4157-98c8-837d0a6f976e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e3491197-4ba2-4434-ac01-72984f63f00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d46b9f7c-7b22-4500-86dd-c9422876a2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e3491197-4ba2-4434-ac01-72984f63f00f" xlink:to="loc_us-gaap_AssetsCurrent_d46b9f7c-7b22-4500-86dd-c9422876a2df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_08e7dfeb-c38f-44c8-9cdd-742a09936e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e3491197-4ba2-4434-ac01-72984f63f00f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_08e7dfeb-c38f-44c8-9cdd-742a09936e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_edf8505b-a8d8-4e64-bcb3-a6b46d26efc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e3491197-4ba2-4434-ac01-72984f63f00f" xlink:to="loc_us-gaap_Goodwill_edf8505b-a8d8-4e64-bcb3-a6b46d26efc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a949d102-920f-4e18-8a1d-1d2ecd5182f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e3491197-4ba2-4434-ac01-72984f63f00f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a949d102-920f-4e18-8a1d-1d2ecd5182f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e7e5d202-73a7-443b-bb7c-997b61fa645e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e3491197-4ba2-4434-ac01-72984f63f00f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e7e5d202-73a7-443b-bb7c-997b61fa645e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4832c695-9df0-4102-981d-9d240ff7f515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e3491197-4ba2-4434-ac01-72984f63f00f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4832c695-9df0-4102-981d-9d240ff7f515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e35da901-d234-415b-b808-6fed3db4de78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e3491197-4ba2-4434-ac01-72984f63f00f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e35da901-d234-415b-b808-6fed3db4de78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_50c490da-4cf4-4362-9818-71961be5d560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_20bfed73-ad14-4614-a034-9ebe8fbeb110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50c490da-4cf4-4362-9818-71961be5d560" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_20bfed73-ad14-4614-a034-9ebe8fbeb110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ddb4981-c7db-4a95-9769-31f9c37686bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50c490da-4cf4-4362-9818-71961be5d560" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ddb4981-c7db-4a95-9769-31f9c37686bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_75193344-b3dd-40a9-95b6-667647ab8818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50c490da-4cf4-4362-9818-71961be5d560" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_75193344-b3dd-40a9-95b6-667647ab8818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f4ec704b-364b-4005-a68c-e983b0037840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50c490da-4cf4-4362-9818-71961be5d560" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f4ec704b-364b-4005-a68c-e983b0037840" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_037432c3-bb8d-45a1-a9bc-b58d6a06c814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50c490da-4cf4-4362-9818-71961be5d560" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_037432c3-bb8d-45a1-a9bc-b58d6a06c814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4880a3b0-deb2-45d9-b1be-a17ba3633029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50c490da-4cf4-4362-9818-71961be5d560" xlink:to="loc_us-gaap_AccountsPayableCurrent_4880a3b0-deb2-45d9-b1be-a17ba3633029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_146e7d8a-d5db-4829-ab13-6a4ea8362c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_25959d36-72e6-4c16-86c0-28caac0c4258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_146e7d8a-d5db-4829-ab13-6a4ea8362c5d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_25959d36-72e6-4c16-86c0-28caac0c4258" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9a87ff8-158d-494a-bbc3-6a7ce54f8319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_146e7d8a-d5db-4829-ab13-6a4ea8362c5d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9a87ff8-158d-494a-bbc3-6a7ce54f8319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_923920ae-b2f2-444e-8351-745591d5a67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_146e7d8a-d5db-4829-ab13-6a4ea8362c5d" xlink:to="loc_us-gaap_InventoryNet_923920ae-b2f2-444e-8351-745591d5a67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_338ab9e3-d1fd-40b0-a74e-f9b205e95a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_146e7d8a-d5db-4829-ab13-6a4ea8362c5d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_338ab9e3-d1fd-40b0-a74e-f9b205e95a2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss_1369c3c7-b392-4a66-876b-f5bb197a2620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_146e7d8a-d5db-4829-ab13-6a4ea8362c5d" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss_1369c3c7-b392-4a66-876b-f5bb197a2620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4869d5f-ac8e-4a14-a969-171e740476ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0d6c922d-b6ba-43d1-8a16-2fbd7d50b915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4869d5f-ac8e-4a14-a969-171e740476ca" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0d6c922d-b6ba-43d1-8a16-2fbd7d50b915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_26d0c0d7-cf53-4e14-9f07-35e11c8ccd99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4869d5f-ac8e-4a14-a969-171e740476ca" xlink:to="loc_us-gaap_Liabilities_26d0c0d7-cf53-4e14-9f07-35e11c8ccd99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_43146d7b-0c76-4ed5-a324-96679c8fea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a4869d5f-ac8e-4a14-a969-171e740476ca" xlink:to="loc_us-gaap_StockholdersEquity_43146d7b-0c76-4ed5-a324-96679c8fea8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8d82a98f-7031-48ba-a895-951a4d6a800d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0bb8b096-96d8-4cca-a9ad-5cad324a19e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d82a98f-7031-48ba-a895-951a4d6a800d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0bb8b096-96d8-4cca-a9ad-5cad324a19e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2780cb9f-8be9-4af9-bd7d-11558d406050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d82a98f-7031-48ba-a895-951a4d6a800d" xlink:to="loc_us-gaap_PreferredStockValue_2780cb9f-8be9-4af9-bd7d-11558d406050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_35435428-b4be-45ca-bc92-5bf41d16696c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d82a98f-7031-48ba-a895-951a4d6a800d" xlink:to="loc_us-gaap_CommonStockValue_35435428-b4be-45ca-bc92-5bf41d16696c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7c34a004-2261-432b-bdcf-bdd926c8cf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d82a98f-7031-48ba-a895-951a4d6a800d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7c34a004-2261-432b-bdcf-bdd926c8cf8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78b571b5-e346-43e6-a35b-e662ece6eee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8d82a98f-7031-48ba-a895-951a4d6a800d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78b571b5-e346-43e6-a35b-e662ece6eee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_be5a2507-6a1d-441d-859d-f6f401a29591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2193fd66-4c40-406c-8769-e16936b5ae60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_be5a2507-6a1d-441d-859d-f6f401a29591" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2193fd66-4c40-406c-8769-e16936b5ae60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6dd5351c-c625-4a08-ac91-906e65c36e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_be5a2507-6a1d-441d-859d-f6f401a29591" xlink:to="loc_us-gaap_LiabilitiesCurrent_6dd5351c-c625-4a08-ac91-906e65c36e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5612929b-692b-4d44-bea9-c0725b5704bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_be5a2507-6a1d-441d-859d-f6f401a29591" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5612929b-692b-4d44-bea9-c0725b5704bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e126a5ff-ed7f-461d-a6ff-40ae9a644d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_be5a2507-6a1d-441d-859d-f6f401a29591" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e126a5ff-ed7f-461d-a6ff-40ae9a644d71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c7b5c58f-43b0-4eef-9816-236371e340f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_be5a2507-6a1d-441d-859d-f6f401a29591" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c7b5c58f-43b0-4eef-9816-236371e340f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_123a103c-2bdf-4bd3-88fe-6222a9e6ab64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5001af2a-b7bb-4b84-8a2c-e4dc83ad5f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_123a103c-2bdf-4bd3-88fe-6222a9e6ab64" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5001af2a-b7bb-4b84-8a2c-e4dc83ad5f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e7984934-eb23-4dca-8424-b9b251793f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_123a103c-2bdf-4bd3-88fe-6222a9e6ab64" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e7984934-eb23-4dca-8424-b9b251793f4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e18ec744-ce33-4052-a725-30da3869b2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_76cfbdcf-9aa3-418a-bc26-967f1ea11a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e18ec744-ce33-4052-a725-30da3869b2e9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_76cfbdcf-9aa3-418a-bc26-967f1ea11a28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c019c266-47f7-4b07-b01a-506fe201f477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e18ec744-ce33-4052-a725-30da3869b2e9" xlink:to="loc_us-gaap_CostOfRevenue_c019c266-47f7-4b07-b01a-506fe201f477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_08caf23a-41c6-4721-bd7a-03d0dd371cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e18ec744-ce33-4052-a725-30da3869b2e9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_08caf23a-41c6-4721-bd7a-03d0dd371cd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_1ac7376c-3abc-4344-b492-a97626fb3ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e18ec744-ce33-4052-a725-30da3869b2e9" xlink:to="loc_us-gaap_SellingAndMarketingExpense_1ac7376c-3abc-4344-b492-a97626fb3ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8acdcedd-6ed6-4cdc-b71d-ef551144d559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e18ec744-ce33-4052-a725-30da3869b2e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8acdcedd-6ed6-4cdc-b71d-ef551144d559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3014f90b-0255-4be6-8dc3-8a6a85576d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45a1a69a-33cc-48ec-9202-01112ea4d7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3014f90b-0255-4be6-8dc3-8a6a85576d02" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45a1a69a-33cc-48ec-9202-01112ea4d7ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_732d6080-cdf9-4be5-8eab-afd873c43bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3014f90b-0255-4be6-8dc3-8a6a85576d02" xlink:to="loc_us-gaap_CostsAndExpenses_732d6080-cdf9-4be5-8eab-afd873c43bf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c61698d-5537-4fb0-8ac4-364b5e3fb1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0a043fd1-df7a-4b60-897d-013d10113cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c61698d-5537-4fb0-8ac4-364b5e3fb1f1" xlink:to="loc_us-gaap_OperatingIncomeLoss_0a043fd1-df7a-4b60-897d-013d10113cb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_86e8e365-360e-4c37-af31-e440586686d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c61698d-5537-4fb0-8ac4-364b5e3fb1f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_86e8e365-360e-4c37-af31-e440586686d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f8c22b63-2aec-459c-9a1a-20d06ffd0c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4ae68b0c-4e77-4682-b267-570db4b25b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f8c22b63-2aec-459c-9a1a-20d06ffd0c71" xlink:to="loc_us-gaap_NetIncomeLoss_4ae68b0c-4e77-4682-b267-570db4b25b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1bdd4149-fdf6-4207-b4b6-531d6d41c5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f8c22b63-2aec-459c-9a1a-20d06ffd0c71" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1bdd4149-fdf6-4207-b4b6-531d6d41c5d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d6dc4f45-c364-4aa5-834c-96c1c960188e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d6dc4f45-c364-4aa5-834c-96c1c960188e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_48bd1e31-1b72-451f-b202-df24bf0c74bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_48bd1e31-1b72-451f-b202-df24bf0c74bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eeacdaaf-5ec3-4c15-b150-ead6448fd031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eeacdaaf-5ec3-4c15-b150-ead6448fd031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ff011582-b449-4b52-a380-1daff49860a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ff011582-b449-4b52-a380-1daff49860a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_13156cb9-a9ef-4397-a76a-eaabac70eca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_13156cb9-a9ef-4397-a76a-eaabac70eca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a924eebf-3864-4187-a301-1b5c30d2ac32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a924eebf-3864-4187-a301-1b5c30d2ac32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8d5624be-2907-4317-804d-54a942803bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8d5624be-2907-4317-804d-54a942803bf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NoncashLeaseExpense_403d578e-e222-4595-9d73-99be5b63e60f" xlink:href="vcyt-20230331.xsd#vcyt_NoncashLeaseExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_vcyt_NoncashLeaseExpense_403d578e-e222-4595-9d73-99be5b63e60f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8f5ec491-f2c4-4f8d-ae93-93ff55c87be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8f5ec491-f2c4-4f8d-ae93-93ff55c87be8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9f9c6cf0-7117-427b-9e8f-fbef5febf4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_ShareBasedCompensation_9f9c6cf0-7117-427b-9e8f-fbef5febf4af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue_768a0200-f559-402d-a5cf-1039fee8c631" xlink:href="vcyt-20230331.xsd#vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue_768a0200-f559-402d-a5cf-1039fee8c631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty_9053f4e8-048b-4903-9d92-38a7cce713c4" xlink:href="vcyt-20230331.xsd#vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty_9053f4e8-048b-4903-9d92-38a7cce713c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6cc55567-2397-47dd-8ad8-9f11677b63c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6cc55567-2397-47dd-8ad8-9f11677b63c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_10a111a7-7e71-43f9-9034-378817dd009f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_10a111a7-7e71-43f9-9034-378817dd009f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_218b15fc-3e9f-49fc-9f6d-d24bcf8b4b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_NetIncomeLoss_218b15fc-3e9f-49fc-9f6d-d24bcf8b4b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f094c183-c440-4a6c-a4d0-6a732f9c220e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_AssetImpairmentCharges_f094c183-c440-4a6c-a4d0-6a732f9c220e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_10143f5e-91c5-4062-b18a-41478f36de5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0f5787-6c0e-4ebc-ace8-786cf491cb37" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_10143f5e-91c5-4062-b18a-41478f36de5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e43c812d-1cfc-437e-bce6-3cb7fd5b231c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d06464de-4b5e-481c-af02-197d2d60aeab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e43c812d-1cfc-437e-bce6-3cb7fd5b231c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d06464de-4b5e-481c-af02-197d2d60aeab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c3fd3aa8-3575-40c8-b30a-e9f6be5d1c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e43c812d-1cfc-437e-bce6-3cb7fd5b231c" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c3fd3aa8-3575-40c8-b30a-e9f6be5d1c05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_37fa487a-2af7-4b79-a5ea-d52cb4f872ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e43c812d-1cfc-437e-bce6-3cb7fd5b231c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_37fa487a-2af7-4b79-a5ea-d52cb4f872ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5935d498-3555-4158-8117-16124cf23ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ca04165c-2a20-4bdb-95b7-d61d5fed09c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5935d498-3555-4158-8117-16124cf23ecc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ca04165c-2a20-4bdb-95b7-d61d5fed09c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_09851e3a-bf7e-4d91-88a3-c577800251cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5935d498-3555-4158-8117-16124cf23ecc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_09851e3a-bf7e-4d91-88a3-c577800251cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_553a4cfb-bfee-4e83-8f68-b5572b7a4653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e77a8c4c-9b70-47ea-a2b9-78df3484453b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_553a4cfb-bfee-4e83-8f68-b5572b7a4653" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e77a8c4c-9b70-47ea-a2b9-78df3484453b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_02fd9451-bdf6-4ccf-844c-c5b3268b8217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_553a4cfb-bfee-4e83-8f68-b5572b7a4653" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_02fd9451-bdf6-4ccf-844c-c5b3268b8217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_203521f2-c4d0-4274-8de7-8c421c8eda32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_e7e4c2d7-e6ec-4246-9c69-2e51e9d39b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_203521f2-c4d0-4274-8de7-8c421c8eda32" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_e7e4c2d7-e6ec-4246-9c69-2e51e9d39b43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_2304f832-a93b-485e-9ee7-29efa318e12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_203521f2-c4d0-4274-8de7-8c421c8eda32" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_2304f832-a93b-485e-9ee7-29efa318e12c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a8d66f95-01db-4fc0-8a6a-92cb19ee8ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_203521f2-c4d0-4274-8de7-8c421c8eda32" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a8d66f95-01db-4fc0-8a6a-92cb19ee8ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_457e8d21-dc67-4e2d-83f4-8b845a2ed7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_203521f2-c4d0-4274-8de7-8c421c8eda32" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_457e8d21-dc67-4e2d-83f4-8b845a2ed7fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5adcb1cc-9bc1-49bd-a3cc-89ec7a2be207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5198c18-53cd-44f9-aefa-7918b6a2d4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5adcb1cc-9bc1-49bd-a3cc-89ec7a2be207" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5198c18-53cd-44f9-aefa-7918b6a2d4ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9668b50-6a26-4401-87e8-148d7bd083f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5adcb1cc-9bc1-49bd-a3cc-89ec7a2be207" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b9668b50-6a26-4401-87e8-148d7bd083f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4169cad7-1feb-4761-a454-539fe9281d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5adcb1cc-9bc1-49bd-a3cc-89ec7a2be207" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4169cad7-1feb-4761-a454-539fe9281d59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fda1ea6d-6cc0-4929-bc6a-4bdc0e426425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2a300b85-dc5d-47ce-b4eb-cfee3706fb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fda1ea6d-6cc0-4929-bc6a-4bdc0e426425" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2a300b85-dc5d-47ce-b4eb-cfee3706fb5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d3cc8d49-1590-4f9d-aea9-d635ab5a128b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fda1ea6d-6cc0-4929-bc6a-4bdc0e426425" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d3cc8d49-1590-4f9d-aea9-d635ab5a128b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_222672a4-024c-4a0a-a415-5493e2d2ccbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ec159df1-6872-43f7-af93-88b772b2ee74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_222672a4-024c-4a0a-a415-5493e2d2ccbd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ec159df1-6872-43f7-af93-88b772b2ee74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_47be87e2-66a1-416b-bf2b-094d444bd4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_222672a4-024c-4a0a-a415-5493e2d2ccbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_47be87e2-66a1-416b-bf2b-094d444bd4db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_545b88be-b7ab-43e9-adba-d608eedf559e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cbe50ac7-cae7-4564-8e37-3ff039e9da4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_545b88be-b7ab-43e9-adba-d608eedf559e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cbe50ac7-cae7-4564-8e37-3ff039e9da4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_76d68aa5-1eaf-4fa7-b114-cf44f223ebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_545b88be-b7ab-43e9-adba-d608eedf559e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_76d68aa5-1eaf-4fa7-b114-cf44f223ebe3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c7a1b7f3-bb01-4f04-ba85-39948a96ac5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2bd08e81-34bb-4eb3-b179-668d4fb5d085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c7a1b7f3-bb01-4f04-ba85-39948a96ac5c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2bd08e81-34bb-4eb3-b179-668d4fb5d085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_623ae404-8ec7-4fc9-83b3-d8c83c0ff0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c7a1b7f3-bb01-4f04-ba85-39948a96ac5c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_623ae404-8ec7-4fc9-83b3-d8c83c0ff0cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ff22b2a8-155e-4351-8a6b-e0a7adb5a97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5a90447b-bbfa-402d-9f25-9d35986d52a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ff22b2a8-155e-4351-8a6b-e0a7adb5a97c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5a90447b-bbfa-402d-9f25-9d35986d52a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f6d39ed5-89dc-4c16-92ce-16ccaa58c037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ff22b2a8-155e-4351-8a6b-e0a7adb5a97c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f6d39ed5-89dc-4c16-92ce-16ccaa58c037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fb6ba7c4-2c58-472e-8ee2-3e93d3b0fdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ff22b2a8-155e-4351-8a6b-e0a7adb5a97c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fb6ba7c4-2c58-472e-8ee2-3e93d3b0fdf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2b84810b-7504-49ff-badc-c9bd4e0759ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ff22b2a8-155e-4351-8a6b-e0a7adb5a97c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2b84810b-7504-49ff-badc-c9bd4e0759ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_9404f6fd-179a-4778-9d91-48f37aec5ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ff22b2a8-155e-4351-8a6b-e0a7adb5a97c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_9404f6fd-179a-4778-9d91-48f37aec5ff3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_5ffda752-1c2b-4c0b-aa7e-bc2d865fb8d6" xlink:href="vcyt-20230331.xsd#vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ff22b2a8-155e-4351-8a6b-e0a7adb5a97c" xlink:to="loc_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_5ffda752-1c2b-4c0b-aa7e-bc2d865fb8d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ba2823e5-e723-42f8-8ffb-51ad9a842544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ddf6af9b-96a4-454c-bdc5-71f7dc995d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ba2823e5-e723-42f8-8ffb-51ad9a842544" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ddf6af9b-96a4-454c-bdc5-71f7dc995d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4d2c7990-65ad-47c7-b966-3bb49724ead5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ba2823e5-e723-42f8-8ffb-51ad9a842544" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4d2c7990-65ad-47c7-b966-3bb49724ead5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ba2ff14-3499-4669-94e3-f27c1b26ba77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d81f6871-073c-4ff1-ab9d-422ef659f9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ba2ff14-3499-4669-94e3-f27c1b26ba77" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d81f6871-073c-4ff1-ab9d-422ef659f9e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cc1d5b09-3fbc-40fd-af7f-d65444b09abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ba2ff14-3499-4669-94e3-f27c1b26ba77" xlink:to="loc_us-gaap_OperatingLeaseLiability_cc1d5b09-3fbc-40fd-af7f-d65444b09abf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_649944db-4210-4ba1-8ab9-7cb8bffb8768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3844d906-89a8-4af7-bd82-f8d8787a71c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_649944db-4210-4ba1-8ab9-7cb8bffb8768" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3844d906-89a8-4af7-bd82-f8d8787a71c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_664d22df-ba19-49f1-bb51-c52dd475a5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_649944db-4210-4ba1-8ab9-7cb8bffb8768" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_664d22df-ba19-49f1-bb51-c52dd475a5ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf6001c4-9be2-4515-826c-6df9de40f639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b17514cb-6415-4ca5-9ce3-eb5adee3d716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf6001c4-9be2-4515-826c-6df9de40f639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b17514cb-6415-4ca5-9ce3-eb5adee3d716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_77d34093-c3cb-4aba-a326-79915415da14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf6001c4-9be2-4515-826c-6df9de40f639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_77d34093-c3cb-4aba-a326-79915415da14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d561f8f0-0c2e-4c3b-bb8c-33367e820f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf6001c4-9be2-4515-826c-6df9de40f639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d561f8f0-0c2e-4c3b-bb8c-33367e820f43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3950ab30-6203-4d8a-9b10-5a1eb15c528b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf6001c4-9be2-4515-826c-6df9de40f639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3950ab30-6203-4d8a-9b10-5a1eb15c528b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_21b47bbd-a8e2-4033-82a3-ef1df0430889" xlink:href="vcyt-20230331.xsd#vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf6001c4-9be2-4515-826c-6df9de40f639" xlink:to="loc_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_21b47bbd-a8e2-4033-82a3-ef1df0430889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e6147d78-0eaa-4336-b7ef-cb75405808ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf6001c4-9be2-4515-826c-6df9de40f639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e6147d78-0eaa-4336-b7ef-cb75405808ed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ad72a993-505d-4a13-8353-5f10f5e60206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fb3764ea-f02d-4d6b-8ccf-2fd743651749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ad72a993-505d-4a13-8353-5f10f5e60206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fb3764ea-f02d-4d6b-8ccf-2fd743651749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99af52eb-646d-4c3c-a3f5-d362bfe5dd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ad72a993-505d-4a13-8353-5f10f5e60206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99af52eb-646d-4c3c-a3f5-d362bfe5dd0a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/ComponentsofOtherIncomeDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#ComponentsofOtherIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.veracyte.com/role/ComponentsofOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3d067171-ccfe-48c1-b0a2-fec1176bde5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseOther_b88a5937-b018-4dac-9db1-f2ff21768de5" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3d067171-ccfe-48c1-b0a2-fec1176bde5c" xlink:to="loc_vcyt_OtherNonoperatingIncomeExpenseOther_b88a5937-b018-4dac-9db1-f2ff21768de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseInterestExpense_c3a71952-cae3-45e0-95ea-407852ff85e6" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseInterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3d067171-ccfe-48c1-b0a2-fec1176bde5c" xlink:to="loc_vcyt_OtherNonoperatingIncomeExpenseInterestExpense_c3a71952-cae3-45e0-95ea-407852ff85e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit_bfa52db6-2a15-4163-a698-5cd2c62b9203" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3d067171-ccfe-48c1-b0a2-fec1176bde5c" xlink:to="loc_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit_bfa52db6-2a15-4163-a698-5cd2c62b9203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss_2aad4429-896b-4164-9b90-2dae5bce6ac4" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3d067171-ccfe-48c1-b0a2-fec1176bde5c" xlink:to="loc_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss_2aad4429-896b-4164-9b90-2dae5bce6ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseInterestIncome_b9fad845-cfa9-4a32-8771-ac59299dfb72" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseInterestIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3d067171-ccfe-48c1-b0a2-fec1176bde5c" xlink:to="loc_vcyt_OtherNonoperatingIncomeExpenseInterestIncome_b9fad845-cfa9-4a32-8771-ac59299dfb72" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>vcyt-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7dabdad4-bfd4-4b85-9e97-316e8975136b,g:d42a5b32-51ee-4157-98c8-837d0a6f976e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended" id="ie401190addd947a29bc1a9184e3127b7_CondensedConsolidatedStatementsofOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_acc65c5b-5993-46f5-85d1-144d52969a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_RevenuesAbstract_acc65c5b-5993-46f5-85d1-144d52969a49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56446790-cd36-46e3-b02b-7cf5e3b378c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_acc65c5b-5993-46f5-85d1-144d52969a49" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56446790-cd36-46e3-b02b-7cf5e3b378c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_7ec8d5c0-7a00-44e8-a9ce-5ec8a8e67976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_CostOfRevenue_7ec8d5c0-7a00-44e8-a9ce-5ec8a8e67976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_524e754b-14bc-4169-840b-06d3eae51eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_524e754b-14bc-4169-840b-06d3eae51eee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_200078fc-0574-4529-b8d8-522d1c524f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_SellingAndMarketingExpense_200078fc-0574-4529-b8d8-522d1c524f77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eeba69eb-82fc-431b-8129-f0e243afc24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eeba69eb-82fc-431b-8129-f0e243afc24d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_069248ea-9821-49ec-9ca5-7c82ffa1fee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_069248ea-9821-49ec-9ca5-7c82ffa1fee3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8ccf1fe5-7771-41b1-8764-9fa8bcc0c202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_CostsAndExpenses_8ccf1fe5-7771-41b1-8764-9fa8bcc0c202" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4a1287d8-8a28-476f-a42e-f36a5847e20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_OperatingIncomeLoss_4a1287d8-8a28-476f-a42e-f36a5847e20f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a60a6bf8-2b3e-48ad-9851-76a49b69ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a60a6bf8-2b3e-48ad-9851-76a49b69ca9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12779095-a4df-4012-95c8-0fed578af16c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12779095-a4df-4012-95c8-0fed578af16c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_279a431d-df78-413d-b1b4-ed1eea13db03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_279a431d-df78-413d-b1b4-ed1eea13db03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cca34ece-a040-473d-9a7a-1da6a355cdae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_NetIncomeLoss_cca34ece-a040-473d-9a7a-1da6a355cdae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3e935ad8-437c-4bb0-a337-f05016b48ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_EarningsPerShareBasic_3e935ad8-437c-4bb0-a337-f05016b48ac0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ae227547-bb47-455f-ae88-edc2be6d7aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ae227547-bb47-455f-ae88-edc2be6d7aaa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2037504-1572-417a-939a-e04d8d028459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2037504-1572-417a-939a-e04d8d028459" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0057025d-124f-46d4-baa3-84372f536a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0057025d-124f-46d4-baa3-84372f536a64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_66d44cb7-95fb-4397-82ab-3a5160024bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_StatementTable_66d44cb7-95fb-4397-82ab-3a5160024bf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_57987cbb-3eca-4b42-896f-ecf2e6720fc1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_66d44cb7-95fb-4397-82ab-3a5160024bf7" xlink:to="loc_srt_ProductOrServiceAxis_57987cbb-3eca-4b42-896f-ecf2e6720fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_57987cbb-3eca-4b42-896f-ecf2e6720fc1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_57987cbb-3eca-4b42-896f-ecf2e6720fc1" xlink:to="loc_srt_ProductsAndServicesDomain_57987cbb-3eca-4b42-896f-ecf2e6720fc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8055274d-0e02-448b-9485-f2956ef6d1d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_57987cbb-3eca-4b42-896f-ecf2e6720fc1" xlink:to="loc_srt_ProductsAndServicesDomain_8055274d-0e02-448b-9485-f2956ef6d1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TestingMember_92dff471-2446-4f0a-8e31-33ddf10f2a65" xlink:href="vcyt-20230331.xsd#vcyt_TestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8055274d-0e02-448b-9485-f2956ef6d1d3" xlink:to="loc_vcyt_TestingMember_92dff471-2446-4f0a-8e31-33ddf10f2a65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8db63135-b4c8-486f-b074-254766570349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8055274d-0e02-448b-9485-f2956ef6d1d3" xlink:to="loc_us-gaap_ProductMember_8db63135-b4c8-486f-b074-254766570349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherMember_5bd75540-635f-4f60-b573-7725bccf279d" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8055274d-0e02-448b-9485-f2956ef6d1d3" xlink:to="loc_vcyt_BiopharmaceuticalAndOtherMember_5bd75540-635f-4f60-b573-7725bccf279d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended" id="i958054464a4b47129f6a1b3b2b91fbc1_CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a7f01a42-9ece-438a-b490-ac94547b4817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a7f01a42-9ece-438a-b490-ac94547b4817" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cfe338af-b4fe-4c8c-bf10-89550e998724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_SharesOutstanding_cfe338af-b4fe-4c8c-bf10-89550e998724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a9a9725b-a54b-40f5-8186-b86db5143f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_StockholdersEquity_a9a9725b-a54b-40f5-8186-b86db5143f74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_1cf77ca5-066f-49df-a155-f5ff6e9b817f" xlink:href="vcyt-20230331.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_1cf77ca5-066f-49df-a155-f5ff6e9b817f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_6a751a49-6b4e-4482-95bf-edf3bbb67919" xlink:href="vcyt-20230331.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_6a751a49-6b4e-4482-95bf-edf3bbb67919" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_73d4584c-ac65-4cef-964b-36f3989cca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_73d4584c-ac65-4cef-964b-36f3989cca5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_068b1439-5734-4f9c-b9ad-3be8ec148217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_068b1439-5734-4f9c-b9ad-3be8ec148217" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_7d24ecbf-6fc1-4d9e-bdce-5a88f765c508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_7d24ecbf-6fc1-4d9e-bdce-5a88f765c508" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_0c7a776f-0c2a-4328-bcb0-857fb24953f3" xlink:href="vcyt-20230331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_0c7a776f-0c2a-4328-bcb0-857fb24953f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_2b9a75a5-ee60-430f-aeb4-e23df216fb52" xlink:href="vcyt-20230331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_2b9a75a5-ee60-430f-aeb4-e23df216fb52" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_4a544288-6c5d-4ab4-a997-3645ed7303f3" xlink:href="vcyt-20230331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_4a544288-6c5d-4ab4-a997-3645ed7303f3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7bafb79-d091-40ac-8376-ab5cce413427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_NetIncomeLoss_c7bafb79-d091-40ac-8376-ab5cce413427" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fee6397c-6e5b-4ab4-b653-d41e3293b389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fee6397c-6e5b-4ab4-b653-d41e3293b389" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_abd64ce0-bdbb-421f-9988-7f22380a2fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_defda063-bff5-43f3-a6be-87952fe1bf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3e9f96df-1851-4966-b332-709ffb93e288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a7f01a42-9ece-438a-b490-ac94547b4817" xlink:to="loc_us-gaap_StatementTable_3e9f96df-1851-4966-b332-709ffb93e288" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ce59f489-d859-41e5-874c-ed809b41fabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3e9f96df-1851-4966-b332-709ffb93e288" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ce59f489-d859-41e5-874c-ed809b41fabf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ce59f489-d859-41e5-874c-ed809b41fabf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ce59f489-d859-41e5-874c-ed809b41fabf" xlink:to="loc_us-gaap_EquityComponentDomain_ce59f489-d859-41e5-874c-ed809b41fabf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ce59f489-d859-41e5-874c-ed809b41fabf" xlink:to="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fb501917-58b3-4252-9f01-39cd10d7a920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:to="loc_us-gaap_CommonStockMember_fb501917-58b3-4252-9f01-39cd10d7a920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_46998822-2f32-47ba-b628-d3925bb11272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_46998822-2f32-47ba-b628-d3925bb11272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cf07eabe-3674-4fd1-baed-006e6ff66ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:to="loc_us-gaap_RetainedEarningsMember_cf07eabe-3674-4fd1-baed-006e6ff66ef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c61f0905-ce03-41ee-8594-1025e19be5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c61f0905-ce03-41ee-8594-1025e19be5d9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="iba6af176338f4d878067b46ebea3f9ab_OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_028577b9-ff89-44b3-9046-fbf121ed93a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_NumberOfOperatingSegments_028577b9-ff89-44b3-9046-fbf121ed93a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest_401c4f46-c9be-475a-b317-7695876e2de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest_401c4f46-c9be-475a-b317-7695876e2de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_20b4d486-f1e3-4fa1-9f25-1f6e0e93aef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_20b4d486-f1e3-4fa1-9f25-1f6e0e93aef1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_719e3467-6422-4772-8700-6e40115c1751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_719e3467-6422-4772-8700-6e40115c1751" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a6c935d0-9ac9-4d69-b055-69a65ff5c254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a6c935d0-9ac9-4d69-b055-69a65ff5c254" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_48448caf-d7fe-48b5-a692-ea38a8d8d950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_48448caf-d7fe-48b5-a692-ea38a8d8d950" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTypeExtensibleList_5fbcc1f0-7e16-43b6-ab8f-58761cfaf5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTypeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation_48448caf-d7fe-48b5-a692-ea38a8d8d950" xlink:to="loc_us-gaap_DefinedBenefitPlanTypeExtensibleList_5fbcc1f0-7e16-43b6-ab8f-58761cfaf5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d0104dfd-f851-4a81-85a2-9bfcec701b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d0104dfd-f851-4a81-85a2-9bfcec701b86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe34f3a1-ad2c-4dba-81b5-969b59eb10aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d0104dfd-f851-4a81-85a2-9bfcec701b86" xlink:to="loc_srt_ProductOrServiceAxis_fe34f3a1-ad2c-4dba-81b5-969b59eb10aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe34f3a1-ad2c-4dba-81b5-969b59eb10aa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fe34f3a1-ad2c-4dba-81b5-969b59eb10aa" xlink:to="loc_srt_ProductsAndServicesDomain_fe34f3a1-ad2c-4dba-81b5-969b59eb10aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bf4a074f-ae48-4711-9ccd-c1b3d516dcf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fe34f3a1-ad2c-4dba-81b5-969b59eb10aa" xlink:to="loc_srt_ProductsAndServicesDomain_bf4a074f-ae48-4711-9ccd-c1b3d516dcf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherMember_62cfd1a6-94da-4d71-a6f5-602eb9a6f503" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bf4a074f-ae48-4711-9ccd-c1b3d516dcf5" xlink:to="loc_vcyt_BiopharmaceuticalAndOtherMember_62cfd1a6-94da-4d71-a6f5-602eb9a6f503" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails" xlink:type="extended" id="i76f3764743154c6b8f1bb74395805f72_OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d4ce2d47-2c85-4201-9fca-f0211bd40c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f5611d3e-ec0a-496a-85fe-952389f5d9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d4ce2d47-2c85-4201-9fca-f0211bd40c16" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f5611d3e-ec0a-496a-85fe-952389f5d9fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d4ce2d47-2c85-4201-9fca-f0211bd40c16" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b262c10c-a274-4ee8-a632-d64b9ecc0f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b262c10c-a274-4ee8-a632-d64b9ecc0f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b262c10c-a274-4ee8-a632-d64b9ecc0f69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b262c10c-a274-4ee8-a632-d64b9ecc0f69" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b262c10c-a274-4ee8-a632-d64b9ecc0f69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6fb6bb61-1208-4405-a0bf-822821f0704c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b262c10c-a274-4ee8-a632-d64b9ecc0f69" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6fb6bb61-1208-4405-a0bf-822821f0704c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8d6bc7bc-2a31-46f1-95cf-1b58d01acf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6fb6bb61-1208-4405-a0bf-822821f0704c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8d6bc7bc-2a31-46f1-95cf-1b58d01acf71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5782bd64-1af2-4423-b4da-0aa791698130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5782bd64-1af2-4423-b4da-0aa791698130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5782bd64-1af2-4423-b4da-0aa791698130_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5782bd64-1af2-4423-b4da-0aa791698130" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5782bd64-1af2-4423-b4da-0aa791698130_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8384ee1d-0e99-4e6e-a2b3-9d77f29d8e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5782bd64-1af2-4423-b4da-0aa791698130" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8384ee1d-0e99-4e6e-a2b3-9d77f29d8e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_2a667831-a95d-4eea-8d81-662abcabd7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8384ee1d-0e99-4e6e-a2b3-9d77f29d8e9f" xlink:to="loc_us-gaap_SalesRevenueNetMember_2a667831-a95d-4eea-8d81-662abcabd7ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_000121ce-86eb-4499-8a88-087f90a1ab57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8384ee1d-0e99-4e6e-a2b3-9d77f29d8e9f" xlink:to="loc_us-gaap_AccountsReceivableMember_000121ce-86eb-4499-8a88-087f90a1ab57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6deb395e-0318-4596-b3dc-9193420b5f6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:to="loc_srt_MajorCustomersAxis_6deb395e-0318-4596-b3dc-9193420b5f6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6deb395e-0318-4596-b3dc-9193420b5f6b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6deb395e-0318-4596-b3dc-9193420b5f6b" xlink:to="loc_srt_NameOfMajorCustomerDomain_6deb395e-0318-4596-b3dc-9193420b5f6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_480e04a2-2d55-4020-9e4e-d414e2b65768" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6deb395e-0318-4596-b3dc-9193420b5f6b" xlink:to="loc_srt_NameOfMajorCustomerDomain_480e04a2-2d55-4020-9e4e-d414e2b65768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MedicareMember_7d3b51ec-d510-4f6c-b87c-b4db1de29063" xlink:href="vcyt-20230331.xsd#vcyt_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_480e04a2-2d55-4020-9e4e-d414e2b65768" xlink:to="loc_vcyt_MedicareMember_7d3b51ec-d510-4f6c-b87c-b4db1de29063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_UnitedHealthcareMember_83268aee-497d-4042-9a20-f38d02f393e2" xlink:href="vcyt-20230331.xsd#vcyt_UnitedHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_480e04a2-2d55-4020-9e4e-d414e2b65768" xlink:to="loc_vcyt_UnitedHealthcareMember_83268aee-497d-4042-9a20-f38d02f393e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MajorCustomersMember_e058940a-d64f-4043-9c81-4f656ff60679" xlink:href="vcyt-20230331.xsd#vcyt_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_480e04a2-2d55-4020-9e4e-d414e2b65768" xlink:to="loc_vcyt_MajorCustomersMember_e058940a-d64f-4043-9c81-4f656ff60679" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails" xlink:type="extended" id="i466f0c29928e4c56b828f70b399f5fd4_OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d71af414-eaf6-44be-918d-730b02af80ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_851eabf4-37a4-4fe3-9171-5ef5dd159727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d71af414-eaf6-44be-918d-730b02af80ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_851eabf4-37a4-4fe3-9171-5ef5dd159727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_554fb0f1-747d-4e46-b761-ae4004674df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d71af414-eaf6-44be-918d-730b02af80ab" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_554fb0f1-747d-4e46-b761-ae4004674df6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0955707f-b338-43da-9f76-a52cf63bc76f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_554fb0f1-747d-4e46-b761-ae4004674df6" xlink:to="loc_srt_ProductOrServiceAxis_0955707f-b338-43da-9f76-a52cf63bc76f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0955707f-b338-43da-9f76-a52cf63bc76f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0955707f-b338-43da-9f76-a52cf63bc76f" xlink:to="loc_srt_ProductsAndServicesDomain_0955707f-b338-43da-9f76-a52cf63bc76f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c90cd8f6-591f-4a8d-95c3-2f6c0b08ee71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0955707f-b338-43da-9f76-a52cf63bc76f" xlink:to="loc_srt_ProductsAndServicesDomain_c90cd8f6-591f-4a8d-95c3-2f6c0b08ee71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember_82179dce-585e-4793-a56f-d70ee7518aef" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c90cd8f6-591f-4a8d-95c3-2f6c0b08ee71" xlink:to="loc_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember_82179dce-585e-4793-a56f-d70ee7518aef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember_45a41dfe-4a8f-4a72-83c0-e1abede4f9b4" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c90cd8f6-591f-4a8d-95c3-2f6c0b08ee71" xlink:to="loc_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember_45a41dfe-4a8f-4a72-83c0-e1abede4f9b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherMember_3815eba7-b00e-4572-a93d-4aa84873cea4" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c90cd8f6-591f-4a8d-95c3-2f6c0b08ee71" xlink:to="loc_vcyt_BiopharmaceuticalAndOtherMember_3815eba7-b00e-4572-a93d-4aa84873cea4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShareDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#NetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShareDetails" xlink:type="extended" id="i1b31072f3d5d47d9868fe3d5993a3286_NetLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_223aa5ff-95c2-44f6-97f5-f51b93bf9d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f9fda822-1f41-441e-bb63-5f4887468cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_223aa5ff-95c2-44f6-97f5-f51b93bf9d31" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f9fda822-1f41-441e-bb63-5f4887468cb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e679b506-e93a-4c89-a3ff-6e31ab99c661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_223aa5ff-95c2-44f6-97f5-f51b93bf9d31" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e679b506-e93a-4c89-a3ff-6e31ab99c661" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_603bf8ec-e269-471c-8611-eb036322f3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e679b506-e93a-4c89-a3ff-6e31ab99c661" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_603bf8ec-e269-471c-8611-eb036322f3ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_603bf8ec-e269-471c-8611-eb036322f3ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_603bf8ec-e269-471c-8611-eb036322f3ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_603bf8ec-e269-471c-8611-eb036322f3ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90397fea-80f3-4b30-9ba4-3928a47a26bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_603bf8ec-e269-471c-8611-eb036322f3ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90397fea-80f3-4b30-9ba4-3928a47a26bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_a5b4f22d-da0a-46ed-8998-51d92a843c3b" xlink:href="vcyt-20230331.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90397fea-80f3-4b30-9ba4-3928a47a26bb" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_a5b4f22d-da0a-46ed-8998-51d92a843c3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d8058dea-0ed2-4851-a36d-afab23113ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90397fea-80f3-4b30-9ba4-3928a47a26bb" xlink:to="loc_us-gaap_EmployeeStockMember_d8058dea-0ed2-4851-a36d-afab23113ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ba38e4f2-c344-4b5d-88be-53900c919230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90397fea-80f3-4b30-9ba4-3928a47a26bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ba38e4f2-c344-4b5d-88be-53900c919230" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i1f06dbb40c7a482dbf0f142d545fd7c8_BalanceSheetComponentsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_08e1d708-5ae1-4877-bd5e-56fb2fdd0694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_08e1d708-5ae1-4877-bd5e-56fb2fdd0694" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_10654f31-ef83-4788-86a3-84fab604296b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_10654f31-ef83-4788-86a3-84fab604296b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_11d091b1-e2a4-4968-9c85-c635f6004efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_11d091b1-e2a4-4968-9c85-c635f6004efd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_63168c4a-42d7-4ae4-bddb-8ffc30e40482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_63168c4a-42d7-4ae4-bddb-8ffc30e40482" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_beb2b343-424f-41e3-8730-c0ced08402d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_beb2b343-424f-41e3-8730-c0ced08402d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_57834a2b-c730-4d0e-8d31-222376904a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_57834a2b-c730-4d0e-8d31-222376904a89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_488e9998-7574-4c43-8469-d0f7616b03f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_488e9998-7574-4c43-8469-d0f7616b03f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c36e979b-2559-4ecd-9b85-094e3b9b2333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c36e979b-2559-4ecd-9b85-094e3b9b2333" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_408e8c86-5197-4fc9-9bc5-574ce48dccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c36e979b-2559-4ecd-9b85-094e3b9b2333" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_408e8c86-5197-4fc9-9bc5-574ce48dccd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_408e8c86-5197-4fc9-9bc5-574ce48dccd0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_408e8c86-5197-4fc9-9bc5-574ce48dccd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_408e8c86-5197-4fc9-9bc5-574ce48dccd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_408e8c86-5197-4fc9-9bc5-574ce48dccd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_PerceptaProductTechnologyMember_a52b2442-dc19-4788-b829-df267d40130c" xlink:href="vcyt-20230331.xsd#vcyt_PerceptaProductTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_PerceptaProductTechnologyMember_a52b2442-dc19-4788-b829-df267d40130c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_96e0a7f0-6805-40c8-9897-650feb176c24" xlink:href="vcyt-20230331.xsd#vcyt_DevelopedProductTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_DevelopedProductTechnologyMember_96e0a7f0-6805-40c8-9897-650feb176c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ProsignaCustomerRelationshipsMember_b07fa142-22dc-4e7d-8bee-c1c90ac6778f" xlink:href="vcyt-20230331.xsd#vcyt_ProsignaCustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_ProsignaCustomerRelationshipsMember_b07fa142-22dc-4e7d-8bee-c1c90ac6778f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NCounterDxLicenseMember_d9b1654d-e3e6-44ee-bbf7-c14619a4f2a6" xlink:href="vcyt-20230331.xsd#vcyt_NCounterDxLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_NCounterDxLicenseMember_d9b1654d-e3e6-44ee-bbf7-c14619a4f2a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LymphmarkProductTechnologyMember_62a956b1-6f62-486b-b9d2-30a972285ace" xlink:href="vcyt-20230331.xsd#vcyt_LymphmarkProductTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_LymphmarkProductTechnologyMember_62a956b1-6f62-486b-b9d2-30a972285ace" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DecipherBioSciencesProductTechnologyMember_a12f0e6b-44fc-4fe0-b4c2-e0ab3f81a716" xlink:href="vcyt-20230331.xsd#vcyt_DecipherBioSciencesProductTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_DecipherBioSciencesProductTechnologyMember_a12f0e6b-44fc-4fe0-b4c2-e0ab3f81a716" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DecipherBiosciencesTradeNamesMember_049445c2-4466-4043-9726-7f53826a4591" xlink:href="vcyt-20230331.xsd#vcyt_DecipherBiosciencesTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_DecipherBiosciencesTradeNamesMember_049445c2-4466-4043-9726-7f53826a4591" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HalioDXDevelopedTechnologyMember_f6835a79-da32-4143-af76-72ba5371bb30" xlink:href="vcyt-20230331.xsd#vcyt_HalioDXDevelopedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_HalioDXDevelopedTechnologyMember_f6835a79-da32-4143-af76-72ba5371bb30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HalioDxCustomerRelationshipsMember_7fe68c47-94b4-4d4c-b956-700b3d62f154" xlink:href="vcyt-20230331.xsd#vcyt_HalioDxCustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_HalioDxCustomerRelationshipsMember_7fe68c47-94b4-4d4c-b956-700b3d62f154" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HalioDxCustomerBacklogMember_6a85c603-4a58-40ea-b791-8b6306a448c3" xlink:href="vcyt-20230331.xsd#vcyt_HalioDxCustomerBacklogMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_HalioDxCustomerBacklogMember_6a85c603-4a58-40ea-b791-8b6306a448c3" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i63f8f07d0daa43dca3817407946b9780_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3dc08df6-f0b9-4dd7-86a9-417b23a7ed16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3dc08df6-f0b9-4dd7-86a9-417b23a7ed16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_a2a4b5ab-f72f-4e1e-8d4d-bd7e256a71aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_SecurityDeposit_a2a4b5ab-f72f-4e1e-8d4d-bd7e256a71aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3a7609a0-8632-4011-9554-59abd7ad3b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3a7609a0-8632-4011-9554-59abd7ad3b25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1ec0ee45-de29-478f-bb8e-2376edc7d13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1ec0ee45-de29-478f-bb8e-2376edc7d13d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationCashToBePaid_cee1ff76-6c50-4212-8532-282fd3770887" xlink:href="vcyt-20230331.xsd#vcyt_BusinessCombinationContingentConsiderationCashToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_vcyt_BusinessCombinationContingentConsiderationCashToBePaid_cee1ff76-6c50-4212-8532-282fd3770887" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43380e40-8dce-45b5-95cf-1c86a31c8bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43380e40-8dce-45b5-95cf-1c86a31c8bb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment_eb44d8a6-b535-49db-9612-23723fa13baa" xlink:href="vcyt-20230331.xsd#vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment_eb44d8a6-b535-49db-9612-23723fa13baa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_90a18683-0b24-43ec-a887-76db2b30f785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_90a18683-0b24-43ec-a887-76db2b30f785" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss_9466b261-eeef-4e65-9c83-fbc69eae4811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss_9466b261-eeef-4e65-9c83-fbc69eae4811" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_b755425d-6cd2-4e89-94ab-ba45af26485b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_b755425d-6cd2-4e89-94ab-ba45af26485b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldAtPar_c0f83b39-4e4a-4d9d-b02b-3e2f92ce63db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesSoldAtPar"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldAtPar_c0f83b39-4e4a-4d9d-b02b-3e2f92ce63db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount_52bfd430-4d1f-4c38-a4c1-08b7b2b913dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturitySoldAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount_52bfd430-4d1f-4c38-a4c1-08b7b2b913dd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_5adcf170-0905-4809-b032-4f6770842de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_5adcf170-0905-4809-b032-4f6770842de3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_52d71892-2fa7-4ff5-be8e-9062f8c974c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_52d71892-2fa7-4ff5-be8e-9062f8c974c9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b00d5cb6-0f04-4fe8-870b-c91cf9f9b454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b00d5cb6-0f04-4fe8-870b-c91cf9f9b454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b00d5cb6-0f04-4fe8-870b-c91cf9f9b454_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b00d5cb6-0f04-4fe8-870b-c91cf9f9b454" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b00d5cb6-0f04-4fe8-870b-c91cf9f9b454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae7a4135-9bf2-41d6-afe9-e2821a67aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b00d5cb6-0f04-4fe8-870b-c91cf9f9b454" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae7a4135-9bf2-41d6-afe9-e2821a67aec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_507307c2-4e18-472b-bd20-9c72532b7a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae7a4135-9bf2-41d6-afe9-e2821a67aec9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_507307c2-4e18-472b-bd20-9c72532b7a3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_c9caa92b-d8e6-44cd-842d-976ad6fb1793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:to="loc_us-gaap_LeaseContractualTermAxis_c9caa92b-d8e6-44cd-842d-976ad6fb1793" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_c9caa92b-d8e6-44cd-842d-976ad6fb1793_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_c9caa92b-d8e6-44cd-842d-976ad6fb1793" xlink:to="loc_us-gaap_LeaseContractualTermDomain_c9caa92b-d8e6-44cd-842d-976ad6fb1793_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_75a056ce-1005-4077-b361-f205b11507fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_c9caa92b-d8e6-44cd-842d-976ad6fb1793" xlink:to="loc_us-gaap_LeaseContractualTermDomain_75a056ce-1005-4077-b361-f205b11507fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember_20ba697a-9c64-401c-90c5-935a57ebcd1b" xlink:href="vcyt-20230331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_75a056ce-1005-4077-b361-f205b11507fa" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember_20ba697a-9c64-401c-90c5-935a57ebcd1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_85393f90-8435-43ac-8781-6d885895e618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_85393f90-8435-43ac-8781-6d885895e618" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85393f90-8435-43ac-8781-6d885895e618_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85393f90-8435-43ac-8781-6d885895e618" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85393f90-8435-43ac-8781-6d885895e618_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6116e36b-35bd-4572-ac6f-ff0c6fc03d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85393f90-8435-43ac-8781-6d885895e618" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6116e36b-35bd-4572-ac6f-ff0c6fc03d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NanostringMember_aece5682-40ae-4563-a78b-887c80e4db3b" xlink:href="vcyt-20230331.xsd#vcyt_NanostringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6116e36b-35bd-4572-ac6f-ff0c6fc03d6b" xlink:to="loc_vcyt_NanostringMember_aece5682-40ae-4563-a78b-887c80e4db3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fd44359a-e778-4ca0-8d2d-fe4ec0c70c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fd44359a-e778-4ca0-8d2d-fe4ec0c70c66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_fd44359a-e778-4ca0-8d2d-fe4ec0c70c66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fd44359a-e778-4ca0-8d2d-fe4ec0c70c66" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_fd44359a-e778-4ca0-8d2d-fe4ec0c70c66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_14b543b9-7324-4dc0-ab3a-392dd93a8e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fd44359a-e778-4ca0-8d2d-fe4ec0c70c66" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_14b543b9-7324-4dc0-ab3a-392dd93a8e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9e587c86-f36d-47ab-bba9-07418c6e5fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_14b543b9-7324-4dc0-ab3a-392dd93a8e61" xlink:to="loc_us-gaap_CommonStockMember_9e587c86-f36d-47ab-bba9-07418c6e5fd6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#FairValueMeasurementsFairValueMeasurementInputDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails" xlink:type="extended" id="if7fe3b8872fe444891a2b84310964fe1_FairValueMeasurementsFairValueMeasurementInputDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c99d406b-03aa-4e29-b8ed-2b7aec092d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6fe6d925-4c30-484f-ba84-acf3f56f8730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c99d406b-03aa-4e29-b8ed-2b7aec092d1d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6fe6d925-4c30-484f-ba84-acf3f56f8730" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_38809e11-ae2a-404b-8bbc-55d49ea37e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c99d406b-03aa-4e29-b8ed-2b7aec092d1d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_38809e11-ae2a-404b-8bbc-55d49ea37e29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_cedbcb5c-7209-4f06-9246-7210ffd1633c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_38809e11-ae2a-404b-8bbc-55d49ea37e29" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_cedbcb5c-7209-4f06-9246-7210ffd1633c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cedbcb5c-7209-4f06-9246-7210ffd1633c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cedbcb5c-7209-4f06-9246-7210ffd1633c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cedbcb5c-7209-4f06-9246-7210ffd1633c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_70932d9e-1d40-495b-a655-a6814b46be80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cedbcb5c-7209-4f06-9246-7210ffd1633c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_70932d9e-1d40-495b-a655-a6814b46be80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a7eb8916-ca44-4837-92b0-0cba943c5a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_70932d9e-1d40-495b-a655-a6814b46be80" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a7eb8916-ca44-4837-92b0-0cba943c5a5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MeasurementInputProbabilityOfAchievementMember_e0d53e62-0714-4711-8b97-3d8084f6cad0" xlink:href="vcyt-20230331.xsd#vcyt_MeasurementInputProbabilityOfAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_70932d9e-1d40-495b-a655-a6814b46be80" xlink:to="loc_vcyt_MeasurementInputProbabilityOfAchievementMember_e0d53e62-0714-4711-8b97-3d8084f6cad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f6b68c1-bc9c-4b5f-bc5a-9fe5f54d5872" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_38809e11-ae2a-404b-8bbc-55d49ea37e29" xlink:to="loc_srt_RangeAxis_7f6b68c1-bc9c-4b5f-bc5a-9fe5f54d5872" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f6b68c1-bc9c-4b5f-bc5a-9fe5f54d5872_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7f6b68c1-bc9c-4b5f-bc5a-9fe5f54d5872" xlink:to="loc_srt_RangeMember_7f6b68c1-bc9c-4b5f-bc5a-9fe5f54d5872_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6009588-0edd-4574-a889-7033377ad500" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7f6b68c1-bc9c-4b5f-bc5a-9fe5f54d5872" xlink:to="loc_srt_RangeMember_c6009588-0edd-4574-a889-7033377ad500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3258b36b-ce6c-476f-a509-52701d4674b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c6009588-0edd-4574-a889-7033377ad500" xlink:to="loc_srt_MinimumMember_3258b36b-ce6c-476f-a509-52701d4674b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8d3c80da-b123-49d8-9c9c-9bdde2d99584" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c6009588-0edd-4574-a889-7033377ad500" xlink:to="loc_srt_MaximumMember_8d3c80da-b123-49d8-9c9c-9bdde2d99584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_be0cea86-3b3d-4c4f-bfe0-e7ef9d390042" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c6009588-0edd-4574-a889-7033377ad500" xlink:to="loc_srt_WeightedAverageMember_be0cea86-3b3d-4c4f-bfe0-e7ef9d390042" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i1700e0df06d545f99ba1072886de1387_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_40c8ae86-6154-4347-9bda-ffc1c10d00c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_40c8ae86-6154-4347-9bda-ffc1c10d00c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_2071deee-7814-4f57-bc7e-89a6fe1d63f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_SecurityDeposit_2071deee-7814-4f57-bc7e-89a6fe1d63f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_863480d4-cf53-4209-a3b2-6ec8d4f6a3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_863480d4-cf53-4209-a3b2-6ec8d4f6a3ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_e276b660-7434-4c8d-8408-1003d7ffdc42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_e276b660-7434-4c8d-8408-1003d7ffdc42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4513f461-a836-49d3-9ff9-e70f10d6b099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_e276b660-7434-4c8d-8408-1003d7ffdc42" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4513f461-a836-49d3-9ff9-e70f10d6b099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_9c332b15-182c-4c52-8c88-a3ad9672765e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_FinanceLeaseLiability_9c332b15-182c-4c52-8c88-a3ad9672765e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1277c0f4-5e07-4aae-83b6-2e4261b86272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinanceLeaseLiability_9c332b15-182c-4c52-8c88-a3ad9672765e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1277c0f4-5e07-4aae-83b6-2e4261b86272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_e0e6a882-10fa-4c85-a7d3-ebfc7dff15d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_e0e6a882-10fa-4c85-a7d3-ebfc7dff15d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount_5292a3b9-af42-4353-8e3a-9b33dbc3790e" xlink:href="vcyt-20230331.xsd#vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount_5292a3b9-af42-4353-8e3a-9b33dbc3790e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0966b593-5f92-42c6-887c-fb8c773d4794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0966b593-5f92-42c6-887c-fb8c773d4794" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b1642309-c1ac-4dee-9344-0f628334bd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0966b593-5f92-42c6-887c-fb8c773d4794" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b1642309-c1ac-4dee-9344-0f628334bd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b1642309-c1ac-4dee-9344-0f628334bd0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b1642309-c1ac-4dee-9344-0f628334bd0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b1642309-c1ac-4dee-9344-0f628334bd0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e96dad74-5b64-43a4-828e-9e3796b17183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b1642309-c1ac-4dee-9344-0f628334bd0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e96dad74-5b64-43a4-828e-9e3796b17183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember_39c79fb0-3ebf-41da-9398-7e1bc6603f62" xlink:href="vcyt-20230331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e96dad74-5b64-43a4-828e-9e3796b17183" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember_39c79fb0-3ebf-41da-9398-7e1bc6603f62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_FacilitiesInMarseilleFranceMember_e872cebf-c17a-4437-8ff3-2fa1da782a4d" xlink:href="vcyt-20230331.xsd#vcyt_FacilitiesInMarseilleFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e96dad74-5b64-43a4-828e-9e3796b17183" xlink:to="loc_vcyt_FacilitiesInMarseilleFranceMember_e872cebf-c17a-4437-8ff3-2fa1da782a4d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="extended" id="icb804813688d4f06a2e58359a7b966ef_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c31b2881-6dd4-4423-85a7-5f47d2ad629c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a57a0dc2-e98a-4e0d-88e9-051bcebb61f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c31b2881-6dd4-4423-85a7-5f47d2ad629c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a57a0dc2-e98a-4e0d-88e9-051bcebb61f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b7e21ee1-c080-4a13-b5af-967cdd2877f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c31b2881-6dd4-4423-85a7-5f47d2ad629c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b7e21ee1-c080-4a13-b5af-967cdd2877f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dbfe6343-0234-43c5-9e4f-f2181dd251af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c31b2881-6dd4-4423-85a7-5f47d2ad629c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dbfe6343-0234-43c5-9e4f-f2181dd251af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_30d93336-6604-4c1b-ba54-2c4868419bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c31b2881-6dd4-4423-85a7-5f47d2ad629c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_30d93336-6604-4c1b-ba54-2c4868419bc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_22d980d9-35f9-4d87-b730-e8123637d3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_30d93336-6604-4c1b-ba54-2c4868419bc9" xlink:to="loc_us-gaap_AwardTypeAxis_22d980d9-35f9-4d87-b730-e8123637d3f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22d980d9-35f9-4d87-b730-e8123637d3f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_22d980d9-35f9-4d87-b730-e8123637d3f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22d980d9-35f9-4d87-b730-e8123637d3f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_266b824c-2691-4e06-95b5-c3320995ff31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_22d980d9-35f9-4d87-b730-e8123637d3f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_266b824c-2691-4e06-95b5-c3320995ff31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_a2b12d08-23b7-4c60-8233-672e1e4a3846" xlink:href="vcyt-20230331.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_266b824c-2691-4e06-95b5-c3320995ff31" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_a2b12d08-23b7-4c60-8233-672e1e4a3846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_02a15cb1-1884-4960-a427-a00e848b21d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_266b824c-2691-4e06-95b5-c3320995ff31" xlink:to="loc_us-gaap_EmployeeStockMember_02a15cb1-1884-4960-a427-a00e848b21d7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vcyt-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7dabdad4-bfd4-4b85-9e97-316e8975136b,g:d42a5b32-51ee-4157-98c8-837d0a6f976e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d97bf886-84c1-484e-8535-59000e932998_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0df9689f-1ee1-4f5e-a66e-b3644223249f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c035fc1-9862-4455-af98-9f10aec4ebf1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05acc919-3bf5-4d94-bb74-ffe197183f74_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_af05f64d-e637-4f3e-ba1a-9a22051b5352_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_52742a73-9938-4556-8cc5-837008dfc749_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_335c1f79-a69f-4c29-8d5e-f5467a6eb235_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4bae52d4-8789-4344-b925-fb5bfc5d720a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8f95a471-3cbc-45e7-9133-48ef95b55459_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_818fac45-8dd7-45bf-9783-d76b654432ce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_dcddede2-4e7a-4564-a75f-1d3a0ccfc57b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_17ea6dab-5b4c-41e8-ba78-5b9971b49d13_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c7fcd929-7e9a-4086-95e8-d21a013e837b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7149dbd2-4e84-45c0-906b-017ca6f5ec04_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_21b86436-20f5-4b04-98e5-6f4f901f090a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_36549f7f-ecc9-4136-831c-8124a4c5ef09_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember_70ece393-38cf-4b41-b092-9c99157a3d7e_terseLabel_en-US" xlink:label="lab_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract manufacturing and testing</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember_label_en-US" xlink:label="lab_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical And Other - Contract Manufacturing And Testing [Member]</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember_documentation_en-US" xlink:label="lab_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical And Other - Contract Manufacturing And Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember" xlink:to="lab_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesSoldAtPar_6d19b13c-a3f4-4785-adb4-0521f6d8d1ce_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesSoldAtPar" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesSoldAtPar_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesSoldAtPar" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Sold at Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldAtPar" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesSoldAtPar"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesSoldAtPar" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesSoldAtPar" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_ba3db0e0-01d8-482c-8f87-115c019632a5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49c41390-49dd-440b-9f45-5493b73e3720_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute net loss per common share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_af110119-f558-4b66-b833-0dcd567b2560_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_96dd884d-f824-4a71-9fa3-5a70b42aaf89_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_291c4895-0917-40ba-9d93-959cb38fe10c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e54bbcde-7a88-40e1-907b-b954e568c6ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 125,000,000 shares authorized, 72,383,140 and 71,959,454 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d8051729-7790-488a-a4ca-5b77f2bec403_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_f4fef7ee-6c0c-4c14-b83a-017a4a72504e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1ae416ad-919b-4be2-ac5d-b55496123e10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Income, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_03a6d930-3c11-4c83-a817-11b1a06b0f05_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_BiopharmaceuticalAndOtherMember_fd425e26-66ae-45c1-9b18-48d38054a783_terseLabel_en-US" xlink:label="lab_vcyt_BiopharmaceuticalAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical and other revenue</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalAndOtherMember_label_en-US" xlink:label="lab_vcyt_BiopharmaceuticalAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical And Other [Member]</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalAndOtherMember_documentation_en-US" xlink:label="lab_vcyt_BiopharmaceuticalAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents biopharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherMember" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_BiopharmaceuticalAndOtherMember" xlink:to="lab_vcyt_BiopharmaceuticalAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5055593a-0c0b-4779-8224-b3555528a0e2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fc6d5fb6-d26a-45ff-ad5f-8922d2014e3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Common Stock Equivalents Excluded From Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_63aee45c-f594-417b-b771-8e27af87ef57_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9068dfb7-e202-47c2-a759-64d8228beeb5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_4616d466-9a50-4183-9acc-e7d75a0fec90_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a88096d-06a7-4688-9f82-73bfbe1df3a4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6338b478-335c-42cf-8054-46e54c633964_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3281b5a6-4c4d-416f-9059-ba59c737c018_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_dbc5183a-d4f8-4bed-8967-2c6a4314e395_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_90ba9238-701e-4c7a-8488-8103bd2caf05_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f5a0d339-af25-47e0-90c4-3f43b8714b20_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_39a77e33-1e55-44cb-a266-30aa1deb58cf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_598da5f6-677e-4abf-a632-69942c40398f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of common stock options and employee stock purchases</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c4a9baea-191b-4c91-bba3-ca84100c6547_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_81faec49-0996-42f0-a578-b0b599d4d1ec_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_302e5186-f4d6-4460-af6e-65785c72c0be_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f2d67af3-b043-4358-99c0-eb15364e1713_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_e33ea503-d4e9-4d84-8895-a3d50bfad6de_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9f99307d-771b-4fbc-bf1b-d5cc1ac83cd7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_685c8b00-cceb-4dfb-95cd-c9d98b032f2a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5d5cb001-edd2-490d-aeb3-4e738ca44fb6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock subject to outstanding options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f8661e54-0096-4e03-9143-c642e00aa869_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment included in accounts payable and accrued liability</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1f5429a7-5e0f-490f-9978-ad7b55fc69ca_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign currency on operations</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_HalioDxCustomerRelationshipsMember_54b77e43-aa82-46e8-b0f6-ebecabcc3afb_terseLabel_en-US" xlink:label="lab_vcyt_HalioDxCustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HalioDx customer relationships</link:label>
    <link:label id="lab_vcyt_HalioDxCustomerRelationshipsMember_label_en-US" xlink:label="lab_vcyt_HalioDxCustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HalioDx Customer Relationships [Member]</link:label>
    <link:label id="lab_vcyt_HalioDxCustomerRelationshipsMember_documentation_en-US" xlink:label="lab_vcyt_HalioDxCustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HalioDx Customer Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HalioDxCustomerRelationshipsMember" xlink:href="vcyt-20230331.xsd#vcyt_HalioDxCustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_HalioDxCustomerRelationshipsMember" xlink:to="lab_vcyt_HalioDxCustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount_c5520c34-49c1-4a55-9606-3e4d44d6c04e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost of short-term investments sold</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Sold, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturitySoldAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7ef45558-c128-40fd-a109-669c5c922f78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f2b99bdc-c8f9-4f15-85f0-0887010f5a69_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f92e8607-d539-4930-b2b0-63629394ea55_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3b9a10ef-ae89-4676-9402-6e9df5553217_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_83d4d8ce-0bad-4748-baa3-505b7a254abd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_c7de335b-4ba9-4c6d-aecb-21b9b992146e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_e5cca8a9-4a5c-4963-bfac-4505ae639fe0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_08b9965e-6593-4a31-86db-f37cdd969c1f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_983d78d1-9787-4d41-a9ec-6dbe7371fc9d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_7ed4f0d6-b6b8-4bd2-b72d-24887d026411_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fcc0f14c-4637-4071-9627-807465f15dc9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ae7ad125-b4da-45ef-b133-9a2fee8d8bdf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9c242d6d-f763-474c-95f1-0d23043a8659_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_fbc41f11-8c94-4bf7-99cb-9cbda40da586_terseLabel_en-US" xlink:label="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations Of Credit And Other Risks And Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:href="vcyt-20230331.xsd#vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_04b2cc42-4b16-44ed-91e6-8f8a16c1ce6c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturity of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_NoncashLeaseExpense_69aae7da-d831-4178-93c5-3bf68329b87d_terseLabel_en-US" xlink:label="lab_vcyt_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash lease expense</link:label>
    <link:label id="lab_vcyt_NoncashLeaseExpense_label_en-US" xlink:label="lab_vcyt_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_vcyt_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_vcyt_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncash portion of lease expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NoncashLeaseExpense" xlink:href="vcyt-20230331.xsd#vcyt_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NoncashLeaseExpense" xlink:to="lab_vcyt_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_37c6ce73-6c3e-49c2-81b0-d0b75c8d0ea3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_eaa74161-0e05-4285-8e41-7b1287f96363_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9d2155c5-ef02-411b-95dc-472bcb665fc8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_0e564eec-2205-46d1-a81f-bc2fb50587c8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c29f3175-59a5-4b72-92e2-70cbba593b89_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_10adf9c3-fdfe-493a-bf8b-6194556e2078_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df8484f1-bf98-4f9c-9c30-560eea3ca11c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_91075eba-8474-495f-9689-5032f552f1b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_99e6caa1-705a-461e-a576-29274d2b61e5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_75f0c733-8037-4441-a68c-432a3359fe07_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_91dfc0ae-4a0c-4b28-bbd3-03bf98fe1a43_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_980306d0-ec9d-41d6-829f-a3ed11082cc8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5442e20e-8723-42ee-b440-ab468d8a31d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_55ef6183-a4c8-4b78-ae6d-92bf1ccfd90f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_698aba21-6dda-438c-bb04-2ff8256a1b81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_83c772e1-005a-4881-9bfe-9629a80d4c86_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a3d585e4-da7b-4224-bcc0-d9ee254b166b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_LymphmarkProductTechnologyMember_fb1cb227-209e-4eb6-bb36-1d20e2c3d0b1_verboseLabel_en-US" xlink:label="lab_vcyt_LymphmarkProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LymphMark product technology</link:label>
    <link:label id="lab_vcyt_LymphmarkProductTechnologyMember_label_en-US" xlink:label="lab_vcyt_LymphmarkProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LymphMark Product Technology [Member]</link:label>
    <link:label id="lab_vcyt_LymphmarkProductTechnologyMember_documentation_en-US" xlink:label="lab_vcyt_LymphmarkProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents LymphMark product technology.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LymphmarkProductTechnologyMember" xlink:href="vcyt-20230331.xsd#vcyt_LymphmarkProductTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LymphmarkProductTechnologyMember" xlink:to="lab_vcyt_LymphmarkProductTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_aeb9f898-a7a5-4bc5-ab89-5d42ec7af5fc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8e86c79d-1702-4ffd-8e5b-8e5ab5a5a59f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: short-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_cb1fb64b-8b63-4f59-ae68-7c9bfcf80b86_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a4f2129c-73ed-42df-b94e-f3918f1b6b87_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a76d32af-2f6f-4064-9d25-0e1d16abeec7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign currency on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue_fe135c3f-6c7f-43a0-b7c5-f9291d5ecacd_terseLabel_en-US" xlink:label="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities and deferred revenue</link:label>
    <link:label id="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue_label_en-US" xlink:label="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities And Deferred Revenue</link:label>
    <link:label id="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue_documentation_en-US" xlink:label="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities And Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue" xlink:href="vcyt-20230331.xsd#vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue" xlink:to="lab_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a0b0b6d7-45b4-42b3-8b20-c21358f2fca8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_73996c8a-3424-4d5f-8c1b-00d60bb459a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTypeExtensibleList_2a8c9234-50da-4d93-9384-aad14f453629_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTypeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Type [Extensible List]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTypeExtensibleList_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTypeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Type [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTypeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTypeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanTypeExtensibleList" xlink:to="lab_us-gaap_DefinedBenefitPlanTypeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_3bdaaca4-f971-418d-99df-aaa48a7462be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f7abb836-cff4-4e17-bf17-de8741386c44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Aggregate Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64882b6b-da74-401c-afa9-da21bed31bbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b4da1fac-7416-40b2-9f23-78afcade34d3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_9ce76315-49e0-4765-a357-f309c2db9015_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_7c604131-e238-486d-916b-19648b862dd2_terseLabel_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense (non-employee)</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_label_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Share Based Compensation, Non Employee</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_documentation_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase In additional paid-in capital (APIC) resulting from non-employee stock-based compensation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:href="vcyt-20230331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:to="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2710e8fc-f569-45bd-990c-5947b88231ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_272e48c6-59e5-4f44-9ce2-285d3a71ce72_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_0a0b8d2b-5740-4337-9e7c-12aae72d6640_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and finished diagnostic kits</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process and Raw Materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_2e483d49-b319-4f59-b847-e8a10608b794_terseLabel_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense (employee)</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_label_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Share Based Compensation, Employee</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_documentation_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in additional paid-in capital (APIC) resulting from employee stock-based compensation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:href="vcyt-20230331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:to="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c418aa95-e838-401d-825e-2f56488aa3b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_HalioDXDevelopedTechnologyMember_71cafec1-e1ad-4bd5-afcf-ced87c51d6a4_terseLabel_en-US" xlink:label="lab_vcyt_HalioDXDevelopedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HalioDx developed technology</link:label>
    <link:label id="lab_vcyt_HalioDXDevelopedTechnologyMember_label_en-US" xlink:label="lab_vcyt_HalioDXDevelopedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HalioDX Developed Technology [Member]</link:label>
    <link:label id="lab_vcyt_HalioDXDevelopedTechnologyMember_documentation_en-US" xlink:label="lab_vcyt_HalioDXDevelopedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HalioDX Developed Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HalioDXDevelopedTechnologyMember" xlink:href="vcyt-20230331.xsd#vcyt_HalioDXDevelopedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_HalioDXDevelopedTechnologyMember" xlink:to="lab_vcyt_HalioDXDevelopedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8dd718c4-b65a-4e86-988d-b3ab63ff5197_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2b490012-b360-41a8-a6ef-98feafb07d0a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ec021458-1125-4838-99b6-e859c1e6cb24_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4e331169-ad50-43b7-bf7a-30f0c629141e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_fd4db98e-6d3f-495c-baee-320d7d0c8133_terseLabel_en-US" xlink:label="lab_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four</link:label>
    <link:label id="lab_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="vcyt-20230331.xsd#vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_3c40f1e9-0f75-42c8-879b-d6d2a2230ace_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_cb25d566-5926-4ba0-ac38-3d051390c5c3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_bfa026e1-cded-4a6e-802f-b8cdddabdaef_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_2428683c-bebc-4521-a626-39a93ee51f78_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0f4f5b4e-7128-4385-9f82-659d3f61ad46_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term deposit</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b31fca22-733a-4758-99da-ff4e218e8bf7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3cd8e8b1-41fa-4374-9d7f-7dc7e29a02c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_PerceptaProductTechnologyMember_fdf668d5-7d8b-420e-a2ef-6012fb566bb4_terseLabel_en-US" xlink:label="lab_vcyt_PerceptaProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percepta product technology</link:label>
    <link:label id="lab_vcyt_PerceptaProductTechnologyMember_label_en-US" xlink:label="lab_vcyt_PerceptaProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percepta Product Technology [Member]</link:label>
    <link:label id="lab_vcyt_PerceptaProductTechnologyMember_documentation_en-US" xlink:label="lab_vcyt_PerceptaProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percepta Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_PerceptaProductTechnologyMember" xlink:href="vcyt-20230331.xsd#vcyt_PerceptaProductTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_PerceptaProductTechnologyMember" xlink:to="lab_vcyt_PerceptaProductTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_936f4012-516c-4a93-808d-6a951ca94db3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6adebf05-0bb2-4695-85e8-d5138af7e465_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Cost of Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_53591766-1fb3-49b4-9a61-7446fc977422_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9b05f204-2688-456d-9551-b0b8cfb1c38e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6bf3687a-5ffa-4408-9e22-cd3a77348168_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2532a0a1-b833-4e19-baad-6106e5ac62b2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_d324177c-80d7-4a99-805a-af78af1ef086_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d3c305c3-7796-4fa4-b70e-8edf82d2978d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_c1c7af51-3787-4133-8faf-7643e71cea09_terseLabel_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock subject to outstanding options</link:label>
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_label_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:href="vcyt-20230331.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:to="lab_vcyt_EmployeeAndNonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c68a72ac-5db5-446f-bb7e-1dae99ca7a37_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_dbbb89a3-f8ee-4ad6-81b3-3ca7f218cd54_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_caf3bed0-baf6-4a1d-898f-24056c9b0025_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4afd79ad-d875-4f62-8b96-781a9984e240_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_MajorCustomersMember_208a8a6a-8716-49bc-a432-3cd460b603ae_terseLabel_en-US" xlink:label="lab_vcyt_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers Representing &gt;10% Of Total Revenue</link:label>
    <link:label id="lab_vcyt_MajorCustomersMember_label_en-US" xlink:label="lab_vcyt_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Member]</link:label>
    <link:label id="lab_vcyt_MajorCustomersMember_documentation_en-US" xlink:label="lab_vcyt_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MajorCustomersMember" xlink:href="vcyt-20230331.xsd#vcyt_MajorCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_MajorCustomersMember" xlink:to="lab_vcyt_MajorCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9cc286d0-7d51-4c14-9f1c-d66e76f9d152_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_58c40382-dd2c-433f-a9ac-9664d52ca8e0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c71ca157-4985-4204-afe0-e668765ae968_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8a531d74-38b3-4196-b6aa-7a087d507a65_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1fb236d2-6cac-4ec5-8c98-213456f286a5_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Third-party Payers as a Percentage of Total</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9ad71fb8-88c5-497e-821d-7f2e6358caec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ecb3bbc-53c8-4678-a52d-93021b662eff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_432b7c1c-8e94-43b1-96d3-391cc011a738_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_68923aa0-b19b-4c9f-8ba1-1f8a9ca21035_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b961da4e-3ed1-42ea-b60d-94a6e63c38f3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember_60cdb5e4-4e03-4e37-9f4b-c14a9228bba4_terseLabel_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters And Laboratory Facilities South San Francisco and San Diego, California, Austin, Texas, Marseille, France and Richmond, Virginia</link:label>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember_label_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters And Laboratory Facilities South San Francisco And San Diego, California, Austin, Texas, Marseille, France And Richmond, Virginia [Member]</link:label>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember_documentation_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters And Laboratory Facilities South San Francisco And San Diego, California, Austin, Texas, Marseille, France And Richmond, Virginia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember" xlink:href="vcyt-20230331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember" xlink:to="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_cd4900cb-d1e3-481d-b75f-7837c55fe699_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_2a0f54ee-cc79-4b1c-a62c-1e96613da43d_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember_9e7dba2e-8bbd-42ae-beea-6ae130d9bc6b_terseLabel_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters And Laboratory Facilities South San Francisco</link:label>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember_label_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters And Laboratory Facilities South San Francisco [Member]</link:label>
    <link:label id="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember_documentation_en-US" xlink:label="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters And Laboratory Facilities South San Francisco</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember" xlink:href="vcyt-20230331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember" xlink:to="lab_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7d481d10-5c4e-4eae-8aa7-ed7f74e66abf_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_3172ee18-95c2-4c1a-b1a5-5161e57f712d_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_46074215-a4d0-498d-acd4-ea62f1d41983_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f96623b3-d6a1-4031-8784-4b38212239e6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_78e7440d-d2c2-450d-85a6-30300929b843_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_eca92e8a-43ec-477b-961a-d9d5422d4e0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8831eeeb-960f-4fc8-81e5-74435903c9fd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_af5b4809-3e62-45a8-bdf4-e4e1a5188304_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_2fc43f5c-2cdc-4e07-8867-690971d3e953_terseLabel_en-US" xlink:label="lab_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="vcyt-20230331.xsd#vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a6866ff-d767-4102-8aa5-aef56b80248f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3f9e0c04-2e92-49bd-9a91-164befa7a866_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a85b4589-cb3d-4a5c-a8fe-be8a9e0e94eb_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b2d72893-3503-48c2-85a8-63ab7a2d19ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_48c25300-ffbb-4ed9-b369-cc9534e1f20c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_0c02e8ed-8edd-4b92-8a1e-c5eb1d274d04_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies and inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4ac5a7a8-f46b-445b-ba3e-35f05bf60d96_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_HalioDxCustomerBacklogMember_89fdaa9a-ff89-4f80-827b-5313fc987410_terseLabel_en-US" xlink:label="lab_vcyt_HalioDxCustomerBacklogMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HalioDx customer backlog</link:label>
    <link:label id="lab_vcyt_HalioDxCustomerBacklogMember_label_en-US" xlink:label="lab_vcyt_HalioDxCustomerBacklogMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HalioDx Customer Backlog [Member]</link:label>
    <link:label id="lab_vcyt_HalioDxCustomerBacklogMember_documentation_en-US" xlink:label="lab_vcyt_HalioDxCustomerBacklogMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HalioDx Customer Backlog</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HalioDxCustomerBacklogMember" xlink:href="vcyt-20230331.xsd#vcyt_HalioDxCustomerBacklogMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_HalioDxCustomerBacklogMember" xlink:to="lab_vcyt_HalioDxCustomerBacklogMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6912a7c9-2a3e-4adf-9462-9e9c47254c1e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f5584ea-8cd2-42e3-b137-5a6cd07cbf83_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8dc3d703-e3a6-4a49-9832-7b0d744ddb94_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bf2ba826-a141-4b0e-a2d8-add06d4303b8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_aaba05c6-204b-43de-b71f-ae5655ba61cc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_af19900e-8fa4-4f68-bd12-9d55b88bb310_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_d38775c2-8e9c-4da0-8bd3-6d8fc5e33d84_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit_9b2ac1ba-5b75-4337-8e97-e867b1500030_terseLabel_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">French research tax credits</link:label>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit_label_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Foreign Tax Credit</link:label>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit_documentation_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Credit, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit" xlink:to="lab_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e313dba3-c43a-4042-9218-7ef5c9eefad5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_83c078d8-c2be-4f13-8228-026fe933478f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9524b617-7e8d-439e-bb71-c185f512ff88_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2b23273f-5e03-4ad4-95ff-36133c6648d4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute net loss per common share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d0f0a7c-c724-41a1-9576-a888a3766a63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss_c5ea7d0c-323a-4cf9-b466-c909c47f4641_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_e45e5b07-0cff-46b2-aa3f-b25c7d126ef1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab supplies and reagents consumed</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7633605e-3ca4-4b06-9fb3-f702004f73ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ba773063-93aa-4ebe-a171-12bce8a8aa24_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9e562029-0405-4cd4-936a-212f5b2ecdd5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c8ef211c-6884-4693-84ad-56259636e6d1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseOther_6062376d-af52-41d7-8679-829970e5b84c_terseLabel_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseOther_label_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Other</link:label>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseOther_documentation_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseOther" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OtherNonoperatingIncomeExpenseOther" xlink:to="lab_vcyt_OtherNonoperatingIncomeExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseInterestIncome_05e10f07-1985-4dd9-af90-389887d926a4_terseLabel_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseInterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseInterestIncome_label_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Interest Income</link:label>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseInterestIncome_documentation_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseInterestIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseInterestIncome" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OtherNonoperatingIncomeExpenseInterestIncome" xlink:to="lab_vcyt_OtherNonoperatingIncomeExpenseInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b22965ad-74dc-4ac1-9056-7b1997b06b1c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DecipherBioSciencesProductTechnologyMember_f899b37d-558b-4c05-b9df-8bca4b9cf250_terseLabel_en-US" xlink:label="lab_vcyt_DecipherBioSciencesProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decipher product technology</link:label>
    <link:label id="lab_vcyt_DecipherBioSciencesProductTechnologyMember_label_en-US" xlink:label="lab_vcyt_DecipherBioSciencesProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decipher BioSciences Product Technology [Member]</link:label>
    <link:label id="lab_vcyt_DecipherBioSciencesProductTechnologyMember_documentation_en-US" xlink:label="lab_vcyt_DecipherBioSciencesProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decipher BioSciences Product Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DecipherBioSciencesProductTechnologyMember" xlink:href="vcyt-20230331.xsd#vcyt_DecipherBioSciencesProductTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DecipherBioSciencesProductTechnologyMember" xlink:to="lab_vcyt_DecipherBioSciencesProductTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest_b4932333-d899-433e-86e7-cabfd55793aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, allowance for expected credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5ab51658-734f-4b96-a5bc-4aea8d814a68_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c01771d9-07c2-478b-8294-9431d62652ad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_643be261-c90a-4123-9fa1-2cd27f1351ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1975fb38-3993-4cd7-8213-4e5490d7731f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9cb8adff-9f8b-48a6-839e-c3d574e62ec0_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_21fe7185-8216-4c0c-83a6-ad91474a66fb_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Exercises In Period</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:href="vcyt-20230331.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b86d7c33-95a1-43db-ab27-34fc16c06fef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f404a100-0932-46ae-80ca-da92a04f5b19_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_BusinessCombinationContingentConsiderationCashToBePaid_2d46895a-525a-4934-97ae-dbe159ddda57_terseLabel_en-US" xlink:label="lab_vcyt_BusinessCombinationContingentConsiderationCashToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash to be paid</link:label>
    <link:label id="lab_vcyt_BusinessCombinationContingentConsiderationCashToBePaid_label_en-US" xlink:label="lab_vcyt_BusinessCombinationContingentConsiderationCashToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Cash To Be Paid</link:label>
    <link:label id="lab_vcyt_BusinessCombinationContingentConsiderationCashToBePaid_documentation_en-US" xlink:label="lab_vcyt_BusinessCombinationContingentConsiderationCashToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Cash To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationCashToBePaid" xlink:href="vcyt-20230331.xsd#vcyt_BusinessCombinationContingentConsiderationCashToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_BusinessCombinationContingentConsiderationCashToBePaid" xlink:to="lab_vcyt_BusinessCombinationContingentConsiderationCashToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4e102d9b-b7a0-42c7-a641-faf0c1a3af66_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_e01885a3-fd8d-420d-91d9-bcde063c174d_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_1d27f5fc-e094-4a08-90e4-4e571198fb62_terseLabel_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense (ESPP)</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_label_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Share Based Compensation, ESPP</link:label>
    <link:label id="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_documentation_en-US" xlink:label="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in additional paid-in capital (APIC) resulting from ESPP stock-based compensation expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:href="vcyt-20230331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:to="lab_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_58cc925f-ea06-4870-b48c-581b6a8430c9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4ecc8f13-4a4a-4c74-8bb9-dcb32247aa28_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_45c5b6be-9f5f-4ae2-8809-fe1611fb29ff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_NCounterDxLicenseMember_d66c924c-bb53-43ea-9a91-58798f8099ee_terseLabel_en-US" xlink:label="lab_vcyt_NCounterDxLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nCounter Dx license</link:label>
    <link:label id="lab_vcyt_NCounterDxLicenseMember_label_en-US" xlink:label="lab_vcyt_NCounterDxLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nCounter Dx License [Member]</link:label>
    <link:label id="lab_vcyt_NCounterDxLicenseMember_documentation_en-US" xlink:label="lab_vcyt_NCounterDxLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">nCounter Dx License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NCounterDxLicenseMember" xlink:href="vcyt-20230331.xsd#vcyt_NCounterDxLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NCounterDxLicenseMember" xlink:to="lab_vcyt_NCounterDxLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f5639475-af85-4d21-8171-a0011161a520_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DecipherBiosciencesTradeNamesMember_acf89f23-f7e7-438c-be6c-1d16afd7d466_terseLabel_en-US" xlink:label="lab_vcyt_DecipherBiosciencesTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decipher trade names</link:label>
    <link:label id="lab_vcyt_DecipherBiosciencesTradeNamesMember_label_en-US" xlink:label="lab_vcyt_DecipherBiosciencesTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decipher Biosciences Trade Names [Member]</link:label>
    <link:label id="lab_vcyt_DecipherBiosciencesTradeNamesMember_documentation_en-US" xlink:label="lab_vcyt_DecipherBiosciencesTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decipher Biosciences Trade Names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DecipherBiosciencesTradeNamesMember" xlink:href="vcyt-20230331.xsd#vcyt_DecipherBiosciencesTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DecipherBiosciencesTradeNamesMember" xlink:to="lab_vcyt_DecipherBiosciencesTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ef1bcfc5-98e1-4175-ba99-6caeb6e832b2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of taxes on vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_bd706663-0e5a-42e9-88bf-23cf0b28a876_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0c718fd4-5607-47f9-b387-84e5bc304db8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c20b31da-6420-4d4c-b3d7-85a7f82624e5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty_3d5492a6-c4c9-4bbc-9480-555b2f059445_terseLabel_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on end-of-term debt obligation</link:label>
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty_label_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, End Of Term Payment Interest Amount And Prepayment Penalty</link:label>
    <link:label id="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty_documentation_en-US" xlink:label="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, End Of Term Payment Interest Amount And Prepayment Penalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty" xlink:href="vcyt-20230331.xsd#vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty" xlink:to="lab_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss_c6e09e8a-62d5-4902-9a08-0198353180aa_terseLabel_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on currency revaluation</link:label>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Foreign Currency Translation Gain (Loss)</link:label>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss_documentation_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Gain (Loss), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss" xlink:to="lab_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f130fc43-bc7a-4f21-a1c3-1f4fff9b26cb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d475fcae-696d-4f50-b170-93f0734f9d2b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ea1a237b-6e4a-4899-a5a1-8329af35a0f0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3ae6a08a-4bde-47c4-b089-013af7715df2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ProsignaCustomerRelationshipsMember_9df42e01-6c44-4cd7-9e4a-901cdebed232_verboseLabel_en-US" xlink:label="lab_vcyt_ProsignaCustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prosigna customer relationships</link:label>
    <link:label id="lab_vcyt_ProsignaCustomerRelationshipsMember_label_en-US" xlink:label="lab_vcyt_ProsignaCustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prosigna Customer Relationships [Member]</link:label>
    <link:label id="lab_vcyt_ProsignaCustomerRelationshipsMember_documentation_en-US" xlink:label="lab_vcyt_ProsignaCustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Prosigna customer relationships.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ProsignaCustomerRelationshipsMember" xlink:href="vcyt-20230331.xsd#vcyt_ProsignaCustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ProsignaCustomerRelationshipsMember" xlink:to="lab_vcyt_ProsignaCustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_c18e2810-b14c-4c15-be80-29084a44777a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cd8b6317-a5e0-49e0-8929-5c8b24df987f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amount representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_c6d6267a-95ba-4462-94d5-7cbaaf5d23bc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_44831f68-4ea8-41c9-a091-812cac71781a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_13210cfe-722a-458e-9f4a-c1898ff2eaec_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3b47327c-9389-4f51-90fc-36f3b5534aa5_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_0d7093de-7419-4b3a-a092-1943509d97bc_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_1874e7b3-dad7-43ac-937f-fab35f34ec03_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Other Income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_59cba3f6-1b75-41d4-8310-12b1b5ced978_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9fbc8be5-b30a-425a-9189-25f9b547eaeb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_473420da-b48d-43ef-8439-93082c013f69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_67e39a9e-4029-4f38-823b-eb6b17350620_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reserved Shares of Common Stock for Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_e7431b11-8185-40c4-af3a-d25ca9c4c2e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_MeasurementInputProbabilityOfAchievementMember_e0242dfe-0737-42e3-a539-2d749b410ad7_terseLabel_en-US" xlink:label="lab_vcyt_MeasurementInputProbabilityOfAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of achievement</link:label>
    <link:label id="lab_vcyt_MeasurementInputProbabilityOfAchievementMember_label_en-US" xlink:label="lab_vcyt_MeasurementInputProbabilityOfAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Achievement [Member]</link:label>
    <link:label id="lab_vcyt_MeasurementInputProbabilityOfAchievementMember_documentation_en-US" xlink:label="lab_vcyt_MeasurementInputProbabilityOfAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input using probability of achievement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MeasurementInputProbabilityOfAchievementMember" xlink:href="vcyt-20230331.xsd#vcyt_MeasurementInputProbabilityOfAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_MeasurementInputProbabilityOfAchievementMember" xlink:to="lab_vcyt_MeasurementInputProbabilityOfAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_51d086d2-6dd0-4211-88d3-b6453ce535d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_71a774bf-9ebb-4edd-a103-9f6e7d7e2fb2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_12c6ecd5-3854-47b4-863c-30a473c9ca11_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_08f0c91c-17b1-487e-bcb9-6128efa18d35_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_1ec3ca7a-d4ed-4bfa-9b66-ec5f9bb8b787_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_NanostringMember_b0b220d6-81f1-4e6e-bb83-aafa538aad22_terseLabel_en-US" xlink:label="lab_vcyt_NanostringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NanoString</link:label>
    <link:label id="lab_vcyt_NanostringMember_label_en-US" xlink:label="lab_vcyt_NanostringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NanoString [Member]</link:label>
    <link:label id="lab_vcyt_NanostringMember_documentation_en-US" xlink:label="lab_vcyt_NanostringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents NanoString.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NanostringMember" xlink:href="vcyt-20230331.xsd#vcyt_NanostringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_NanostringMember" xlink:to="lab_vcyt_NanostringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f261f560-4b21-4f1b-9981-2142cafe09d9_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5b96d3ce-d926-4648-98e7-edc18a95dd7e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_db6ee7a8-a7aa-47c8-ae45-932371c244ac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_17798556-6522-4b1b-88ca-8819bb1957ef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_MedicareMember_a2fde280-fb44-4873-b214-31f2a161f3f4_terseLabel_en-US" xlink:label="lab_vcyt_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_vcyt_MedicareMember_label_en-US" xlink:label="lab_vcyt_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_vcyt_MedicareMember_documentation_en-US" xlink:label="lab_vcyt_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MedicareMember" xlink:href="vcyt-20230331.xsd#vcyt_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_MedicareMember" xlink:to="lab_vcyt_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_39362e35-f030-438a-a38a-ced5d0e6e0d2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_648ab068-fff0-4792-aa4a-e737f88ceea3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_TestingMember_9ba9a79f-8fc9-40db-b87f-a6e0acd0af64_terseLabel_en-US" xlink:label="lab_vcyt_TestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing revenue</link:label>
    <link:label id="lab_vcyt_TestingMember_label_en-US" xlink:label="lab_vcyt_TestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing [Member]</link:label>
    <link:label id="lab_vcyt_TestingMember_documentation_en-US" xlink:label="lab_vcyt_TestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents testing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TestingMember" xlink:href="vcyt-20230331.xsd#vcyt_TestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_TestingMember" xlink:to="lab_vcyt_TestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ce2f51bb-e94a-433b-b68a-573970047dfa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_50ccb5ef-71b1-408c-9a62-bc9f6e3a9182_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_04f56f33-4c07-454c-b6e7-2a1e9c5355d4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1b278c59-d72f-48fe-a451-a78b2782d47b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_b47ab4dc-4f1b-48d2-a40a-461fd266c388_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_86a5cf2d-a382-490e-a49e-62bd87a30dab_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_261a7b21-5c76-4f62-a3e1-2c53acb08152_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3605f839-92a5-44f0-bf8e-5da535e36da4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d2884f52-000c-45a4-9ad8-828edc29e0ca_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c374b873-2598-4857-8618-a7479f80746f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_aeefbc96-e4dc-4a7f-b2a3-9e98e98358a4_terseLabel_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock on exercise of stock options and vesting of restricted stock units</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_label_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Value, Options And Non-Option Equity Instruments, Exercises In Period</link:label>
    <link:label id="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_documentation_en-US" xlink:label="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Value, Options And Non-Option Equity Instruments, Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:href="vcyt-20230331.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:to="lab_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_ceec9731-54bf-42c4-9fe2-c1c1acdd025b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1124a7a6-398f-4703-8579-1e0225716b68_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8c1c6d73-ee4a-4c29-bbf3-0eb9183e76af_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5d013574-d10e-4b92-8cf5-d362a118846a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_FacilitiesInMarseilleFranceMember_c05f6a26-8207-4c7b-8358-71680d75597d_terseLabel_en-US" xlink:label="lab_vcyt_FacilitiesInMarseilleFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities in Marseille, France</link:label>
    <link:label id="lab_vcyt_FacilitiesInMarseilleFranceMember_label_en-US" xlink:label="lab_vcyt_FacilitiesInMarseilleFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities In Marseille, France [Member]</link:label>
    <link:label id="lab_vcyt_FacilitiesInMarseilleFranceMember_documentation_en-US" xlink:label="lab_vcyt_FacilitiesInMarseilleFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities In Marseille, France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_FacilitiesInMarseilleFranceMember" xlink:href="vcyt-20230331.xsd#vcyt_FacilitiesInMarseilleFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_FacilitiesInMarseilleFranceMember" xlink:to="lab_vcyt_FacilitiesInMarseilleFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3292b402-a8aa-4947-95d6-b98d3ec8958c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1fab24c8-4d73-4d5e-8656-5d5328107b52_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8311dc19-3c2d-49c2-92d6-a725086aad25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_77a75aa8-9aba-4ac1-9ce5-de2e7d1ff718_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9115a3d7-79bc-4fbc-8a42-378fa5dd70e8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_55691303-83fe-458b-a569-c9b767e5ce7b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_21d8fa32-1f6a-49a3-a998-396ef75be6dc_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9af52d54-ab51-404d-8b75-668ad0a90de2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1f81dd5c-397c-46f3-987b-eb5e30014e69_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_762552de-afd2-4c6b-bd0b-f4f35e83b882_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Expense and Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5e458be-9078-411a-8b39-9557cad5ff5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6a3136d4-4ffa-4045-b096-c488530b8fcc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration, net of current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_085657d6-a045-480d-835f-7438d4754a2c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_af4b8826-fd77-4d7a-bdb5-d14650f5a9b5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6a4b8da7-745b-4ed2-bcc8-2526fc2f74d9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 remainder of year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0bfd1654-bec8-4ad2-91f7-58f4278d7c4b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9df53b9d-5f77-4cad-9d07-a1365d6c1b7f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b7ba5b29-b17f-4565-a22e-c3e1c77e153c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0a5d3757-8760-4c68-8988-f0b247f8e5ba_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_71b95189-d1a1-4c10-9c57-dd51d41295a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_841a3674-e456-4231-a36f-cc4cd0a8e927_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ba2d949b-d844-4884-8798-b293ce73e8e2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_583de65c-648e-49ee-a656-ec1b571fa64a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_767c0510-0aa7-4869-8e3c-efea57d58357_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_3a300ab8-1f6e-4d71-8b94-80053a563ead_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_5c6f0680-897f-448a-908b-e335a48d86fd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e1f8e0f6-332b-4687-a9ed-703484f4d3c9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_223f943f-b506-4089-a2a2-e9e4318a5b6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4e3f4794-4b71-49a1-944b-72ce23f31726_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3a400e34-e1f4-4376-8cbd-99ac9a9ac883_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_82c274c6-b4a0-4374-b7cb-ea9169e74de3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_48ca45c4-887d-47e3-a604-9f8a4ad80be1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_30d3ab58-8e86-4a0a-89ef-6e00b891a144_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax portion of vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_a65b5c29-fbe1-440a-9aca-d8cdc175109c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseInterestExpense_47358c33-c47c-4ac6-9cbb-3a1b7d0b2776_negatedTerseLabel_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseInterestExpense_label_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Interest Expense</link:label>
    <link:label id="lab_vcyt_OtherNonoperatingIncomeExpenseInterestExpense_documentation_en-US" xlink:label="lab_vcyt_OtherNonoperatingIncomeExpenseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseInterestExpense" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_OtherNonoperatingIncomeExpenseInterestExpense" xlink:to="lab_vcyt_OtherNonoperatingIncomeExpenseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_9bca8476-e4a1-40a7-ac13-cc98ae83a116_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_e9d24caa-8ea9-4679-976a-d9e4d742f16e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_71448a9f-af46-4cdd-9d92-2dc1005a09ee_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_74a0c83e-b88e-4aa8-a1ea-51abf4e7613d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_6f1be206-61fb-4157-a09f-23c4795c3c17_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_01b73579-c6ee-4ba6-8b91-d984cb28b260_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_64119e75-d223-40e5-be35-298cbc135438_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf0a2882-847a-492e-8541-d22a18d75a5c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8cbf7151-9236-4952-8e14-49bec32f68eb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_4e58981f-fe14-4de9-95e0-597a5533f9f3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term contingent considerations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_76aab59b-bce5-42ed-82dc-9447480a2f50_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_3da7d829-f423-4592-8b44-a2259cd38de4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3e550f78-d04e-4b2b-a353-e3527b0e20da_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_0e84dcd0-3bd4-4429-8f52-2bf4c4a5ba15_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_412b9c32-479b-4887-a13f-433c29223394_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ce055829-1140-45a5-bfbb-c3c44b164695_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_4edb4285-83f1-44a4-8f9e-209baadb28ba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Description of Business and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2c087e39-35ef-4d40-be0a-cfaa24d82c27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d7dc98f3-e16a-4cb3-b5cc-6750cb3927cf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_91068375-9f2d-4ee4-a354-386c0338d84c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6b61f3d1-2657-4554-b81a-d9e1140efed6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_05ea5428-7113-44ef-be1f-7842ca4bbacd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_ac01125b-7839-4ff9-ad13-4b277b19b4d6_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains (losses) from sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Sold, Realized Gain (Loss), Excluding Other-than-temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_DevelopedProductTechnologyMember_4cfed941-bb54-42ce-a884-8b2c47250189_verboseLabel_en-US" xlink:label="lab_vcyt_DevelopedProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prosigna product technology</link:label>
    <link:label id="lab_vcyt_DevelopedProductTechnologyMember_label_en-US" xlink:label="lab_vcyt_DevelopedProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Product Technology [Member]</link:label>
    <link:label id="lab_vcyt_DevelopedProductTechnologyMember_documentation_en-US" xlink:label="lab_vcyt_DevelopedProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Product Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DevelopedProductTechnologyMember" xlink:href="vcyt-20230331.xsd#vcyt_DevelopedProductTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_DevelopedProductTechnologyMember" xlink:to="lab_vcyt_DevelopedProductTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e74faeee-4532-48df-b1db-109d62021ba8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_583ed7df-fa02-4e56-bf88-11dbb6e10d40_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2062c2a8-b490-4bdf-99dc-56177d36aee2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount_5493172f-e113-4290-80e9-daa99c6df18a_terseLabel_en-US" xlink:label="lab_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent</link:label>
    <link:label id="lab_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount_label_en-US" xlink:label="lab_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Annual Undiscounted Amount</link:label>
    <link:label id="lab_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount_documentation_en-US" xlink:label="lab_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Annual Undiscounted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount" xlink:href="vcyt-20230331.xsd#vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount" xlink:to="lab_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_193c7fd1-3bf1-46c2-b135-82db4469d469_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_06adb855-dd5d-4657-853f-c5045398f600_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies and inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_ea3b65c3-42bc-4d3d-8a2a-90d97f5b090c_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b64a91a5-e6c8-4f62-863e-2accfb1064c3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_fdbcafce-f917-4930-a460-f9172075053f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_UnitedHealthcareMember_e5930c6e-2550-4c45-864a-93306f2377e7_terseLabel_en-US" xlink:label="lab_vcyt_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UnitedHealthcare</link:label>
    <link:label id="lab_vcyt_UnitedHealthcareMember_label_en-US" xlink:label="lab_vcyt_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare [Member]</link:label>
    <link:label id="lab_vcyt_UnitedHealthcareMember_documentation_en-US" xlink:label="lab_vcyt_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents United Healthcare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_UnitedHealthcareMember" xlink:href="vcyt-20230331.xsd#vcyt_UnitedHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_UnitedHealthcareMember" xlink:to="lab_vcyt_UnitedHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_62093af6-4357-44f0-a574-4b0d93a0bce8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember_c952ced4-29eb-4cfc-9e5e-ca6801e63c06_terseLabel_en-US" xlink:label="lab_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical revenue</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember_label_en-US" xlink:label="lab_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical And Other - Biopharmaceutical Revenue [Member]</link:label>
    <link:label id="lab_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember_documentation_en-US" xlink:label="lab_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharmaceutical And Other - Biopharmaceutical Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember" xlink:to="lab_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_57dd8dd3-15f4-4740-98e6-bae7f54bf075_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_40c38221-d7f6-4d22-8c6d-02d1466f056e_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Liability</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a122d313-9435-48ff-9ef1-3db7d0755749_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment_ec155856-137c-420f-b4f0-86d4e472ff14_terseLabel_en-US" xlink:label="lab_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, changes in fair value</link:label>
    <link:label id="lab_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment_label_en-US" xlink:label="lab_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Fair Value Adjustment</link:label>
    <link:label id="lab_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment_documentation_en-US" xlink:label="lab_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment" xlink:href="vcyt-20230331.xsd#vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment" xlink:to="lab_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_0f12bbfb-cbf3-4d89-9c17-ccee8fc75213_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_9380bbc4-c5a4-482c-bb9d-10b38b0f0b70_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vcyt-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7dabdad4-bfd4-4b85-9e97-316e8975136b,g:d42a5b32-51ee-4157-98c8-837d0a6f976e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.veracyte.com/role/CoverPage" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2fb6579d-a512-4c4d-bf81-9bcb0bbc7a46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_DocumentType_2fb6579d-a512-4c4d-bf81-9bcb0bbc7a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_19a22dfc-67f5-4447-94d7-a26603447aa6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_DocumentQuarterlyReport_19a22dfc-67f5-4447-94d7-a26603447aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_879bfe67-883d-481c-ad2e-cdd092f93e47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_DocumentPeriodEndDate_879bfe67-883d-481c-ad2e-cdd092f93e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9d34e435-342f-4da4-9088-0ba5e476952e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_DocumentTransitionReport_9d34e435-342f-4da4-9088-0ba5e476952e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5760d833-f579-4264-9941-a5b809d05ca7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityFileNumber_5760d833-f579-4264-9941-a5b809d05ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5ac95390-fbeb-41e1-b70f-ea37248b2273" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityRegistrantName_5ac95390-fbeb-41e1-b70f-ea37248b2273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a52e7ea5-c4fd-43d7-8849-cb9eea4bc5bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a52e7ea5-c4fd-43d7-8849-cb9eea4bc5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_addf3492-8e94-4f28-a567-78805a83212c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityTaxIdentificationNumber_addf3492-8e94-4f28-a567-78805a83212c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_50127270-d7a8-4bb5-8eb3-61ea140fbe53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityAddressAddressLine1_50127270-d7a8-4bb5-8eb3-61ea140fbe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_de1ada78-7f15-4c01-a9b4-ab5c1f7ea5c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityAddressAddressLine2_de1ada78-7f15-4c01-a9b4-ab5c1f7ea5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cf759533-5bf0-4871-9288-ee9aa5e626ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityAddressCityOrTown_cf759533-5bf0-4871-9288-ee9aa5e626ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4a075872-07e1-480c-a9cc-d13a809199d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityAddressStateOrProvince_4a075872-07e1-480c-a9cc-d13a809199d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_81d5e8d5-9cd3-4df5-894a-c71cd6ea8d60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityAddressPostalZipCode_81d5e8d5-9cd3-4df5-894a-c71cd6ea8d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_60af2c64-09ce-4be1-976d-cf3c7f020ad3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_CityAreaCode_60af2c64-09ce-4be1-976d-cf3c7f020ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_87468a5c-76a5-4f49-9ef1-d0a446125fa9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_LocalPhoneNumber_87468a5c-76a5-4f49-9ef1-d0a446125fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0e54685c-c8da-4b84-86da-659b576c3c00" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_Security12bTitle_0e54685c-c8da-4b84-86da-659b576c3c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c3acf458-fe94-490e-8328-fa2da98c653a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_TradingSymbol_c3acf458-fe94-490e-8328-fa2da98c653a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_62eca05e-7899-4aeb-84dc-18f16106524b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_SecurityExchangeName_62eca05e-7899-4aeb-84dc-18f16106524b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f34ff8e5-d402-49c4-8b82-78451ae09d1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityCurrentReportingStatus_f34ff8e5-d402-49c4-8b82-78451ae09d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7d0bf4a4-d779-4be3-bf94-da5d4410311d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityInteractiveDataCurrent_7d0bf4a4-d779-4be3-bf94-da5d4410311d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1c012bff-b84e-4ff0-96cb-6327cf02f02f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityFilerCategory_1c012bff-b84e-4ff0-96cb-6327cf02f02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8cd56101-26f3-48f4-9c8f-16ae963afbfa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntitySmallBusiness_8cd56101-26f3-48f4-9c8f-16ae963afbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ebdb58c8-cc92-4976-96a9-457e10f71c1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityEmergingGrowthCompany_ebdb58c8-cc92-4976-96a9-457e10f71c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7ab593d2-da3b-4236-9c9f-376cf719f307" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityShellCompany_7ab593d2-da3b-4236-9c9f-376cf719f307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d00b34dc-ba6b-439c-9fa9-b60253f1bbd7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d00b34dc-ba6b-439c-9fa9-b60253f1bbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c6d10ec0-aa7a-4726-a4e6-d7e8e57ca01a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_EntityCentralIndexKey_c6d10ec0-aa7a-4726-a4e6-d7e8e57ca01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_74ea2b8b-0a6e-4c3c-9afc-fa6c6620679f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_AmendmentFlag_74ea2b8b-0a6e-4c3c-9afc-fa6c6620679f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f556bfac-6dd6-4e75-8b95-effbfc2090e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_CurrentFiscalYearEndDate_f556bfac-6dd6-4e75-8b95-effbfc2090e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5a2fc222-e834-42a5-8f7b-26784092da44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5a2fc222-e834-42a5-8f7b-26784092da44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4ce6ad3f-c176-4c60-afb6-b83dc6d960e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_08359173-2c58-453f-82d3-4ae391e5eca2" xlink:to="loc_dei_DocumentFiscalYearFocus_4ce6ad3f-c176-4c60-afb6-b83dc6d960e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c8286b15-f9c8-49ab-acc3-e874fedfebe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_780c0142-9231-4055-9a62-1b4e5202f7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c8286b15-f9c8-49ab-acc3-e874fedfebe1" xlink:to="loc_us-gaap_AssetsAbstract_780c0142-9231-4055-9a62-1b4e5202f7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_fc95728a-5706-417d-9d03-e9dfaddf740c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_780c0142-9231-4055-9a62-1b4e5202f7b4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_fc95728a-5706-417d-9d03-e9dfaddf740c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2debfc11-b42b-4b36-8634-a7f0c79ea53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fc95728a-5706-417d-9d03-e9dfaddf740c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2debfc11-b42b-4b36-8634-a7f0c79ea53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss_95f0c351-37ed-4be5-9d04-479df5bbbedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fc95728a-5706-417d-9d03-e9dfaddf740c" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss_95f0c351-37ed-4be5-9d04-479df5bbbedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6925e34b-0d3f-407f-bfad-fb671a79988f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fc95728a-5706-417d-9d03-e9dfaddf740c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6925e34b-0d3f-407f-bfad-fb671a79988f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_685a24fe-964d-4c08-a654-ff4097068186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fc95728a-5706-417d-9d03-e9dfaddf740c" xlink:to="loc_us-gaap_InventoryNet_685a24fe-964d-4c08-a654-ff4097068186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7e0428c9-7f91-4367-a35f-ee550a056785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fc95728a-5706-417d-9d03-e9dfaddf740c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7e0428c9-7f91-4367-a35f-ee550a056785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_966fa5a9-b29d-443e-8553-680a9cebfbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fc95728a-5706-417d-9d03-e9dfaddf740c" xlink:to="loc_us-gaap_AssetsCurrent_966fa5a9-b29d-443e-8553-680a9cebfbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c7c780a5-f1f1-4776-b274-c585eedb194d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_780c0142-9231-4055-9a62-1b4e5202f7b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c7c780a5-f1f1-4776-b274-c585eedb194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b4148551-e6ea-4bd2-9a6f-4c5aaf630633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_780c0142-9231-4055-9a62-1b4e5202f7b4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b4148551-e6ea-4bd2-9a6f-4c5aaf630633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2047f011-b29f-43ee-8ad2-177c6dcf53ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_780c0142-9231-4055-9a62-1b4e5202f7b4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2047f011-b29f-43ee-8ad2-177c6dcf53ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bdcc6c3d-da90-40fb-9cf7-1709be9643ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_780c0142-9231-4055-9a62-1b4e5202f7b4" xlink:to="loc_us-gaap_Goodwill_bdcc6c3d-da90-40fb-9cf7-1709be9643ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6e35fed0-e4d2-405c-85a3-9fbf76d2b8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_780c0142-9231-4055-9a62-1b4e5202f7b4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6e35fed0-e4d2-405c-85a3-9fbf76d2b8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_85cf1f60-93f6-4d29-9abb-c9d573492c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_780c0142-9231-4055-9a62-1b4e5202f7b4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_85cf1f60-93f6-4d29-9abb-c9d573492c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ae316154-3798-4caa-80ad-a15b082ac16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_780c0142-9231-4055-9a62-1b4e5202f7b4" xlink:to="loc_us-gaap_Assets_ae316154-3798-4caa-80ad-a15b082ac16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c8286b15-f9c8-49ab-acc3-e874fedfebe1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7a8676a4-0529-405a-938e-f8e62d95edb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7a8676a4-0529-405a-938e-f8e62d95edb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9b6926ad-a9b5-497a-9958-7237d788ff02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a8676a4-0529-405a-938e-f8e62d95edb9" xlink:to="loc_us-gaap_AccountsPayableCurrent_9b6926ad-a9b5-497a-9958-7237d788ff02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9e673297-e293-4b07-9e10-89802c166cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a8676a4-0529-405a-938e-f8e62d95edb9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9e673297-e293-4b07-9e10-89802c166cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5f57c3bd-bd24-4d4a-b1ba-a9c0a956ac8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a8676a4-0529-405a-938e-f8e62d95edb9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5f57c3bd-bd24-4d4a-b1ba-a9c0a956ac8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ae00040a-2e94-4b0b-937e-aa194194e609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a8676a4-0529-405a-938e-f8e62d95edb9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ae00040a-2e94-4b0b-937e-aa194194e609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bf01d27b-93c6-46d1-8fe2-e3fbf48288ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a8676a4-0529-405a-938e-f8e62d95edb9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bf01d27b-93c6-46d1-8fe2-e3fbf48288ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d4374911-474e-479c-8549-a6381d8e740d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a8676a4-0529-405a-938e-f8e62d95edb9" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d4374911-474e-479c-8549-a6381d8e740d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_18a704f7-a7ce-431a-8532-37f0d91c366a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a8676a4-0529-405a-938e-f8e62d95edb9" xlink:to="loc_us-gaap_LiabilitiesCurrent_18a704f7-a7ce-431a-8532-37f0d91c366a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_92c42961-170b-4b5e-a3b8-ae9284c3f164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_92c42961-170b-4b5e-a3b8-ae9284c3f164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_35be78ee-41f4-4934-929e-8fb2d8aaaa57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_35be78ee-41f4-4934-929e-8fb2d8aaaa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9388d27e-1637-452c-a5fa-573a93f32196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9388d27e-1637-452c-a5fa-573a93f32196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_50168d4b-964d-4f32-9086-559224efb0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_50168d4b-964d-4f32-9086-559224efb0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e938b3af-2d70-49a2-a67b-fd2623b696b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:to="loc_us-gaap_Liabilities_e938b3af-2d70-49a2-a67b-fd2623b696b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_61d2f541-5412-4284-9910-eccc878d9001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:to="loc_us-gaap_CommitmentsAndContingencies_61d2f541-5412-4284-9910-eccc878d9001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9dcfc3fe-77b7-4afc-ac0f-68cdb5d1bbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9dcfc3fe-77b7-4afc-ac0f-68cdb5d1bbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6a667e90-3235-4de0-b544-e3060e2e5321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dcfc3fe-77b7-4afc-ac0f-68cdb5d1bbfc" xlink:to="loc_us-gaap_PreferredStockValue_6a667e90-3235-4de0-b544-e3060e2e5321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f9c69fe6-1ab2-4f6f-9942-7b1aa018da1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dcfc3fe-77b7-4afc-ac0f-68cdb5d1bbfc" xlink:to="loc_us-gaap_CommonStockValue_f9c69fe6-1ab2-4f6f-9942-7b1aa018da1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f39aa208-31b6-46c9-8ffe-0037922d51ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dcfc3fe-77b7-4afc-ac0f-68cdb5d1bbfc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f39aa208-31b6-46c9-8ffe-0037922d51ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_590fbe88-703d-4602-bda9-cb8e2edef1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dcfc3fe-77b7-4afc-ac0f-68cdb5d1bbfc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_590fbe88-703d-4602-bda9-cb8e2edef1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c6bb2c95-cdad-4543-a7fd-05c3c001e719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dcfc3fe-77b7-4afc-ac0f-68cdb5d1bbfc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c6bb2c95-cdad-4543-a7fd-05c3c001e719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_79f4ca8d-84e5-4c50-9b7a-4bcbe6ed6363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9dcfc3fe-77b7-4afc-ac0f-68cdb5d1bbfc" xlink:to="loc_us-gaap_StockholdersEquity_79f4ca8d-84e5-4c50-9b7a-4bcbe6ed6363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ca6252b-670e-4c70-8f5f-5fa5c833c23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f93b8ff-05a2-4558-b409-ac26361f98ea" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0ca6252b-670e-4c70-8f5f-5fa5c833c23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f8392a1f-8e2f-4cfe-bb23-e7e5d9720050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3f2911e9-3f39-4364-a620-3691a62bcdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f8392a1f-8e2f-4cfe-bb23-e7e5d9720050" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3f2911e9-3f39-4364-a620-3691a62bcdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_44f7ad4a-3d84-4001-8f1c-54a034e932be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f8392a1f-8e2f-4cfe-bb23-e7e5d9720050" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_44f7ad4a-3d84-4001-8f1c-54a034e932be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0cdbccc7-bea5-4781-8b6d-8343e72ae759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f8392a1f-8e2f-4cfe-bb23-e7e5d9720050" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0cdbccc7-bea5-4781-8b6d-8343e72ae759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8d6543de-028a-4d57-9038-a2c6086b8169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f8392a1f-8e2f-4cfe-bb23-e7e5d9720050" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8d6543de-028a-4d57-9038-a2c6086b8169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_41a29606-04d5-47b0-8aba-87abc47832b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f8392a1f-8e2f-4cfe-bb23-e7e5d9720050" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_41a29606-04d5-47b0-8aba-87abc47832b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6dc53a21-cba9-4b43-82f7-d5af39b9131f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f8392a1f-8e2f-4cfe-bb23-e7e5d9720050" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6dc53a21-cba9-4b43-82f7-d5af39b9131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_48b49e0a-2338-44ee-ad45-f65dfb8abb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f8392a1f-8e2f-4cfe-bb23-e7e5d9720050" xlink:to="loc_us-gaap_CommonStockSharesIssued_48b49e0a-2338-44ee-ad45-f65dfb8abb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d3145f96-4a8b-4c05-aa2c-163b13412753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f8392a1f-8e2f-4cfe-bb23-e7e5d9720050" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d3145f96-4a8b-4c05-aa2c-163b13412753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2cb2298c-9db2-4f72-b842-6ef318f8d636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_66d44cb7-95fb-4397-82ab-3a5160024bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2cb2298c-9db2-4f72-b842-6ef318f8d636" xlink:to="loc_us-gaap_StatementTable_66d44cb7-95fb-4397-82ab-3a5160024bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_57987cbb-3eca-4b42-896f-ecf2e6720fc1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66d44cb7-95fb-4397-82ab-3a5160024bf7" xlink:to="loc_srt_ProductOrServiceAxis_57987cbb-3eca-4b42-896f-ecf2e6720fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8055274d-0e02-448b-9485-f2956ef6d1d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_57987cbb-3eca-4b42-896f-ecf2e6720fc1" xlink:to="loc_srt_ProductsAndServicesDomain_8055274d-0e02-448b-9485-f2956ef6d1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_TestingMember_92dff471-2446-4f0a-8e31-33ddf10f2a65" xlink:href="vcyt-20230331.xsd#vcyt_TestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8055274d-0e02-448b-9485-f2956ef6d1d3" xlink:to="loc_vcyt_TestingMember_92dff471-2446-4f0a-8e31-33ddf10f2a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8db63135-b4c8-486f-b074-254766570349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8055274d-0e02-448b-9485-f2956ef6d1d3" xlink:to="loc_us-gaap_ProductMember_8db63135-b4c8-486f-b074-254766570349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherMember_5bd75540-635f-4f60-b573-7725bccf279d" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8055274d-0e02-448b-9485-f2956ef6d1d3" xlink:to="loc_vcyt_BiopharmaceuticalAndOtherMember_5bd75540-635f-4f60-b573-7725bccf279d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66d44cb7-95fb-4397-82ab-3a5160024bf7" xlink:to="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_acc65c5b-5993-46f5-85d1-144d52969a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_RevenuesAbstract_acc65c5b-5993-46f5-85d1-144d52969a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56446790-cd36-46e3-b02b-7cf5e3b378c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_acc65c5b-5993-46f5-85d1-144d52969a49" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56446790-cd36-46e3-b02b-7cf5e3b378c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_7ec8d5c0-7a00-44e8-a9ce-5ec8a8e67976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_CostOfRevenue_7ec8d5c0-7a00-44e8-a9ce-5ec8a8e67976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_524e754b-14bc-4169-840b-06d3eae51eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_524e754b-14bc-4169-840b-06d3eae51eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_200078fc-0574-4529-b8d8-522d1c524f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_SellingAndMarketingExpense_200078fc-0574-4529-b8d8-522d1c524f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eeba69eb-82fc-431b-8129-f0e243afc24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eeba69eb-82fc-431b-8129-f0e243afc24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_069248ea-9821-49ec-9ca5-7c82ffa1fee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_069248ea-9821-49ec-9ca5-7c82ffa1fee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8ccf1fe5-7771-41b1-8764-9fa8bcc0c202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e987d4e7-9948-444f-a86e-8f9fe8252350" xlink:to="loc_us-gaap_CostsAndExpenses_8ccf1fe5-7771-41b1-8764-9fa8bcc0c202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4a1287d8-8a28-476f-a42e-f36a5847e20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_OperatingIncomeLoss_4a1287d8-8a28-476f-a42e-f36a5847e20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a60a6bf8-2b3e-48ad-9851-76a49b69ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a60a6bf8-2b3e-48ad-9851-76a49b69ca9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12779095-a4df-4012-95c8-0fed578af16c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12779095-a4df-4012-95c8-0fed578af16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_279a431d-df78-413d-b1b4-ed1eea13db03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_279a431d-df78-413d-b1b4-ed1eea13db03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cca34ece-a040-473d-9a7a-1da6a355cdae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_NetIncomeLoss_cca34ece-a040-473d-9a7a-1da6a355cdae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3e935ad8-437c-4bb0-a337-f05016b48ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_EarningsPerShareBasic_3e935ad8-437c-4bb0-a337-f05016b48ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ae227547-bb47-455f-ae88-edc2be6d7aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ae227547-bb47-455f-ae88-edc2be6d7aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2037504-1572-417a-939a-e04d8d028459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2037504-1572-417a-939a-e04d8d028459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0057025d-124f-46d4-baa3-84372f536a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393c0289-4e76-4982-82e0-735e87bd96a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0057025d-124f-46d4-baa3-84372f536a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1cd0a1c0-7548-4534-b1b9-49be5d925c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_207b6e97-8a87-4862-b3c0-3ac47d37f40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1cd0a1c0-7548-4534-b1b9-49be5d925c16" xlink:to="loc_us-gaap_NetIncomeLoss_207b6e97-8a87-4862-b3c0-3ac47d37f40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f6212ce5-2375-4346-857c-5cf3d1289a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1cd0a1c0-7548-4534-b1b9-49be5d925c16" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f6212ce5-2375-4346-857c-5cf3d1289a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18808c85-0550-49ef-b0f3-aa42fd490493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f6212ce5-2375-4346-857c-5cf3d1289a6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18808c85-0550-49ef-b0f3-aa42fd490493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f04887e-743b-4cb5-bc67-d589e733db83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1cd0a1c0-7548-4534-b1b9-49be5d925c16" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f04887e-743b-4cb5-bc67-d589e733db83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a2dd6d34-bc13-4901-8c19-22a474beac13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3e9f96df-1851-4966-b332-709ffb93e288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a2dd6d34-bc13-4901-8c19-22a474beac13" xlink:to="loc_us-gaap_StatementTable_3e9f96df-1851-4966-b332-709ffb93e288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ce59f489-d859-41e5-874c-ed809b41fabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3e9f96df-1851-4966-b332-709ffb93e288" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ce59f489-d859-41e5-874c-ed809b41fabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ce59f489-d859-41e5-874c-ed809b41fabf" xlink:to="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fb501917-58b3-4252-9f01-39cd10d7a920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:to="loc_us-gaap_CommonStockMember_fb501917-58b3-4252-9f01-39cd10d7a920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_46998822-2f32-47ba-b628-d3925bb11272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_46998822-2f32-47ba-b628-d3925bb11272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cf07eabe-3674-4fd1-baed-006e6ff66ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:to="loc_us-gaap_RetainedEarningsMember_cf07eabe-3674-4fd1-baed-006e6ff66ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c61f0905-ce03-41ee-8594-1025e19be5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9d01dd6a-baec-4214-9782-f3aa3d3d6941" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c61f0905-ce03-41ee-8594-1025e19be5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a7f01a42-9ece-438a-b490-ac94547b4817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3e9f96df-1851-4966-b332-709ffb93e288" xlink:to="loc_us-gaap_StatementLineItems_a7f01a42-9ece-438a-b490-ac94547b4817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a7f01a42-9ece-438a-b490-ac94547b4817" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cfe338af-b4fe-4c8c-bf10-89550e998724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_SharesOutstanding_cfe338af-b4fe-4c8c-bf10-89550e998724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a9a9725b-a54b-40f5-8186-b86db5143f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_StockholdersEquity_a9a9725b-a54b-40f5-8186-b86db5143f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_1cf77ca5-066f-49df-a155-f5ff6e9b817f" xlink:href="vcyt-20230331.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_1cf77ca5-066f-49df-a155-f5ff6e9b817f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_6a751a49-6b4e-4482-95bf-edf3bbb67919" xlink:href="vcyt-20230331.xsd#vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod_6a751a49-6b4e-4482-95bf-edf3bbb67919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_73d4584c-ac65-4cef-964b-36f3989cca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_73d4584c-ac65-4cef-964b-36f3989cca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_068b1439-5734-4f9c-b9ad-3be8ec148217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_068b1439-5734-4f9c-b9ad-3be8ec148217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_7d24ecbf-6fc1-4d9e-bdce-5a88f765c508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_7d24ecbf-6fc1-4d9e-bdce-5a88f765c508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_0c7a776f-0c2a-4328-bcb0-857fb24953f3" xlink:href="vcyt-20230331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee_0c7a776f-0c2a-4328-bcb0-857fb24953f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_2b9a75a5-ee60-430f-aeb4-e23df216fb52" xlink:href="vcyt-20230331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee_2b9a75a5-ee60-430f-aeb4-e23df216fb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_4a544288-6c5d-4ab4-a997-3645ed7303f3" xlink:href="vcyt-20230331.xsd#vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP_4a544288-6c5d-4ab4-a997-3645ed7303f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7bafb79-d091-40ac-8376-ab5cce413427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_NetIncomeLoss_c7bafb79-d091-40ac-8376-ab5cce413427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fee6397c-6e5b-4ab4-b653-d41e3293b389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fee6397c-6e5b-4ab4-b653-d41e3293b389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_abd64ce0-bdbb-421f-9988-7f22380a2fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_SharesOutstanding_abd64ce0-bdbb-421f-9988-7f22380a2fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_defda063-bff5-43f3-a6be-87952fe1bf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b1fc9e0-e669-4e9c-9f64-1aeaf6633119" xlink:to="loc_us-gaap_StockholdersEquity_defda063-bff5-43f3-a6be-87952fe1bf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cff04bd2-0606-4a28-94d0-fd7ce128ff43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cff04bd2-0606-4a28-94d0-fd7ce128ff43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7477ac26-b090-4da3-941a-c99e346edc68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cff04bd2-0606-4a28-94d0-fd7ce128ff43" xlink:to="loc_us-gaap_NetIncomeLoss_7477ac26-b090-4da3-941a-c99e346edc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cff04bd2-0606-4a28-94d0-fd7ce128ff43" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_147c468b-8cea-46cf-8b48-205a4ce142a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_147c468b-8cea-46cf-8b48-205a4ce142a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_68c004c7-b0ae-4b31-8dda-c4f62bafa9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_68c004c7-b0ae-4b31-8dda-c4f62bafa9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3fd37163-7eef-4e3b-af0a-a8b36c2be0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:to="loc_us-gaap_ShareBasedCompensation_3fd37163-7eef-4e3b-af0a-a8b36c2be0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0891de53-0cad-4f5a-a7aa-ca6a1ba9fbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0891de53-0cad-4f5a-a7aa-ca6a1ba9fbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty_3402b2e5-3d37-44c7-8e4e-0f7c080b477b" xlink:href="vcyt-20230331.xsd#vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:to="loc_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty_3402b2e5-3d37-44c7-8e4e-0f7c080b477b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NoncashLeaseExpense_c3defab0-6e3b-4f1c-b8cd-91d70c41baec" xlink:href="vcyt-20230331.xsd#vcyt_NoncashLeaseExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:to="loc_vcyt_NoncashLeaseExpense_c3defab0-6e3b-4f1c-b8cd-91d70c41baec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5b89ebc6-a04f-48fd-8308-acffa0b8ab6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5b89ebc6-a04f-48fd-8308-acffa0b8ab6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ce8b9d32-64b4-4d9d-9395-5234787225ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ce8b9d32-64b4-4d9d-9395-5234787225ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_2692e7dc-c0ee-4926-99c7-c27dbcd2faf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bd39d3a-b8ff-48ee-8007-f8b8033625c7" xlink:to="loc_us-gaap_AssetImpairmentCharges_2692e7dc-c0ee-4926-99c7-c27dbcd2faf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bb8a383-6da7-43ab-b032-48d0597e8ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cff04bd2-0606-4a28-94d0-fd7ce128ff43" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bb8a383-6da7-43ab-b032-48d0597e8ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f8ad08f3-5bff-40bf-9cc5-9c288fc23712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bb8a383-6da7-43ab-b032-48d0597e8ea9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f8ad08f3-5bff-40bf-9cc5-9c288fc23712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4cfa09f6-1e6f-460d-9fba-e03aee60c936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bb8a383-6da7-43ab-b032-48d0597e8ea9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4cfa09f6-1e6f-460d-9fba-e03aee60c936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_45dbabf8-0134-4791-ad3f-71b637833937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bb8a383-6da7-43ab-b032-48d0597e8ea9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_45dbabf8-0134-4791-ad3f-71b637833937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5e578c1e-f731-434f-b424-2b2a3a2aa5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bb8a383-6da7-43ab-b032-48d0597e8ea9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5e578c1e-f731-434f-b424-2b2a3a2aa5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_81dfd906-b0ec-4c67-b6dd-44b2b39ff018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bb8a383-6da7-43ab-b032-48d0597e8ea9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_81dfd906-b0ec-4c67-b6dd-44b2b39ff018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_92e3d1a1-a71b-46af-8d71-65b97007035e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bb8a383-6da7-43ab-b032-48d0597e8ea9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_92e3d1a1-a71b-46af-8d71-65b97007035e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue_9e1f2946-55e0-43e4-8755-85ec7320905a" xlink:href="vcyt-20230331.xsd#vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2bb8a383-6da7-43ab-b032-48d0597e8ea9" xlink:to="loc_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue_9e1f2946-55e0-43e4-8755-85ec7320905a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ef7de76-6bd2-4b2a-86f8-ff7f41d4d0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cff04bd2-0606-4a28-94d0-fd7ce128ff43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ef7de76-6bd2-4b2a-86f8-ff7f41d4d0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ae83fcba-46a6-458b-950c-85676f67399a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ae83fcba-46a6-458b-950c-85676f67399a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_a037eca2-517d-4741-b677-487960750139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ae83fcba-46a6-458b-950c-85676f67399a" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_a037eca2-517d-4741-b677-487960750139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_e6d69b57-954c-47ce-91bb-45c7d243d324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ae83fcba-46a6-458b-950c-85676f67399a" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_e6d69b57-954c-47ce-91bb-45c7d243d324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_746558ee-a265-473f-a29f-43f4a4ee39ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ae83fcba-46a6-458b-950c-85676f67399a" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_746558ee-a265-473f-a29f-43f4a4ee39ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26806282-a5af-4884-a6d0-4f86829f35aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ae83fcba-46a6-458b-950c-85676f67399a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26806282-a5af-4884-a6d0-4f86829f35aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ad9b413-036d-4277-926f-2013b60afe91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_ae83fcba-46a6-458b-950c-85676f67399a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ad9b413-036d-4277-926f-2013b60afe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5f9f25ca-68e2-4ecf-8db0-767cc1d19265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5f9f25ca-68e2-4ecf-8db0-767cc1d19265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8c38ffe8-f706-49f8-a2c3-1ea9ad0a7b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5f9f25ca-68e2-4ecf-8db0-767cc1d19265" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8c38ffe8-f706-49f8-a2c3-1ea9ad0a7b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7a1421d4-1019-4e5b-af62-916cafd54cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5f9f25ca-68e2-4ecf-8db0-767cc1d19265" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7a1421d4-1019-4e5b-af62-916cafd54cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ea526ce1-2437-422b-a3b6-03abebb0766f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5f9f25ca-68e2-4ecf-8db0-767cc1d19265" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ea526ce1-2437-422b-a3b6-03abebb0766f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1c8721aa-3a8f-4791-8396-5fd34c6f36cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5f9f25ca-68e2-4ecf-8db0-767cc1d19265" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1c8721aa-3a8f-4791-8396-5fd34c6f36cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_45b17e3e-5042-47f9-86d6-a327882a9e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_45b17e3e-5042-47f9-86d6-a327882a9e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90080ea8-9d13-44fd-851a-ee666e542bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90080ea8-9d13-44fd-851a-ee666e542bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62ab4a2e-89f2-45e7-a87a-f81d7fa759dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62ab4a2e-89f2-45e7-a87a-f81d7fa759dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba58a51c-20a4-4529-9de6-37d9c33859c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba58a51c-20a4-4529-9de6-37d9c33859c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_04dbf053-d95e-415d-a69d-702f14bf10fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_04dbf053-d95e-415d-a69d-702f14bf10fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f2cc0ca2-dbb5-415a-840c-aa6f4f518084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f2cc0ca2-dbb5-415a-840c-aa6f4f518084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_96083d5b-ff39-4e97-b349-571f7a7eff81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f2cc0ca2-dbb5-415a-840c-aa6f4f518084" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_96083d5b-ff39-4e97-b349-571f7a7eff81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d115f55-4623-4051-83a2-33ecf507b4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d115f55-4623-4051-83a2-33ecf507b4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_346508b2-ca01-4665-959b-5057926bc417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_346508b2-ca01-4665-959b-5057926bc417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98ff70d5-5738-4221-9ffa-25bd2e2010cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1f79f5f7-0e3e-4c98-8e72-05e13a2db83b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98ff70d5-5738-4221-9ffa-25bd2e2010cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vcyt-20230331.xsd#OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34838efd-dbed-4048-9173-97693ebd5d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_4afc87fd-ca6d-467f-843f-e4037dd50f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34838efd-dbed-4048-9173-97693ebd5d50" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_4afc87fd-ca6d-467f-843f-e4037dd50f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShare" xlink:type="simple" xlink:href="vcyt-20230331.xsd#NetLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8b91d108-78ec-4bd9-882a-fbecfb18a301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9030c233-3429-42ce-a426-05868c80e586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b91d108-78ec-4bd9-882a-fbecfb18a301" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9030c233-3429-42ce-a426-05868c80e586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_251e3dff-9010-42bc-9857-5d020fade3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_505ea2e0-0ce2-4c78-9da3-2c580244d6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_251e3dff-9010-42bc-9857-5d020fade3c3" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_505ea2e0-0ce2-4c78-9da3-2c580244d6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="vcyt-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7bb97d88-bf03-4097-976f-3cff41a57aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0c219785-98ae-4155-b8f2-66fa43dcf3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7bb97d88-bf03-4097-976f-3cff41a57aa6" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0c219785-98ae-4155-b8f2-66fa43dcf3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a5f0d019-0002-4316-b92e-9765e3957c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_272a1e7e-7be3-4054-afc5-f90f46fe8f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a5f0d019-0002-4316-b92e-9765e3957c61" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_272a1e7e-7be3-4054-afc5-f90f46fe8f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquity" xlink:type="simple" xlink:href="vcyt-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_341019a3-65e2-46b2-9a41-f839172d60cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cb68d36d-984a-4b1f-acf2-983f04f7a097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_341019a3-65e2-46b2-9a41-f839172d60cb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cb68d36d-984a-4b1f-acf2-983f04f7a097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/ComponentsofOtherIncome" xlink:type="simple" xlink:href="vcyt-20230331.xsd#ComponentsofOtherIncome"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ComponentsofOtherIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_d712a066-f3da-4f50-8577-524baabf6d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_f1998211-b559-4182-a7b2-d02409a592ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_d712a066-f3da-4f50-8577-524baabf6d39" xlink:to="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_f1998211-b559-4182-a7b2-d02409a592ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vcyt-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6445594b-fa37-4aa6-8468-16732bec9416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_51d3e5a2-72b9-446a-bf50-5ba996a749f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6445594b-fa37-4aa6-8468-16732bec9416" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_51d3e5a2-72b9-446a-bf50-5ba996a749f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vcyt-20230331.xsd#OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31028ac9-3a65-43bb-acc5-6a1ab0bb7550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6b57fc59-5897-48b1-b034-691aa578258b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31028ac9-3a65-43bb-acc5-6a1ab0bb7550" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6b57fc59-5897-48b1-b034-691aa578258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a54c1d8f-0ccb-4ff3-aa22-d52c1d8156aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31028ac9-3a65-43bb-acc5-6a1ab0bb7550" xlink:to="loc_us-gaap_UseOfEstimates_a54c1d8f-0ccb-4ff3-aa22-d52c1d8156aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_1c941bc5-e84a-427c-aef7-2023ede6d29e" xlink:href="vcyt-20230331.xsd#vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31028ac9-3a65-43bb-acc5-6a1ab0bb7550" xlink:to="loc_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock_1c941bc5-e84a-427c-aef7-2023ede6d29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_53d1733d-d654-45bf-a40b-b0101269d6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31028ac9-3a65-43bb-acc5-6a1ab0bb7550" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_53d1733d-d654-45bf-a40b-b0101269d6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_6d5b062d-2b34-46c3-ad3b-a810f2407ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31028ac9-3a65-43bb-acc5-6a1ab0bb7550" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_6d5b062d-2b34-46c3-ad3b-a810f2407ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_05c6b8a7-a0a3-40be-afdf-9f7d2145d058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31028ac9-3a65-43bb-acc5-6a1ab0bb7550" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_05c6b8a7-a0a3-40be-afdf-9f7d2145d058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_7b742b9d-8b08-4172-bf7d-d340583628b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31028ac9-3a65-43bb-acc5-6a1ab0bb7550" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_7b742b9d-8b08-4172-bf7d-d340583628b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ee4a0fe1-64a3-4a5e-b21d-c3923dbe15d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31028ac9-3a65-43bb-acc5-6a1ab0bb7550" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ee4a0fe1-64a3-4a5e-b21d-c3923dbe15d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vcyt-20230331.xsd#OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_afa7eea4-64af-4d04-b91c-97a7df2d56f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_dae285ab-1d91-401f-b3b7-c95cd176604d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_afa7eea4-64af-4d04-b91c-97a7df2d56f6" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_dae285ab-1d91-401f-b3b7-c95cd176604d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_c9c69245-ed97-4fe3-8222-c3cadc7db949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_afa7eea4-64af-4d04-b91c-97a7df2d56f6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_c9c69245-ed97-4fe3-8222-c3cadc7db949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShareTables" xlink:type="simple" xlink:href="vcyt-20230331.xsd#NetLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e87a1396-e926-4b1e-b8c5-66abaa700d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5dce86b8-46e2-44f4-abd6-25c6267cba80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e87a1396-e926-4b1e-b8c5-66abaa700d3b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5dce86b8-46e2-44f4-abd6-25c6267cba80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1ce40f49-e731-478e-b307-d36db496bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b78a9335-84c3-4ca5-880b-c55adee5bc37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1ce40f49-e731-478e-b307-d36db496bbb1" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b78a9335-84c3-4ca5-880b-c55adee5bc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b17f3dbd-b1c5-4169-b946-d297e3b1a103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1ce40f49-e731-478e-b307-d36db496bbb1" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b17f3dbd-b1c5-4169-b946-d297e3b1a103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7d33f9f2-1fba-4e58-963c-857911a9d7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1ce40f49-e731-478e-b307-d36db496bbb1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7d33f9f2-1fba-4e58-963c-857911a9d7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="vcyt-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_76f2fc72-4eeb-4b4b-8f38-17c290cf0714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ecc32e73-d020-4b1c-adf5-3c55bc0b10e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_76f2fc72-4eeb-4b4b-8f38-17c290cf0714" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ecc32e73-d020-4b1c-adf5-3c55bc0b10e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_489d72cb-ab59-4b4b-a668-1b08a2c8cbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_239d1a6d-40c2-4c48-ac10-0f5ce9b78058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_489d72cb-ab59-4b4b-a668-1b08a2c8cbe8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_239d1a6d-40c2-4c48-ac10-0f5ce9b78058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_45bc08b5-cca6-4481-86bd-70565833e38e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_489d72cb-ab59-4b4b-a668-1b08a2c8cbe8" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_45bc08b5-cca6-4481-86bd-70565833e38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="vcyt-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8e2c5c2c-ceb9-4f37-89d3-780951e85138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_8b1b2023-4c04-4c19-a491-02e2d3cb4315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8e2c5c2c-ceb9-4f37-89d3-780951e85138" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_8b1b2023-4c04-4c19-a491-02e2d3cb4315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/ComponentsofOtherIncomeTables" xlink:type="simple" xlink:href="vcyt-20230331.xsd#ComponentsofOtherIncomeTables"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ComponentsofOtherIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac1fdb03-469e-42b6-8728-23d39e36d892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_fc232adc-79b5-47dd-8e13-63b37c2756d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac1fdb03-469e-42b6-8728-23d39e36d892" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_fc232adc-79b5-47dd-8e13-63b37c2756d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54c1df79-4b4b-4672-9fbd-6bd53b53c507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d0104dfd-f851-4a81-85a2-9bfcec701b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54c1df79-4b4b-4672-9fbd-6bd53b53c507" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d0104dfd-f851-4a81-85a2-9bfcec701b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe34f3a1-ad2c-4dba-81b5-969b59eb10aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d0104dfd-f851-4a81-85a2-9bfcec701b86" xlink:to="loc_srt_ProductOrServiceAxis_fe34f3a1-ad2c-4dba-81b5-969b59eb10aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bf4a074f-ae48-4711-9ccd-c1b3d516dcf5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fe34f3a1-ad2c-4dba-81b5-969b59eb10aa" xlink:to="loc_srt_ProductsAndServicesDomain_bf4a074f-ae48-4711-9ccd-c1b3d516dcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherMember_62cfd1a6-94da-4d71-a6f5-602eb9a6f503" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bf4a074f-ae48-4711-9ccd-c1b3d516dcf5" xlink:to="loc_vcyt_BiopharmaceuticalAndOtherMember_62cfd1a6-94da-4d71-a6f5-602eb9a6f503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d0104dfd-f851-4a81-85a2-9bfcec701b86" xlink:to="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_028577b9-ff89-44b3-9046-fbf121ed93a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_NumberOfOperatingSegments_028577b9-ff89-44b3-9046-fbf121ed93a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest_401c4f46-c9be-475a-b317-7695876e2de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest_401c4f46-c9be-475a-b317-7695876e2de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_20b4d486-f1e3-4fa1-9f25-1f6e0e93aef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_20b4d486-f1e3-4fa1-9f25-1f6e0e93aef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_719e3467-6422-4772-8700-6e40115c1751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_719e3467-6422-4772-8700-6e40115c1751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a6c935d0-9ac9-4d69-b055-69a65ff5c254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a6c935d0-9ac9-4d69-b055-69a65ff5c254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_48448caf-d7fe-48b5-a692-ea38a8d8d950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9b50ee19-b8ea-436d-bf90-106b25eaaa18" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_48448caf-d7fe-48b5-a692-ea38a8d8d950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTypeExtensibleList_5fbcc1f0-7e16-43b6-ab8f-58761cfaf5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTypeExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation_48448caf-d7fe-48b5-a692-ea38a8d8d950" xlink:to="loc_us-gaap_DefinedBenefitPlanTypeExtensibleList_5fbcc1f0-7e16-43b6-ab8f-58761cfaf5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_516da043-1ef1-4660-929a-873c537895e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_516da043-1ef1-4660-929a-873c537895e3" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b262c10c-a274-4ee8-a632-d64b9ecc0f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b262c10c-a274-4ee8-a632-d64b9ecc0f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6fb6bb61-1208-4405-a0bf-822821f0704c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b262c10c-a274-4ee8-a632-d64b9ecc0f69" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6fb6bb61-1208-4405-a0bf-822821f0704c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8d6bc7bc-2a31-46f1-95cf-1b58d01acf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6fb6bb61-1208-4405-a0bf-822821f0704c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8d6bc7bc-2a31-46f1-95cf-1b58d01acf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5782bd64-1af2-4423-b4da-0aa791698130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5782bd64-1af2-4423-b4da-0aa791698130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8384ee1d-0e99-4e6e-a2b3-9d77f29d8e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5782bd64-1af2-4423-b4da-0aa791698130" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8384ee1d-0e99-4e6e-a2b3-9d77f29d8e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_2a667831-a95d-4eea-8d81-662abcabd7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8384ee1d-0e99-4e6e-a2b3-9d77f29d8e9f" xlink:to="loc_us-gaap_SalesRevenueNetMember_2a667831-a95d-4eea-8d81-662abcabd7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_000121ce-86eb-4499-8a88-087f90a1ab57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8384ee1d-0e99-4e6e-a2b3-9d77f29d8e9f" xlink:to="loc_us-gaap_AccountsReceivableMember_000121ce-86eb-4499-8a88-087f90a1ab57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6deb395e-0318-4596-b3dc-9193420b5f6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:to="loc_srt_MajorCustomersAxis_6deb395e-0318-4596-b3dc-9193420b5f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_480e04a2-2d55-4020-9e4e-d414e2b65768" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6deb395e-0318-4596-b3dc-9193420b5f6b" xlink:to="loc_srt_NameOfMajorCustomerDomain_480e04a2-2d55-4020-9e4e-d414e2b65768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MedicareMember_7d3b51ec-d510-4f6c-b87c-b4db1de29063" xlink:href="vcyt-20230331.xsd#vcyt_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_480e04a2-2d55-4020-9e4e-d414e2b65768" xlink:to="loc_vcyt_MedicareMember_7d3b51ec-d510-4f6c-b87c-b4db1de29063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_UnitedHealthcareMember_83268aee-497d-4042-9a20-f38d02f393e2" xlink:href="vcyt-20230331.xsd#vcyt_UnitedHealthcareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_480e04a2-2d55-4020-9e4e-d414e2b65768" xlink:to="loc_vcyt_UnitedHealthcareMember_83268aee-497d-4042-9a20-f38d02f393e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MajorCustomersMember_e058940a-d64f-4043-9c81-4f656ff60679" xlink:href="vcyt-20230331.xsd#vcyt_MajorCustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_480e04a2-2d55-4020-9e4e-d414e2b65768" xlink:to="loc_vcyt_MajorCustomersMember_e058940a-d64f-4043-9c81-4f656ff60679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d4ce2d47-2c85-4201-9fca-f0211bd40c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_b4fd120d-e382-4058-91d6-e468c1b6f6df" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d4ce2d47-2c85-4201-9fca-f0211bd40c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f5611d3e-ec0a-496a-85fe-952389f5d9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_d4ce2d47-2c85-4201-9fca-f0211bd40c16" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f5611d3e-ec0a-496a-85fe-952389f5d9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fbd8d8fe-02bd-4358-ae7a-597ebdfb42ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_554fb0f1-747d-4e46-b761-ae4004674df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fbd8d8fe-02bd-4358-ae7a-597ebdfb42ad" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_554fb0f1-747d-4e46-b761-ae4004674df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0955707f-b338-43da-9f76-a52cf63bc76f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_554fb0f1-747d-4e46-b761-ae4004674df6" xlink:to="loc_srt_ProductOrServiceAxis_0955707f-b338-43da-9f76-a52cf63bc76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c90cd8f6-591f-4a8d-95c3-2f6c0b08ee71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0955707f-b338-43da-9f76-a52cf63bc76f" xlink:to="loc_srt_ProductsAndServicesDomain_c90cd8f6-591f-4a8d-95c3-2f6c0b08ee71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember_82179dce-585e-4793-a56f-d70ee7518aef" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c90cd8f6-591f-4a8d-95c3-2f6c0b08ee71" xlink:to="loc_vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember_82179dce-585e-4793-a56f-d70ee7518aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember_45a41dfe-4a8f-4a72-83c0-e1abede4f9b4" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c90cd8f6-591f-4a8d-95c3-2f6c0b08ee71" xlink:to="loc_vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember_45a41dfe-4a8f-4a72-83c0-e1abede4f9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BiopharmaceuticalAndOtherMember_3815eba7-b00e-4572-a93d-4aa84873cea4" xlink:href="vcyt-20230331.xsd#vcyt_BiopharmaceuticalAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c90cd8f6-591f-4a8d-95c3-2f6c0b08ee71" xlink:to="loc_vcyt_BiopharmaceuticalAndOtherMember_3815eba7-b00e-4572-a93d-4aa84873cea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d71af414-eaf6-44be-918d-730b02af80ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_554fb0f1-747d-4e46-b761-ae4004674df6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d71af414-eaf6-44be-918d-730b02af80ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_851eabf4-37a4-4fe3-9171-5ef5dd159727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d71af414-eaf6-44be-918d-730b02af80ab" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_851eabf4-37a4-4fe3-9171-5ef5dd159727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/NetLossPerCommonShareDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#NetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/NetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d93c71b3-4869-4240-9edd-c3a9e9b6662c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e679b506-e93a-4c89-a3ff-6e31ab99c661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d93c71b3-4869-4240-9edd-c3a9e9b6662c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e679b506-e93a-4c89-a3ff-6e31ab99c661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_603bf8ec-e269-471c-8611-eb036322f3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e679b506-e93a-4c89-a3ff-6e31ab99c661" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_603bf8ec-e269-471c-8611-eb036322f3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90397fea-80f3-4b30-9ba4-3928a47a26bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_603bf8ec-e269-471c-8611-eb036322f3ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90397fea-80f3-4b30-9ba4-3928a47a26bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_a5b4f22d-da0a-46ed-8998-51d92a843c3b" xlink:href="vcyt-20230331.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90397fea-80f3-4b30-9ba4-3928a47a26bb" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_a5b4f22d-da0a-46ed-8998-51d92a843c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_d8058dea-0ed2-4851-a36d-afab23113ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90397fea-80f3-4b30-9ba4-3928a47a26bb" xlink:to="loc_us-gaap_EmployeeStockMember_d8058dea-0ed2-4851-a36d-afab23113ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ba38e4f2-c344-4b5d-88be-53900c919230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90397fea-80f3-4b30-9ba4-3928a47a26bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ba38e4f2-c344-4b5d-88be-53900c919230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_223aa5ff-95c2-44f6-97f5-f51b93bf9d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e679b506-e93a-4c89-a3ff-6e31ab99c661" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_223aa5ff-95c2-44f6-97f5-f51b93bf9d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f9fda822-1f41-441e-bb63-5f4887468cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_223aa5ff-95c2-44f6-97f5-f51b93bf9d31" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f9fda822-1f41-441e-bb63-5f4887468cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_162c5ca5-a9c8-495e-ab8a-c594bc7cb078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bdd1d8b9-4fc4-4f31-8665-a88ae94ac3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_162c5ca5-a9c8-495e-ab8a-c594bc7cb078" xlink:to="loc_us-gaap_Goodwill_bdd1d8b9-4fc4-4f31-8665-a88ae94ac3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7c803b03-1380-425d-b5f9-22987d439d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_162c5ca5-a9c8-495e-ab8a-c594bc7cb078" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7c803b03-1380-425d-b5f9-22987d439d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_7cf5862a-e0b2-4e66-b302-4c42c4bc396d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_162c5ca5-a9c8-495e-ab8a-c594bc7cb078" xlink:to="loc_us-gaap_InventoryFinishedGoods_7cf5862a-e0b2-4e66-b302-4c42c4bc396d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_8608aa58-82e7-4398-9503-4fd606968ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_162c5ca5-a9c8-495e-ab8a-c594bc7cb078" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_8608aa58-82e7-4398-9503-4fd606968ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2777ddff-3bda-4988-90ad-7295d40b5d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c36e979b-2559-4ecd-9b85-094e3b9b2333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_2777ddff-3bda-4988-90ad-7295d40b5d9c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c36e979b-2559-4ecd-9b85-094e3b9b2333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_408e8c86-5197-4fc9-9bc5-574ce48dccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c36e979b-2559-4ecd-9b85-094e3b9b2333" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_408e8c86-5197-4fc9-9bc5-574ce48dccd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_408e8c86-5197-4fc9-9bc5-574ce48dccd0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_PerceptaProductTechnologyMember_a52b2442-dc19-4788-b829-df267d40130c" xlink:href="vcyt-20230331.xsd#vcyt_PerceptaProductTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_PerceptaProductTechnologyMember_a52b2442-dc19-4788-b829-df267d40130c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DevelopedProductTechnologyMember_96e0a7f0-6805-40c8-9897-650feb176c24" xlink:href="vcyt-20230331.xsd#vcyt_DevelopedProductTechnologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_DevelopedProductTechnologyMember_96e0a7f0-6805-40c8-9897-650feb176c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_ProsignaCustomerRelationshipsMember_b07fa142-22dc-4e7d-8bee-c1c90ac6778f" xlink:href="vcyt-20230331.xsd#vcyt_ProsignaCustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_ProsignaCustomerRelationshipsMember_b07fa142-22dc-4e7d-8bee-c1c90ac6778f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NCounterDxLicenseMember_d9b1654d-e3e6-44ee-bbf7-c14619a4f2a6" xlink:href="vcyt-20230331.xsd#vcyt_NCounterDxLicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_NCounterDxLicenseMember_d9b1654d-e3e6-44ee-bbf7-c14619a4f2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LymphmarkProductTechnologyMember_62a956b1-6f62-486b-b9d2-30a972285ace" xlink:href="vcyt-20230331.xsd#vcyt_LymphmarkProductTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_LymphmarkProductTechnologyMember_62a956b1-6f62-486b-b9d2-30a972285ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DecipherBioSciencesProductTechnologyMember_a12f0e6b-44fc-4fe0-b4c2-e0ab3f81a716" xlink:href="vcyt-20230331.xsd#vcyt_DecipherBioSciencesProductTechnologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_DecipherBioSciencesProductTechnologyMember_a12f0e6b-44fc-4fe0-b4c2-e0ab3f81a716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_DecipherBiosciencesTradeNamesMember_049445c2-4466-4043-9726-7f53826a4591" xlink:href="vcyt-20230331.xsd#vcyt_DecipherBiosciencesTradeNamesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_DecipherBiosciencesTradeNamesMember_049445c2-4466-4043-9726-7f53826a4591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HalioDXDevelopedTechnologyMember_f6835a79-da32-4143-af76-72ba5371bb30" xlink:href="vcyt-20230331.xsd#vcyt_HalioDXDevelopedTechnologyMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_HalioDXDevelopedTechnologyMember_f6835a79-da32-4143-af76-72ba5371bb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HalioDxCustomerRelationshipsMember_7fe68c47-94b4-4d4c-b956-700b3d62f154" xlink:href="vcyt-20230331.xsd#vcyt_HalioDxCustomerRelationshipsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_HalioDxCustomerRelationshipsMember_7fe68c47-94b4-4d4c-b956-700b3d62f154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HalioDxCustomerBacklogMember_6a85c603-4a58-40ea-b791-8b6306a448c3" xlink:href="vcyt-20230331.xsd#vcyt_HalioDxCustomerBacklogMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4c14c75-3f69-426b-8043-8c66e7f8c44f" xlink:to="loc_vcyt_HalioDxCustomerBacklogMember_6a85c603-4a58-40ea-b791-8b6306a448c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c36e979b-2559-4ecd-9b85-094e3b9b2333" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_08e1d708-5ae1-4877-bd5e-56fb2fdd0694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_08e1d708-5ae1-4877-bd5e-56fb2fdd0694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_10654f31-ef83-4788-86a3-84fab604296b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_10654f31-ef83-4788-86a3-84fab604296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_11d091b1-e2a4-4968-9c85-c635f6004efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_11d091b1-e2a4-4968-9c85-c635f6004efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_63168c4a-42d7-4ae4-bddb-8ffc30e40482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_63168c4a-42d7-4ae4-bddb-8ffc30e40482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_beb2b343-424f-41e3-8730-c0ced08402d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_beb2b343-424f-41e3-8730-c0ced08402d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_57834a2b-c730-4d0e-8d31-222376904a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_57834a2b-c730-4d0e-8d31-222376904a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_488e9998-7574-4c43-8469-d0f7616b03f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_dd937c78-2f5f-4df5-9509-e2cfb1ef9dfe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_488e9998-7574-4c43-8469-d0f7616b03f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65fa00bf-58bd-47d3-94d6-3c3378d88d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e247b6b3-9d4a-49d2-b49f-6decf524211b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65fa00bf-58bd-47d3-94d6-3c3378d88d62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e247b6b3-9d4a-49d2-b49f-6decf524211b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_785bf2cd-7187-4138-b77f-6a2904d9055f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65fa00bf-58bd-47d3-94d6-3c3378d88d62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_785bf2cd-7187-4138-b77f-6a2904d9055f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_02705957-0f74-4ef4-af40-bb19b5773d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65fa00bf-58bd-47d3-94d6-3c3378d88d62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_02705957-0f74-4ef4-af40-bb19b5773d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3e251e24-fab7-4c26-ad08-af2ded9fe79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65fa00bf-58bd-47d3-94d6-3c3378d88d62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3e251e24-fab7-4c26-ad08-af2ded9fe79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f076218f-040e-4038-a7b5-1b59907befbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65fa00bf-58bd-47d3-94d6-3c3378d88d62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f076218f-040e-4038-a7b5-1b59907befbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3be6ae0c-97e5-4909-b9b8-934befc8bf1f" xlink:href="vcyt-20230331.xsd#vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65fa00bf-58bd-47d3-94d6-3c3378d88d62" xlink:to="loc_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3be6ae0c-97e5-4909-b9b8-934befc8bf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1ac45de4-532c-4fb0-a180-e380af76dd39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_65fa00bf-58bd-47d3-94d6-3c3378d88d62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1ac45de4-532c-4fb0-a180-e380af76dd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8e95e608-39aa-4cd9-bbbe-0a8c6efe8113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_66cf5c50-22cf-46bb-a76e-2702e05830fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8e95e608-39aa-4cd9-bbbe-0a8c6efe8113" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_66cf5c50-22cf-46bb-a76e-2702e05830fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d09dd15b-4897-411a-8082-67ba483efa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8e95e608-39aa-4cd9-bbbe-0a8c6efe8113" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d09dd15b-4897-411a-8082-67ba483efa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d5f101a8-9165-49c9-8032-9e358100ae97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_8e95e608-39aa-4cd9-bbbe-0a8c6efe8113" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d5f101a8-9165-49c9-8032-9e358100ae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9fdc03b1-6ee5-4554-a301-d660c7896081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9fdc03b1-6ee5-4554-a301-d660c7896081" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b00d5cb6-0f04-4fe8-870b-c91cf9f9b454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b00d5cb6-0f04-4fe8-870b-c91cf9f9b454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae7a4135-9bf2-41d6-afe9-e2821a67aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b00d5cb6-0f04-4fe8-870b-c91cf9f9b454" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae7a4135-9bf2-41d6-afe9-e2821a67aec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_507307c2-4e18-472b-bd20-9c72532b7a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae7a4135-9bf2-41d6-afe9-e2821a67aec9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_507307c2-4e18-472b-bd20-9c72532b7a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_c9caa92b-d8e6-44cd-842d-976ad6fb1793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:to="loc_us-gaap_LeaseContractualTermAxis_c9caa92b-d8e6-44cd-842d-976ad6fb1793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_75a056ce-1005-4077-b361-f205b11507fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_c9caa92b-d8e6-44cd-842d-976ad6fb1793" xlink:to="loc_us-gaap_LeaseContractualTermDomain_75a056ce-1005-4077-b361-f205b11507fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember_20ba697a-9c64-401c-90c5-935a57ebcd1b" xlink:href="vcyt-20230331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_75a056ce-1005-4077-b361-f205b11507fa" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember_20ba697a-9c64-401c-90c5-935a57ebcd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_85393f90-8435-43ac-8781-6d885895e618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_85393f90-8435-43ac-8781-6d885895e618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6116e36b-35bd-4572-ac6f-ff0c6fc03d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_85393f90-8435-43ac-8781-6d885895e618" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6116e36b-35bd-4572-ac6f-ff0c6fc03d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_NanostringMember_aece5682-40ae-4563-a78b-887c80e4db3b" xlink:href="vcyt-20230331.xsd#vcyt_NanostringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6116e36b-35bd-4572-ac6f-ff0c6fc03d6b" xlink:to="loc_vcyt_NanostringMember_aece5682-40ae-4563-a78b-887c80e4db3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fd44359a-e778-4ca0-8d2d-fe4ec0c70c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fd44359a-e778-4ca0-8d2d-fe4ec0c70c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_14b543b9-7324-4dc0-ab3a-392dd93a8e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_fd44359a-e778-4ca0-8d2d-fe4ec0c70c66" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_14b543b9-7324-4dc0-ab3a-392dd93a8e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9e587c86-f36d-47ab-bba9-07418c6e5fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_14b543b9-7324-4dc0-ab3a-392dd93a8e61" xlink:to="loc_us-gaap_CommonStockMember_9e587c86-f36d-47ab-bba9-07418c6e5fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb3a51e-eb76-4864-b0a1-7b5cd4ea422f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3dc08df6-f0b9-4dd7-86a9-417b23a7ed16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3dc08df6-f0b9-4dd7-86a9-417b23a7ed16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_a2a4b5ab-f72f-4e1e-8d4d-bd7e256a71aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_SecurityDeposit_a2a4b5ab-f72f-4e1e-8d4d-bd7e256a71aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3a7609a0-8632-4011-9554-59abd7ad3b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3a7609a0-8632-4011-9554-59abd7ad3b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1ec0ee45-de29-478f-bb8e-2376edc7d13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_1ec0ee45-de29-478f-bb8e-2376edc7d13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationCashToBePaid_cee1ff76-6c50-4212-8532-282fd3770887" xlink:href="vcyt-20230331.xsd#vcyt_BusinessCombinationContingentConsiderationCashToBePaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_vcyt_BusinessCombinationContingentConsiderationCashToBePaid_cee1ff76-6c50-4212-8532-282fd3770887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43380e40-8dce-45b5-95cf-1c86a31c8bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43380e40-8dce-45b5-95cf-1c86a31c8bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment_eb44d8a6-b535-49db-9612-23723fa13baa" xlink:href="vcyt-20230331.xsd#vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment_eb44d8a6-b535-49db-9612-23723fa13baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_90a18683-0b24-43ec-a887-76db2b30f785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_90a18683-0b24-43ec-a887-76db2b30f785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss_9466b261-eeef-4e65-9c83-fbc69eae4811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss_9466b261-eeef-4e65-9c83-fbc69eae4811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_b755425d-6cd2-4e89-94ab-ba45af26485b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_b755425d-6cd2-4e89-94ab-ba45af26485b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldAtPar_c0f83b39-4e4a-4d9d-b02b-3e2f92ce63db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesSoldAtPar"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldAtPar_c0f83b39-4e4a-4d9d-b02b-3e2f92ce63db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount_52bfd430-4d1f-4c38-a4c1-08b7b2b913dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturitySoldAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount_52bfd430-4d1f-4c38-a4c1-08b7b2b913dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_5adcf170-0905-4809-b032-4f6770842de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_5adcf170-0905-4809-b032-4f6770842de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_52d71892-2fa7-4ff5-be8e-9062f8c974c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_54ad14dc-3e7a-457f-b3a7-7b5fac92e8a2" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_52d71892-2fa7-4ff5-be8e-9062f8c974c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#FairValueMeasurementsFairValueMeasurementInputDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_84ce014b-a642-47bb-95de-eefece9c3afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_38809e11-ae2a-404b-8bbc-55d49ea37e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_84ce014b-a642-47bb-95de-eefece9c3afb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_38809e11-ae2a-404b-8bbc-55d49ea37e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_cedbcb5c-7209-4f06-9246-7210ffd1633c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_38809e11-ae2a-404b-8bbc-55d49ea37e29" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_cedbcb5c-7209-4f06-9246-7210ffd1633c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_70932d9e-1d40-495b-a655-a6814b46be80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cedbcb5c-7209-4f06-9246-7210ffd1633c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_70932d9e-1d40-495b-a655-a6814b46be80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a7eb8916-ca44-4837-92b0-0cba943c5a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_70932d9e-1d40-495b-a655-a6814b46be80" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a7eb8916-ca44-4837-92b0-0cba943c5a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_MeasurementInputProbabilityOfAchievementMember_e0d53e62-0714-4711-8b97-3d8084f6cad0" xlink:href="vcyt-20230331.xsd#vcyt_MeasurementInputProbabilityOfAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_70932d9e-1d40-495b-a655-a6814b46be80" xlink:to="loc_vcyt_MeasurementInputProbabilityOfAchievementMember_e0d53e62-0714-4711-8b97-3d8084f6cad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f6b68c1-bc9c-4b5f-bc5a-9fe5f54d5872" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_38809e11-ae2a-404b-8bbc-55d49ea37e29" xlink:to="loc_srt_RangeAxis_7f6b68c1-bc9c-4b5f-bc5a-9fe5f54d5872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6009588-0edd-4574-a889-7033377ad500" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7f6b68c1-bc9c-4b5f-bc5a-9fe5f54d5872" xlink:to="loc_srt_RangeMember_c6009588-0edd-4574-a889-7033377ad500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3258b36b-ce6c-476f-a509-52701d4674b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c6009588-0edd-4574-a889-7033377ad500" xlink:to="loc_srt_MinimumMember_3258b36b-ce6c-476f-a509-52701d4674b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8d3c80da-b123-49d8-9c9c-9bdde2d99584" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c6009588-0edd-4574-a889-7033377ad500" xlink:to="loc_srt_MaximumMember_8d3c80da-b123-49d8-9c9c-9bdde2d99584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_be0cea86-3b3d-4c4f-bfe0-e7ef9d390042" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c6009588-0edd-4574-a889-7033377ad500" xlink:to="loc_srt_WeightedAverageMember_be0cea86-3b3d-4c4f-bfe0-e7ef9d390042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c99d406b-03aa-4e29-b8ed-2b7aec092d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_38809e11-ae2a-404b-8bbc-55d49ea37e29" xlink:to="loc_us-gaap_StatementLineItems_c99d406b-03aa-4e29-b8ed-2b7aec092d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6fe6d925-4c30-484f-ba84-acf3f56f8730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c99d406b-03aa-4e29-b8ed-2b7aec092d1d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6fe6d925-4c30-484f-ba84-acf3f56f8730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00c43c05-0bcc-4a6a-8114-122d62c02c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0966b593-5f92-42c6-887c-fb8c773d4794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_00c43c05-0bcc-4a6a-8114-122d62c02c9e" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0966b593-5f92-42c6-887c-fb8c773d4794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b1642309-c1ac-4dee-9344-0f628334bd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0966b593-5f92-42c6-887c-fb8c773d4794" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b1642309-c1ac-4dee-9344-0f628334bd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e96dad74-5b64-43a4-828e-9e3796b17183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b1642309-c1ac-4dee-9344-0f628334bd0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e96dad74-5b64-43a4-828e-9e3796b17183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember_39c79fb0-3ebf-41da-9398-7e1bc6603f62" xlink:href="vcyt-20230331.xsd#vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e96dad74-5b64-43a4-828e-9e3796b17183" xlink:to="loc_vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember_39c79fb0-3ebf-41da-9398-7e1bc6603f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_FacilitiesInMarseilleFranceMember_e872cebf-c17a-4437-8ff3-2fa1da782a4d" xlink:href="vcyt-20230331.xsd#vcyt_FacilitiesInMarseilleFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e96dad74-5b64-43a4-828e-9e3796b17183" xlink:to="loc_vcyt_FacilitiesInMarseilleFranceMember_e872cebf-c17a-4437-8ff3-2fa1da782a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0966b593-5f92-42c6-887c-fb8c773d4794" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_40c8ae86-6154-4347-9bda-ffc1c10d00c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_40c8ae86-6154-4347-9bda-ffc1c10d00c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_2071deee-7814-4f57-bc7e-89a6fe1d63f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_SecurityDeposit_2071deee-7814-4f57-bc7e-89a6fe1d63f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_863480d4-cf53-4209-a3b2-6ec8d4f6a3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_863480d4-cf53-4209-a3b2-6ec8d4f6a3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_e276b660-7434-4c8d-8408-1003d7ffdc42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_e276b660-7434-4c8d-8408-1003d7ffdc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4513f461-a836-49d3-9ff9-e70f10d6b099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_e276b660-7434-4c8d-8408-1003d7ffdc42" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4513f461-a836-49d3-9ff9-e70f10d6b099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_9c332b15-182c-4c52-8c88-a3ad9672765e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_FinanceLeaseLiability_9c332b15-182c-4c52-8c88-a3ad9672765e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1277c0f4-5e07-4aae-83b6-2e4261b86272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiability_9c332b15-182c-4c52-8c88-a3ad9672765e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_1277c0f4-5e07-4aae-83b6-2e4261b86272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_e0e6a882-10fa-4c85-a7d3-ebfc7dff15d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_e0e6a882-10fa-4c85-a7d3-ebfc7dff15d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount_5292a3b9-af42-4353-8e3a-9b33dbc3790e" xlink:href="vcyt-20230331.xsd#vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_20f3e67f-d335-4d0c-961a-81559fd718e9" xlink:to="loc_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount_5292a3b9-af42-4353-8e3a-9b33dbc3790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ed0e35d-5006-4697-bcf8-fb5ae591f59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ed0e35d-5006-4697-bcf8-fb5ae591f59d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a80d74ce-2d84-4a06-9b0f-53030e0b8c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a80d74ce-2d84-4a06-9b0f-53030e0b8c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_255cc7b6-e819-4b25-9a92-1f7df2ba407c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_255cc7b6-e819-4b25-9a92-1f7df2ba407c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_22374200-b307-46fa-832f-5bf333852b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_22374200-b307-46fa-832f-5bf333852b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d189a43a-1938-4f83-b038-9823f33874a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d189a43a-1938-4f83-b038-9823f33874a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0aa9f15d-8ae8-4593-b4c6-ceff6e691cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0aa9f15d-8ae8-4593-b4c6-ceff6e691cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_caf0764d-e08e-40aa-8728-d60e42197d84" xlink:href="vcyt-20230331.xsd#vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_caf0764d-e08e-40aa-8728-d60e42197d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0a455a3-90e3-43ae-a27b-f9e949512ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0a455a3-90e3-43ae-a27b-f9e949512ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d9222b6-3387-4181-8544-2dfd91f0c9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d9222b6-3387-4181-8544-2dfd91f0c9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e91e9bd6-a063-4f54-914d-0097167a3752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_us-gaap_OperatingLeaseLiability_e91e9bd6-a063-4f54-914d-0097167a3752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b285a502-c5d7-4ec1-8502-5a81ca4424a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b285a502-c5d7-4ec1-8502-5a81ca4424a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3f3c6295-db2d-448a-8cff-7bb814a32f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_6a90047b-132f-448d-8f7d-4c0ac7f2083d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3f3c6295-db2d-448a-8cff-7bb814a32f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseExpenseDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#CommitmentsandContingenciesScheduleofOperatingLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fbc60b04-b96b-4b49-baa3-6bbf557dc69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e7d95420-8797-41dd-be2e-f04fd9c463e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fbc60b04-b96b-4b49-baa3-6bbf557dc69d" xlink:to="loc_us-gaap_OperatingLeaseExpense_e7d95420-8797-41dd-be2e-f04fd9c463e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_7014a6d4-0cd9-4e91-873f-95beb0929bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fbc60b04-b96b-4b49-baa3-6bbf557dc69d" xlink:to="loc_us-gaap_OperatingLeasePayments_7014a6d4-0cd9-4e91-873f-95beb0929bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_70d68382-4530-41ea-9d0d-023c24e5db32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_30d93336-6604-4c1b-ba54-2c4868419bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_70d68382-4530-41ea-9d0d-023c24e5db32" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_30d93336-6604-4c1b-ba54-2c4868419bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_22d980d9-35f9-4d87-b730-e8123637d3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_30d93336-6604-4c1b-ba54-2c4868419bc9" xlink:to="loc_us-gaap_AwardTypeAxis_22d980d9-35f9-4d87-b730-e8123637d3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_266b824c-2691-4e06-95b5-c3320995ff31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_22d980d9-35f9-4d87-b730-e8123637d3f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_266b824c-2691-4e06-95b5-c3320995ff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_a2b12d08-23b7-4c60-8233-672e1e4a3846" xlink:href="vcyt-20230331.xsd#vcyt_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_266b824c-2691-4e06-95b5-c3320995ff31" xlink:to="loc_vcyt_EmployeeAndNonEmployeeStockOptionMember_a2b12d08-23b7-4c60-8233-672e1e4a3846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_02a15cb1-1884-4960-a427-a00e848b21d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_266b824c-2691-4e06-95b5-c3320995ff31" xlink:to="loc_us-gaap_EmployeeStockMember_02a15cb1-1884-4960-a427-a00e848b21d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c31b2881-6dd4-4423-85a7-5f47d2ad629c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_30d93336-6604-4c1b-ba54-2c4868419bc9" xlink:to="loc_us-gaap_ClassOfStockLineItems_c31b2881-6dd4-4423-85a7-5f47d2ad629c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a57a0dc2-e98a-4e0d-88e9-051bcebb61f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c31b2881-6dd4-4423-85a7-5f47d2ad629c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a57a0dc2-e98a-4e0d-88e9-051bcebb61f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b7e21ee1-c080-4a13-b5af-967cdd2877f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c31b2881-6dd4-4423-85a7-5f47d2ad629c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b7e21ee1-c080-4a13-b5af-967cdd2877f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dbfe6343-0234-43c5-9e4f-f2181dd251af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c31b2881-6dd4-4423-85a7-5f47d2ad629c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dbfe6343-0234-43c5-9e4f-f2181dd251af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/ComponentsofOtherIncomeDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#ComponentsofOtherIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/ComponentsofOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_441b27c5-df09-4612-ae1f-d94064cd0991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit_c9dae5e8-7f3c-41ac-afab-8fafa5eb49c9" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_441b27c5-df09-4612-ae1f-d94064cd0991" xlink:to="loc_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit_c9dae5e8-7f3c-41ac-afab-8fafa5eb49c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseInterestIncome_60ea0bfd-6df2-4250-abce-d4283d1683c8" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseInterestIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_441b27c5-df09-4612-ae1f-d94064cd0991" xlink:to="loc_vcyt_OtherNonoperatingIncomeExpenseInterestIncome_60ea0bfd-6df2-4250-abce-d4283d1683c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseInterestExpense_b058006c-1400-4402-bd2a-9e7b30831ec5" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_441b27c5-df09-4612-ae1f-d94064cd0991" xlink:to="loc_vcyt_OtherNonoperatingIncomeExpenseInterestExpense_b058006c-1400-4402-bd2a-9e7b30831ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss_ebcf8618-8143-4647-abe6-50cc1ae5b21f" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_441b27c5-df09-4612-ae1f-d94064cd0991" xlink:to="loc_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss_ebcf8618-8143-4647-abe6-50cc1ae5b21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vcyt_OtherNonoperatingIncomeExpenseOther_642dcfb4-543b-4427-abf6-1d2d1a594763" xlink:href="vcyt-20230331.xsd#vcyt_OtherNonoperatingIncomeExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_441b27c5-df09-4612-ae1f-d94064cd0991" xlink:to="loc_vcyt_OtherNonoperatingIncomeExpenseOther_642dcfb4-543b-4427-abf6-1d2d1a594763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8267c219-2e87-420b-814f-d4d505a050d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_441b27c5-df09-4612-ae1f-d94064cd0991" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8267c219-2e87-420b-814f-d4d505a050d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.veracyte.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="vcyt-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.veracyte.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_db975302-dac3-4eeb-98ad-a365c206e1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3c5862b7-08bd-4afb-9c64-24d1221a5212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_db975302-dac3-4eeb-98ad-a365c206e1ae" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3c5862b7-08bd-4afb-9c64-24d1221a5212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767760528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VERACYTE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5455398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6000 Shoreline Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-6300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VCYT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,417,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001384101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767871568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 177,890,000<span></span>
</td>
<td class="nump">$ 154,247,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,605,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">45,489,000<span></span>
</td>
<td class="nump">44,021,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Supplies and inventory</a></td>
<td class="nump">13,306,000<span></span>
</td>
<td class="nump">14,294,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,818,000<span></span>
</td>
<td class="nump">11,469,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">251,503,000<span></span>
</td>
<td class="nump">248,636,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, net</a></td>
<td class="nump">18,072,000<span></span>
</td>
<td class="nump">17,702,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">11,308,000<span></span>
</td>
<td class="nump">13,160,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">170,226,000<span></span>
</td>
<td class="nump">174,866,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">699,718,000<span></span>
</td>
<td class="nump">695,891,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">749,000<span></span>
</td>
<td class="nump">749,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,543,000<span></span>
</td>
<td class="nump">5,418,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,157,119,000<span></span>
</td>
<td class="nump">1,156,422,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,655,000<span></span>
</td>
<td class="nump">11,911,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">30,641,000<span></span>
</td>
<td class="nump">37,774,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">2,194,000<span></span>
</td>
<td class="nump">2,613,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of acquisition-related contingent consideration</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">6,060,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">4,076,000<span></span>
</td>
<td class="nump">4,070,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Current portion of other liabilities</a></td>
<td class="nump">127,000<span></span>
</td>
<td class="nump">186,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">55,993,000<span></span>
</td>
<td class="nump">62,614,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">4,594,000<span></span>
</td>
<td class="nump">4,531,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration, net of current portion</a></td>
<td class="nump">4,773,000<span></span>
</td>
<td class="nump">2,498,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">9,709,000<span></span>
</td>
<td class="nump">10,648,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">791,000<span></span>
</td>
<td class="nump">931,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">75,860,000<span></span>
</td>
<td class="nump">81,222,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 125,000,000 shares authorized, 72,383,140 and 71,959,454 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,509,861,000<span></span>
</td>
<td class="nump">1,500,191,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(401,808,000)<span></span>
</td>
<td class="num">(393,717,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(26,866,000)<span></span>
</td>
<td class="num">(31,346,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,081,259,000<span></span>
</td>
<td class="nump">1,075,200,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,157,119,000<span></span>
</td>
<td class="nump">$ 1,156,422,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094769180384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">72,383,140<span></span>
</td>
<td class="nump">71,959,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">72,383,140<span></span>
</td>
<td class="nump">71,959,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767818272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 82,422,000<span></span>
</td>
<td class="nump">$ 67,783,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,769,000<span></span>
</td>
<td class="nump">9,166,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">26,130,000<span></span>
</td>
<td class="nump">23,754,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,463,000<span></span>
</td>
<td class="nump">20,912,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">5,329,000<span></span>
</td>
<td class="nump">5,486,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">92,920,000<span></span>
</td>
<td class="nump">83,031,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,498,000)<span></span>
</td>
<td class="num">(15,248,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,407,000<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(8,091,000)<span></span>
</td>
<td class="num">(14,464,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,091,000)<span></span>
</td>
<td class="num">$ (14,461,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in USD per share)</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in USD per share)</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute net loss per common share, basic (in shares)</a></td>
<td class="nump">72,175,457<span></span>
</td>
<td class="nump">71,229,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute net loss per common share, diluted (in shares)</a></td>
<td class="nump">72,175,457<span></span>
</td>
<td class="nump">71,229,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_TestingMember', window );">Testing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 72,396,000<span></span>
</td>
<td class="nump">$ 55,980,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">19,648,000<span></span>
</td>
<td class="nump">17,523,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">3,892,000<span></span>
</td>
<td class="nump">2,979,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">2,162,000<span></span>
</td>
<td class="nump">1,575,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherMember', window );">Biopharmaceutical and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">6,134,000<span></span>
</td>
<td class="nump">8,824,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">$ 4,419,000<span></span>
</td>
<td class="nump">$ 4,615,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_TestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_TestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767849792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,091)<span></span>
</td>
<td class="num">$ (14,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Change in currency translation adjustments</a></td>
<td class="nump">4,480<span></span>
</td>
<td class="num">(5,598)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (3,611)<span></span>
</td>
<td class="num">$ (20,059)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767965552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 1,096,514<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 1,468,683<span></span>
</td>
<td class="num">$ (357,157)<span></span>
</td>
<td class="num">$ (15,083)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="nump">2,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax portion of vested restricted stock units</a></td>
<td class="num">(1,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee', window );">Stock-based compensation expense (employee)</a></td>
<td class="nump">6,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee', window );">Stock-based compensation expense (non-employee)</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP', window );">Stock-based compensation expense (ESPP)</a></td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(5,598)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,598)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2022</a></td>
<td class="nump">1,085,190<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">1,477,418<span></span>
</td>
<td class="num">(371,618)<span></span>
</td>
<td class="num">(20,681)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2022</a></td>
<td class="nump">1,075,200<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">1,500,191<span></span>
</td>
<td class="num">(393,717)<span></span>
</td>
<td class="num">(31,346)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod', window );">Issuance of common stock on exercise of stock options and vesting of restricted stock units</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under ESPP</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax portion of vested restricted stock units</a></td>
<td class="num">(2,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee', window );">Stock-based compensation expense (employee)</a></td>
<td class="nump">7,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP', window );">Stock-based compensation expense (ESPP)</a></td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">4,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,480<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2023</a></td>
<td class="nump">$ 1,081,259<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 1,509,861<span></span>
</td>
<td class="num">$ (401,808)<span></span>
</td>
<td class="num">$ (26,866)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) resulting from ESPP stock-based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) resulting from employee stock-based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase In additional paid-in capital (APIC) resulting from non-employee stock-based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Value, Options And Non-Option Equity Instruments, Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094765317280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,091)<span></span>
</td>
<td class="num">$ (14,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,670<span></span>
</td>
<td class="nump">6,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property, plant and equipment</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,985<span></span>
</td>
<td class="nump">6,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty', window );">Interest on end-of-term debt obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">903<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Revaluation of acquisition-related contingent consideration</a></td>
<td class="num">(485)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Effect of foreign currency on operations</a></td>
<td class="num">(224)<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,302)<span></span>
</td>
<td class="num">(3,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Supplies and inventory</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="num">(1,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,064)<span></span>
</td>
<td class="num">(2,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(491)<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(950)<span></span>
</td>
<td class="num">(597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,012<span></span>
</td>
<td class="num">(960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue', window );">Accrued liabilities and deferred revenue</a></td>
<td class="num">(7,721)<span></span>
</td>
<td class="num">(390)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,172)<span></span>
</td>
<td class="num">(8,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchase of short-term investments</a></td>
<td class="num">(19,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Proceeds from sale of short-term investments</a></td>
<td class="nump">39,773<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities', window );">Proceeds from maturity of short-term investments</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(993)<span></span>
</td>
<td class="num">(2,453)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">24,080<span></span>
</td>
<td class="num">(2,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of taxes on vested restricted stock units</a></td>
<td class="num">(2,277)<span></span>
</td>
<td class="num">(1,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options and employee stock purchases</a></td>
<td class="nump">3,962<span></span>
</td>
<td class="nump">3,537<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">23,593<span></span>
</td>
<td class="num">(9,335)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign currency on cash, cash equivalents and restricted cash</a></td>
<td class="nump">50<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">23,643<span></span>
</td>
<td class="num">(9,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">154,996<span></span>
</td>
<td class="nump">173,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">178,639<span></span>
</td>
<td class="nump">164,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment included in accounts payable and accrued liability</a></td>
<td class="nump">1,624<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">177,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 178,639<span></span>
</td>
<td class="nump">$ 164,364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, End Of Term Payment Interest Amount And Prepayment Penalty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Liabilities And Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncash portion of lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094771131584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization, Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization, Description of Business and Summary of Significant Accounting Policies<div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veracyte, Inc., or Veracyte, or the Company, is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Veracyte's high-performing tests enable clinicians to make more confident diagnostic, prognostic and treatment decisions, helping patients avoid unnecessary procedures and interventions, and speed time to appropriate treatment, thereby improving outcomes for patients all over the world. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veracyte was incorporated in the state of Delaware on August 15, 2006, as Calderome, Inc. Calderome operated as an incubator until early 2008. On March 4, 2008, the Company changed its name to Veracyte, Inc. The Company&#8217;s headquarters are in South San Francisco, California, and it also has operations in San Diego, California; Austin, Texas; and Marseille, France. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently offers tests in thyroid cancer (Afirma); prostate cancer (Decipher Prostate); breast cancer (Prosigna); interstitial lung diseases (Envisia); and bladder cancer (Decipher Bladder). The Company&#8217;s Percepta Nasal Swab test is being run in its CLIA lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company serves global markets with two complementary models. In the United States, it offers laboratory developed tests, or LDTs, through its centralized, Clinical Laboratory Improvement Amendments of 1988, or CLIA, certified laboratories in South San Francisco and San Diego, California, supported by its cytopathology expertise in Austin, Texas. Additionally, primarily outside of the United States, the Company provides its Prosigna test to patients through distribution to laboratories and hospitals that can perform the tests locally as an in vitro diagnostic, or IVD, test that runs on the nCounter Analysis System.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of March&#160;31, 2023, the condensed consolidated statements of operations for the three months ended March&#160;31, 2023 and 2022, the condensed consolidated statements of comprehensive loss for the three months ended March&#160;31, 2023 and 2022, the condensed consolidated statements of stockholders' equity for the three months ended March&#160;31, 2023 and 2022, and the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results, stockholders' equity and cash flows for the periods presented. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from audited financial statements. The results for the three months ended March&#160;31, 2023 are not indicative of the results expected for the full year or any other period. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.  The Company operates in one segment.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim period condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property, plant and equipment; the recoverability of long-lived assets; the incremental borrowing rates for leases; accounting for acquisitions; the estimation of the fair value of intangible assets and contingent consideration; stock based compensation; income tax uncertainties, including a valuation allowance for deferred tax assets; credit related losses on investments; and allowance for credit losses and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have. As a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company&#8217;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict. If the financial markets or the overall economy are impacted for an extended period, the Company&#8217;s liquidity, revenue, supplies, goodwill and intangibles may be adversely affected. The Company considers the effects, to the extent knowable, of the COVID-19 pandemic in developing its estimates.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s cash and cash equivalents are deposited with two major financial institutions in the United States. Deposits in these institutions may exceed the amount of insurance provided on such deposits. The Company has not realized any losses on its deposits of cash and cash equivalents other than exchange rate losses related to foreign currency denominated accounts.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of the components of the Company&#8217;s sample collection kits and test reagents, and the nCounter system and related diagnostic kits, are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company&#8217;s requirements on a timely basis, or are unable to provide the Company with reagents that perform to specifications, the Company could suffer delays in being able to deliver its diagnostic solutions, suffer a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March&#160;31, 2023, the Company has derived most of its revenue from the sale of Decipher and Afirma testing. To date, Decipher and Afirma testing have been delivered primarily to physicians in the United States. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect. The Company generally does not perform evaluations of customers&#8217; financial condition for testing revenue and generally does not require collateral. The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and other revenue based on collection history, current developments and credit worthiness of the customer. The estimate of credit losses is not material at March&#160;31, 2023.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"/><td style="width:55.467%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UnitedHealthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's significant third-party payers in excess of 10% of total accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UnitedHealthcare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash&#160;and&#160;Cash&#160;Equivalents</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers demand deposits in a bank, money market funds and highly liquid investments with an original maturity of 90 days or less to be cash equivalents. </span></div><div style="text-indent:42.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's short-term investments consist of U.S. treasury securities with maturities at the time of purchase that were between 90 days and one year. The Company classifies these investments as held-to-maturity debt securities, which are reported at amortized cost. The amortization of discounts or premiums from the purchase of the securities are recognized as a component of interest income in other income (loss), net in the condensed consolidated statements of operations. Investments are initially recorded net of an allowance for expected credit losses, if any, which are remeasured each period and any impairments are recognized as an expense. Unrealized gains and losses are not recognized in income. As of both March&#160;31, 2023 and December&#160;31, 2022, no allowances for expected credit losses had been recorded and there have been no impairment or credit losses on the Company's short term investments.</span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had deposits of $0.7 million included in long-term assets as of both March&#160;31, 2023 and December&#160;31, 2022, restricted from withdrawal and held by banks in the form of collateral for irrevocable standby letters of credit held as security for the Company's leases. </span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with the provisions of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has completed a service or transferred control of a product to the customer. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one service or good, each required service or good is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the service or good either on its own or together with other resources that are readily available and (ii) the service or good is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred which may be at a point in time or over time.</span></div><div><span><br/></span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Testing Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bills for testing services at the time of test completion as defined by the delivery of test results. The Company recognizes revenue based on estimates of the amount that will ultimately be realized. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management. Actual results could differ from those estimates and assumptions.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Product Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products consist of the Prosigna breast cancer assay, the nCounter Analysis System and related diagnostic kits. Product revenue from diagnostic kits is generally recognized upon shipment. Product revenue from instruments is </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally recognized when the instrument is ready for use by the end customer. Shipping and handling costs incurred for product shipments are included in product revenue. Revenue is presented net of the taxes that are collected from customers and remitted to governmental authorities. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Biopharmaceutical and Other Revenue</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into arrangements for biopharmaceutical research and development, commercialization, contract manufacturing and development, and testing services, which are classified under biopharmaceutical and other revenue. Such arrangements may require the Company to deliver various rights, manufactured diagnostic test kits, services and/or samples, including intellectual property rights/licenses, biopharmaceutical research and development services, and/or commercialization services. The Company receives consideration in the form of upfront license fees; payments on delivery of data, test results or manufactured products; costs of service plus margin; and development and commercial performance milestone payments. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price may include independent evidence of market price, forecasted revenue or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if the obligation can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. Milestone payments that are not within either party&#8217;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within either party&#8217;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative revenue and earnings in the period of adjustment. One collaboration arrangement with milestone payments falls under the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 808. These milestone payments are recognized in the same manner as milestone payments from customers and are classified under biopharmaceutical and other revenue.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable from biopharmaceutical and other revenue was $8.8&#160;million&#160;at March&#160;31, 2023 and $9.3&#160;million at December&#160;31, 2022. There was $2.2&#160;million and $2.6&#160;million of deferred revenue related to these agreements at March&#160;31, 2023 and December&#160;31, 2022, respectively. Revenue included in biopharmaceutical and other revenue for the three months ended March&#160;31, 2023 and 2022 was as follows (in thousands of dollars):</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:42.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"/><td style="width:55.467%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biopharmaceutical revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing and testing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Testing Revenue</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue consists primarily of costs of purchasing instruments and diagnostic kits from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">third</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-party contract manufacturers, installation, service and packaging and delivery costs, and the Company's internal labor expenses. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#8217;s products. Cost of product revenue for instruments and diagnostic kits&#160;is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the condensed consolidated statements of operations.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Biopharmaceutical and Other Revenue</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of biopharmaceutical and other revenue consists of costs of performing activities under arrangements that require the Company to perform biopharmaceutical research and development, commercialization, contract manufacturing and contract testing services on behalf of a customer.&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pension Liability</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers a defined benefit <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_c42f36f4-4860-4a82-9f52-48c65e91ae48"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_dbd24477-8f44-4199-93ad-3dfd106ab395">pension plan</span></span> to certain non-U.S. employees of its Veracyte SAS subsidiary.  As of both March&#160;31, 2023 and December&#160;31, 2022, the total pension obligation was $0.7&#160;million and is included in other liabilities on the condensed consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 2014-09, Revenue from Contracts with Customers (Topic 606). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. The new standard is effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance in 2023 and such adoption had no material impact on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094770937744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">Net Loss Per Common Share<div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. The following outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive:</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:19.225%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of common stock subject to outstanding options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,767,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,703,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,998&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,622&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,349,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,559,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,150,235&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,293,818&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094770928784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="text-align:justify;text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was $699.7&#160;million and $695.9&#160;million as of March&#160;31, 2023 and December&#160;31, 2022, respectively. The changes in the carrying amounts of goodwill during the three months ended March 31, 2023 were due to foreign currency translation.  The Company has not recorded any impairment related to goodwill.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include finite-lived product technology, customer relationships, licenses and trade names and indefinite-lived in-process research and development. Intangible assets consisted of the following (in thousands of dollars):</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:29.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.099%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Amortization Period (Years)</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Percepta product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,533)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,267)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prosigna product technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prosigna customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">nCounter Dx license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LymphMark product technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decipher product technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decipher trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HalioDx developed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,001)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,899)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HalioDx customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HalioDx customer backlog</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,759)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,213)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,708)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,213)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,708)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the finite-lived intangible assets is recognized on a straight-line basis. Amortization expense of $5.3&#160;million and $5.5&#160;million was recognized for the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future aggregate amortization expense as of March&#160;31, 2023 is as follows (in thousands of dollars):</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:86.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December&#160;31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 remainder of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,926&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplies and Inventory</span></div><div style="text-align:justify;text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, supplies and inventory consisted of $10.0&#160;million and $10.2&#160;million, respectively, of lab supplies and reagents consumed in the performance of testing services, and $3.3&#160;million and $4.1&#160;million, respectively, of inventory related to raw materials consumed in the contract manufacturing process, as well as finished and semi-finished components used in the assembly of diagnostic kits related to product sales.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands of dollars):</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,688&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094771037808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records certain of its financial assets and liabilities at fair value. The accounting guidance for fair value provides a framework for measuring fair value and clarifies the definition of fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level I: Inputs which include quoted prices in active markets for identical assets and liabilities;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level II: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The fair value of the Company&#8217;s financial assets includes money market funds and deposits for leases of the Company's facilities. Money market funds, included in cash and cash equivalents in the accompanying condensed consolidated balance sheets, were $42.3 million and $131.2 million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and are Level&#160;I assets as described above. The deposits for the leases, included in restricted cash, were $0.7 million as of both March&#160;31, 2023 and December&#160;31, 2022 and are a Level I assets as described above. There were no transfers between Levels 1, 2 or 3 for the three months ended March 31, 2023 and 2022.</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2019, the Company acquired from NanoString the exclusive global diagnostics license to the nCounter Analysis System, the Prosigna breast cancer prognostic gene signature assay, and the LymphMark lymphoma subtyping assay. Pursuant to the terms of the agreement, Veracyte paid NanoString $40.0 million in cash and $10.0 million in Veracyte common stock, and may pay up to an additional $10.0 million in cash, contingent upon first achievement or occurrence, by or on behalf of Veracyte, of the commercial launch of the first, second and third diagnostic tests for use on the nCounter multiplex analysis system. This contingency was valued at $6.1&#160;million as of the acquisition date and is remeasured to fair value at each reporting date until the contingent consideration is settled. As of March&#160;31, 2023 and December&#160;31, 2022, this contingency was remeasured to $8.1 million and $8.6 million, respectively, with the corresponding changes included in general and administrative expense in the Company's condensed consolidated statements of operations. For the three months ended March 31, 2023, a reversal of expense of $0.5 million was recorded in general and administrative expense for the changes in carrying value and, for the three months ended March 31, 2022, no expense was recorded. As of March&#160;31, 2023, the achievement of one of the milestones is forecasted to occur within the next 12 months. As a result, $3.3 million of the contingent consideration is included in short term liabilities at March&#160;31, 2023. The fair value of the contingent consideration includes inputs that are not observable in the market and thus represents a Level III financial liability. The estimation of the fair value of the contingent consideration is based on the present value of the expected payments calculated by assessing the likelihood of when the related milestones would be achieved and estimating the Company's borrowing rate. These estimates form the basis for making judgments about the carrying value of the contingent consideration that are not readily apparent from other sources. Changes to the forecasts for the achievement of the milestones and the borrowing rate can significantly affect the estimated fair value of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingent consideration. As of March&#160;31, 2023 and December&#160;31, 2022, the Company calculated the estimated fair value of the milestones using the following significant unobservable inputs:</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value or Range (Weighted-Average)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80% - 100% (92%)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80% - 100% (94%)</span></div></td></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments Held-to-Maturity</span></div><div style="text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's short-term investments consist of U.S. treasury securities with maturities at the time of purchase that were between 90 days and one year. The Company classifies these investments as held-to-maturity debt securities, which are reported at amortized cost, and are Level&#160;I assets as described above. As of March&#160;31, 2023, the Company held no short-term investments and, as of December&#160;31, 2022, short-term investments comprised U.S. treasury bills recorded at amortized cost of $24.6 million with a fair value of approximately $24.6 million. As of December&#160;31, 2022, gross unrealized losses on short-term investments were insignificant. As part of its banking partner diversification efforts, the Company sold $40.0&#160;million U.S. treasury bills with an amortized cost of $39.8&#160;million for $39.8&#160;million and realized a gross gain of $13&#160;thousand during the three months ended March 31, 2023. No realized gains or losses on short-term investments were recognized in 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094771097152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office and laboratory facilities in South San Francisco and San Diego, California; Austin, Texas; Marseille, France; and Richmond, Virginia, and leases certain equipment under various non-cancelable lease agreements. The lease terms extend to October 2030 and contain extension of lease terms and expansion options. The leases have a weighted average remaining lease term of 3.6 years as of March&#160;31, 2023. The Company had deposits of $0.7&#160;million included in long-term assets as of both March&#160;31, 2023 and December&#160;31, 2022 restricted from withdrawal and held by banks in the form of collateral for irrevocable standby letters of credit held as security for the leases.</span></div><div style="text-align:justify;text-indent:42.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its operating lease liabilities using payments through their current expiration dates and a weighted average discount rate of 6.4% based on the rate that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments in a similar economic environment. Operating lease liabilities along with the associated right-of-use assets are disclosed in the accompanying condensed consolidated balance sheets.  After the adoption of ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 842, the Company classified its deferred rent for tenant improvements with its operating lease right-of-use assets on the consolidated balance sheets.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable operating leases as of March&#160;31, 2023 are as follows (in thousands of dollars):</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.331%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: short-term lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,076&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes operating lease expense on a straight-line basis over the non-cancelable lease period. The following table summarizes operating lease expense and cash paid for amounts included in the measurement of lease liabilities (in thousands of dollars): </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"><tr><td style="width:1.0%"/><td style="width:64.086%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has leased laboratory equipment under various financing leases. The total right-of-use assets and total financing lease liabilities for these financing leases were $0.2&#160;million and $0.2&#160;million, respectively, as of March&#160;31, 2023, and are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MQ_8dcd2a74-c451-48ee-8234-99b6286ac891"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MQ_b8e18883-b7ca-498a-8118-1cbdf8c548c4">property, plant and equipment, net</span></span> and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1Mg_135ebc69-b606-42ce-b152-da2f2dbc668a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1Mg_7fac536f-70a2-4239-a5bf-1ba0e01d202a">other liabilities</span></span> in the accompanying condensed consolidated balance sheets. As of December&#160;31, 2022, the total right-of-use assets and total financing lease liabilities for these financing leases were $0.4&#160;million and $0.4&#160;million, respectively. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s wholly-owned foreign subsidiary has entered into an arrangement under which it expects to sign a lease agreement for facilities which will be constructed in Marseille, France. The lease will commence upon completion of the construction of the office building which the Company currently expects to occur in the third quarter of 2023 at which time the Company will record a lease liability and a corresponding ROU asset. The initial term of the lease will be twelve years with annual rent of approximately $1.3&#160;million, which is subject to change based on final construction.</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no litigation pending that could have, either individually or in the aggregate, a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094855820832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows:</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock units issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,054,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,881,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock units available for grant under stock option plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,322,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,591,977&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock available for the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,242,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,335,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,620,056&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,809,236&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094771097152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Other Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Components of Other Income</a></td>
<td class="text">Components of Other Income<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Other income, net consists of the following (in thousands of dollars):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"/><td style="width:55.467%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">French research tax credits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on currency revaluation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094774753440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded no income tax expense for the three months ended March 31, 2023 and an income tax benefit of $3.0&#160;thousand for the three months ended March 31, 2022. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022 was signed into law August 16, 2022, and includes significant legislation addressing taxes, inflation, climate change and renewable energy incentives, and healthcare.  Key tax provisions include a 15% corporate minimum tax, clean energy incentives, and a 1% excise tax on stock buybacks. The Company does not expect the provisions of such legislation to have any impact on the effective tax rate of the Company but will continue to evaluate the tax effects should any provisions become applicable to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767860752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of March&#160;31, 2023, the condensed consolidated statements of operations for the three months ended March&#160;31, 2023 and 2022, the condensed consolidated statements of comprehensive loss for the three months ended March&#160;31, 2023 and 2022, the condensed consolidated statements of stockholders' equity for the three months ended March&#160;31, 2023 and 2022, and the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results, stockholders' equity and cash flows for the periods presented. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from audited financial statements. The results for the three months ended March&#160;31, 2023 are not indicative of the results expected for the full year or any other period. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.  The Company operates in one segment.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim period condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property, plant and equipment; the recoverability of long-lived assets; the incremental borrowing rates for leases; accounting for acquisitions; the estimation of the fair value of intangible assets and contingent consideration; stock based compensation; income tax uncertainties, including a valuation allowance for deferred tax assets; credit related losses on investments; and allowance for credit losses and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions </span></div>that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have. As a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company&#8217;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict. If the financial markets or the overall economy are impacted for an extended period, the Company&#8217;s liquidity, revenue, supplies, goodwill and intangibles may be adversely affected. The Company considers the effects, to the extent knowable, of the COVID-19 pandemic in developing its estimates.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s cash and cash equivalents are deposited with two major financial institutions in the United States. Deposits in these institutions may exceed the amount of insurance provided on such deposits. The Company has not realized any losses on its deposits of cash and cash equivalents other than exchange rate losses related to foreign currency denominated accounts.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of the components of the Company&#8217;s sample collection kits and test reagents, and the nCounter system and related diagnostic kits, are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company&#8217;s requirements on a timely basis, or are unable to provide the Company with reagents that perform to specifications, the Company could suffer delays in being able to deliver its diagnostic solutions, suffer a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March&#160;31, 2023, the Company has derived most of its revenue from the sale of Decipher and Afirma testing. To date, Decipher and Afirma testing have been delivered primarily to physicians in the United States. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect. The Company generally does not perform evaluations of customers&#8217; financial condition for testing revenue and generally does not require collateral. The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and other revenue based on collection history, current developments and credit worthiness of the customer. The estimate of credit losses is not material at March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash&#160;and&#160;Cash&#160;Equivalents</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>The Company considers demand deposits in a bank, money market funds and highly liquid investments with an original maturity of 90 days or less to be cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>The Company's short-term investments consist of U.S. treasury securities with maturities at the time of purchase that were between 90 days and one year. The Company classifies these investments as held-to-maturity debt securities, which are reported at amortized cost. The amortization of discounts or premiums from the purchase of the securities are recognized as a component of interest income in other income (loss), net in the condensed consolidated statements of operations. Investments are initially recorded net of an allowance for expected credit losses, if any, which are remeasured each period and any impairments are recognized as an expense. Unrealized gains and losses are not recognized in income.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Cost of Revenue</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with the provisions of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has completed a service or transferred control of a product to the customer. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arrangements involving more than one service or good, each required service or good is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the service or good either on its own or together with other resources that are readily available and (ii) the service or good is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred which may be at a point in time or over time.</span></div><div><span><br/></span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Testing Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bills for testing services at the time of test completion as defined by the delivery of test results. The Company recognizes revenue based on estimates of the amount that will ultimately be realized. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management. Actual results could differ from those estimates and assumptions.</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Product Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products consist of the Prosigna breast cancer assay, the nCounter Analysis System and related diagnostic kits. Product revenue from diagnostic kits is generally recognized upon shipment. Product revenue from instruments is </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally recognized when the instrument is ready for use by the end customer. Shipping and handling costs incurred for product shipments are included in product revenue. Revenue is presented net of the taxes that are collected from customers and remitted to governmental authorities. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Biopharmaceutical and Other Revenue</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into arrangements for biopharmaceutical research and development, commercialization, contract manufacturing and development, and testing services, which are classified under biopharmaceutical and other revenue. Such arrangements may require the Company to deliver various rights, manufactured diagnostic test kits, services and/or samples, including intellectual property rights/licenses, biopharmaceutical research and development services, and/or commercialization services. The Company receives consideration in the form of upfront license fees; payments on delivery of data, test results or manufactured products; costs of service plus margin; and development and commercial performance milestone payments. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price may include independent evidence of market price, forecasted revenue or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if the obligation can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. Milestone payments that are not within either party&#8217;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within either party&#8217;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative revenue and earnings in the period of adjustment. One collaboration arrangement with milestone payments falls under the scope of ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 808. These milestone payments are recognized in the same manner as milestone payments from customers and are classified under biopharmaceutical and other revenue.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable from biopharmaceutical and other revenue was $8.8&#160;million&#160;at March&#160;31, 2023 and $9.3&#160;million at December&#160;31, 2022. There was $2.2&#160;million and $2.6&#160;million of deferred revenue related to these agreements at March&#160;31, 2023 and December&#160;31, 2022, respectively. Revenue included in biopharmaceutical and other revenue for the three months ended March&#160;31, 2023 and 2022 was as follows (in thousands of dollars):</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:42.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"/><td style="width:55.467%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biopharmaceutical revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing and testing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Testing Revenue</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue consists primarily of costs of purchasing instruments and diagnostic kits from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">third</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-party contract manufacturers, installation, service and packaging and delivery costs, and the Company's internal labor expenses. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#8217;s products. Cost of product revenue for instruments and diagnostic kits&#160;is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the condensed consolidated statements of operations.</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Biopharmaceutical and Other Revenue</span></div><div style="text-align:justify;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Cost of biopharmaceutical and other revenue consists of costs of performing activities under arrangements that require the Company to perform biopharmaceutical research and development, commercialization, contract manufacturing and contract testing services on behalf of a customer.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy', window );">Pension Liability</a></td>
<td class="text">Pension LiabilityThe Company offers a defined benefit <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_c42f36f4-4860-4a82-9f52-48c65e91ae48"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_dbd24477-8f44-4199-93ad-3dfd106ab395">pension plan</span></span> to certain non-U.S. employees of its Veracyte SAS subsidiary.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 2014-09, Revenue from Contracts with Customers (Topic 606). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. The new standard is effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance in 2023 and such adoption had no material impact on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094770906096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization , Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Third-party Payers as a Percentage of Total</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"/><td style="width:55.467%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UnitedHealthcare</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's significant third-party payers in excess of 10% of total accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:</span></div><div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UnitedHealthcare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue</a></td>
<td class="text">Revenue included in biopharmaceutical and other revenue for the three months ended March&#160;31, 2023 and 2022 was as follows (in thousands of dollars):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"/><td style="width:55.467%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biopharmaceutical revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing and testing</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094770995824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Common Stock Equivalents Excluded From Diluted Net Loss Per Common Share</a></td>
<td class="text">The following outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive:<div style="text-align:justify;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:19.225%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares of common stock subject to outstanding options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,767,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,703,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,998&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,622&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,349,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,559,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,150,235&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,293,818&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094773553680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">Intangible assets consisted of the following (in thousands of dollars):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:29.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.099%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Amortization Period (Years)</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Percepta product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,533)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,267)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prosigna product technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prosigna customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">nCounter Dx license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LymphMark product technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decipher product technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decipher trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HalioDx developed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,001)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,899)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HalioDx customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HalioDx customer backlog</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,759)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,213)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,708)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,213)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170,226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,708)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Aggregate Amortization Expense</a></td>
<td class="text">The estimated future aggregate amortization expense as of March&#160;31, 2023 is as follows (in thousands of dollars):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:86.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December&#160;31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 remainder of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,926&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands of dollars):</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,688&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094771023776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">As of March&#160;31, 2023 and December&#160;31, 2022, the Company calculated the estimated fair value of the milestones using the following significant unobservable inputs:<div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value or Range (Weighted-Average)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of achievement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80% - 100% (92%)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80% - 100% (94%)</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094771108416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable operating leases as of March&#160;31, 2023 are as follows (in thousands of dollars):</span></div><div style="text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.331%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: amount representing interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: short-term lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,076&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Expense and Measurement Of Lease Liabilities</a></td>
<td class="text">The following table summarizes operating lease expense and cash paid for amounts included in the measurement of lease liabilities (in thousands of dollars): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"><tr><td style="width:1.0%"/><td style="width:64.086%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.486%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094770943232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Reserved Shares of Common Stock for Issuance</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows:</span></div><div style="text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.029%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock units issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,054,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,881,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and restricted stock units available for grant under stock option plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,322,628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,591,977&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock available for the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,242,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,335,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,620,056&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,809,236&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094771041664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Other Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Income, net</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Other income, net consists of the following (in thousands of dollars):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"><tr><td style="width:1.0%"/><td style="width:55.467%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">French research tax credits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on currency revaluation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094764197632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of Business and Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest', window );">Short-term investments, allowance for expected credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long term deposit</a></td>
<td class="nump">749,000<span></span>
</td>
<td class="nump">749,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">45,489,000<span></span>
</td>
<td class="nump">44,021,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Pension obligation</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTypeExtensibleList', window );">Defined Benefit Plan, Type [Extensible List]</a></td>
<td class="text">Pension Plan [Member]<span></span>
</td>
<td class="text">Pension Plan [Member]<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherMember', window );">Biopharmaceutical and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding accrued interest, of allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTypeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of defined benefit plan. Includes, but is not limited to, pension plan, other postretirement plan and special and contractual termination benefits payable upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(8)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(B)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2410-114920<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (n)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6410066&amp;loc=d3e79218-111664<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6410066&amp;loc=d3e79218-111664<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(C)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(9)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTypeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767991344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Third-party Payers And Other Customers (Details) - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | UnitedHealthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue | Customers Representing &gt;10% Of Total Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | UnitedHealthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vcyt_MajorCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vcyt_MajorCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094764196912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 82,422<span></span>
</td>
<td class="nump">$ 67,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember', window );">Biopharmaceutical revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">4,447<span></span>
</td>
<td class="nump">7,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember', window );">Contract manufacturing and testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherMember', window );">Biopharmaceutical and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 6,134<span></span>
</td>
<td class="nump">$ 8,824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vcyt_BiopharmaceuticalAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094764217776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock subject to outstanding options (in shares)</a></td>
<td class="nump">6,150,235<span></span>
</td>
<td class="nump">5,293,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember', window );">Shares of common stock subject to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock subject to outstanding options (in shares)</a></td>
<td class="nump">3,767,086<span></span>
</td>
<td class="nump">3,703,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock subject to outstanding options (in shares)</a></td>
<td class="nump">33,998<span></span>
</td>
<td class="nump">30,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock subject to outstanding options (in shares)</a></td>
<td class="nump">2,349,151<span></span>
</td>
<td class="nump">1,559,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094764217072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 699,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">5,329<span></span>
</td>
<td class="nump">$ 5,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Lab supplies and reagents consumed</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and finished diagnostic kits</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094765189632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 216,139<span></span>
</td>
<td class="nump">$ 215,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(53,213)<span></span>
</td>
<td class="num">(47,708)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">162,926<span></span>
</td>
<td class="nump">167,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets</a></td>
<td class="nump">223,439<span></span>
</td>
<td class="nump">222,574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 170,226<span></span>
</td>
<td class="nump">174,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_PerceptaProductTechnologyMember', window );">Percepta product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(8,533)<span></span>
</td>
<td class="num">(8,267)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 7,467<span></span>
</td>
<td class="nump">7,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember', window );">Prosigna product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 4,120<span></span>
</td>
<td class="nump">4,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(915)<span></span>
</td>
<td class="num">(847)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 3,205<span></span>
</td>
<td class="nump">3,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_ProsignaCustomerRelationshipsMember', window );">Prosigna customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 2,430<span></span>
</td>
<td class="nump">2,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,620)<span></span>
</td>
<td class="num">(1,499)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterDxLicenseMember', window );">nCounter Dx license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 46,880<span></span>
</td>
<td class="nump">46,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(10,418)<span></span>
</td>
<td class="num">(9,636)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 36,462<span></span>
</td>
<td class="nump">37,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_LymphmarkProductTechnologyMember', window );">LymphMark product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 990<span></span>
</td>
<td class="nump">990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(471)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 519<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DecipherBioSciencesProductTechnologyMember', window );">Decipher product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(18,484)<span></span>
</td>
<td class="num">(16,234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 71,516<span></span>
</td>
<td class="nump">73,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DecipherBiosciencesTradeNamesMember', window );">Decipher trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,643)<span></span>
</td>
<td class="num">(1,443)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 2,357<span></span>
</td>
<td class="nump">2,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_HalioDXDevelopedTechnologyMember', window );">HalioDx developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 40,400<span></span>
</td>
<td class="nump">39,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(7,001)<span></span>
</td>
<td class="num">(5,899)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 33,399<span></span>
</td>
<td class="nump">33,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_HalioDxCustomerRelationshipsMember', window );">HalioDx customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 4,680<span></span>
</td>
<td class="nump">4,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,369)<span></span>
</td>
<td class="num">(1,144)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 3,311<span></span>
</td>
<td class="nump">3,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_HalioDxCustomerBacklogMember', window );">HalioDx customer backlog</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 6,639<span></span>
</td>
<td class="nump">6,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,759)<span></span>
</td>
<td class="num">(2,303)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 3,880<span></span>
</td>
<td class="nump">$ 4,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Amortization Period (Years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_PerceptaProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_PerceptaProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DevelopedProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_ProsignaCustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_ProsignaCustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterDxLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_NCounterDxLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_LymphmarkProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_LymphmarkProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DecipherBioSciencesProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DecipherBioSciencesProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DecipherBiosciencesTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_DecipherBiosciencesTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_HalioDXDevelopedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_HalioDXDevelopedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_HalioDxCustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_HalioDxCustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_HalioDxCustomerBacklogMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vcyt_HalioDxCustomerBacklogMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094764115504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023 remainder of year</a></td>
<td class="nump">$ 16,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">21,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">20,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">18,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">17,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">69,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 162,926<span></span>
</td>
<td class="nump">$ 167,566<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094764128256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation expenses</a></td>
<td class="nump">$ 21,953<span></span>
</td>
<td class="nump">$ 30,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">8,688<span></span>
</td>
<td class="nump">7,137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 30,641<span></span>
</td>
<td class="nump">$ 37,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094765637968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 03, 2019</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,773,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,498,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Short term contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,060,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,605,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldtomaturitySecuritiesSoldAtPar', window );">Sale of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount', window );">Amortized cost of short-term investments sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Proceeds from sale of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,773,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gains (losses) from sale of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanostringMember', window );">NanoString</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Cash paid in acquisition</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_BusinessCombinationContingentConsiderationCashToBePaid', window );">Additional cash to be paid</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration, net of current portion</a></td>
<td class="nump">6,100,000<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment', window );">Contingent consideration, changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Short term contingent considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanostringMember', window );">NanoString | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares issued in acquisition</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember', window );">Headquarters And Laboratory Facilities South San Francisco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturitySoldAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturitySoldAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldtomaturitySecuritiesSoldAtPar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), with interest rate reset through auction process, sold at par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldtomaturitySecuritiesSoldAtPar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale of investment in debt security measured at amortized cost (held-to-maturity), excluding other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_BusinessCombinationContingentConsiderationCashToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Cash To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_BusinessCombinationContingentConsiderationCashToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Fair Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vcyt_NanostringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vcyt_NanostringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767913360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurement Input (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.076<span></span>
</td>
<td class="nump">0.083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=vcyt_MeasurementInputProbabilityOfAchievementMember', window );">Probability of achievement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.80<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=vcyt_MeasurementInputProbabilityOfAchievementMember', window );">Probability of achievement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=vcyt_MeasurementInputProbabilityOfAchievementMember', window );">Probability of achievement | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.92<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vcyt_MeasurementInputProbabilityOfAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vcyt_MeasurementInputProbabilityOfAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094765493712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Discount rate</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance right-of-use assets</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Property, plant and equipment, net<span></span>
</td>
<td class="text">Property, plant and equipment, net<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liabilities</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember', window );">Headquarters And Laboratory Facilities South San Francisco and San Diego, California, Austin, Texas, Marseille, France and Richmond, Virginia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vcyt_FacilitiesInMarseilleFranceMember', window );">Facilities in Marseille, France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Term of lease</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount', window );">Annual rent</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Annual Undiscounted Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vcyt_FacilitiesInMarseilleFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vcyt_FacilitiesInMarseilleFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767937744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">4,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">4,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">15,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="nump">1,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="nump">13,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: short-term lease liabilities</a></td>
<td class="nump">4,076<span></span>
</td>
<td class="nump">$ 4,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 9,709<span></span>
</td>
<td class="nump">$ 10,648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094770520768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Operating Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 1,123<span></span>
</td>
<td class="nump">$ 1,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 1,177<span></span>
</td>
<td class="nump">$ 1,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767665712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total number of shares reserved for issuance (in shares)</a></td>
<td class="nump">13,620,056<span></span>
</td>
<td class="nump">12,809,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember', window );">Shares of common stock subject to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options issued and outstanding (in shares)</a></td>
<td class="nump">7,054,474<span></span>
</td>
<td class="nump">5,881,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">5,322,628<span></span>
</td>
<td class="nump">5,591,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">1,242,954<span></span>
</td>
<td class="nump">1,335,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vcyt_EmployeeAndNonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767945600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Other Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit', window );">French research tax credits</a></td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">$ 892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_OtherNonoperatingIncomeExpenseInterestIncome', window );">Interest income</a></td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_OtherNonoperatingIncomeExpenseInterestExpense', window );">Interest expense</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss', window );">Gain (loss) on currency revaluation</a></td>
<td class="nump">229<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vcyt_OtherNonoperatingIncomeExpenseOther', window );">Other</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 2,407<span></span>
</td>
<td class="nump">$ 784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Translation Gain (Loss), Nonoperating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Tax Credit, Nonoperating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_OtherNonoperatingIncomeExpenseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Nonoperating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_OtherNonoperatingIncomeExpenseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_OtherNonoperatingIncomeExpenseInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Interest Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_OtherNonoperatingIncomeExpenseInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vcyt_OtherNonoperatingIncomeExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vcyt_OtherNonoperatingIncomeExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vcyt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140094767763264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>vcyt-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:vcyt="http://www.veracyte.com/20230331"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vcyt-20230331.xsd" xlink:type="simple"/>
    <context id="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7847b145543840bd99af437751321cf8_I20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="i228462769a464129ba617b5c0e672ec2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i17d209f7b20f4172bb058631b2f4238e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i847532d1474b4753b04c345c4ed3d2bb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i872cd6a83fb94eeb96794042e25cae89_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:TestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3084d7ec4bd64f8eaabed4981928a134_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i635aa95b5b3a4c40abecbcbe6550bef2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if31dd8bd6f8b4fb3b8a6f145af4d5d59_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie309aab35ae147468bed50274b964061_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i95b8df0ff5f640d8a141c19c5bd881fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9dbd02e335643de8ce058f59321f616_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i924230acce20424dabe447ae137dbf83_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id752a28a43c4436681909d1cc3eed3b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id1881985bc124c028c3c3dbad3abd14b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i86fbf95cd4b5437dbec9986bc1144ec2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5753c1b61e2d42e58a2276f17d5fb19a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icf29b5a393ba4124abdaee15f6859cb8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if523cf067c5f4dbebed00daf0386fb51_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i55b285ff45524728a3082fa425970706_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia0d48f67cf5c4722884b1138ecc775f2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i87aca5bd093645dda8ac7488b345dc9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2f11f413da04f52830af895a72e45a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4e26fa70903498190d2e5c48dd87a5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a4723b9349f4234b5edb4fc1dd4f8b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e2e9b82dc8546598d4d83b5a9b32dcd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64c8dbded3c748c0ac0a7f3125954a4f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibc136e0ed6db40aa933f473850279a4c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib5aea6fc5bfd40498c71f885f3a5b84c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i906486b05220499884f0e0763ff0fcc5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ida3550a7c5734f6d9ca5aaf01e299960_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibff0ccc6162b425f8af12108f388f189_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ife0bc1a9501244b59b18b76ac93dbfb8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia60f7004a2544b82937e0bf55326ce59_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic43b0b3fe6664d3cbdb8a3f4f93ee2bd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i19f99811b32f40d18acdc45b83384992_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i32cc63b081d34737b7c09f18254a0369_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if73c87216b7e431cbb1a5132319fc1ba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iecc0d9d5bd4645f4a7aa6c4d79ddcca0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MajorCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icdbdbc6fb5304aa6a286a799abfdc7c5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MajorCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icadd7189bc5c4c3385082591611320f5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if563c75164164060aab1e980fe9c7b0b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic8ca971045914a1a9146c9113b0b663d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i35250c2e6deb44c4ac481dd4e6f612e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vcyt:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifd3b24d188c147d0894ca33558f96f88_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i998dea8702a44f32b783fad66ceaef6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i274a02acfdb5475dac6457d7c3ee154b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0ae14244c4fb41a999ccf232d576984d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2099bc12c8224f319528343bdffe545e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherContractManufacturingAndTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06548eac75174f9ca6d2b92d2d9f74ca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vcyt:BiopharmaceuticalAndOtherContractManufacturingAndTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81d34a4128834b43aa56aba5f1ba758a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1d63ecdd09ee4ceeb3894542f9e9a7b1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0cc183be53114cd5ae6844b58582cac8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iec98084255e1437ca83d101b89bdff0f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i03e5c566c2b44d13b38e3125968a69bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i87ca496310a4471fab481bd7a0025487_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie962846780634c4abb77f3207cab491b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if1c2bbdf5d7e4d15a0928f584d49978a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icdf1cd50fe084f529b3b433569983a49_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia23eed41b3e74c09a3af1063a3dfaaa4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:PerceptaProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i36048a1bd9c5433d93652f6da7dcba37_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4b268539086c467aab96e29940e65c30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic189876c9f5b49a491d19b401863e5c7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DevelopedProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if02c3ec7045e44e992b345c1c6f4e8db_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:ProsignaCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i45490cef3786448bb194a53c1a4925b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:ProsignaCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf00f1922dfe4be3ac3b55ead1c6f375_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:ProsignaCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id4759963ae1646649f60d583de01125c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterDxLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9a449a72bae04d50925d90a798163f1c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterDxLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c22e100729e4221b19089c051e020bd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:NCounterDxLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id96dd7074a874f3ab955a93c939fd0e2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:LymphmarkProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7b06dd23ef3c466caa291f27746d9f0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:LymphmarkProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2dd2214b7954827af13bad315eaeef6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:LymphmarkProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i465f5da059d4485493001b166d4b40d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBioSciencesProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibbaa1203aac34a38a5d064b5630c2dbc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBioSciencesProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e1a841c902147639f42aaf1fc24846c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBioSciencesProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if5af60edaf174d3dbf0da38ad4778d42_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBiosciencesTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id51f3fcca6344c0d8acf9827a75d098d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBiosciencesTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96b14c1a4f46482383ed19e470792768_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:DecipherBiosciencesTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id1ea9d43677e4c86b1d71be599ac6865_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDXDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9cf1b2134c6848bc8109d15f1016674a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDXDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43160a473e5b4aa6975f0c9b8f8a4911_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDXDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iac93bb77e6df4adebb1fce8ac3eb1425_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1d58f9fdd9f24ea7beeb7a99ed47f1fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibcf4b5a8d9ac4269b9a4b8890c7ae167_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if28f8ef0b3354ef5abe5718fad617afd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerBacklogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia17c0ca4207743efbafee0e3b75a8c67_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerBacklogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac056f15377a4e1a939745868f857e1d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vcyt:HalioDxCustomerBacklogMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i34f2f83e07404b9d85ed5e0e5c227d9a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07f2d93ca49a414380853162fba3a86c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia0afc28f37da46bb8ed8617d3e377f9d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3e25dbe0d25644d0a01543012862a8ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id21ec14e64244f3c9d1c3685ce9e8719_D20191203-20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="ie03a5b408d42420d880fd6b44b057d7b_D20191203-20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-03</startDate>
            <endDate>2019-12-03</endDate>
        </period>
    </context>
    <context id="ia65218b5801a4550bb42420dd8cece53_I20191203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-03</instant>
        </period>
    </context>
    <context id="i3c9422a55af4419da61a04b81e81fff6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i155fac1703104d38b903faacc0c23041_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i06680ff3bcf24e32836ef9479192a82f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i339749b1f05542c299fce2f9a4340ccf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vcyt:NanostringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6732d99af20b4ace884710631c821dc1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i56eb27109dad47bc902852a7e617ff8a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f89531611514010b1fddd2d6b74728c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibe50f34924204d0f9cb24feac29d3c92_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5b2066a3df0741c0a292648be37edb62_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic4ebc4a8eea343589c8c8c3823833416_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56240dd72d974100bdcfa48ff0885b32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d7ee7173c0f4858a01e1d1da5a312b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vcyt:MeasurementInputProbabilityOfAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib3cca4fb364f4aa1a78fc4dbfe0f75ee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vcyt:HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i38b169efb35741c0a4e5cbe287a00d95_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vcyt:FacilitiesInMarseilleFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idd87d5a6accd4b1fbbdd377429adeb05_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i41c953ff703f4c40b8196a40233b0bea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vcyt:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i589fe7123b7241eea985d689b319d8bb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibf67fe5c4e9c4625bf91b35cf11db759_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001384101</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>vcyt:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180L2ZyYWc6NzEyOTBjMTFiZmJiNDg3MDkzNzE4ODljOWNlMWU2OTEvdGFibGU6OTEzYjIxMjlkODcwNDY0OWFjOWQ3ZWRiMGFiNzEzNmUvdGFibGVyYW5nZTo5MTNiMjEyOWQ4NzA0NjQ5YWM5ZDdlZGIwYWI3MTM2ZV8zLTEtMS0xLTcyMTIz_813b4423-e3d9-4ffb-b92a-b111cd587d73">0001384101</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180L2ZyYWc6NzEyOTBjMTFiZmJiNDg3MDkzNzE4ODljOWNlMWU2OTEvdGFibGU6OTEzYjIxMjlkODcwNDY0OWFjOWQ3ZWRiMGFiNzEzNmUvdGFibGVyYW5nZTo5MTNiMjEyOWQ4NzA0NjQ5YWM5ZDdlZGIwYWI3MTM2ZV81LTEtMS0xLTcyMTIz_32962afa-c79e-4a24-be4d-adbb2d2c1936">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180L2ZyYWc6NzEyOTBjMTFiZmJiNDg3MDkzNzE4ODljOWNlMWU2OTEvdGFibGU6OTEzYjIxMjlkODcwNDY0OWFjOWQ3ZWRiMGFiNzEzNmUvdGFibGVyYW5nZTo5MTNiMjEyOWQ4NzA0NjQ5YWM5ZDdlZGIwYWI3MTM2ZV82LTEtMS0xLTcyMTIz_aea187cb-c8a6-44cd-aad7-5fd002ecdd50">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180L2ZyYWc6NzEyOTBjMTFiZmJiNDg3MDkzNzE4ODljOWNlMWU2OTEvdGFibGU6OTEzYjIxMjlkODcwNDY0OWFjOWQ3ZWRiMGFiNzEzNmUvdGFibGVyYW5nZTo5MTNiMjEyOWQ4NzA0NjQ5YWM5ZDdlZGIwYWI3MTM2ZV83LTEtMS0xLTcyMTIz_bbe675b9-bd70-4299-90b8-8a8d1e0e0d0a">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180L2ZyYWc6NzEyOTBjMTFiZmJiNDg3MDkzNzE4ODljOWNlMWU2OTEvdGFibGU6OTEzYjIxMjlkODcwNDY0OWFjOWQ3ZWRiMGFiNzEzNmUvdGFibGVyYW5nZTo5MTNiMjEyOWQ4NzA0NjQ5YWM5ZDdlZGIwYWI3MTM2ZV84LTEtMS0xLTcyMTIz_d2be12d3-14ba-418e-9650-9adf2887de0a">2023</dei:DocumentFiscalYearFocus>
    <us-gaap:DefinedBenefitPlanTypeExtensibleList
      contextRef="i81d34a4128834b43aa56aba5f1ba758a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_c42f36f4-4860-4a82-9f52-48c65e91ae48">http://fasb.org/us-gaap/2022#PensionPlansDefinedBenefitMember</us-gaap:DefinedBenefitPlanTypeExtensibleList>
    <us-gaap:DefinedBenefitPlanTypeExtensibleList
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_dbd24477-8f44-4199-93ad-3dfd106ab395">http://fasb.org/us-gaap/2022#PensionPlansDefinedBenefitMember</us-gaap:DefinedBenefitPlanTypeExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MQ_8dcd2a74-c451-48ee-8234-99b6286ac891">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MQ_b8e18883-b7ca-498a-8118-1cbdf8c548c4">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1Mg_135ebc69-b606-42ce-b152-da2f2dbc668a">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1Mg_7fac536f-70a2-4239-a5bf-1ba0e01d202a">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk4_d439d823-2918-4749-abb0-6a0258c4c3ff">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6YjFkOWU0YzIzNDhhNGU4Y2E1YTdhZTMzZjc1MTdhOTMvdGFibGVyYW5nZTpiMWQ5ZTRjMjM0OGE0ZThjYTVhN2FlMzNmNzUxN2E5M18wLTAtMS0xLTcyMTIz_e1d85394-cb08-4f32-9245-cd367ea86a67">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8xNDA_6b21e259-3cae-41f4-9dd9-75da197e2006">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NTk1OTgxM2FhNDI2NDk1OWIyNmU2MTA1YzAwYzNkMDUvdGFibGVyYW5nZTo1OTU5ODEzYWE0MjY0OTU5YjI2ZTYxMDVjMDBjM2QwNV8wLTAtMS0xLTcyMTIz_0f0b49b9-ec62-4b28-9e38-23af46ffd08e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk0_c3c5fcd4-0d0c-4773-9b63-7d6877b37c6b">001-36156</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTA1_87d75c35-9e9d-44a2-9d3c-8ac101534c8b">VERACYTE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NDU3ZWJiYTAwMGZmNDFhM2JjOGMyYmI1MDUyNTkyNzAvdGFibGVyYW5nZTo0NTdlYmJhMDAwZmY0MWEzYmM4YzJiYjUwNTI1OTI3MF8wLTAtMS0xLTcyMTIz_cfe2a17e-d1f8-4504-b911-934d2cec6804">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NDU3ZWJiYTAwMGZmNDFhM2JjOGMyYmI1MDUyNTkyNzAvdGFibGVyYW5nZTo0NTdlYmJhMDAwZmY0MWEzYmM4YzJiYjUwNTI1OTI3MF8wLTYtMS0xLTcyMTIz_91337ea8-046a-4a60-a66f-86574d1869b9">20-5455398</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk1_964c1bd1-973a-40bd-9401-2886f87f47fb">6000 Shoreline Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk5_352d906a-fd3e-47d5-8b27-5576f170bcab">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTA2_b8625da5-4f0f-45bb-8db0-d4e1f8e1cad9">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTAy_245b2a6e-92f3-4260-8bc0-d33dbe347155">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk2_f30d05fa-7871-4f1d-b972-2f1d326d049f">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTAw_502e3b19-c917-4392-94ff-9557c0edac7e">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTAz_5ad91def-8e9e-472e-84b1-cd53aa42f86e">243-6300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6ODIzYjRiOGFiZmE3NGIwZDg2ZGZkNmRjODY1NjhkZmIvdGFibGVyYW5nZTo4MjNiNGI4YWJmYTc0YjBkODZkZmQ2ZGM4NjU2OGRmYl8xLTAtMS0xLTcyMTIz_a266e165-65f2-4370-8457-54ab3ae4802e">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6ODIzYjRiOGFiZmE3NGIwZDg2ZGZkNmRjODY1NjhkZmIvdGFibGVyYW5nZTo4MjNiNGI4YWJmYTc0YjBkODZkZmQ2ZGM4NjU2OGRmYl8xLTQtMS0xLTcyMTIz_ee67cc66-9606-4ef1-bde3-925e9791bab2">VCYT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6ODIzYjRiOGFiZmE3NGIwZDg2ZGZkNmRjODY1NjhkZmIvdGFibGVyYW5nZTo4MjNiNGI4YWJmYTc0YjBkODZkZmQ2ZGM4NjU2OGRmYl8xLTgtMS0xLTcyMTIz_8b7a8db9-8b67-4868-9629-d9826c4502ea">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDk3_c4585fa4-6014-4a2a-a62f-ec79af94d3b8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMTA3_49103be7-8893-4fe5-80f7-a106501c2b60">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NTY0MzQ2MmQzNDlhNGRiNGJkZGYyMjEzMDg3MGVlMmMvdGFibGVyYW5nZTo1NjQzNDYyZDM0OWE0ZGI0YmRkZjIyMTMwODcwZWUyY18wLTAtMS0xLTcyMTIz_8fa679f0-6276-4adb-84fb-c33cf4db0952">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NTY0MzQ2MmQzNDlhNGRiNGJkZGYyMjEzMDg3MGVlMmMvdGFibGVyYW5nZTo1NjQzNDYyZDM0OWE0ZGI0YmRkZjIyMTMwODcwZWUyY18xLTQtMS0xLTcyMTIz_a7d000f2-945d-4fac-9adf-bbde3b196b4c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGFibGU6NTY0MzQ2MmQzNDlhNGRiNGJkZGYyMjEzMDg3MGVlMmMvdGFibGVyYW5nZTo1NjQzNDYyZDM0OWE0ZGI0YmRkZjIyMTMwODcwZWUyY18yLTQtMS0xLTcyMTIz_c7ee280d-123a-4361-ad54-9e4cfa57e085">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8xNjQ5MjY3NDQzNzgx_e85b03d6-2496-4fed-aa69-cb0ee207843a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7847b145543840bd99af437751321cf8_I20230501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xL2ZyYWc6MTBlZjIwMzg5MTljNDBjNGI4ZmQ1Y2JkYzY1MTk2MmEvdGV4dHJlZ2lvbjoxMGVmMjAzODkxOWM0MGM0YjhmZDVjYmRjNjUxOTYyYV8yMDI2_4636ac88-455f-4ef5-853a-30b59ce2622f"
      unitRef="shares">72417156</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNC0xLTEtMS03MjEyMw_0af09472-c39c-483e-b5ff-47f71a125753"
      unitRef="usd">177890000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNC0zLTEtMS03MjEyMw_b5ac76e6-1a39-454a-9f0f-72fa38a81f49"
      unitRef="usd">154247000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNS0xLTEtMS03MjEyMw_1ae90033-0d0d-4bde-b461-6d119aa2d74f"
      unitRef="usd">0</us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNS0zLTEtMS03MjEyMw_e057164c-02b8-4f1c-926e-e8f081bd16c8"
      unitRef="usd">24605000</us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNi0xLTEtMS03MjEyMw_c298bb18-4acc-40a5-9cb1-e2040fc95f2f"
      unitRef="usd">45489000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNi0zLTEtMS03MjEyMw_8b541bc9-a5a1-4b80-9b5a-3d08dce67a68"
      unitRef="usd">44021000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNy0xLTEtMS03MjEyMw_3c57cc4b-8a64-4762-b4ee-ef933e3437b5"
      unitRef="usd">13306000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNy0zLTEtMS03MjEyMw_0b75a240-ef5f-413d-81d0-d634b90dd67d"
      unitRef="usd">14294000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfOC0xLTEtMS03MjEyMw_1505cc91-f67e-4cc3-b8a2-7c698d7f786d"
      unitRef="usd">14818000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfOC0zLTEtMS03MjEyMw_0a6366f4-f5ce-4f21-982d-62b2c04d3398"
      unitRef="usd">11469000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfOS0xLTEtMS03MjEyMw_3acfe216-4f28-4fa9-ab6c-a13d93f9256f"
      unitRef="usd">251503000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfOS0zLTEtMS03MjEyMw_8aa71cec-b58d-4863-9985-cd283ff30c2e"
      unitRef="usd">248636000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTAtMS0xLTEtNzIxMjM_dc62a0a8-90a6-4f86-aab6-91dc1606c3fb"
      unitRef="usd">18072000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTAtMy0xLTEtNzIxMjM_d968474b-6279-4081-8557-0143ac2a7588"
      unitRef="usd">17702000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTEtMS0xLTEtNzIxMjM_29b3d9bc-9648-4dfa-a71d-a9d9a93c6aab"
      unitRef="usd">11308000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTEtMy0xLTEtNzIxMjM_a9553e15-c2f5-4e9b-91bd-47dec097f9b2"
      unitRef="usd">13160000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTItMS0xLTEtNzIxMjM_4949e208-76ba-4075-bdaf-5a845c2296e0"
      unitRef="usd">170226000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTItMy0xLTEtNzIxMjM_efa11fc6-e6bc-45bd-8307-80062f4f1aaf"
      unitRef="usd">174866000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTMtMS0xLTEtNzIxMjM_b8c55ccf-3b4b-4865-ad4d-bdb1c5625469"
      unitRef="usd">699718000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTMtMy0xLTEtNzIxMjM_a45bb413-99ad-4d59-875e-a5e0f3c2e312"
      unitRef="usd">695891000</us-gaap:Goodwill>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTQtMS0xLTEtNzIxMjM_f0add60b-f402-40c0-bd3f-45b4493f7116"
      unitRef="usd">749000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTQtMy0xLTEtNzIxMjM_dbbaf2b3-965b-4c0d-bd0c-9555a513e3a4"
      unitRef="usd">749000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTUtMS0xLTEtNzIxMjM_b0483da4-4395-4ef0-b598-b742ab071f48"
      unitRef="usd">5543000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTUtMy0xLTEtNzIxMjM_7b088412-3bde-4923-855e-a0951f06020b"
      unitRef="usd">5418000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTYtMS0xLTEtNzIxMjM_5053e811-906a-472b-a521-6e0f8436b252"
      unitRef="usd">1157119000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTYtMy0xLTEtNzIxMjM_8566ddf5-177b-45e7-a66e-4bccf6bc0b06"
      unitRef="usd">1156422000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTktMS0xLTEtNzIxMjM_38e3ca8c-cdab-4fda-984d-dc58ba7b1ef3"
      unitRef="usd">15655000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMTktMy0xLTEtNzIxMjM_8de4c7ea-bf48-4328-8b2e-0c19e0bc356c"
      unitRef="usd">11911000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjAtMS0xLTEtNzIxMjM_09ecf94f-1d5b-48ba-a9f9-47a47f771420"
      unitRef="usd">30641000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjAtMy0xLTEtNzIxMjM_39956a09-7bc6-4146-9020-74cbfc51bf66"
      unitRef="usd">37774000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjItMS0xLTEtNzIxMjM_137cd930-5da3-4ddf-b34d-1669d6ffbe4c"
      unitRef="usd">2194000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjItMy0xLTEtNzIxMjM_0d56c81b-a0e7-4501-b7ed-7b0567f3e5c0"
      unitRef="usd">2613000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjMtMS0xLTEtNzIxMjM_4b845b61-4f6e-472d-9c84-7a6712480b43"
      unitRef="usd">3300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjMtMy0xLTEtNzIxMjM_0b1c0fed-0ddf-4594-955a-1e20b95e5a6a"
      unitRef="usd">6060000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjQtMS0xLTEtNzIxMjM_f801684d-eeca-487d-ac38-dd2ea54e8dde"
      unitRef="usd">4076000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjQtMy0xLTEtNzIxMjM_eda64230-454e-4d2d-8162-49a30cdc785c"
      unitRef="usd">4070000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjUtMS0xLTEtNzIxMjM_7a267ed0-529f-41f7-a41e-29e42b1e6ea7"
      unitRef="usd">127000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjUtMy0xLTEtNzIxMjM_58cac4bd-4811-40df-96d0-78606fac6c3a"
      unitRef="usd">186000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjYtMS0xLTEtNzIxMjM_2b2411de-effc-4d7d-8b19-6ae5065b814c"
      unitRef="usd">55993000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjYtMy0xLTEtNzIxMjM_244cd885-2def-4c2c-945d-2c4335cd0824"
      unitRef="usd">62614000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjgtMS0xLTEtNzIxMjM_c0eaf193-fd72-4d1f-b95a-7be9a354cc01"
      unitRef="usd">4594000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjgtMy0xLTEtNzIxMjM_88209dca-c840-4bbc-b792-33432bec7ee8"
      unitRef="usd">4531000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjktMS0xLTEtNzIxMjM_2bb40bb6-da82-4580-907a-39e15f0b5005"
      unitRef="usd">4773000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMjktMy0xLTEtNzIxMjM_35366c10-4d4e-44f3-9ef9-0e70c244af96"
      unitRef="usd">2498000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzAtMS0xLTEtNzIxMjM_4727ae42-e6c3-4c64-b5d1-63501d60829f"
      unitRef="usd">9709000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzAtMy0xLTEtNzIxMjM_ee39c851-eae0-4356-8843-1e8a07b95c35"
      unitRef="usd">10648000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzEtMS0xLTEtNzIxMjM_5165b7b4-500c-41ac-af14-52229e7d8ee0"
      unitRef="usd">791000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzEtMy0xLTEtNzIxMjM_a716e531-dc4c-4693-a485-c370fbac2481"
      unitRef="usd">931000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzItMS0xLTEtNzIxMjM_51988161-66db-40f9-bfca-eeed61f8366d"
      unitRef="usd">75860000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzItMy0xLTEtNzIxMjM_71dcdae1-5de0-4db9-9a96-acfdf28302c3"
      unitRef="usd">81222000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzMtMS0xLTEtNzIxMjM_272c367f-04ea-4de8-a211-95da2c9f4f94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzMtMy0xLTEtNzIxMjM_a6d2f0f0-63f3-4db9-afc2-fdaf6bb18e8f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY18yMQ_b50ecd68-0f4a-44b1-884f-c700f6351deb"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY18yMQ_b6e9990d-38a7-4ae6-a358-5a4993571125"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY18zNQ_868fd9a1-f0eb-4c76-b1e7-4c0dde82e8e3"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY18zNQ_91e07a06-2b03-428c-a3bb-3ff17ce944ea"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY181Nw_307e9742-ec71-473f-b011-d9d45ebf81dc"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY181Nw_30b95715-f0c7-46e0-8f63-3b48ebeb6886"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY181Nw_7f10c862-e947-4a57-99ce-e52b1cc07d9c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjo2MjM5ZTBiMTQ4MzI0YmJmOGYyZjIyMjJhYmU3YjBhY181Nw_e9531449-50fb-408b-87f8-16a2c7e44306"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMS0xLTEtNzIxMjM_64fd44c9-dc06-4ba3-bfd9-5525cb8d5523"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzUtMy0xLTEtNzIxMjM_410aafbd-5f46-41cd-8682-52fa902831c9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N18xOA_2e33a767-2634-401d-89f5-3655487ac6ef"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N18xOA_395d0d1d-5a69-4a71-9e81-1b7a7be9b4b7"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N18zMg_3b14b437-2592-4285-aef3-c042e9022231"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N18zMg_3d4ced90-238a-46a2-936c-3941291d16a8"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N181NA_0b145ee2-17da-4673-bc64-96e60618ce55"
      unitRef="shares">72383140</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N181NA_4b5c50e1-09cd-4036-8388-8ecabb4da387"
      unitRef="shares">72383140</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N182MQ_baf72de7-cfb7-491c-a5c7-26ea35acdfdf"
      unitRef="shares">71959454</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMC0xLTEtNzIxMjMvdGV4dHJlZ2lvbjpiOGJiNWUxNjQyY2Y0NDY5OWQ0ODA2NWIwMzM2YzQ1N182MQ_c3f639f5-6da3-4334-b605-775bfff2b457"
      unitRef="shares">71959454</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMS0xLTEtNzIxMjM_27af53e5-5d5b-4eb7-84dd-dcbf9bc034b3"
      unitRef="usd">72000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzYtMy0xLTEtNzIxMjM_9d853f3e-df78-43da-86bb-5b4fc71a5359"
      unitRef="usd">72000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzctMS0xLTEtNzIxMjM_e620bbbf-9116-4b67-aba5-38c9aea4b7a9"
      unitRef="usd">1509861000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzctMy0xLTEtNzIxMjM_0ddb7d23-4f32-44db-b332-7ca4dd5888ae"
      unitRef="usd">1500191000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzgtMS0xLTEtNzIxMjM_3d316a43-fd8e-4ecb-8205-d6e6100ddfbf"
      unitRef="usd">-401808000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzgtMy0xLTEtNzIxMjM_178cf70e-f418-463e-89bc-e39e132a4bd5"
      unitRef="usd">-393717000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzktMS0xLTEtNzIxMjM_f1014249-b29c-4219-9b4b-93ab94e13897"
      unitRef="usd">-26866000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfMzktMy0xLTEtNzIxMjM_8f64d7cf-0c25-4210-a7c8-2afeef1589d4"
      unitRef="usd">-31346000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNDAtMS0xLTEtNzIxMjM_c9037085-7e20-4ac5-a4d7-a5bb667c780d"
      unitRef="usd">1081259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNDAtMy0xLTEtNzIxMjM_d635bbb7-68ba-4901-93e1-05b93d1ecb88"
      unitRef="usd">1075200000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNDEtMS0xLTEtNzIxMjM_e1eda4d6-d5f6-4dbd-a76a-754f1e653894"
      unitRef="usd">1157119000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xNi9mcmFnOjI2NTU5NjllNDA4NjRkZWI5MWM2YTEyNzhmOWRlZWM1L3RhYmxlOmU4NmI1MWRiOGNmMzQwMWM5ZWJjNWZkZmQxYjEyMzZlL3RhYmxlcmFuZ2U6ZTg2YjUxZGI4Y2YzNDAxYzllYmM1ZmRmZDFiMTIzNmVfNDEtMy0xLTEtNzIxMjM_c8335a61-6d43-4e7f-80bc-309cc39d758d"
      unitRef="usd">1156422000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i847532d1474b4753b04c345c4ed3d2bb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMy01LTEtMS03MjEyMw_f722fd99-86b5-4c56-903a-4dda50268f84"
      unitRef="usd">72396000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i872cd6a83fb94eeb96794042e25cae89_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMy03LTEtMS03MjEyMw_c5241d26-fb16-43d2-9a2b-a9370ce9f6a7"
      unitRef="usd">55980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3084d7ec4bd64f8eaabed4981928a134_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNC01LTEtMS03MjEyMw_257eaf5d-870e-4df6-86a7-f922800669ee"
      unitRef="usd">3892000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i635aa95b5b3a4c40abecbcbe6550bef2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNC03LTEtMS03MjEyMw_0108b800-58df-4968-a776-f769de0e801c"
      unitRef="usd">2979000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if31dd8bd6f8b4fb3b8a6f145af4d5d59_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNS01LTEtMS03MjEyMw_a098fe13-adca-4eee-aceb-1e9aba68b3d0"
      unitRef="usd">6134000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie309aab35ae147468bed50274b964061_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNS03LTEtMS03MjEyMw_019639da-d0a5-47ba-9f73-368be80e5568"
      unitRef="usd">8824000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNi01LTEtMS03MjEyMw_f9a7a63e-6084-4936-9ce6-d59fd491adf9"
      unitRef="usd">82422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfNi03LTEtMS03MjEyMw_a3f8ca13-90ae-48fb-bacd-cf4781a0bb14"
      unitRef="usd">67783000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="i847532d1474b4753b04c345c4ed3d2bb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfOC01LTEtMS03MjEyMw_26cbb4cb-4fcf-4011-9030-b32786d9c10e"
      unitRef="usd">19648000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i872cd6a83fb94eeb96794042e25cae89_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfOC03LTEtMS03MjEyMw_5c970b23-addb-448a-871a-de270a1d36a6"
      unitRef="usd">17523000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i3084d7ec4bd64f8eaabed4981928a134_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfOS01LTEtMS03MjEyMw_efed608f-a9c3-4ef4-9c11-fc07d4e73407"
      unitRef="usd">2162000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i635aa95b5b3a4c40abecbcbe6550bef2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfOS03LTEtMS03MjEyMw_3d21e1a4-bad5-4d72-9d2d-60c3d3b12220"
      unitRef="usd">1575000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="if31dd8bd6f8b4fb3b8a6f145af4d5d59_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTAtNS0xLTEtNzIxMjM_fdf4464f-b016-44ed-bbad-3cf7067da9d3"
      unitRef="usd">4419000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ie309aab35ae147468bed50274b964061_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTAtNy0xLTEtNzIxMjM_1c5f5a03-a01d-43db-abc2-655bcccadb7a"
      unitRef="usd">4615000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTEtNS0xLTEtNzIxMjM_17d2b9e7-3652-4f04-9809-f15688d17139"
      unitRef="usd">12769000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTEtNy0xLTEtNzIxMjM_3734fb3d-9038-449d-81c8-39de9d147623"
      unitRef="usd">9166000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTItNS0xLTEtNzIxMjM_0542a0dd-a1af-4d64-b14f-6e6f9bfaae61"
      unitRef="usd">26130000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTItNy0xLTEtNzIxMjM_6d6d87ee-c921-4ff7-8c99-8150e01e39ba"
      unitRef="usd">23754000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTMtNS0xLTEtNzIxMjM_2c52c6bc-856d-4abc-96d7-368029c8e315"
      unitRef="usd">22463000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTMtNy0xLTEtNzIxMjM_bb3ef2d4-fef8-4197-b490-cb2212f09299"
      unitRef="usd">20912000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTQtNS0xLTEtNzIxMjM_653b5235-b90b-4349-8246-f829803292d5"
      unitRef="usd">5329000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTQtNy0xLTEtNzIxMjM_50254451-e117-439a-831f-efa34128fe68"
      unitRef="usd">5486000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTUtNS0xLTEtNzIxMjM_7b31d0c5-5357-4a55-8554-8c37ae23ca01"
      unitRef="usd">92920000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTUtNy0xLTEtNzIxMjM_46e90251-63c5-402c-97fe-12ff429ac2f6"
      unitRef="usd">83031000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTYtNS0xLTEtNzIxMjM_2fd3eb17-edc3-481b-ad3b-38330e078792"
      unitRef="usd">-10498000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTYtNy0xLTEtNzIxMjM_9cb1e05b-dd10-4319-8063-c9f2f7832e0e"
      unitRef="usd">-15248000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTctNS0xLTEtNzIxMjM_757485e6-fdf4-4330-9c25-cefd3e54d9ff"
      unitRef="usd">2407000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTctNy0xLTEtNzIxMjM_fe8126ad-1b22-4c14-b06e-8b8ce635eb89"
      unitRef="usd">784000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTgtNS0xLTEtNzIxMjM_b5606177-9cfb-4fa7-97b3-5baacc2b4d61"
      unitRef="usd">-8091000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTgtNy0xLTEtNzIxMjM_e59331c1-ed4d-41c9-a19b-67e70706881d"
      unitRef="usd">-14464000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTktNS0xLTEtNzIxMjM_0cd2f45d-d481-45e4-bb62-df78340ea0aa"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMTktNy0xLTEtNzIxMjM_c4cdc3f7-82c7-4eb8-9535-ff778270ba43"
      unitRef="usd">-3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjAtNS0xLTEtNzIxMjM_6a9c5d47-536f-4b0a-b5aa-703c471fe57b"
      unitRef="usd">-8091000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjAtNy0xLTEtNzIxMjM_1375711f-1691-494b-9e0a-c3e21adb9f86"
      unitRef="usd">-14461000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjEtNS0xLTEtNzIxMjM_3cb52f6d-147d-487e-a7cc-fd4cb43ccb47"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjEtNS0xLTEtNzIxMjM_54738b51-6878-4a87-bb14-3a3ef9db4cfb"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjEtNy0xLTEtNzIxMjM_0aea3854-9985-4366-bbbc-2d26c0a09803"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjEtNy0xLTEtNzIxMjM_b7747972-9551-496f-bfdc-684c4ddf1dd7"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjItNS0xLTEtNzIxMjM_0043e872-ff36-4ab2-aeca-f48490d9f50f"
      unitRef="shares">72175457</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjItNS0xLTEtNzIxMjM_41027c96-5166-4589-9f09-677a4db74813"
      unitRef="shares">72175457</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjItNy0xLTEtNzIxMjM_013bd912-61aa-4fc3-933e-d7d2b91ba052"
      unitRef="shares">71229672</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18xOS9mcmFnOjkxNWRiZGQ0NTJmYjQ0OTBiMzVlOTFkMTE5MDgwMTg4L3RhYmxlOjc1Y2ZhMzMwZGMzMzQ0NWM4MDkxYzc5NWE1MTc1MzQzL3RhYmxlcmFuZ2U6NzVjZmEzMzBkYzMzNDQ1YzgwOTFjNzk1YTUxNzUzNDNfMjItNy0xLTEtNzIxMjM_d498e6d6-dd00-4589-8d25-a0124dce9148"
      unitRef="shares">71229672</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfMi01LTEtMS03MjEyMw_955a9343-3373-49fc-8d09-a301bc2ca2c7"
      unitRef="usd">-8091000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfMi03LTEtMS03MjEyMw_aac607bb-3926-42c4-a95f-e6fa2dadcacc"
      unitRef="usd">-14461000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfNC01LTEtMS03MjEyMw_c0f4f68a-0234-4e29-8ef2-6f16f24fccfa"
      unitRef="usd">4480000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfNC03LTEtMS03MjEyMw_f8016e27-fbd8-4ad9-ad77-16c678e9a331"
      unitRef="usd">-5598000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfMTMtNS0xLTEtNzIxMjM_3d852e73-55de-409a-91a1-b680a6a43ba2"
      unitRef="usd">-3611000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yMi9mcmFnOmZjMjc1ZjgyMWU3MTQ0YTI5NjMxYjdmYTg3YzIwZTcxL3RhYmxlOmI4NDBhY2I4NDUyMzRmZTBhODEzMTNiNTY5ZDc0ZWNkL3RhYmxlcmFuZ2U6Yjg0MGFjYjg0NTIzNGZlMGE4MTMxM2I1NjlkNzRlY2RfMTMtNy0xLTEtNzIxMjM_5b6c11a1-1332-411a-9e04-e9410330a68c"
      unitRef="usd">-20059000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i95b8df0ff5f640d8a141c19c5bd881fa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi0xLTEtMS03MjEyMw_c5e53a76-1492-4ce4-a059-a490c553ea7e"
      unitRef="shares">71959000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i95b8df0ff5f640d8a141c19c5bd881fa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi0zLTEtMS03MjEyMw_e06d3a57-b8f4-408e-ad42-001ff891a566"
      unitRef="usd">72000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9dbd02e335643de8ce058f59321f616_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi01LTEtMS03MjEyMw_701373c4-82ef-4fcc-8ea1-ab781a05eb08"
      unitRef="usd">1500191000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i924230acce20424dabe447ae137dbf83_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi03LTEtMS03MjEyMw_576cbf11-89c1-4c9e-a478-5db8ecae0744"
      unitRef="usd">-393717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id752a28a43c4436681909d1cc3eed3b6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi05LTEtMS03MjEyMw_111a3dd5-5d74-474e-966a-d6ad21b15780"
      unitRef="usd">-31346000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMi0xMS0xLTEtNzIxMjM_d9a75cb3-e769-49dc-bb3c-1fe18096a749"
      unitRef="usd">1075200000</us-gaap:StockholdersEquity>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod
      contextRef="id1881985bc124c028c3c3dbad3abd14b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMy0xLTEtMS03MjEyMw_0f0fb91f-0e06-494a-a47e-56ca4a6478a8"
      unitRef="shares">332000</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod
      contextRef="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMy01LTEtMS03MjEyMw_f122401a-f209-4641-82d9-2f3bee801d13"
      unitRef="usd">1988000</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMy0xMS0xLTEtNzIxMjM_26945744-56a4-429a-921e-d6c693b35c26"
      unitRef="usd">1988000</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id1881985bc124c028c3c3dbad3abd14b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNC0xLTEtMS03MjEyMw_fdc09717-196d-4eed-a9de-db64fe1faea9"
      unitRef="shares">92000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNC01LTEtMS03MjEyMw_2855477b-0873-425b-a262-63f4f74f562c"
      unitRef="usd">1974000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNC0xMS0xLTEtNzIxMjM_cdf147a8-4d80-47ab-be97-e824773fe4ee"
      unitRef="usd">1974000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNS01LTEtMS03MjEyMw_8d14ddea-8f8a-4b41-b592-32faf0165029"
      unitRef="usd">2277000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNS0xMS0xLTEtNzIxMjM_cb2191ed-ca00-4cee-b5ac-619fdf8deeeb"
      unitRef="usd">2277000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNi01LTEtMS03MjEyMw_8aac44ac-8c0e-45a9-b409-7bc48bd8cfef"
      unitRef="usd">7612000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfNi0xMS0xLTEtNzIxMjM_cf9876ea-3590-49a7-b3a4-e8d06969e0ae"
      unitRef="usd">7612000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="ic9be9ce139634431ac1ea9e11aadf94e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfOC01LTEtMS03MjEyMw_2c85bd90-0055-4c92-beda-e2fe887d6717"
      unitRef="usd">373000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfOC0xMS0xLTEtNzIxMjM_e7062e3b-a199-4c87-8ffc-fe805831c7d8"
      unitRef="usd">373000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <us-gaap:NetIncomeLoss
      contextRef="i86fbf95cd4b5437dbec9986bc1144ec2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfOS03LTEtMS03MjEyMw_31a48bf8-4d3e-4ca3-a3fd-4705907b02a1"
      unitRef="usd">-8091000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfOS0xMS0xLTEtNzIxMjM_1e528ff8-7f74-4ed6-a6d3-b1d2bffef7cb"
      unitRef="usd">-8091000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5753c1b61e2d42e58a2276f17d5fb19a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTAtOS0xLTEtNzIxMjM_4cc72460-6ccf-42e0-acc2-1c174ae7711d"
      unitRef="usd">4480000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTAtMTEtMS0xLTcyMTIz_105db9ec-191d-4252-ab83-65cb4e79710e"
      unitRef="usd">4480000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="icf29b5a393ba4124abdaee15f6859cb8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtMS0xLTEtNzIxMjM_fa90cc53-1bc8-4cbf-9ef4-b7f05b320ae3"
      unitRef="shares">72383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icf29b5a393ba4124abdaee15f6859cb8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtMy0xLTEtNzIxMjM_5fa11d99-5010-48b0-9bca-b48eb61d32f3"
      unitRef="usd">72000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if523cf067c5f4dbebed00daf0386fb51_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtNS0xLTEtNzIxMjM_339c3c52-57b9-41fb-98e7-c1a902b0ddc8"
      unitRef="usd">1509861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55b285ff45524728a3082fa425970706_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtNy0xLTEtNzIxMjM_83e8d322-573e-4f2d-8a3c-558cdaa6ad02"
      unitRef="usd">-401808000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0d48f67cf5c4722884b1138ecc775f2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtOS0xLTEtNzIxMjM_2b203843-4fa3-455f-bb7d-d22a3e04429d"
      unitRef="usd">-26866000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOjUxMjRiMjQ5YTRkZDRmMWQ5NDNhYzg3MDAwN2EzN2Q5L3RhYmxlcmFuZ2U6NTEyNGIyNDlhNGRkNGYxZDk0M2FjODcwMDA3YTM3ZDlfMTEtMTEtMS0xLTcyMTIz_4bd79324-09b4-41bf-b2eb-8cd1bd030a3e"
      unitRef="usd">1081259000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i87aca5bd093645dda8ac7488b345dc9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi0xLTEtMS03MjEyMw_bb5bc304-dcc6-4baf-83b0-5a1d90a84e40"
      unitRef="shares">71123000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i87aca5bd093645dda8ac7488b345dc9f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi0zLTEtMS03MjEyMw_a54e9546-5985-409e-b5d7-cfa1334154cc"
      unitRef="usd">71000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2f11f413da04f52830af895a72e45a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi01LTEtMS03MjEyMw_c8acb343-545a-42db-a8c9-4a826888a211"
      unitRef="usd">1468683000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie4e26fa70903498190d2e5c48dd87a5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi03LTEtMS03MjEyMw_cb5b38c8-3a2a-4c9f-b48b-7d16ae818af8"
      unitRef="usd">-357157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a4723b9349f4234b5edb4fc1dd4f8b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi05LTEtMS03MjEyMw_ba154676-9ab2-4b37-a2c4-e47e9b4f0995"
      unitRef="usd">-15083000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e2e9b82dc8546598d4d83b5a9b32dcd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMi0xMS0xLTEtNzIxMjM_ef36e939-da70-41e8-8458-2c7243eb499a"
      unitRef="usd">1096514000</us-gaap:StockholdersEquity>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod
      contextRef="i64c8dbded3c748c0ac0a7f3125954a4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNC0xLTEtMS03MjEyMw_f6e78e4a-ab11-4a0d-b7be-8bc16b25654a"
      unitRef="shares">228000</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod
      contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNC01LTEtMS03MjEyMw_bc332ae3-10b5-45e7-969c-7537e8b1e180"
      unitRef="usd">1422000</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod>
    <vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNC0xMS0xLTEtNzIxMjM_4fd8594f-6019-4466-b968-a3d6fe885f1c"
      unitRef="usd">1422000</vcyt:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i64c8dbded3c748c0ac0a7f3125954a4f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNS0xLTEtMS03MjEyMw_b344378c-9e71-47ed-8ea3-d23b79e5b92b"
      unitRef="shares">82000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNS01LTEtMS03MjEyMw_72e4e70c-2da2-4d9b-9575-4ac81ebed653"
      unitRef="usd">2115000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNS0xMS0xLTEtNzIxMjM_438d50ef-bbe5-4de4-a509-09037aed396c"
      unitRef="usd">2115000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNi01LTEtMS03MjEyMw_fc693685-9d6b-40aa-a871-a3c113bd7742"
      unitRef="usd">1447000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNi0xMS0xLTEtNzIxMjM_7398d40c-0562-4fc5-8efc-36d5f959bf94"
      unitRef="usd">1447000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNy01LTEtMS03MjEyMw_d4d7e57b-f01e-4264-95ee-f6ff1f31e10b"
      unitRef="usd">6230000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfNy0xMS0xLTEtNzIxMjM_4f85c6bd-840b-4531-925c-813e379c9b86"
      unitRef="usd">6230000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee
      contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfOC01LTEtMS03MjEyMw_2cbb2043-c486-426d-9d60-aa55efb1b994"
      unitRef="usd">11000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfOC0xMS0xLTEtNzIxMjM_3acb530f-f8d7-4f0c-b0db-7c2042dc8135"
      unitRef="usd">11000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="i9d0e1836df2841ce8998d1e4198775f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfOS01LTEtMS03MjEyMw_e6ca7184-a6e8-4490-a464-c0b926f615fa"
      unitRef="usd">404000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfOS0xMS0xLTEtNzIxMjM_c6e2067b-109f-4fa6-8cae-8cc6d5af4494"
      unitRef="usd">404000</vcyt:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP>
    <us-gaap:NetIncomeLoss
      contextRef="ibc136e0ed6db40aa933f473850279a4c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTAtNy0xLTEtNzIxMjM_8bbd4075-413e-4662-bd88-5320d4db3ece"
      unitRef="usd">-14461000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTAtMTEtMS0xLTcyMTIz_b832a6c0-1344-4ecf-ab4e-e5e27970dc81"
      unitRef="usd">-14461000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib5aea6fc5bfd40498c71f885f3a5b84c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTEtOS0xLTEtNzIxMjM_baa066a6-ef64-4477-a76e-e26602ea7f29"
      unitRef="usd">-5598000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTEtMTEtMS0xLTcyMTIz_288f653e-0cf1-4f0b-9c42-00781cf05890"
      unitRef="usd">-5598000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i906486b05220499884f0e0763ff0fcc5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItMS0xLTEtNzIxMjM_2a0cd007-eb58-4c02-b53a-6a3a9ade8f87"
      unitRef="shares">71433000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i906486b05220499884f0e0763ff0fcc5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItMy0xLTEtNzIxMjM_5910fac1-281f-4ac5-9652-aee56963ef99"
      unitRef="usd">71000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida3550a7c5734f6d9ca5aaf01e299960_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItNS0xLTEtNzIxMjM_bd98594c-9104-4486-a246-e0eebb17060b"
      unitRef="usd">1477418000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibff0ccc6162b425f8af12108f388f189_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItNy0xLTEtNzIxMjM_51f02e90-92d7-44dc-ad3e-2d15e8abe362"
      unitRef="usd">-371618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife0bc1a9501244b59b18b76ac93dbfb8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItOS0xLTEtNzIxMjM_b0f6ce59-7906-47dd-a60e-4d38fb479f35"
      unitRef="usd">-20681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia60f7004a2544b82937e0bf55326ce59_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yNS9mcmFnOjBiZTEyMmZkZWI2MzQxNmNiYmMyY2JmYzQ2MzY0OTVmL3RhYmxlOmNmMDBkODE0NDI5NjQzMzhiOGIzZTJjN2JkYTE5NjEyL3RhYmxlcmFuZ2U6Y2YwMGQ4MTQ0Mjk2NDMzOGI4YjNlMmM3YmRhMTk2MTJfMTItMTEtMS0xLTcyMTIz_f7ee08a1-53b5-48ed-a198-3d08a35bf79d"
      unitRef="usd">1085190000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMy0xLTEtMS03MjEyMw_e4fa74b7-2d7d-4a74-a970-173b7d8a362f"
      unitRef="usd">-8091000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMy0zLTEtMS03MjEyMw_8197a9c4-7dba-47f9-9f85-56b4a08f7031"
      unitRef="usd">-14461000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNS0xLTEtMS03MjEyMw_9a538204-fd4b-49cf-83af-fe2e1c20158c"
      unitRef="usd">6670000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNS0zLTEtMS03MjEyMw_ce30d9f2-3b82-496f-8613-a9cafe50a273"
      unitRef="usd">6556000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNi0xLTEtMS03MjEyMw_a587d4eb-767c-4bb3-9d59-37d75ad2da69"
      unitRef="usd">-121000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNi0zLTEtMS03MjEyMw_70873d1f-a613-4cbe-ae90-b7860eb53722"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNy0xLTEtMS03MjEyMw_988a2b61-fd25-425a-8cca-1b71ea8eb7b5"
      unitRef="usd">7985000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNy0zLTEtMS03MjEyMw_e3343a0d-d7ba-4ce8-af35-06491775ac34"
      unitRef="usd">6645000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfOC0xLTEtMS03MjEyMw_e0f1f5cb-a114-4045-b038-fe9d6705b1d7"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfOC0zLTEtMS03MjEyMw_60a8a1a5-7d34-4840-86c4-68870daf7383"
      unitRef="usd">-3000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <vcyt:DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfOS0xLTEtMS03MjEyMw_13ba3b4f-43d4-4ebb-ad7c-ce05ca1edda7"
      unitRef="usd">0</vcyt:DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty>
    <vcyt:DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfOS0zLTEtMS03MjEyMw_ff9d6cce-e7f9-49ef-832b-649f77e9b0a9"
      unitRef="usd">53000</vcyt:DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty>
    <vcyt:NoncashLeaseExpense
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTAtMS0xLTEtNzIxMjM_a4f385a2-f48f-4dd6-9ecc-c9b6264b8134"
      unitRef="usd">903000</vcyt:NoncashLeaseExpense>
    <vcyt:NoncashLeaseExpense
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTAtMy0xLTEtNzIxMjM_0be43d5e-2cac-49bb-b62d-c064f9aa3e04"
      unitRef="usd">587000</vcyt:NoncashLeaseExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTEtMS0xLTEtNzIxMjM_e17277e9-bc77-418b-877d-2e33a08f051f"
      unitRef="usd">-485000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTEtMy0xLTEtNzIxMjM_fd75b786-f793-4096-a77e-37401fceca45"
      unitRef="usd">31000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTItMS0xLTEtNzIxMjM_ad1e2820-a1c7-4eef-846f-2b4a7a62ef39"
      unitRef="usd">224000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTItMy0xLTEtNzIxMjM_8a927eaa-c2c9-4e75-b1d3-f99191059363"
      unitRef="usd">-131000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:AssetImpairmentCharges
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTMtMS0xLTEtNzIxMjM_f6fff5ba-c245-498a-ac92-1d9be45de868"
      unitRef="usd">1410000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTMtMy0xLTEtNzIxMjM_c26bfaff-c614-4983-a1bc-aad65ffe4a26"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTUtMS0xLTEtNzIxMjM_8b7e0f84-ce5f-40cf-89df-f37b89da3fc6"
      unitRef="usd">1302000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTUtMy0xLTEtNzIxMjM_3d33a84d-0c09-497c-9533-a3446f5c96be"
      unitRef="usd">3575000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTYtMS0xLTEtNzIxMjM_2621f272-273c-4d56-80ac-ecfa703df939"
      unitRef="usd">-1055000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTYtMy0xLTEtNzIxMjM_0dfbb07a-5d0b-4ae6-8c03-98e81301f232"
      unitRef="usd">1201000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTctMS0xLTEtNzIxMjM_f25832d4-d06d-4164-9fff-c233d2be66c2"
      unitRef="usd">3064000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTctMy0xLTEtNzIxMjM_798fa0f5-5b89-4fd1-83ea-81d70ee3ab2a"
      unitRef="usd">2139000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTgtMS0xLTEtNzIxMjM_00b24894-1adb-45c9-a0ee-d262dedc50fc"
      unitRef="usd">491000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTgtMy0xLTEtNzIxMjM_d6b530e6-ffee-4df7-9c2e-aa7293cbe570"
      unitRef="usd">-451000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTktMS0xLTEtNzIxMjM_ff86325d-b82a-43ca-bf9d-5d6e2fc61dc6"
      unitRef="usd">-950000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMTktMy0xLTEtNzIxMjM_4ff278df-9244-43ed-b60a-15d778da90d6"
      unitRef="usd">-597000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjAtMS0xLTEtNzIxMjM_1d5e9392-1026-409c-af29-0c6b7fc331d4"
      unitRef="usd">2012000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjAtMy0xLTEtNzIxMjM_8f8780b1-2579-4c04-8f3d-e23c6f0ccaf4"
      unitRef="usd">-960000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjEtMS0xLTEtNzIxMjM_8f48cece-b527-46fe-bcf6-8338ca203a7c"
      unitRef="usd">-7721000</vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue>
    <vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjEtMy0xLTEtNzIxMjM_eb9b6283-0112-4470-9f7e-68099c96ddde"
      unitRef="usd">-390000</vcyt:IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjItMS0xLTEtNzIxMjM_beef1b7a-8f0f-409e-93b6-8619886b0795"
      unitRef="usd">-2172000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjItMy0xLTEtNzIxMjM_031b7600-870d-4d83-a44a-df7ed2eabc73"
      unitRef="usd">-8872000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjYtMS0xLTEtNzIxMjM_59670a8e-04bf-4d7f-932d-bbf99819c6fe"
      unitRef="usd">19700000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjYtMy0xLTEtNzIxMjM_f68043f4-4ae5-4113-8ead-f92910aaf4f8"
      unitRef="usd">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjctMS0xLTEtNzIxMjM_f722c773-f071-4d96-b049-98f451db7e18"
      unitRef="usd">39773000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjctMy0xLTEtNzIxMjM_3b2dfc6b-2cb6-4320-b433-e5e61df12d78"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjgtMS0xLTEtNzIxMjM_cc000e24-25de-48db-adad-4bab22261c0f"
      unitRef="usd">5000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMjgtMy0xLTEtNzIxMjM_498542f0-50da-49eb-979c-40d2cd1a035b"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzAtMS0xLTEtNzIxMjM_18b76372-6da7-4ff5-8e5a-c899feceeeb7"
      unitRef="usd">993000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzAtMy0xLTEtNzIxMjM_c1d63b8a-fb54-4ecb-8c60-4d8f23daf28d"
      unitRef="usd">2453000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzEtMS0xLTEtNzIxMjM_abd61eb5-95c2-4ba5-8a27-192f3260a810"
      unitRef="usd">24080000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzEtMy0xLTEtNzIxMjM_50cc9de7-aacd-4ae2-ba75-30ce18e30038"
      unitRef="usd">-2453000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzQtMS0xLTEtNzIxMjM_6da8c725-3fa9-4f6f-a1e9-b6998904f162"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzQtMy0xLTEtNzIxMjM_dbf2c281-a9f7-44e2-9e18-e464fbca8d8d"
      unitRef="usd">100000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzUtMS0xLTEtNzIxMjM_be31e1e9-2a29-4b63-adb6-a5a1ef5a8f20"
      unitRef="usd">2277000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzUtMy0xLTEtNzIxMjM_1e274a0e-1f27-4801-af10-a397876e4a8c"
      unitRef="usd">1447000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzYtMS0xLTEtNzIxMjM_f81dce3d-837c-497b-86b4-3dcd88295907"
      unitRef="usd">3962000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzYtMy0xLTEtNzIxMjM_de0be713-0b39-41c4-a94e-5bbe991d77e8"
      unitRef="usd">3537000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzctMS0xLTEtNzIxMjM_253fc396-d625-4c06-b0a9-ad97e8314a05"
      unitRef="usd">1685000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzctMy0xLTEtNzIxMjM_dbee56c6-6706-4692-8898-8def4f797f8b"
      unitRef="usd">1990000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzgtMS0xLTEtNzIxMjM_81bb48b6-9aee-40fb-9221-1791b7a62499"
      unitRef="usd">23593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzgtMy0xLTEtNzIxMjM_9bdf7c1b-61f4-4978-a9b6-e6ff8f5885f5"
      unitRef="usd">-9335000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzktMS0xLTEtNzIxMjM_c423fccb-18ac-4714-b265-1b5d3d185909"
      unitRef="usd">50000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfMzktMy0xLTEtNzIxMjM_a5aa0a92-6d15-45b0-b768-b48ff0743358"
      unitRef="usd">-247000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDAtMS0xLTEtNzIxMjM_99c14cf2-682e-4ade-8f9d-c5ea5cf8931a"
      unitRef="usd">23643000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDAtMy0xLTEtNzIxMjM_634d2047-2628-486e-b763-4753f64902d5"
      unitRef="usd">-9582000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDEtMS0xLTEtNzIxMjM_19533cde-86a6-4c98-a0a5-f6ddb9be7f93"
      unitRef="usd">154996000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9e2e9b82dc8546598d4d83b5a9b32dcd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDEtMy0xLTEtNzIxMjM_0c8ce6bb-4dc4-4163-b16a-600ae1ac21d0"
      unitRef="usd">173946000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDItMS0xLTEtNzIxMjM_cbc2b2e3-d3f3-43a3-bf3d-a79224c26e9b"
      unitRef="usd">178639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia60f7004a2544b82937e0bf55326ce59_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDItMy0xLTEtNzIxMjM_2d016552-d26c-496f-94da-18c0b498f239"
      unitRef="usd">164364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDQtMS0xLTEtNzIxMjM_999ab3be-9230-43a9-8596-7ca8acffca38"
      unitRef="usd">1624000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjIyZmI5NTlkYTNmMDRjMGM4MDZjYjY5MjEyYzNhNDYyL3RhYmxlcmFuZ2U6MjJmYjk1OWRhM2YwNGMwYzgwNmNiNjkyMTJjM2E0NjJfNDQtMy0xLTEtNzIxMjM_3e5d6c04-3e03-4592-b070-8e7f437d728c"
      unitRef="usd">342000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMS0xLTEtMS03MjEyMw_389316a3-7cec-4657-8859-f12383b6fd32"
      unitRef="usd">177890000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMS0zLTEtMS03MjEyMw_569a74a9-a8c9-4ead-bc71-f1a9d11112df"
      unitRef="usd">154247000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMi0xLTEtMS03MjEyMw_7b29eecf-d74a-49d0-bb46-f208fba5548d"
      unitRef="usd">749000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMi0zLTEtMS03MjEyMw_bbf0a461-aabb-4ba8-81e1-5c35bb8a41fd"
      unitRef="usd">749000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMy0xLTEtMS03MjEyMw_59f17f1f-d112-4793-961e-e593ff9eec2b"
      unitRef="usd">178639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18yOC9mcmFnOjQ4OTQ2ZDE0YTI1NDRjNmRhZjAxYTg1YjFlMDJkNTg2L3RhYmxlOjg3MmI1ZTAxZTJhNDRjYjY4ZGY2MWIyN2E1M2YxMTg4L3RhYmxlcmFuZ2U6ODcyYjVlMDFlMmE0NGNiNjhkZjYxYjI3YTUzZjExODhfMy0zLTEtMS03MjEyMw_54702027-6518-43c5-9317-996ee3fb690b"
      unitRef="usd">154996000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDI_1f4d7ebd-d901-44fb-9f00-25fef6f0b686">Organization, Description of Business and Summary of Significant Accounting Policies&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Veracyte, Inc., or Veracyte, or the Company, is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Veracyte's high-performing tests enable clinicians to make more confident diagnostic, prognostic and treatment decisions, helping patients avoid unnecessary procedures and interventions, and speed time to appropriate treatment, thereby improving outcomes for patients all over the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Veracyte was incorporated in the state of Delaware on August 15, 2006, as Calderome, Inc. Calderome operated as an incubator until early 2008. On March 4, 2008, the Company changed its name to Veracyte, Inc. The Company&#x2019;s headquarters are in South San Francisco, California, and it also has operations in San Diego, California; Austin, Texas; and Marseille, France. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently offers tests in thyroid cancer (Afirma); prostate cancer (Decipher Prostate); breast cancer (Prosigna); interstitial lung diseases (Envisia); and bladder cancer (Decipher Bladder). The Company&#x2019;s Percepta Nasal Swab test is being run in its CLIA lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company serves global markets with two complementary models. In the United States, it offers laboratory developed tests, or LDTs, through its centralized, Clinical Laboratory Improvement Amendments of 1988, or CLIA, certified laboratories in South San Francisco and San Diego, California, supported by its cytopathology expertise in Austin, Texas. Additionally, primarily outside of the United States, the Company provides its Prosigna test to patients through distribution to laboratories and hospitals that can perform the tests locally as an in vitro diagnostic, or IVD, test that runs on the nCounter Analysis System.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of March&#160;31, 2023, the condensed consolidated statements of operations for the three months ended March&#160;31, 2023 and 2022, the condensed consolidated statements of comprehensive loss for the three months ended March&#160;31, 2023 and 2022, the condensed consolidated statements of stockholders' equity for the three months ended March&#160;31, 2023 and 2022, and the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results, stockholders' equity and cash flows for the periods presented. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from audited financial statements. The results for the three months ended March&#160;31, 2023 are not indicative of the results expected for the full year or any other period. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.  The Company operates in one segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim period condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property, plant and equipment; the recoverability of long-lived assets; the incremental borrowing rates for leases; accounting for acquisitions; the estimation of the fair value of intangible assets and contingent consideration; stock based compensation; income tax uncertainties, including a valuation allowance for deferred tax assets; credit related losses on investments; and allowance for credit losses and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have. As a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company&#x2019;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict. If the financial markets or the overall economy are impacted for an extended period, the Company&#x2019;s liquidity, revenue, supplies, goodwill and intangibles may be adversely affected. The Company considers the effects, to the extent knowable, of the COVID-19 pandemic in developing its estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s cash and cash equivalents are deposited with two major financial institutions in the United States. Deposits in these institutions may exceed the amount of insurance provided on such deposits. The Company has not realized any losses on its deposits of cash and cash equivalents other than exchange rate losses related to foreign currency denominated accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several of the components of the Company&#x2019;s sample collection kits and test reagents, and the nCounter system and related diagnostic kits, are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company&#x2019;s requirements on a timely basis, or are unable to provide the Company with reagents that perform to specifications, the Company could suffer delays in being able to deliver its diagnostic solutions, suffer a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through March&#160;31, 2023, the Company has derived most of its revenue from the sale of Decipher and Afirma testing. To date, Decipher and Afirma testing have been delivered primarily to physicians in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect. The Company generally does not perform evaluations of customers&#x2019; financial condition for testing revenue and generally does not require collateral. The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and other revenue based on collection history, current developments and credit worthiness of the customer. The estimate of credit losses is not material at March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;UnitedHealthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's significant third-party payers in excess of 10% of total accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;UnitedHealthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash&#160;and&#160;Cash&#160;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers demand deposits in a bank, money market funds and highly liquid investments with an original maturity of 90 days or less to be cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's short-term investments consist of U.S. treasury securities with maturities at the time of purchase that were between 90 days and one year. The Company classifies these investments as held-to-maturity debt securities, which are reported at amortized cost. The amortization of discounts or premiums from the purchase of the securities are recognized as a component of interest income in other income (loss), net in the condensed consolidated statements of operations. Investments are initially recorded net of an allowance for expected credit losses, if any, which are remeasured each period and any impairments are recognized as an expense. Unrealized gains and losses are not recognized in income. As of both March&#160;31, 2023 and December&#160;31, 2022, no allowances for expected credit losses had been recorded and there have been no impairment or credit losses on the Company's short term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had deposits of $0.7 million included in long-term assets as of both March&#160;31, 2023 and December&#160;31, 2022, restricted from withdrawal and held by banks in the form of collateral for irrevocable standby letters of credit held as security for the Company's leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with the provisions of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 606. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has completed a service or transferred control of a product to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements involving more than one service or good, each required service or good is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the service or good either on its own or together with other resources that are readily available and (ii) the service or good is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred which may be at a point in time or over time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%"&gt;Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company bills for testing services at the time of test completion as defined by the delivery of test results. The Company recognizes revenue based on estimates of the amount that will ultimately be realized. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's products consist of the Prosigna breast cancer assay, the nCounter Analysis System and related diagnostic kits. Product revenue from diagnostic kits is generally recognized upon shipment. Product revenue from instruments is &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;generally recognized when the instrument is ready for use by the end customer. Shipping and handling costs incurred for product shipments are included in product revenue. Revenue is presented net of the taxes that are collected from customers and remitted to governmental authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%"&gt;Biopharmaceutical and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into arrangements for biopharmaceutical research and development, commercialization, contract manufacturing and development, and testing services, which are classified under biopharmaceutical and other revenue. Such arrangements may require the Company to deliver various rights, manufactured diagnostic test kits, services and/or samples, including intellectual property rights/licenses, biopharmaceutical research and development services, and/or commercialization services. The Company receives consideration in the form of upfront license fees; payments on delivery of data, test results or manufactured products; costs of service plus margin; and development and commercial performance milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price may include independent evidence of market price, forecasted revenue or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if the obligation can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. Milestone payments that are not within either party&#x2019;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within either party&#x2019;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative revenue and earnings in the period of adjustment. One collaboration arrangement with milestone payments falls under the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 808. These milestone payments are recognized in the same manner as milestone payments from customers and are classified under biopharmaceutical and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable from biopharmaceutical and other revenue was $8.8&#160;million&#160;at March&#160;31, 2023 and $9.3&#160;million at December&#160;31, 2022. There was $2.2&#160;million and $2.6&#160;million of deferred revenue related to these agreements at March&#160;31, 2023 and December&#160;31, 2022, respectively. Revenue included in biopharmaceutical and other revenue for the three months ended March&#160;31, 2023 and 2022 was as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:42.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biopharmaceutical revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract manufacturing and testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product revenue consists primarily of costs of purchasing instruments and diagnostic kits from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;third&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-party contract manufacturers, installation, service and packaging and delivery costs, and the Company's internal labor expenses. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#x2019;s products. Cost of product revenue for instruments and diagnostic kits&#160;is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Biopharmaceutical and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of biopharmaceutical and other revenue consists of costs of performing activities under arrangements that require the Company to perform biopharmaceutical research and development, commercialization, contract manufacturing and contract testing services on behalf of a customer.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pension Liability&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company offers a defined benefit &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_c42f36f4-4860-4a82-9f52-48c65e91ae48"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_dbd24477-8f44-4199-93ad-3dfd106ab395"&gt;pension plan&lt;/span&gt;&lt;/span&gt; to certain non-U.S. employees of its Veracyte SAS subsidiary.  As of both March&#160;31, 2023 and December&#160;31, 2022, the total pension obligation was $0.7&#160;million and is included in other liabilities on the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 2014-09, Revenue from Contracts with Customers (Topic 606). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. The new standard is effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance in 2023 and such adoption had no material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTc_f9963afc-14bf-4fb8-9df1-5d877494e89f">&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of March&#160;31, 2023, the condensed consolidated statements of operations for the three months ended March&#160;31, 2023 and 2022, the condensed consolidated statements of comprehensive loss for the three months ended March&#160;31, 2023 and 2022, the condensed consolidated statements of stockholders' equity for the three months ended March&#160;31, 2023 and 2022, and the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of its financial position, operating results, stockholders' equity and cash flows for the periods presented. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from audited financial statements. The results for the three months ended March&#160;31, 2023 are not indicative of the results expected for the full year or any other period. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.  The Company operates in one segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim period condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfNTM5Mw_05b815b0-b784-40b5-bdca-c7b42e027e91"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDc_8f9a8e78-d745-48d8-bf5f-44453d7c69d0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the useful lives of property, plant and equipment; the recoverability of long-lived assets; the incremental borrowing rates for leases; accounting for acquisitions; the estimation of the fair value of intangible assets and contingent consideration; stock based compensation; income tax uncertainties, including a valuation allowance for deferred tax assets; credit related losses on investments; and allowance for credit losses and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions &lt;/span&gt;&lt;/div&gt;that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</us-gaap:UseOfEstimates>
    <vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDQ_29ff4fd0-292d-44bc-b226-cc4462cdba8a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The worldwide spread of coronavirus, or COVID-19, has created significant uncertainty in the global economy. There have been no comparable recent events that provide guidance as to the effect the spread of COVID-19 as a global pandemic may have. As a result, the ultimate impact of COVID-19 and the extent to which COVID-19 impacts the Company&#x2019;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict. If the financial markets or the overall economy are impacted for an extended period, the Company&#x2019;s liquidity, revenue, supplies, goodwill and intangibles may be adversely affected. The Company considers the effects, to the extent knowable, of the COVID-19 pandemic in developing its estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s cash and cash equivalents are deposited with two major financial institutions in the United States. Deposits in these institutions may exceed the amount of insurance provided on such deposits. The Company has not realized any losses on its deposits of cash and cash equivalents other than exchange rate losses related to foreign currency denominated accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several of the components of the Company&#x2019;s sample collection kits and test reagents, and the nCounter system and related diagnostic kits, are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company&#x2019;s requirements on a timely basis, or are unable to provide the Company with reagents that perform to specifications, the Company could suffer delays in being able to deliver its diagnostic solutions, suffer a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through March&#160;31, 2023, the Company has derived most of its revenue from the sale of Decipher and Afirma testing. To date, Decipher and Afirma testing have been delivered primarily to physicians in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect. The Company generally does not perform evaluations of customers&#x2019; financial condition for testing revenue and generally does not require collateral. The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and other revenue based on collection history, current developments and credit worthiness of the customer. The estimate of credit losses is not material at March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</vcyt:ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDU_28f3d9e4-eef1-4e75-8d93-ec5adcded1fe">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;UnitedHealthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's significant third-party payers in excess of 10% of total accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;UnitedHealthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic43b0b3fe6664d3cbdb8a3f4f93ee2bd_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfMi01LTEtMS03MjEyMw_0a54dcc1-d7ea-45ea-8300-e699654ed620"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i19f99811b32f40d18acdc45b83384992_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfMi03LTEtMS03MjEyMw_d9537926-a88d-4199-aefb-b9f1cbfb92c5"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i32cc63b081d34737b7c09f18254a0369_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfMy01LTEtMS03MjEyMw_deaf5b51-5580-4010-8b21-f4d6b2b388bb"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if73c87216b7e431cbb1a5132319fc1ba_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfMy03LTEtMS03MjEyMw_ecdf936e-bbf1-4e8e-8fff-01fd981ddcba"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iecc0d9d5bd4645f4a7aa6c4d79ddcca0_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfNC01LTEtMS03MjEyMw_b93e4eab-345c-45b4-bf2b-f65f9d31fdff"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icdbdbc6fb5304aa6a286a799abfdc7c5_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjMwZDU4YjVmOGNlMzQ5MDFiMjEyN2ZlYTUyZmEyNWFkL3RhYmxlcmFuZ2U6MzBkNThiNWY4Y2UzNDkwMWIyMTI3ZmVhNTJmYTI1YWRfNC03LTEtMS03MjEyMw_ab840a55-ef69-4570-b4d3-870c7bc51e75"
      unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icadd7189bc5c4c3385082591611320f5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOmJkOTI5MTI3Zjk2NTRkMjg5ODk4NGNhYmI0MGViYWVmL3RhYmxlcmFuZ2U6YmQ5MjkxMjdmOTY1NGQyODk4OTg0Y2FiYjQwZWJhZWZfMS0xLTEtMS03MjEyMw_c6771cb2-707d-4690-be06-788bcc95950c"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if563c75164164060aab1e980fe9c7b0b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOmJkOTI5MTI3Zjk2NTRkMjg5ODk4NGNhYmI0MGViYWVmL3RhYmxlcmFuZ2U6YmQ5MjkxMjdmOTY1NGQyODk4OTg0Y2FiYjQwZWJhZWZfMS0zLTEtMS03MjEyMw_94d845c3-328d-4a07-9d56-f3857e0e2350"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic8ca971045914a1a9146c9113b0b663d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOmJkOTI5MTI3Zjk2NTRkMjg5ODk4NGNhYmI0MGViYWVmL3RhYmxlcmFuZ2U6YmQ5MjkxMjdmOTY1NGQyODk4OTg0Y2FiYjQwZWJhZWZfMi0xLTEtMS03MjEyMw_c5fa961d-317a-4774-bea3-a89a1b8b06b7"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i35250c2e6deb44c4ac481dd4e6f612e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOmJkOTI5MTI3Zjk2NTRkMjg5ODk4NGNhYmI0MGViYWVmL3RhYmxlcmFuZ2U6YmQ5MjkxMjdmOTY1NGQyODk4OTg0Y2FiYjQwZWJhZWZfMi0zLTEtMS03MjEyMw_b32b62e1-7bca-42c9-b2b4-ad989739d658"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDY_6b579b1a-4f35-4d21-8876-2544c9649335">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash&#160;and&#160;Cash&#160;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The Company considers demand deposits in a bank, money market funds and highly liquid investments with an original maturity of 90 days or less to be cash equivalents.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDg_b7b66b8a-bfa3-45b2-83c9-f60871f268fe">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The Company's short-term investments consist of U.S. treasury securities with maturities at the time of purchase that were between 90 days and one year. The Company classifies these investments as held-to-maturity debt securities, which are reported at amortized cost. The amortization of discounts or premiums from the purchase of the securities are recognized as a component of interest income in other income (loss), net in the condensed consolidated statements of operations. Investments are initially recorded net of an allowance for expected credit losses, if any, which are remeasured each period and any impairments are recognized as an expense. Unrealized gains and losses are not recognized in income.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTE3NTk_4fbc8853-822c-4be1-928d-71dc3228afa7"
      unitRef="usd">0</us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTE3NTk_f1d20560-4f46-45de-b18e-0644142744f9"
      unitRef="usd">0</us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTE5NTc_b9b99076-ecf6-4944-900c-1092116730fc"
      unitRef="usd">700000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTE5NTc_c9c77fa5-19bf-4698-b945-ca474e87df49"
      unitRef="usd">700000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDA_5cd87ede-a3cb-404c-a148-d27f1164908e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with the provisions of ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 606. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has completed a service or transferred control of a product to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arrangements involving more than one service or good, each required service or good is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the service or good either on its own or together with other resources that are readily available and (ii) the service or good is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available. The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred which may be at a point in time or over time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%"&gt;Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company bills for testing services at the time of test completion as defined by the delivery of test results. The Company recognizes revenue based on estimates of the amount that will ultimately be realized. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management. Actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's products consist of the Prosigna breast cancer assay, the nCounter Analysis System and related diagnostic kits. Product revenue from diagnostic kits is generally recognized upon shipment. Product revenue from instruments is &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;generally recognized when the instrument is ready for use by the end customer. Shipping and handling costs incurred for product shipments are included in product revenue. Revenue is presented net of the taxes that are collected from customers and remitted to governmental authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%"&gt;Biopharmaceutical and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into arrangements for biopharmaceutical research and development, commercialization, contract manufacturing and development, and testing services, which are classified under biopharmaceutical and other revenue. Such arrangements may require the Company to deliver various rights, manufactured diagnostic test kits, services and/or samples, including intellectual property rights/licenses, biopharmaceutical research and development services, and/or commercialization services. The Company receives consideration in the form of upfront license fees; payments on delivery of data, test results or manufactured products; costs of service plus margin; and development and commercial performance milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company develops estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price may include independent evidence of market price, forecasted revenue or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if the obligation can be satisfied at a point in time or over time, and it measures the services delivered to the collaborative partner which are periodically reviewed based on the progress of the related program. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. Milestone payments that are not within either party&#x2019;s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within either party&#x2019;s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative revenue and earnings in the period of adjustment. One collaboration arrangement with milestone payments falls under the scope of ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 808. These milestone payments are recognized in the same manner as milestone payments from customers and are classified under biopharmaceutical and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable from biopharmaceutical and other revenue was $8.8&#160;million&#160;at March&#160;31, 2023 and $9.3&#160;million at December&#160;31, 2022. There was $2.2&#160;million and $2.6&#160;million of deferred revenue related to these agreements at March&#160;31, 2023 and December&#160;31, 2022, respectively. Revenue included in biopharmaceutical and other revenue for the three months ended March&#160;31, 2023 and 2022 was as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:42.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biopharmaceutical revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract manufacturing and testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Testing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's cost of testing services are laboratory expenses, sample collection expenses, compensation expense, license fees and royalties, depreciation, other expenses such as equipment and laboratory supplies, and allocations of facility and information technology expenses. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product revenue consists primarily of costs of purchasing instruments and diagnostic kits from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;third&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-party contract manufacturers, installation, service and packaging and delivery costs, and the Company's internal labor expenses. In addition, cost of product includes royalty costs for licensed technologies included in the Company&#x2019;s products. Cost of product revenue for instruments and diagnostic kits&#160;is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Biopharmaceutical and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Cost of biopharmaceutical and other revenue consists of costs of performing activities under arrangements that require the Company to perform biopharmaceutical research and development, commercialization, contract manufacturing and contract testing services on behalf of a customer.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifd3b24d188c147d0894ca33558f96f88_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTkwNzk_91c4e61f-fcb7-452b-9432-ec7d9a1246d2"
      unitRef="usd">8800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i998dea8702a44f32b783fad66ceaef6f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTkwOTI_de0989db-13dd-4acf-be36-c8fbe266c761"
      unitRef="usd">9300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifd3b24d188c147d0894ca33558f96f88_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTkxMTI_6450951b-1334-4435-8386-6e69be87a405"
      unitRef="usd">2200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i998dea8702a44f32b783fad66ceaef6f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMTkxMTk_2f23213d-1097-4f5a-b9cc-21437964e0fc"
      unitRef="usd">2600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjIwMDE_61755a89-98af-4e87-98ec-95a18cc1082d">Revenue included in biopharmaceutical and other revenue for the three months ended March&#160;31, 2023 and 2022 was as follows (in thousands of dollars):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biopharmaceutical revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract manufacturing and testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i274a02acfdb5475dac6457d7c3ee154b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfMi01LTEtMS03MjEyMw_c0dec4e2-567e-47de-8633-307831fe28d0"
      unitRef="usd">4447000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ae14244c4fb41a999ccf232d576984d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfMi03LTEtMS03MjEyMw_0cdc55d8-b3d1-4248-bb59-fb5e4f807c31"
      unitRef="usd">7046000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2099bc12c8224f319528343bdffe545e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfMy01LTEtMS03MjEyMw_bf33ce37-893e-4002-99e0-1f429b07367d"
      unitRef="usd">1687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06548eac75174f9ca6d2b92d2d9f74ca_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfMy03LTEtMS03MjEyMw_24ee331c-7ed5-40e1-9246-5dcaefeb9373"
      unitRef="usd">1778000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if31dd8bd6f8b4fb3b8a6f145af4d5d59_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfNC01LTEtMS03MjEyMw_5f3e1495-db1a-46e4-987a-02de27a46567"
      unitRef="usd">6134000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie309aab35ae147468bed50274b964061_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RhYmxlOjM2YTk0MjRkZTFjNjQ5MWU5N2IwNjA5OGIzZmFlYmEzL3RhYmxlcmFuZ2U6MzZhOTQyNGRlMWM2NDkxZTk3YjA2MDk4YjNmYWViYTNfNC03LTEtMS03MjEyMw_ff7446b7-0490-4308-bd2b-396d6e22f4fe"
      unitRef="usd">8824000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTg_899ee160-2029-4e8c-95da-f1566d3484d2">Pension LiabilityThe Company offers a defined benefit &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_c42f36f4-4860-4a82-9f52-48c65e91ae48"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTk_dbd24477-8f44-4199-93ad-3dfd106ab395"&gt;pension plan&lt;/span&gt;&lt;/span&gt; to certain non-U.S. employees of its Veracyte SAS subsidiary.</us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjA5NTk_11af291c-1806-4e16-ae80-1b1934ccb9b7"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjA5NTk_ddd0aa6b-d8b1-43f2-9a30-3fd4f1c2255d"
      unitRef="usd">700000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNC9mcmFnOmYyNTZkNjk1YjI2ZjQ4ZDc5ZjhiZTJiYTgyYWM1OGUwL3RleHRyZWdpb246ZjI1NmQ2OTViMjZmNDhkNzlmOGJlMmJhODJhYzU4ZTBfMjE5OTY_55e97823-070d-426b-9464-99c0a1e8ccdd">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 2014-09, Revenue from Contracts with Customers (Topic 606). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. The new standard is effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance in 2023 and such adoption had no material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RleHRyZWdpb246MjFlN2FiNTg2MTEyNDdkZmIxMTAwNDM0Y2I4M2FiMzhfNjYy_be989436-d610-4572-9dfe-1e36a01e3f6e">Net Loss Per Common Share&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. The following outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares of common stock subject to outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,767,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,703,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,349,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,559,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,150,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,293,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RleHRyZWdpb246MjFlN2FiNTg2MTEyNDdkZmIxMTAwNDM0Y2I4M2FiMzhfNjYz_eafb51e7-9f47-43f8-8f3d-7530118d2e7e">The following outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive:&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares of common stock subject to outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,767,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,703,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,349,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,559,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,150,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,293,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1d63ecdd09ee4ceeb3894542f9e9a7b1_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfMi01LTEtMS03MjEyMw_25de6431-5e49-4483-bde3-f253e7df3f15"
      unitRef="shares">3767086</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0cc183be53114cd5ae6844b58582cac8_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfMi03LTEtMS03MjEyMw_c91282cb-0f0d-4c39-9a7a-cc7965656502"
      unitRef="shares">3703656</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec98084255e1437ca83d101b89bdff0f_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfMy01LTEtMS03MjEyMw_3eb24f52-1923-4cf5-a68b-b7c75104bf61"
      unitRef="shares">33998</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i03e5c566c2b44d13b38e3125968a69bf_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfMy03LTEtMS03MjEyMw_2bd83f1d-5e5b-4e99-b0da-750ddd0d8d4b"
      unitRef="shares">30622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i87ca496310a4471fab481bd7a0025487_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfNC01LTEtMS03MjEyMw_471f2132-be9d-4291-b649-87517cfddf24"
      unitRef="shares">2349151</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie962846780634c4abb77f3207cab491b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfNC03LTEtMS03MjEyMw_3f270d79-be68-453e-ad1d-0e415b481d3d"
      unitRef="shares">1559540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfNS01LTEtMS03MjEyMw_d57e71e1-bed7-4fc1-97fc-fd2ba4691b3b"
      unitRef="shares">6150235</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y18zNy9mcmFnOjIxZTdhYjU4NjExMjQ3ZGZiMTEwMDQzNGNiODNhYjM4L3RhYmxlOjE5ZWVmNzBmMDI4MzQzODU5MTBlNDhhMzFiYzBlNGU0L3RhYmxlcmFuZ2U6MTllZWY3MGYwMjgzNDM4NTkxMGU0OGEzMWJjMGU0ZTRfNS03LTEtMS03MjEyMw_0105613c-dc2a-4b10-a4bf-224bf23d61c5"
      unitRef="shares">5293818</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMjI4Mg_0455c787-9130-43b7-87c0-c1c866185cd6">Balance Sheet Components&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill was $699.7&#160;million and $695.9&#160;million as of March&#160;31, 2023 and December&#160;31, 2022, respectively. The changes in the carrying amounts of goodwill during the three months ended March 31, 2023 were due to foreign currency translation.  The Company has not recorded any impairment related to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include finite-lived product technology, customer relationships, licenses and trade names and indefinite-lived in-process research and development. Intangible assets consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Percepta product technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prosigna product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;nCounter Dx license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;LymphMark product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decipher product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,484)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decipher trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;HalioDx developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;HalioDx customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;HalioDx customer backlog&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;223,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of the finite-lived intangible assets is recognized on a straight-line basis. Amortization expense of $5.3&#160;million and $5.5&#160;million was recognized for the three months ended March 31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future aggregate amortization expense as of March&#160;31, 2023 is as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 remainder of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supplies and Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, supplies and inventory consisted of $10.0&#160;million and $10.2&#160;million, respectively, of lab supplies and reagents consumed in the performance of testing services, and $3.3&#160;million and $4.1&#160;million, respectively, of inventory related to raw materials consumed in the contract manufacturing process, as well as finished and semi-finished components used in the assembly of diagnostic kits related to product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:Goodwill
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNTc_a0b4ac08-84f6-4b80-929b-7e88807157b8"
      unitRef="usd">699700000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNjQ_01e4cffd-08dc-4057-81e0-39556c8fe49f"
      unitRef="usd">695900000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMjI4NA_7013c671-b633-4a7d-86c5-4dd4875e0d6a">Intangible assets consisted of the following (in thousands of dollars):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Percepta product technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prosigna product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prosigna customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;nCounter Dx license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;LymphMark product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decipher product technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,484)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decipher trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;HalioDx developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;HalioDx customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;HalioDx customer backlog&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;223,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if1c2bbdf5d7e4d15a0928f584d49978a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi0xLTEtMS03MjEyMw_297d3102-348a-4fe7-95a8-64a687878987"
      unitRef="usd">16000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if1c2bbdf5d7e4d15a0928f584d49978a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi0zLTEtMS03MjEyMw_d7eb15c5-b9af-4821-8e06-31b7bb122c64"
      unitRef="usd">8533000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if1c2bbdf5d7e4d15a0928f584d49978a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi01LTEtMS03MjEyMw_5e932304-d67a-4a9a-8c03-1e6e6832a992"
      unitRef="usd">7467000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icdf1cd50fe084f529b3b433569983a49_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi03LTEtMS03MjEyMw_bb7ac323-05c2-4d51-b7c8-ee3b29a8b601"
      unitRef="usd">16000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icdf1cd50fe084f529b3b433569983a49_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi05LTEtMS03MjEyMw_4b5cf30f-1909-4082-9793-a8725675aec2"
      unitRef="usd">8267000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icdf1cd50fe084f529b3b433569983a49_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi0xMS0xLTEtNzIxMjM_dc8e71f5-cb47-41ac-9fb8-7bb11cd43bd4"
      unitRef="usd">7733000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia23eed41b3e74c09a3af1063a3dfaaa4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMi0xMy0xLTEtNzIxMjM_07503673-e2c3-4a25-898d-242b6971ebd1">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i36048a1bd9c5433d93652f6da7dcba37_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy0xLTEtMS03MjEyMw_f44bca9c-d2b7-4098-b33b-f021e70c3819"
      unitRef="usd">4120000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i36048a1bd9c5433d93652f6da7dcba37_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy0zLTEtMS03MjEyMw_3caf0bbc-78a1-4531-ae78-9c6fde568db9"
      unitRef="usd">915000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i36048a1bd9c5433d93652f6da7dcba37_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy01LTEtMS03MjEyMw_8496befb-3c8a-4f31-a0be-d9ff56c30df8"
      unitRef="usd">3205000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4b268539086c467aab96e29940e65c30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy03LTEtMS03MjEyMw_1bbe81c6-a4ba-4162-9fa7-e06bbb2f480e"
      unitRef="usd">4120000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4b268539086c467aab96e29940e65c30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy05LTEtMS03MjEyMw_d64105c9-6f3e-42df-9307-3c7f421da736"
      unitRef="usd">847000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4b268539086c467aab96e29940e65c30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy0xMS0xLTEtNzIxMjM_dd0ae676-914d-45fd-a8b3-ebb3d55f1f50"
      unitRef="usd">3273000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic189876c9f5b49a491d19b401863e5c7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMy0xMy0xLTEtNzIxMjM_fbd1d07f-6f2e-4f39-8f46-99de8a3e078e">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if02c3ec7045e44e992b345c1c6f4e8db_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC0xLTEtMS03MjEyMw_dcdee01a-a9c4-46ac-8b8d-ce45f4ec3ae7"
      unitRef="usd">2430000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if02c3ec7045e44e992b345c1c6f4e8db_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC0zLTEtMS03MjEyMw_559550ed-eacf-40ee-8e50-027288b076b1"
      unitRef="usd">1620000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if02c3ec7045e44e992b345c1c6f4e8db_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC01LTEtMS03MjEyMw_40708b62-f373-40e3-9f33-d736c8039a0f"
      unitRef="usd">810000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i45490cef3786448bb194a53c1a4925b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC03LTEtMS03MjEyMw_2986c58e-89a8-4af3-946c-d9b9944cc2d6"
      unitRef="usd">2430000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i45490cef3786448bb194a53c1a4925b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC05LTEtMS03MjEyMw_b52e0e2a-3c74-48d0-b66e-05aab6593435"
      unitRef="usd">1499000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i45490cef3786448bb194a53c1a4925b9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC0xMS0xLTEtNzIxMjM_01e283f5-f12f-4bdb-bc45-8fca5031d49a"
      unitRef="usd">931000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idf00f1922dfe4be3ac3b55ead1c6f375_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNC0xMy0xLTEtNzIxMjM_7c831ca7-87bf-42d0-a5c5-f2a7926de20e">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id4759963ae1646649f60d583de01125c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS0xLTEtMS03MjEyMw_0bddbab6-2a67-4dc4-b883-e2627c932e13"
      unitRef="usd">46880000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id4759963ae1646649f60d583de01125c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS0zLTEtMS03MjEyMw_77054772-8fbd-4673-9f2e-3673bebc8f40"
      unitRef="usd">10418000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id4759963ae1646649f60d583de01125c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS01LTEtMS03MjEyMw_9d90929c-57ce-4c68-a4c2-7a7bfa57ae4f"
      unitRef="usd">36462000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9a449a72bae04d50925d90a798163f1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS03LTEtMS03MjEyMw_c9def112-8f78-43b8-9f94-fbdf84cda548"
      unitRef="usd">46880000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9a449a72bae04d50925d90a798163f1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS05LTEtMS03MjEyMw_c344c826-eb9b-4086-81e8-9a30db769ab0"
      unitRef="usd">9636000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9a449a72bae04d50925d90a798163f1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS0xMS0xLTEtNzIxMjM_493da314-30aa-4182-8105-efcb0ea3a976"
      unitRef="usd">37244000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2c22e100729e4221b19089c051e020bd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNS0xMy0xLTEtNzIxMjM_77dabb2e-333f-4abf-b568-544342fa3ebd">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id96dd7074a874f3ab955a93c939fd0e2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi0xLTEtMS03MjEyMw_7748d95d-1900-4256-94c2-041b29c00965"
      unitRef="usd">990000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id96dd7074a874f3ab955a93c939fd0e2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi0zLTEtMS03MjEyMw_25565d8a-8e7a-4f4a-a8b3-6814998b95ff"
      unitRef="usd">471000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id96dd7074a874f3ab955a93c939fd0e2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi01LTEtMS03MjEyMw_a57f65f7-94dd-4da4-bcbe-7ca065e1217b"
      unitRef="usd">519000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7b06dd23ef3c466caa291f27746d9f0f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi03LTEtMS03MjEyMw_b8f8bdeb-4545-41a3-b3d2-00b068d874b9"
      unitRef="usd">990000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7b06dd23ef3c466caa291f27746d9f0f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi05LTEtMS03MjEyMw_f1f18ee7-9ef8-4dec-8a18-f13585c689c6"
      unitRef="usd">436000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7b06dd23ef3c466caa291f27746d9f0f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi0xMS0xLTEtNzIxMjM_37d4c87d-413d-4c8c-a4c9-412f3a95246d"
      unitRef="usd">554000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if2dd2214b7954827af13bad315eaeef6_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNi0xMy0xLTEtNzIxMjM_802e210d-16d3-486f-9e9f-c953809e84b1">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i465f5da059d4485493001b166d4b40d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy0xLTEtMS03MjEyMw_0924ff04-bc8a-4a9b-86ed-d737f538e6b8"
      unitRef="usd">90000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i465f5da059d4485493001b166d4b40d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy0zLTEtMS03MjEyMw_277e9711-417d-4911-ac00-c770385d7f24"
      unitRef="usd">18484000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i465f5da059d4485493001b166d4b40d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy01LTEtMS03MjEyMw_18809489-5129-485f-8aa4-68541e39b1fc"
      unitRef="usd">71516000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibbaa1203aac34a38a5d064b5630c2dbc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy03LTEtMS03MjEyMw_d4896844-9e28-4f3b-ac56-77152fceb43c"
      unitRef="usd">90000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibbaa1203aac34a38a5d064b5630c2dbc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy05LTEtMS03MjEyMw_1a7b8f63-6dd5-4d09-9a84-3315c3ebf626"
      unitRef="usd">16234000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibbaa1203aac34a38a5d064b5630c2dbc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy0xMS0xLTEtNzIxMjM_cfbfe713-3435-4f09-b62c-856917d6c5a0"
      unitRef="usd">73766000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6e1a841c902147639f42aaf1fc24846c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfNy0xMy0xLTEtNzIxMjM_3ec9bfd6-bf1d-4ed2-ba5c-c1b98c2effb3">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if5af60edaf174d3dbf0da38ad4778d42_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC0xLTEtMS03MjEyMw_265365ef-d32a-4991-9ca1-4942803d170e"
      unitRef="usd">4000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if5af60edaf174d3dbf0da38ad4778d42_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC0zLTEtMS03MjEyMw_ca02a5c0-583c-4931-a94c-a41fce9626fa"
      unitRef="usd">1643000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if5af60edaf174d3dbf0da38ad4778d42_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC01LTEtMS03MjEyMw_fcb3c5b5-fd45-4fcf-88c6-989746944516"
      unitRef="usd">2357000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id51f3fcca6344c0d8acf9827a75d098d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC03LTEtMS03MjEyMw_b199eefc-4da5-4296-bdce-96c66480a160"
      unitRef="usd">4000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id51f3fcca6344c0d8acf9827a75d098d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC05LTEtMS03MjEyMw_98e9b822-7215-4077-8f08-f16f53fbe7b3"
      unitRef="usd">1443000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id51f3fcca6344c0d8acf9827a75d098d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC0xMS0xLTEtNzIxMjM_a62273c4-4535-442f-9571-710c3ed18b7a"
      unitRef="usd">2557000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i96b14c1a4f46482383ed19e470792768_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOC0xMy0xLTEtNzIxMjM_d7b22786-033c-4831-9ee4-be438bb5105e">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id1ea9d43677e4c86b1d71be599ac6865_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS0xLTEtMS03MjEyMw_b7a0c383-0966-45d3-960f-fafd7de88f91"
      unitRef="usd">40400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id1ea9d43677e4c86b1d71be599ac6865_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS0zLTEtMS03MjEyMw_fce4c1ad-6314-4588-9f9b-5eaffff2490b"
      unitRef="usd">7001000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id1ea9d43677e4c86b1d71be599ac6865_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS01LTEtMS03MjEyMw_5e32fb90-4046-4d5a-b5dc-4efbdb9e8143"
      unitRef="usd">33399000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9cf1b2134c6848bc8109d15f1016674a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS03LTEtMS03MjEyMw_58f3e52a-350d-47c4-95e3-9fb3509ded6f"
      unitRef="usd">39724000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9cf1b2134c6848bc8109d15f1016674a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS05LTEtMS03MjEyMw_73cd4591-9e43-4c60-9e9d-3e9ec9cb6708"
      unitRef="usd">5899000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9cf1b2134c6848bc8109d15f1016674a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS0xMS0xLTEtNzIxMjM_2f381738-a87a-4188-a3dc-e53b0b295a4b"
      unitRef="usd">33825000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i43160a473e5b4aa6975f0c9b8f8a4911_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfOS0xMy0xLTEtNzIxMjM_3b2acd0c-0369-4372-a911-e2337dc2fe2f">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iac93bb77e6df4adebb1fce8ac3eb1425_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtMS0xLTEtNzIxMjM_fc313b65-0cbb-44d6-bfa7-0e3a07d0e5af"
      unitRef="usd">4680000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iac93bb77e6df4adebb1fce8ac3eb1425_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtMy0xLTEtNzIxMjM_ba465b1d-4db7-457b-8791-4cbba2c78b37"
      unitRef="usd">1369000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iac93bb77e6df4adebb1fce8ac3eb1425_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtNS0xLTEtNzIxMjM_a27960e3-dab9-48e8-86df-e68d85a4fac6"
      unitRef="usd">3311000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1d58f9fdd9f24ea7beeb7a99ed47f1fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtNy0xLTEtNzIxMjM_8c6848ec-cfb6-4828-8d0a-371d1475f787"
      unitRef="usd">4602000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1d58f9fdd9f24ea7beeb7a99ed47f1fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtOS0xLTEtNzIxMjM_4718186f-6faf-47f3-ad70-9e282a71e70a"
      unitRef="usd">1144000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1d58f9fdd9f24ea7beeb7a99ed47f1fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtMTEtMS0xLTcyMTIz_ec0e822a-36e0-49eb-a365-19c28f2b507a"
      unitRef="usd">3458000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ibcf4b5a8d9ac4269b9a4b8890c7ae167_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTAtMTMtMS0xLTcyMTIz_bfe38673-d553-46b5-bb45-e1f02439dd1e">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if28f8ef0b3354ef5abe5718fad617afd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtMS0xLTEtNzIxMjM_f1fcbafb-13d5-46cf-9448-fba31e828ad6"
      unitRef="usd">6639000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if28f8ef0b3354ef5abe5718fad617afd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtMy0xLTEtNzIxMjM_32e623fd-9f96-45e2-840b-771cadfdc6a1"
      unitRef="usd">2759000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if28f8ef0b3354ef5abe5718fad617afd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtNS0xLTEtNzIxMjM_1fdad9cb-a409-4562-b1db-ba2fb7d890f2"
      unitRef="usd">3880000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia17c0ca4207743efbafee0e3b75a8c67_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtNy0xLTEtNzIxMjM_201d47a8-5bd2-4642-ba2e-31091b067764"
      unitRef="usd">6528000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia17c0ca4207743efbafee0e3b75a8c67_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtOS0xLTEtNzIxMjM_922e0bc2-0672-4127-b117-02beb69dfb33"
      unitRef="usd">2303000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia17c0ca4207743efbafee0e3b75a8c67_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtMTEtMS0xLTcyMTIz_11210323-0f05-4a62-8521-737912b84c5a"
      unitRef="usd">4225000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iac056f15377a4e1a939745868f857e1d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTEtMTMtMS0xLTcyMTIz_797a7585-f9c7-498c-a412-d6a8bfb2e786">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItMS0xLTEtNzIxMjM_7db42cfd-21dd-405b-93c3-f32137f61980"
      unitRef="usd">216139000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItMy0xLTEtNzIxMjM_9944c58b-bea4-4980-aa07-3a050691727c"
      unitRef="usd">53213000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItNS0xLTEtNzIxMjM_8e7b59e7-2ceb-4171-9f2f-f39556b63db4"
      unitRef="usd">162926000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItNy0xLTEtNzIxMjM_f7b23112-f06c-48ba-9014-5e55203c484a"
      unitRef="usd">215274000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItOS0xLTEtNzIxMjM_3130a2f3-9fed-4468-bac1-9234810ae192"
      unitRef="usd">47708000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItMTEtMS0xLTcyMTIz_f4706e9f-819a-4e3e-affe-703ef5a35935"
      unitRef="usd">167566000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTItMTMtMS0xLTcyMTIz_3ec3a622-122d-40ac-bce0-66f6617c842b">P8Y4M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTMtMS0xLTEtNzIxMjM_09fdc90f-6115-4e9d-9e31-70608d61d284"
      unitRef="usd">7300000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTMtNS0xLTEtNzIxMjM_13e7dcdb-6b5d-483c-b1f9-1941499d48d0"
      unitRef="usd">7300000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTMtNy0xLTEtNzIxMjM_d9f5b9fa-1a03-49b5-9c97-e7cd27a99377"
      unitRef="usd">7300000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTMtMTEtMS0xLTcyMTIz_22880b6b-6325-4307-9da8-f51d4df1be3e"
      unitRef="usd">7300000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtMS0xLTEtNzIxMjM_841cda22-b869-420b-9949-e0762ef9c4cd"
      unitRef="usd">223439000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtMy0xLTEtNzIxMjM_a8b7e8d8-6518-4a64-b640-b89cf7b4fe4f"
      unitRef="usd">53213000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtNS0xLTEtNzIxMjM_aa8d5ca9-c4ef-4611-a132-0d1e3ba39779"
      unitRef="usd">170226000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtNy0xLTEtNzIxMjM_aea29b87-ffad-41f7-9958-d879262389ed"
      unitRef="usd">222574000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtOS0xLTEtNzIxMjM_0c68bd3e-9965-4cdc-8077-b6d572e1b5bc"
      unitRef="usd">47708000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjc3ZjdlZjkzYjQxYTQ5Mzc5Y2Y3OWU2YjEwMGNkYTdmL3RhYmxlcmFuZ2U6NzdmN2VmOTNiNDFhNDkzNzljZjc5ZTZiMTAwY2RhN2ZfMTQtMTEtMS0xLTcyMTIz_7d5ecb9e-a091-4ce0-b74c-a684bcd8a3d5"
      unitRef="usd">174866000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMTU2NA_1d628d4c-f29f-4537-893e-772a34e78df5"
      unitRef="usd">5300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMTU3MQ_00f98377-c845-4883-b0db-2d1b91a25256"
      unitRef="usd">5500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMjI4NQ_d1ea9271-8ddc-4bcc-8310-3478466bc901">The estimated future aggregate amortization expense as of March&#160;31, 2023 is as follows (in thousands of dollars):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 remainder of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfMS0xLTEtMS03MjEyMw_3f670298-e76e-4ca3-b68d-3df3ed27e181"
      unitRef="usd">16037000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfMi0xLTEtMS03MjEyMw_ae62cd9b-fca0-451e-840f-68754828f595"
      unitRef="usd">21343000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfMy0xLTEtMS03MjEyMw_54d017ed-6506-49d5-abb9-554747d37428"
      unitRef="usd">20215000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfNC0xLTEtMS03MjEyMw_912f61db-a7b3-4889-b586-1e3d52accc7d"
      unitRef="usd">18359000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfNS0xLTEtMS03MjEyMw_0fae8979-163a-4b20-bbfb-416f6d56aab2"
      unitRef="usd">17752000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <vcyt:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfNi0xLTEtMS03MjEyMw_ae1229d7-3458-4676-9de0-d5c0a07e8fdc"
      unitRef="usd">69220000</vcyt:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjdjYTZjMDU1MDRlMzQ1MzhhMTU1YmUxZTg4Y2Y2MmJlL3RhYmxlcmFuZ2U6N2NhNmMwNTUwNGUzNDUzOGExNTViZTFlODhjZjYyYmVfNy0xLTEtMS03MjEyMw_fccfa553-9fd3-4e82-a89a-b38b81f52cfd"
      unitRef="usd">162926000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:InventoryFinishedGoods
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNTQ5NzU1ODE2ODI0_5870a6a8-9415-49b4-9831-cad7750f2d0d"
      unitRef="usd">10000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNTQ5NzU1ODE2ODEw_c4b7df84-6e40-41bf-92e9-9bf53caa0da1"
      unitRef="usd">10200000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNTQ5NzU1ODE2ODI4_d79f51e6-0e9c-47e3-b83e-4838d3a4e568"
      unitRef="usd">3300000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfNTQ5NzU1ODE2ODE0_d597050d-ab7a-4141-a8dd-46bb391ef80d"
      unitRef="usd">4100000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RleHRyZWdpb246ZjliOGI0NmE4ZmY4NDI3ZWE4YTEwNTMyMWI0ZTkwNGNfMjI4Ng_7e16da47-24f6-476b-b7e0-da3487902e88">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMS0xLTEtMS03MjEyMw_294e0ed5-628d-4366-9889-1c1dbcd39469"
      unitRef="usd">21953000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMS0zLTEtMS03MjEyMw_32c0e7f9-70d2-4c21-8c59-62b9acff0ab6"
      unitRef="usd">30637000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMi0xLTEtMS03MjEyMw_d5a2d252-b6ba-45d5-ae34-f1e540f74e70"
      unitRef="usd">8688000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMi0zLTEtMS03MjEyMw_2b3e20d9-a7f1-44b6-9c22-dd898a282e92"
      unitRef="usd">7137000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMy0xLTEtMS03MjEyMw_f0b08e11-eb60-4529-8efe-7018c5f02e8d"
      unitRef="usd">30641000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180MC9mcmFnOmY5YjhiNDZhOGZmODQyN2VhOGExMDUzMjFiNGU5MDRjL3RhYmxlOjE3NDBmNTRiNTgyMzRkN2NhYmUyNjc5ZDY1ODhmMzMzL3RhYmxlcmFuZ2U6MTc0MGY1NGI1ODIzNGQ3Y2FiZTI2NzlkNjU4OGYzMzNfMy0zLTEtMS03MjEyMw_aaea4310-6ef2-44db-9a74-ce38600a38c1"
      unitRef="usd">37774000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfNDkxNQ_219c695b-f45c-4c2f-a3d8-e68cdb93c861">Fair Value Measurements&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records certain of its financial assets and liabilities at fair value. The accounting guidance for fair value provides a framework for measuring fair value and clarifies the definition of fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level I: Inputs which include quoted prices in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level II: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The fair value of the Company&#x2019;s financial assets includes money market funds and deposits for leases of the Company's facilities. Money market funds, included in cash and cash equivalents in the accompanying condensed consolidated balance sheets, were $42.3 million and $131.2 million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and are Level&#160;I assets as described above. The deposits for the leases, included in restricted cash, were $0.7 million as of both March&#160;31, 2023 and December&#160;31, 2022 and are a Level I assets as described above. There were no transfers between Levels 1, 2 or 3 for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2019, the Company acquired from NanoString the exclusive global diagnostics license to the nCounter Analysis System, the Prosigna breast cancer prognostic gene signature assay, and the LymphMark lymphoma subtyping assay. Pursuant to the terms of the agreement, Veracyte paid NanoString $40.0 million in cash and $10.0 million in Veracyte common stock, and may pay up to an additional $10.0 million in cash, contingent upon first achievement or occurrence, by or on behalf of Veracyte, of the commercial launch of the first, second and third diagnostic tests for use on the nCounter multiplex analysis system. This contingency was valued at $6.1&#160;million as of the acquisition date and is remeasured to fair value at each reporting date until the contingent consideration is settled. As of March&#160;31, 2023 and December&#160;31, 2022, this contingency was remeasured to $8.1 million and $8.6 million, respectively, with the corresponding changes included in general and administrative expense in the Company's condensed consolidated statements of operations. For the three months ended March 31, 2023, a reversal of expense of $0.5 million was recorded in general and administrative expense for the changes in carrying value and, for the three months ended March 31, 2022, no expense was recorded. As of March&#160;31, 2023, the achievement of one of the milestones is forecasted to occur within the next 12 months. As a result, $3.3 million of the contingent consideration is included in short term liabilities at March&#160;31, 2023. The fair value of the contingent consideration includes inputs that are not observable in the market and thus represents a Level III financial liability. The estimation of the fair value of the contingent consideration is based on the present value of the expected payments calculated by assessing the likelihood of when the related milestones would be achieved and estimating the Company's borrowing rate. These estimates form the basis for making judgments about the carrying value of the contingent consideration that are not readily apparent from other sources. Changes to the forecasts for the achievement of the milestones and the borrowing rate can significantly affect the estimated fair value of the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contingent consideration. As of March&#160;31, 2023 and December&#160;31, 2022, the Company calculated the estimated fair value of the milestones using the following significant unobservable inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value or Range (Weighted-Average)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Probability of achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80% - 100% (92%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80% - 100% (94%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments Held-to-Maturity&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's short-term investments consist of U.S. treasury securities with maturities at the time of purchase that were between 90 days and one year. The Company classifies these investments as held-to-maturity debt securities, which are reported at amortized cost, and are Level&#160;I assets as described above. As of March&#160;31, 2023, the Company held no short-term investments and, as of December&#160;31, 2022, short-term investments comprised U.S. treasury bills recorded at amortized cost of $24.6 million with a fair value of approximately $24.6 million. As of December&#160;31, 2022, gross unrealized losses on short-term investments were insignificant. As part of its banking partner diversification efforts, the Company sold $40.0&#160;million U.S. treasury bills with an amortized cost of $39.8&#160;million for $39.8&#160;million and realized a gross gain of $13&#160;thousand during the three months ended March 31, 2023. No realized gains or losses on short-term investments were recognized in 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i34f2f83e07404b9d85ed5e0e5c227d9a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTcxOQ_979fcddc-2637-46d4-af67-6df2851dfca2"
      unitRef="usd">42300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i07f2d93ca49a414380853162fba3a86c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTcyNg_25393448-caaf-4a74-a089-63799c260e17"
      unitRef="usd">131200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:SecurityDeposit
      contextRef="ia0afc28f37da46bb8ed8617d3e377f9d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTg2Ng_79f95626-ba30-4ea9-b7f6-f2274e00f306"
      unitRef="usd">700000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="i3e25dbe0d25644d0a01543012862a8ba_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTg2Ng_f825ee1e-039a-4547-ba15-ec9bca5fe659"
      unitRef="usd">700000</us-gaap:SecurityDeposit>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="id21ec14e64244f3c9d1c3685ce9e8719_D20191203-20191203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjMxNg_ee888c44-796a-4734-b54b-e2947e2a8066"
      unitRef="usd">40000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="ie03a5b408d42420d880fd6b44b057d7b_D20191203-20191203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjMzMQ_2b7d6bc2-8e86-4d4a-8ff8-d5c99b77f4d7"
      unitRef="usd">10000000.0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <vcyt:BusinessCombinationContingentConsiderationCashToBePaid
      contextRef="id21ec14e64244f3c9d1c3685ce9e8719_D20191203-20191203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjM5Mg_439fe7bb-8ea2-4818-a7ea-e51aec0e5d57"
      unitRef="usd">10000000.0</vcyt:BusinessCombinationContingentConsiderationCashToBePaid>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia65218b5801a4550bb42420dd8cece53_I20191203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjYzNw_9fd3170d-224a-4be6-b3e3-66258022526c"
      unitRef="usd">6100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3c9422a55af4419da61a04b81e81fff6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjgyMQ_82e72afc-d171-45af-81f7-6386cf00e10b"
      unitRef="usd">8100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i155fac1703104d38b903faacc0c23041_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMjgyOA_f140c827-d950-441b-8348-148f3085f3ce"
      unitRef="usd">8600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <vcyt:BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment
      contextRef="i06680ff3bcf24e32836ef9479192a82f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMzAyMQ_b377770a-6344-4d9d-bc42-47e609dde6e5"
      unitRef="usd">-500000</vcyt:BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment>
    <vcyt:BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment
      contextRef="i339749b1f05542c299fce2f9a4340ccf_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMzAyOA_4dfe0be2-7f67-4633-a4d3-ec02ba330880"
      unitRef="usd">0</vcyt:BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i3c9422a55af4419da61a04b81e81fff6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMzM0NQ_20a9945c-37f3-44c3-9fa2-0954f6cd04af"
      unitRef="usd">3300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfNDkxNA_ea7d4a06-135e-4aba-8627-6a2fc5c7d0c4">As of March&#160;31, 2023 and December&#160;31, 2022, the Company calculated the estimated fair value of the milestones using the following significant unobservable inputs:&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value or Range (Weighted-Average)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Probability of achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80% - 100% (92%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80% - 100% (94%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6732d99af20b4ace884710631c821dc1_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMi0yLTEtMS03MjEyMw_814191c9-96bb-4b9b-b3f3-2bef6a2f7b9a"
      unitRef="number">0.076</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i56eb27109dad47bc902852a7e617ff8a_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMi00LTEtMS03MjEyMw_32836233-82d5-422a-8dd7-a5616ef179cb"
      unitRef="number">0.083</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i9f89531611514010b1fddd2d6b74728c_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy0yLTEtMS03MjEyMy90ZXh0cmVnaW9uOmFjM2M0ZDRmMDgyMDRhMTZiMGM1Nzg0ZjAwNjAzMDM1XzQ_dd4474ba-5f58-4745-a050-cb9bfcaa1fef"
      unitRef="number">0.80</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ibe50f34924204d0f9cb24feac29d3c92_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy0yLTEtMS03MjEyMy90ZXh0cmVnaW9uOmFjM2M0ZDRmMDgyMDRhMTZiMGM1Nzg0ZjAwNjAzMDM1Xzk_e39db3f1-c404-432c-ad9c-d2b301b46c40"
      unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i5b2066a3df0741c0a292648be37edb62_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy0yLTEtMS03MjEyMy90ZXh0cmVnaW9uOmFjM2M0ZDRmMDgyMDRhMTZiMGM1Nzg0ZjAwNjAzMDM1XzEz_af53b722-56ca-4490-92bd-5f891a4d30dc"
      unitRef="number">0.92</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic4ebc4a8eea343589c8c8c3823833416_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy00LTEtMS03MjEyMy90ZXh0cmVnaW9uOjNiMGZlYzljMDRmZDQyMTJhNDYxODM4Y2JmMDkxMzRhXzQ_0102960c-9b86-417c-85e1-e61b27a93063"
      unitRef="number">0.80</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i56240dd72d974100bdcfa48ff0885b32_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy00LTEtMS03MjEyMy90ZXh0cmVnaW9uOjNiMGZlYzljMDRmZDQyMTJhNDYxODM4Y2JmMDkxMzRhXzk_1c3f8858-269a-4b9a-b0c2-cc476b041fef"
      unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3d7ee7173c0f4858a01e1d1da5a312b6_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RhYmxlOjRiZWNhNjE0Yzc1MjQ4NmNhMDMyODBhZGEwYzNjZDFlL3RhYmxlcmFuZ2U6NGJlY2E2MTRjNzUyNDg2Y2EwMzI4MGFkYTBjM2NkMWVfMy00LTEtMS03MjEyMy90ZXh0cmVnaW9uOjNiMGZlYzljMDRmZDQyMTJhNDYxODM4Y2JmMDkxMzRhXzEz_c7247033-dc99-4dad-86df-147eb1e5f205"
      unitRef="number">0.94</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODYzNQ_d4650f9b-6b44-4559-90d3-fdba4b769328"
      unitRef="usd">0</us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfNDc4Mw_e94c6afc-69c3-4b3e-8e70-4e4f6646d5a1"
      unitRef="usd">24600000</us-gaap:DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfNDgyNA_aca50851-4271-4e86-86f8-e0679403a960"
      unitRef="usd">24600000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldtomaturitySecuritiesSoldAtPar
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODU2NA_3bb24c1a-b498-47c7-b2e5-4523100e2c18"
      unitRef="usd">40000000</us-gaap:HeldtomaturitySecuritiesSoldAtPar>
    <us-gaap:DebtSecuritiesHeldToMaturitySoldAmount
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODU3OQ_67f5d328-867b-4485-abcb-3d6d18b47526"
      unitRef="usd">39800000</us-gaap:DebtSecuritiesHeldToMaturitySoldAmount>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODU5NA_b0ee12b8-309b-4b20-bb13-c3b3bc6239b2"
      unitRef="usd">39800000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODYwOQ_6350eb55-a52a-473a-8cb4-986b0f2d2a8e"
      unitRef="usd">13000</us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="i81d34a4128834b43aa56aba5f1ba758a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180Ni9mcmFnOjg4OGZkZWVhZGFhODRmZDliNjQ3NWIxMjFhNmViNDE3L3RleHRyZWdpb246ODg4ZmRlZWFkYWE4NGZkOWI2NDc1YjEyMWE2ZWI0MTdfMTY0OTI2NzQ0ODYyNg_43b7e825-ecfc-45f2-a226-69e9dbbc7c39"
      unitRef="usd">0</us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc0OA_cbb69d92-82f9-496b-9c58-f62adaefa585">Commitments and Contingencies&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office and laboratory facilities in South San Francisco and San Diego, California; Austin, Texas; Marseille, France; and Richmond, Virginia, and leases certain equipment under various non-cancelable lease agreements. The lease terms extend to October 2030 and contain extension of lease terms and expansion options. The leases have a weighted average remaining lease term of 3.6 years as of March&#160;31, 2023. The Company had deposits of $0.7&#160;million included in long-term assets as of both March&#160;31, 2023 and December&#160;31, 2022 restricted from withdrawal and held by banks in the form of collateral for irrevocable standby letters of credit held as security for the leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined its operating lease liabilities using payments through their current expiration dates and a weighted average discount rate of 6.4% based on the rate that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments in a similar economic environment. Operating lease liabilities along with the associated right-of-use assets are disclosed in the accompanying condensed consolidated balance sheets.  After the adoption of ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 842, the Company classified its deferred rent for tenant improvements with its operating lease right-of-use assets on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancelable operating leases as of March&#160;31, 2023 are as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: short-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes operating lease expense on a straight-line basis over the non-cancelable lease period. The following table summarizes operating lease expense and cash paid for amounts included in the measurement of lease liabilities (in thousands of dollars): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company has leased laboratory equipment under various financing leases. The total right-of-use assets and total financing lease liabilities for these financing leases were $0.2&#160;million and $0.2&#160;million, respectively, as of March&#160;31, 2023, and are included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MQ_8dcd2a74-c451-48ee-8234-99b6286ac891"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MQ_b8e18883-b7ca-498a-8118-1cbdf8c548c4"&gt;property, plant and equipment, net&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1Mg_135ebc69-b606-42ce-b152-da2f2dbc668a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1Mg_7fac536f-70a2-4239-a5bf-1ba0e01d202a"&gt;other liabilities&lt;/span&gt;&lt;/span&gt; in the accompanying condensed consolidated balance sheets. As of December&#160;31, 2022, the total right-of-use assets and total financing lease liabilities for these financing leases were $0.4&#160;million and $0.4&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s wholly-owned foreign subsidiary has entered into an arrangement under which it expects to sign a lease agreement for facilities which will be constructed in Marseille, France. The lease will commence upon completion of the construction of the office building which the Company currently expects to occur in the third quarter of 2023 at which time the Company will record a lease liability and a corresponding ROU asset. The initial term of the lease will be twelve years with annual rent of approximately $1.3&#160;million, which is subject to change based on final construction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no litigation pending that could have, either individually or in the aggregate, a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib3cca4fb364f4aa1a78fc4dbfe0f75ee_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfNDUz_9950179b-89d0-4e6f-ab50-66741a818b7a">P3Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:SecurityDeposit
      contextRef="ia0afc28f37da46bb8ed8617d3e377f9d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfNDk0_79f95626-ba30-4ea9-b7f6-f2274e00f306"
      unitRef="usd">700000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="i3e25dbe0d25644d0a01543012862a8ba_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfNDk0_f825ee1e-039a-4547-ba15-ec9bca5fe659"
      unitRef="usd">700000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfODQ0_1efde12b-ab39-4c82-8563-3076e1cdc2ba"
      unitRef="number">0.064</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc0OQ_422f1ef7-a2ec-4670-ba4b-93dbe34be12e">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancelable operating leases as of March&#160;31, 2023 are as follows (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: short-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfMS0xLTEtMS03MjEyMw_1da39706-fbc4-4bd4-a94b-13dbe74d7ff1"
      unitRef="usd">3551000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfMi0xLTEtMS03MjEyMw_6614a22c-fb44-4529-b0e3-d66870cc1303"
      unitRef="usd">4449000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfMy0xLTEtMS03MjEyMw_c9170777-09fe-4288-bd19-3d3f1c5a49b8"
      unitRef="usd">4491000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfNC0xLTEtMS03MjEyMw_93012c6c-1d90-465e-a2ec-c518d64bf2f5"
      unitRef="usd">1405000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfNS0xLTEtMS03MjEyMw_707fce1f-5c8c-4dce-ade7-88136507e7ad"
      unitRef="usd">699000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <vcyt:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfNi0xLTEtMS03MjEyMw_0d1dd97c-40d6-4c11-a40e-5ec861f4bd96"
      unitRef="usd">885000</vcyt:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfNy0xLTEtMS03MjEyMw_28ecda9e-1b5d-4d41-b9cf-b6d076ba9515"
      unitRef="usd">15480000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfOC0xLTEtMS03MjEyMw_318af399-6b3c-4588-975a-53471037f43b"
      unitRef="usd">1695000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfOS0xLTEtMS03MjEyMw_d16c86ca-d8a2-4b03-b62e-537e2571e185"
      unitRef="usd">13785000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfMTAtMS0xLTEtNzIxMjM_4a2626e3-3288-4b6e-a84b-747a8e75520d"
      unitRef="usd">4076000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjk1NjE1NjA2ODViZDQyNThiNjdhYTFmODE5Mjk2NDMzL3RhYmxlcmFuZ2U6OTU2MTU2MDY4NWJkNDI1OGI2N2FhMWY4MTkyOTY0MzNfMTEtMS0xLTEtNzIxMjM_b6cdcb2c-d7bc-49c7-b516-fae7cfcbeacc"
      unitRef="usd">9709000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMzc1MA_337f08c0-be87-42bf-9816-9668ed79eec1">The following table summarizes operating lease expense and cash paid for amounts included in the measurement of lease liabilities (in thousands of dollars): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjA5ZDAxNGY1YzQ2NjQwMTJhZDAxNGI3YTdhZDU2ZTA2L3RhYmxlcmFuZ2U6MDlkMDE0ZjVjNDY2NDAxMmFkMDE0YjdhN2FkNTZlMDZfMi01LTEtMS03MjEyMw_293a3d37-9ac8-4699-bbf5-4dac8c371e26"
      unitRef="usd">1123000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjA5ZDAxNGY1YzQ2NjQwMTJhZDAxNGI3YTdhZDU2ZTA2L3RhYmxlcmFuZ2U6MDlkMDE0ZjVjNDY2NDAxMmFkMDE0YjdhN2FkNTZlMDZfMi03LTEtMS03MjEyMw_1f8b66a8-5516-4a6e-9654-39279b7f5e1e"
      unitRef="usd">1054000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjA5ZDAxNGY1YzQ2NjQwMTJhZDAxNGI3YTdhZDU2ZTA2L3RhYmxlcmFuZ2U6MDlkMDE0ZjVjNDY2NDAxMmFkMDE0YjdhN2FkNTZlMDZfMy01LTEtMS03MjEyMw_ab6db79e-ec93-4aef-b82d-b75a2b3b6af5"
      unitRef="usd">1177000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RhYmxlOjA5ZDAxNGY1YzQ2NjQwMTJhZDAxNGI3YTdhZDU2ZTA2L3RhYmxlcmFuZ2U6MDlkMDE0ZjVjNDY2NDAxMmFkMDE0YjdhN2FkNTZlMDZfMy03LTEtMS03MjEyMw_f92e6c71-2a5b-40f6-af47-10301989e4dc"
      unitRef="usd">1068000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjE4OA_97ab0153-ed5a-4b9d-ac2f-7ddfa3b83578"
      unitRef="usd">200000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjE5NQ_667fbf76-744e-46fe-be22-d4cc58e3aa57"
      unitRef="usd">200000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjQ2Mg_d73d5fd9-0aee-4796-80ac-811abe743328"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjQ2OQ_8f6e4d85-dae8-44a7-b704-6e540ad2b728"
      unitRef="usd">400000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="i38b169efb35741c0a4e5cbe287a00d95_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjk2Mg_5151b7f6-f0ca-4038-928e-9007e323561f">P12Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <vcyt:LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount
      contextRef="i38b169efb35741c0a4e5cbe287a00d95_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y180OS9mcmFnOmUxNGE3N2Y3ZWYzNzQ3MjhiYjhlYWY4ZDQ3NDhiMGE0L3RleHRyZWdpb246ZTE0YTc3ZjdlZjM3NDcyOGJiOGVhZjhkNDc0OGIwYTRfMjk5OQ_29cfb0b1-4414-4f41-85c0-1c774683e653"
      unitRef="usd">1300000</vcyt:LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RleHRyZWdpb246MmUzNjVlZDQ0M2EwNGQ4MmExZjNkOWNiOTQzY2I5ZmVfMTIy_db626b5a-9e11-4627-97f3-f12fb6fd6e44">Stockholders&#x2019; Equity&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options and restricted stock units issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,054,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,881,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options and restricted stock units available for grant under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,322,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,591,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock available for the Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,242,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,335,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,620,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,809,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RleHRyZWdpb246MmUzNjVlZDQ0M2EwNGQ4MmExZjNkOWNiOTQzY2I5ZmVfMTIz_c058c70a-f5d8-4fad-95f3-5a2f7b19a940">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options and restricted stock units issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,054,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,881,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options and restricted stock units available for grant under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,322,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,591,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock available for the Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,242,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,335,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,620,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,809,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idd87d5a6accd4b1fbbdd377429adeb05_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMS0xLTEtMS03MjEyMw_c2d130da-0246-4b40-aa96-fb04d5e6da60"
      unitRef="shares">7054474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i41c953ff703f4c40b8196a40233b0bea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMS0zLTEtMS03MjEyMw_eab06743-65cb-42d3-86b1-68df90ab9fbf"
      unitRef="shares">5881906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="idd87d5a6accd4b1fbbdd377429adeb05_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMi0xLTEtMS03MjEyMw_943900e5-9690-49bc-a076-1947f3f599f5"
      unitRef="shares">5322628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i41c953ff703f4c40b8196a40233b0bea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMi0zLTEtMS03MjEyMw_e719dcb4-2eb1-4a58-b5e6-cb895ad54357"
      unitRef="shares">5591977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i589fe7123b7241eea985d689b319d8bb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMy0xLTEtMS03MjEyMw_94f4331e-4171-4458-9cf5-8ca8e4e64e77"
      unitRef="shares">1242954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ibf67fe5c4e9c4625bf91b35cf11db759_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfMy0zLTEtMS03MjEyMw_4dd70600-276d-4b3c-a677-b2e5d1c61e5c"
      unitRef="shares">1335353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i228462769a464129ba617b5c0e672ec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfNC0xLTEtMS03MjEyMw_1b570690-370c-45e0-851d-698fab0f0226"
      unitRef="shares">13620056</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i17d209f7b20f4172bb058631b2f4238e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181NS9mcmFnOjJlMzY1ZWQ0NDNhMDRkODJhMWYzZDljYjk0M2NiOWZlL3RhYmxlOjg0ODQ0NWE4NGNlNTQ2YzFiMGJhNGMwMjFlOGIxMDhlL3RhYmxlcmFuZ2U6ODQ4NDQ1YTg0Y2U1NDZjMWIwYmE0YzAyMWU4YjEwOGVfNC0zLTEtMS03MjEyMw_45d00b7d-5093-4068-800b-dc2be1925ae7"
      unitRef="shares">12809236</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RleHRyZWdpb246MjBjODczMGRkMGUyNDhlY2IyYWFlZDkyNTY5MmJlNmZfMTI0_db96c4bc-257a-43be-a282-388579425f81">Components of Other Income&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Other income, net consists of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;French research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain (loss) on currency revaluation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RleHRyZWdpb246MjBjODczMGRkMGUyNDhlY2IyYWFlZDkyNTY5MmJlNmZfMTI1_d4b02c4d-9132-456a-9316-7b0e87d2c0a4">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Other income, net consists of the following (in thousands of dollars):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.088%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;French research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain (loss) on currency revaluation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <vcyt:OtherNonoperatingIncomeExpenseForeignTaxCredit
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfMi01LTEtMS03MjEyMw_2b722e7d-58e8-4684-ac75-d6c59ec89f3e"
      unitRef="usd">1009000</vcyt:OtherNonoperatingIncomeExpenseForeignTaxCredit>
    <vcyt:OtherNonoperatingIncomeExpenseForeignTaxCredit
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfMi03LTEtMS03MjEyMw_394e4b5a-0625-40b7-ad99-142c73839e62"
      unitRef="usd">892000</vcyt:OtherNonoperatingIncomeExpenseForeignTaxCredit>
    <vcyt:OtherNonoperatingIncomeExpenseInterestIncome
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfMy01LTEtMS03MjEyMw_557ac925-49bc-43d7-bdbf-307130e1fc27"
      unitRef="usd">1189000</vcyt:OtherNonoperatingIncomeExpenseInterestIncome>
    <vcyt:OtherNonoperatingIncomeExpenseInterestIncome
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfMy03LTEtMS03MjEyMw_731fbc68-88d5-4eaf-b629-3fe231f49f3e"
      unitRef="usd">39000</vcyt:OtherNonoperatingIncomeExpenseInterestIncome>
    <vcyt:OtherNonoperatingIncomeExpenseInterestExpense
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNC01LTEtMS03MjEyMw_984c17e6-b7a8-4ff9-b6c4-c680ebb44635"
      unitRef="usd">7000</vcyt:OtherNonoperatingIncomeExpenseInterestExpense>
    <vcyt:OtherNonoperatingIncomeExpenseInterestExpense
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNC03LTEtMS03MjEyMw_e2fadaf6-cb21-431b-981f-e8c4bad363e3"
      unitRef="usd">61000</vcyt:OtherNonoperatingIncomeExpenseInterestExpense>
    <vcyt:OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNS01LTEtMS03MjEyMw_9bde3649-556b-49d0-87fd-0399db26c33a"
      unitRef="usd">229000</vcyt:OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss>
    <vcyt:OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNS03LTEtMS03MjEyMw_5c5d9546-66a3-4d80-889b-8104f4b0c8df"
      unitRef="usd">-100000</vcyt:OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss>
    <vcyt:OtherNonoperatingIncomeExpenseOther
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNi01LTEtMS03MjEyMw_fc8915a6-22b5-40df-85df-f35d61634e7e"
      unitRef="usd">-13000</vcyt:OtherNonoperatingIncomeExpenseOther>
    <vcyt:OtherNonoperatingIncomeExpenseOther
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNi03LTEtMS03MjEyMw_c33c4617-0cab-4c04-a625-9f518a735fee"
      unitRef="usd">14000</vcyt:OtherNonoperatingIncomeExpenseOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNy01LTEtMS03MjEyMw_d6fa45b3-0a02-4970-9865-99abfdbca988"
      unitRef="usd">2407000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y181OC9mcmFnOjIwYzg3MzBkZDBlMjQ4ZWNiMmFhZWQ5MjU2OTJiZTZmL3RhYmxlOjMzY2ZlNjY3OGExNTQ3MGZiNmJhYTM2MDRlMDIxMGM1L3RhYmxlcmFuZ2U6MzNjZmU2Njc4YTE1NDcwZmI2YmFhMzYwNGUwMjEwYzVfNy03LTEtMS03MjEyMw_873f12e9-d13e-426c-9d5c-c2f0775364c5"
      unitRef="usd">784000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y182MS9mcmFnOjc2MmRkM2VlYjk4OTQ4ZGViODZlMGI0YjNjZWE0N2FlL3RleHRyZWdpb246NzYyZGQzZWViOTg5NDhkZWI4NmUwYjRiM2NlYTQ3YWVfODYy_2591558c-19c9-4181-9f77-ca39a5143193">Income Taxes&lt;div style="text-indent:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded no income tax expense for the three months ended March 31, 2023 and an income tax benefit of $3.0&#160;thousand for the three months ended March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Inflation Reduction Act of 2022 was signed into law August 16, 2022, and includes significant legislation addressing taxes, inflation, climate change and renewable energy incentives, and healthcare.  Key tax provisions include a 15% corporate minimum tax, clean energy incentives, and a 1% excise tax on stock buybacks. The Company does not expect the provisions of such legislation to have any impact on the effective tax rate of the Company but will continue to evaluate the tax effects should any provisions become applicable to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y182MS9mcmFnOjc2MmRkM2VlYjk4OTQ4ZGViODZlMGI0YjNjZWE0N2FlL3RleHRyZWdpb246NzYyZGQzZWViOTg5NDhkZWI4NmUwYjRiM2NlYTQ3YWVfMTY0OTI2NzQ0NDAyOQ_1ff8a178-d544-4be1-b48a-f87f037fadd4"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9ac7ebefdfbf4f2e87bb6c2fcbff7d3a_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRmMmVmM2Q4MDcyODRmYjhiMmJmMjI4NGQ4NTdmMDhjL3NlYzo0ZjJlZjNkODA3Mjg0ZmI4YjJiZjIyODRkODU3ZjA4Y182MS9mcmFnOjc2MmRkM2VlYjk4OTQ4ZGViODZlMGI0YjNjZWE0N2FlL3RleHRyZWdpb246NzYyZGQzZWViOTg5NDhkZWI4NmUwYjRiM2NlYTQ3YWVfNTQ5NzU1ODE1OTAw_808fbac0-7fa5-4522-80fe-36539b196495"
      unitRef="usd">-3000</us-gaap:IncomeTaxExpenseBenefit>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .Q I58'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #L0*56^5 -G>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VU1(71S43PI""XHWD(RNQMLTI",M/OVIG&WB^@#"+EDYL\W
MWT!Z'80>(S[',6 DB^EJ=H-/0H<-.Q % 9#T 9U*=4[XW-R-T2G*U[B'H/2'
MVB.TG-^ 0U)&D8(%6(65R&1OM- 1%8WQA#=ZQ8?/.!28T8 #.O24H*D;8'*9
M&([ST,,%L, (HTO?!30KL53_Q)8.L%-R3G9-3=-43UW)Y1T:>'MZ?"GK5M8G
M4EYC?I6LH&/ #3M/?NWN[K</3+:\[2I^G<^V:06_%0U_7UQ_^%V$W6CLSOYC
MX[.@[.'7OY!?4$L#!!0    ( .Q I5:97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M&9A.2& LL"8/5RJZ766_0^,;<IX5G&<U6Z;B,(WDLT!U'G&M&8]2:R+1L(:
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M2Z[(BD>9."$_.Z?@&<D25KCY\M]:"\>P5*RT5 PW/>#W@S"9D\DFGLK(!G]
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M*Y252U'P=ZCDUGQPB-$;C[X769":AE$\/,MP5S.QLUHUK7K+09OR UBDV/W
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M-G"Z#DEA2A>YOA>K3U#Y$QF^1.3*_I)59>LY)%DH+8H*C H*QLLG?:KBL %
MGF: 7P'\74!X !!4@, Z6BJS;EU33>.^%"LBC36RF86-C46C-XR;+(ZUQ%N&
M.!V/!$\Q)Y 27"F1LY1JW(PU/C!96A$QQ:L"2R0SN5L"^2R4(J</G"Y2AK9G
MY)P\C*_)Z<D9.2&,DV^96"C*4]5W-2HT[W&32LVP5.,?4!.06\%UIL@'5)5N
MXUWTK';/7[LW](\2WE)Y08+6.^)[?M"@9_3_</^(G*".=F#Y@@-\=5CWHWK#
M$U$ ^7DU45IB<?]JBE[)'C:SFP^^I^8T@8&#Q KD$ISX[9M6VWO?Y/HKD6T%
M(JP#$1YCC[]@?\JQCIJ<+)%MBS1-:!F?=[W+5M]=;JIOL&J%8?O%;$M75.N*
MCB;HJ\Y DF0K,ZS,S*G1>]9K4AR]9EI>B6S+_7;M?OMH6D89Y3/C,;8>*8$G
MSP2+D:N<ECTW_8T=R;:%IC"4W-%&2L*PZ^WD;=_H/(HNN\UIZ]2Z._\LI^VD
M'2JNSG[9!.W6;G$U6.%8C"YW5+H;?;< .;/C2*&2!==ECZI/ZXEW91O]SOD0
M)V$YN%YHRC&*'6C&N"(Y3)'2N^A@Y&0YFLJ-%G/;W2="XZRPRPRG.4AC@/=3
M(?1Z8UY0_S^(_P)02P,$%     @ [$"E5HR[#U\S!P  F#4  !@   !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6S%6UUSFS@4_2L:;V>WF:EK)+Z[B6>V-LQV
M9C\R3;O[L+,/!)28*2 7<)+^^Y4P-4;("B1WVY<$;-USI'MT!1SA\WM6?JHV
ME-;H(<^*ZF*VJ>OMF\6BBC<TCZK7;$L+_LT-*_.HYJ?E[:+:EC1*FJ \6Q##
M<!9YE!:SY7GSV66Y/&>[.DL+>EFB:I?G4?GE+<W8_<4,S[Y^\#Z]W=3B@\7R
M?!O=TBM:?]Q>EOQL<4!)TIP65<H*5-*;B]DO^$UH&B*@:?%72N^KHV,DAG+-
MV"=Q\BZYF!FB1S2C<2T@(O[OCJYHE@DDWH_/+>CLP"D"CX^_HH?-X/E@KJ.*
MKECV=YK4FXN9-T,)O8EV6?V>W?]*VP'9 B]F6=7\1?=M6V.&XEU5L[P-YCW(
MTV+_/WIH$W$4@,T3 :0-(&,#S#; E *(>R+ :@,L.>#4&.PVP)8"S%,,3AO@
M-+G?)ZO)]#JJH^5YR>Y1*5IS-''0R-5$\P2GA9A95W7)OTUY7+U<L2+A\X0F
MB!]5+$N3J.8G5S7_QR=072%VP\]8_&G#LH26U4\H^+Q+ZR_HY<<BVB4I;WV&
MYNCCU1J]?'&&JDU4T@JE!?JP8;LJ*I+J%7K1.S]?U+SC@GX1MYU\N^\D.=')
M#ZR.,D782A^V8GG.)V_3>T7T6A_]2\('QR=_E*'+*$WF? BK:)NJ>Q(\@A7'
MNWR7-:E=TYLT3FL%2#@>Y,]Z0TLN6<Z7DXVH\SN*?F.5E-L%GPR'&4$.,X(T
M--8)FK=1%A4Q15&-KNEM6A1I<2LFP9:6*4O02YZ'O<AGHLF:QJ^1B5\A8A"L
M4E9+)M;--]4VBNG%C(^DHN4=G2U__ $[QL\JO?=@=@,FULR[I8LQ,<\7=\>Z
M0E(&D& A$%A/5_.@J_D<7<=HN2=PCM*/#=^QL=478#5LYV))(P64Y7B.)VD9
M#-O-3=O%MMMO%RK:8=LX@NOES#KDS&KBS!,Y>U?$_')=4?22YZ8Y.A-+F7(]
M_.<]RS+$+W?W49G\JTJ?!5D*D&!K2+  $BP$ NNI;Q_4M[45\ZZJ=DW)\"J)
M]]>22BB/^ %]H&6<5LUW[8=;<;6H$+_$H3M:U6UY\6[591J+17O?;E>D_*IZ
MM(RJIHJV8U.GBCU8-0GQI'J$) P@P4(@L-X,< XSP/E>,T"ENC,0"EN$2(NK
MML=3"W\,8P#)& *!]>1T#W*Z3Y-SQV^"2Q1<75X^5IA:@JF%Z0ZR[TFY7T/R
M!9!@(1!83TCO(*3W7"%5XGG#A1!C6ZHO+?/4^AK#&$ RAD!@/5G\@RR^5I8/
MT0/:LK*Q#+@R8@WDB][X]<\?9&N.+4NZU5MI^S!5H%&4 21E" 364P@;W?.^
MH=6HN7>="S,F$:6SY0^/42,8?1#'_%:7YMN,?:%4N?ZUZ,<)<XAI2!+I^S!5
MHU&< 2AG"(765^G(E<'/5*E@Q5RO%!Y>V[&LD[87DW5ZG#$ 90RAT/HJ=4X)
MUELECZLDKD1J=896AF7(S]%Z^LGRC* ,0"E#*+2^/IWC@?66QQ^T1MG %6L%
M,)4KOS,H$2W%9 T@T8*18PBA6/LR="8*UCZE+_=F9=PS*]."G_,"$?*H"\0:
MCLVV?4^6!]0' 44+0-'"1Q/25Z<S.;#>Y3CR!2E_<#WI]/X>E0=WD"@5 S4M
M\-"U<+%EREXO*&D BA9"H?6%[;P+K#<O3@H[2DR%,V!X-O8'MWK.XV:O"LQR
M70M[\M5GV'!NNMB1&X:JAL1P/'RB&CJ' .LM@J?O?JC3".H7X*%AX&+?]N5T
M@YH&H&@A%%I?WLXWP'KC8-HFB%K2X3,]-ER;&(/*\(:5(=L[*C#;,+ _N&\>
M-IR;/J\->2-$V1";EG.B,KIG>^Q_P[T0#/E(O0)%6X.B!:!H(11:?VNX<P^(
MWCWXCELB^IY-WDD>>@JF*5<G*&4 BA9"H?4G0F=0$+U!\8UW1HC"6O ]^6%
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M!DE>;G[Y[<WKX_-O9@QD2BJH4;S.'$PR@ET((UH.@-":=KWCHX)T4JQNI#*
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M=\AU."]C:)X$<M?65-'D@3>WV(4J?*F+J4N/"&(646EX4M$CT]O.:[<THQI
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MHTP39!"EA!V9CDZWQ1C\IZOC#7=+;S@_A.VV1$U LP??WD%BT9>J,'(7OFM
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ME<2!:F@!YA=:N_&#-MC_8^'VWU!+ P04    " #L0*56KOW]P04*   =&P
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M92ZO*1D?;>VLIC.S0CH]HQ,#CD#:::,YK0&T"^#3>IOV<9W* 9ZW54X#2U@
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MLZY@OBU&+,(+DDW9-FF5X:)"\4+=G*)N;A<Z C00_S(=F/1V]+;?#1YX&Q%
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M&Z[5;X@ND@6FV.0"(54*E$@0.R4ILL*X[("H!'QMK"PX@GO8L.O%'*;: V>
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MY3FS;#[5:@W:G28TM_!2?321X])=RHW5M,LISLXO&-=PST2#<(7,-!JIXM;
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MHK(&I%]):?87&Z ;Z,D_4$L#!!0    ( .Q I588)GIUU0,  $L-   9
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MTAJ8YRLA]'YB-ZB_G\;? %!+ P04    " #L0*56PP*R$Q\$  !M%P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R]6%UOVS84_2N$AA4;D$:?L9/4
M-I!8*UJ@60R[[1Z&/3#2M45$(CV2MIMB/WXD)<N6(0MV0.3%$BF>0]ZC>^1+
M#C:,/XL,0*(?14[%T,FD7-ZZKD@R*+"X9$N@ZLF<\0)+U>0+5RPYX-2 BMP-
M/*_G%IA09S0P?1,^&K"5S F%"4=B5128O]Q#SC9#QW>V'5.RR*3N<$>#)5[
M#.2WY82KEENSI*0 *@BCB,-\Z-SYM['?UP SXCN!C=B[1SJ4)\:>=>-S.G0\
MO2+((9&: JO+&L:0YYI)K>/?BM2IY]3 _?LM^T<3O KF"0L8L_PODLILZ%P[
M*(4Y7N5RRC:?H KH2O,E+!?F%VVJL9Z#DI60K*C :@4%H>45_ZB$V ,HGG9
M4 &"0T!T!!!6@/ 0T#L"B"I 9)0I0S$ZQ%CBT8"S#>)ZM&+3-T9,@U;A$ZK?
M^TQR]90HG!P]\@6FY"?6+^$"Q2 23I;FC; YNE\)-5P(A&F*9F5FZ/X965 R
M)PFF$MTE"5M12>@"35A.$@("O4<SE9_I*@<]^FM&>/I^B;E\01/\ ER@.\7W
M*#/@:&Q"U'V_Q2 QR<7O"K[M10FC"5#)S?H0)^)YX$H5MEZ\FU0AWI<A!D="
M#-$#HS(3Z ^:0MJ"C[OQ?M!!X"J]:]&#K>CW02?C ^:7*/0O4. %8<N"QJ?#
M@[9XNN$Q),?@C6C".H5"PQ<=X9O"&N@*T'_H 5*5%!S:WE$GA_ZZW8HE3F#H
MJ,^7 +X&9_3N%[_G?6C3QR99;(FLH5U4:Q<9]O"(=I5[Q 7ZDTE0ER\,T])O
M'PG%--&^FD("9(V?E)W^_J((T&<)A?BG3>7(ILHVR6)+9 V5KVJ5KSHS='S2
M5Z3DN#$<^N]R/?(N0W_@KO<U:1W4'!-W+N:5H?;J4'LGFO$;)1+23X!SF1TS
M92?7N>EBDRRV1-;0L%]KV']34_9MJFR3++9$UE#YNE;YVH(IKUO\=NC)MC'>
MS8$I.Q?SRE!OZE!O3C3EKMR9@IFHK)S>+>0'W_L5/:IJB4F<HPK1IDCG5.=F
MDTVRV!)90V+?VQ6RWINZMIK.DM!6V6);;$VI]_8,O@7K5B1-7T:'YFT=%1ZZ
MMWM!KPTXV 4<= :\S2VUTZWSI[O<[28\.WMLLL6VV)IB[K8+?OBV1K6ZM;#*
M%MMB:TJ]VUWXG67UJ4:-VOYDPT.C6MT.M,\9U7,V ]X5^GYWI=]NU%-*X6[B
ML[/()EMLBZTIZFY+X??>UK!6MQU6V6);;$VI=SL/O[/D/M6P_1.JXNZ9SM:E
M>\HR7'?O'%(5N0MSGBN0R9[R=*SNK<^,[\Q)Z4'_O7\[+D]^=S3E0?0#Y@NB
MDB^'N:+T+OO*&KP\VRT;DBW-:><3DZK2-K<9X!2X'J">SYG*X:JA)ZA/V$?_
M U!+ P04    " #L0*56>\2)+WD#  #W#0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6RU5]MNVS@0_15"6RQ:H!M=8SNI+2"V=[$%6C2(V^U#T0=&
M&DM$)=)+4G9WO[Y#2E9\480&55YLDIIS/'-X3 VG.R&_J1Q D^]EP=7,R;7>
M7+NN2G(HJ;H0&^#X9"UD235.9>:JC02:6E!9N('GC=R2,N[$4[MV*^.IJ'3!
M.-Q*HJJRI/*_.11B-W-\9[]PQ[)<FP4WGFYH!BO0GS:W$F=NRY*R$KAB@A,)
MZYESXU\O_-  ;,0_#';J8$Q,*?="?#.3M^G,\4Q&4$"B#07%KRTLH"@,$^;Q
M;T/JM+]I@(?C/?M?MG@LYIXJ6(CB,TMU/G,F#DEA3:M"WXG=W] 4=&GX$E$H
M^TEV3:SGD*126I0-&#,H&:^_Z?=&B , \G0#@@80G *B1P!A [#*N75FMJPE
MU32>2K$CTD0CFQE8;2P:JV'<;.-*2WS*$*?C#S*CG/U/C::OR1)4(MG&"BS6
M9%XI#%>*4)Z25;W19GW%,L[6+*%<DYLD$177C&?D5A0L8:#('V2%=DNK BP+
M$YN<HN0)5!I!A:7[H'.0Y ZVP"N$O%R"IJQ0KQ#\:;4D+U^\(B\(X^1C+BJ%
M #5U-=9KLG:3IK9Y75OP2&TA>2^XSA7YDZ>0'N-=U*D5*]B+-0]Z"=]3>4%"
M_S4)O"#LR&?Q\_"@)YVPW;O0\H6/\"V9HEDF(:/[#6OD)%_>82AYJZ%47[MT
MJWFC;EYS<ERK#6[7S,&C08'<@A/__IL_\MYT%3T0V9$$42M!U,<>?Q0:_23K
MLKLJK>$C"S='VC:>!)%1?WM8PGG4:#R>A&W446Z7;6Z7O;F=^[XGSUZJI^[(
M0&1'58_:JD?/9,K1D!(,1'8DP;B58/QKIJSAEP=VBZ)H?.+)\Z"Q%XVZ+3EI
M,YOT9K; \U#BFQ/?(+Q:XZ"2YN VY[$&90[QKG1[.9^Z,0.1'95_U99_]4S>
MO!I2@H'(CB3PO8<7OO=K[FSPA\[S1Y-3>W9%X9G9[4__H!WQGWAH&G,*VRST
MY=S+^M0-&HKM6(/@08/@F6S:$ \EPT!LQS(\=#=^;^?P$T8-SU_;?AB=&O4\
M:H(]P(E1W8,6N@29V9N%(K:WK1O$=K6]O=S8GOUD?6YN-;8U?Z"IKT38_F6,
M*U+ &BF]BS'^=V1]RZ@G6FQLHWXO-+;]=ICCS0RD"<#G:R'T?F)^H+WKQ3\
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MN.Q@7E1Q62@F1F9Y^YQ)@\TX'R[Q?@7*'L#]N91F-[$&RAM;^!=02P,$%
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M6/+':)O6WXKG7WDW(-KDBXNT:O^"YR[6FX%X6]5%UC46"+(DW_V/?G03L=<
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M!(C/'XNB?KUH.NB?O5W\'U!+ P04    " #L0*56+'VO>.,"  "E"0  &0
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MY[M#E[L;R;;%J<)[)B5+B\N-JO8HUP^HWU>,R9<;[: Z^CK_#U!+ P04
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M0ZW06T5SMK#]1=X8P-3;N#HI2[[\Q-E4%-1-_N"$PSY9\8*95.S)9(-2F9@
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MQ?-;W[/U]1F3V<J0YJ4[MYG.FMU444MYZ>ONU(UF>?]LI7\N=/X'4$L#!!0
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M]U=@]@502P$"% ,4    " #L0*56!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .Q I5;Y4 V=[0
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( .Q I5:97)PC$ 8  )PG   3              "  <L!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ [$"E5FP.NACY!0  T!\  !@
M             ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( .Q I58^O$!?] 8  -D>   8              " @3L.  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #L0*56:KQ((@,#  !C
M"@  &               @(%E%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ [$"E5L\")JBR!0  XAP  !@              ("!GA@
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .Q I58\,PDU
MX@(  "L(   8              " @88>  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " #L0*56C+L/7S,'  "8-0  &
M@(&>(0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ [$"E
M5JR;%88 "   @"0  !@              ("!!RD  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( .Q I5;]I@#)$!L  (12   8
M      " @3TQ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" #L0*56K=%L77 #   U"   &               @(&#3   >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ [$"E5DM?+#&V!@  9!   !D
M             ("!*5   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " #L0*56KOW]P04*   =&P  &0              @($65P  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .Q I5:=-MZIIP<
M &H2   9              " @5)A  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ [$"E5J47F _6 @  6 8  !D              ("!
M,&D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #L0*56
M0BZ.5:0"  #K!0  &0              @($];   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( .Q I58+E:'P3 ,  &$'   9
M      " @1AO  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ [$"E5DT" +W+%0  UD0  !D              ("!FW(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #L0*56[RKP++$#   6"0
M&0              @(&=B   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( .Q I5:]W<]+!0,  )D&   9              " @86,  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ [$"E5J$&$O5:
M!0  \@P  !D              ("!P8\  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " #L0*56=KC*<\,"   2!@  &0
M@(%2E0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .Q
MI58VKIFTF ,  .8(   9              " @4R8  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ [$"E5GRW<7KG @  708  !D
M         ("!&YP  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " #L0*56T07U6K$"  #<!0  &0              @($YGP  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .Q I588)GIUU0,  $L-
M   9              " @2&B  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ [$"E5L,"LA,?!   ;1<  !D              ("!+:8
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #L0*56>\2)
M+WD#  #W#0  &0              @(&#J@  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( .Q I5;87@$D<0,  ( /   9
M  " @3.N  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M[$"E5I1T0$<B P  O0D  !D              ("!V[$  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " #L0*56$HU&;WT(  "'.P  &0
M            @($TM0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( .Q I58L?:]XXP(  *4)   9              " @>B]  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ [$"E5CJFCAN+ @
M@08  !D              ("! L$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " #L0*56JA#X32,&   &*P  &0              @('$
MPP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .Q I5:!
MR1;6IP(  .D)   9              " @1[*  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ [$"E5J <?", !   M \  !D
M     ("!_,P  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .Q I58>_*@52P(  )4%   9              "
M@6_>  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ [$"E
M5H:T]69) P  SA0   T              ( !\>   'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #L0*56EXJ[',     3 @  "P              @ %EY
M7W)E;',O+G)E;'-02P$"% ,4    " #L0*56*KR9A&@#  ";&@  #P
M        @ %.Y0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ [$"E5D"[
MPRV' 0  O!<  !H              ( !X^@  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ [$"E5O]Y:I*? 0  '1@  !,
M     ( !HNH  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "\ +P# #
&<NP

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>115</ContextCount>
  <ElementCount>218</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization, Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Components of Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ComponentsofOtherIncome</Role>
      <ShortName>Components of Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization, Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Organization , Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization , Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/NetLossPerCommonShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/BalanceSheetComponents</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Components of Other Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ComponentsofOtherIncomeTables</Role>
      <ShortName>Components of Other Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/ComponentsofOtherIncome</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization, Description of Business and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Third-party Payers And Other Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails</Role>
      <ShortName>Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Third-party Payers And Other Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails</Role>
      <ShortName>Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/NetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Balance Sheet Components - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Balance Sheet Components - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Balance Sheet Components - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Balance Sheet Components - Schedule of Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Fair Value Measurements - Fair Value Measurement Input (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurement Input (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseExpenseDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Operating Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/StockholdersEquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Components of Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/ComponentsofOtherIncomeDetails</Role>
      <ShortName>Components of Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/ComponentsofOtherIncomeTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="vcyt-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.veracyte.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.veracyte.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="vcyt-20230331.htm">vcyt-20230331.htm</File>
    <File>exhibit31103-31x2023.htm</File>
    <File>exhibit31203-31x2023.htm</File>
    <File>exhibit32103-31x2023.htm</File>
    <File>exhibit32203-31x2023.htm</File>
    <File>vcyt-20230331.xsd</File>
    <File>vcyt-20230331_cal.xml</File>
    <File>vcyt-20230331_def.xml</File>
    <File>vcyt-20230331_lab.xml</File>
    <File>vcyt-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="473">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vcyt-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 473,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 115,
   "dts": {
    "calculationLink": {
     "local": [
      "vcyt-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vcyt-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vcyt-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vcyt-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vcyt-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vcyt-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 333,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 11
   },
   "keyCustom": 19,
   "keyStandard": 199,
   "memberCustom": 23,
   "memberStandard": 15,
   "nsprefix": "vcyt",
   "nsuri": "http://www.veracyte.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.veracyte.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.veracyte.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.veracyte.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.veracyte.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.veracyte.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Components of Other Income",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.veracyte.com/role/ComponentsofOtherIncome",
     "shortName": "Components of Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.veracyte.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "16",
     "role": "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization, Description of Business and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Organization , Description of Business and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Organization , Description of Business and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Net Loss Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.veracyte.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i17d209f7b20f4172bb058631b2f4238e_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.veracyte.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.veracyte.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.veracyte.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Components of Other Income (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.veracyte.com/role/ComponentsofOtherIncomeTables",
     "shortName": "Components of Other Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Organization, Description of Business and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "ic43b0b3fe6664d3cbdb8a3f4f93ee2bd_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Third-party Payers And Other Customers (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails",
     "shortName": "Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Third-party Payers And Other Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "ic43b0b3fe6664d3cbdb8a3f4f93ee2bd_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails",
     "shortName": "Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i274a02acfdb5475dac6457d7c3ee154b_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Net Loss Per Common Share (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.veracyte.com/role/NetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Balance Sheet Components - Narrative (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsNarrativeDetails",
     "shortName": "Balance Sheet Components - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Balance Sheet Components - Schedule of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails",
     "shortName": "Balance Sheet Components - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Balance Sheet Components - Schedule of Future Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails",
     "shortName": "Balance Sheet Components - Schedule of Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i17d209f7b20f4172bb058631b2f4238e_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i6732d99af20b4ace884710631c821dc1_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Fair Value Measurements - Fair Value Measurement Input (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails",
     "shortName": "Fair Value Measurements - Fair Value Measurement Input (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i6732d99af20b4ace884710631c821dc1_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Expense (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseExpenseDetails",
     "shortName": "Commitments and Contingencies - Schedule of Operating Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.veracyte.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i228462769a464129ba617b5c0e672ec2_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vcyt:OtherNonoperatingIncomeExpenseForeignTaxCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Components of Other Income (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails",
     "shortName": "Components of Other Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vcyt:OtherNonoperatingIncomeExpenseForeignTaxCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.veracyte.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i87aca5bd093645dda8ac7488b345dc9f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i87aca5bd093645dda8ac7488b345dc9f_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization, Description of Business and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization, Description of Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Net Loss Per Common Share",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.veracyte.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vcyt-20230331.htm",
      "contextRef": "i89b8c32126d04b2f8d6bd5e54c228e45_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.veracyte.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r206",
      "r492",
      "r544",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r338",
      "r455",
      "r468",
      "r479",
      "r480",
      "r489",
      "r499",
      "r503",
      "r543",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r338",
      "r455",
      "r468",
      "r479",
      "r480",
      "r489",
      "r499",
      "r503",
      "r543",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r206",
      "r492",
      "r544",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r204",
      "r456",
      "r490",
      "r502",
      "r538",
      "r539",
      "r544",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r204",
      "r456",
      "r490",
      "r502",
      "r538",
      "r539",
      "r544",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r301",
      "r338",
      "r361",
      "r362",
      "r363",
      "r431",
      "r455",
      "r468",
      "r479",
      "r480",
      "r489",
      "r499",
      "r503",
      "r537",
      "r543",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r301",
      "r338",
      "r361",
      "r362",
      "r363",
      "r431",
      "r455",
      "r468",
      "r479",
      "r480",
      "r489",
      "r499",
      "r503",
      "r537",
      "r543",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r479",
      "r480",
      "r558",
      "r560",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r501"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r139",
      "r464",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r18",
      "r21",
      "r108",
      "r424",
      "r469",
      "r470",
      "r517",
      "r518",
      "r519",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r524",
      "r525",
      "r526",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Tax portion of vested restricted stock units"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r37",
      "r61",
      "r66"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Intangible asset amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Shares of common stock subject to outstanding options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r37",
      "r69"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment loss"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r120",
      "r135",
      "r157",
      "r195",
      "r198",
      "r202",
      "r217",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r389",
      "r391",
      "r404",
      "r501",
      "r541",
      "r542",
      "r556"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r129",
      "r141",
      "r157",
      "r217",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r389",
      "r391",
      "r404",
      "r501",
      "r541",
      "r542",
      "r556"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r386",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r96",
      "r97",
      "r386",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r99",
      "r100",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Cash paid in acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "verboseLabel": "Value of shares issued in acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r388",
      "r520"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Revaluation of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r98",
      "r101",
      "r387"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Acquisition-related contingent consideration, net of current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r98",
      "r102"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of acquisition-related contingent consideration",
        "verboseLabel": "Short term contingent considerations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "verboseLabel": "Measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r45",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization, Description of Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, plant and equipment included in accounts payable and accrued liability"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39",
      "r131",
      "r481"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r34",
      "r39",
      "r44"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r34",
      "r113"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r34",
      "r113"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r13",
      "r117",
      "r123"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r232",
      "r233",
      "r478",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.veracyte.com/role/StockholdersEquityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "totalLabel": "Total number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r524",
      "r525",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r501"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 125,000,000 shares authorized, 72,383,140 and 71,959,454 shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r22",
      "r144",
      "r146",
      "r150",
      "r461",
      "r465"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r49",
      "r50",
      "r110",
      "r111",
      "r206",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r49",
      "r50",
      "r110",
      "r111",
      "r206",
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r49",
      "r50",
      "r110",
      "r111",
      "r206",
      "r477",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r49",
      "r50",
      "r110",
      "r111",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r49",
      "r50",
      "r110",
      "r111",
      "r206",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r265",
      "r266",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r277"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r26",
      "r157",
      "r217",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r404",
      "r541"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r48",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding accrued interest, of allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Excluding Accrued Interest",
        "terseLabel": "Short-term investments, allowance for expected credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r211",
      "r212",
      "r533"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Excluding Accrued Interest, after Allowance for Credit Loss",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturitySoldAmount": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), sold.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Sold, Amount",
        "terseLabel": "Amortized cost of short-term investments sold"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturitySoldAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r37",
      "r95",
      "r374",
      "r379",
      "r380",
      "r523"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "terseLabel": "Pension obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanTypeExtensibleList": {
     "auth_ref": [
      "r86",
      "r87",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of defined benefit plan. Includes, but is not limited to, pension plan, other postretirement plan and special and contractual termination benefits payable upon retirement.",
        "label": "Defined Benefit Plan, Type [Extensible Enumeration]",
        "terseLabel": "Defined Benefit Plan, Type [Extensible List]"
       }
      }
     },
     "localname": "DefinedBenefitPlanTypeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r37",
      "r193"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r276",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r151",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r173",
      "r175",
      "r177",
      "r178",
      "r179",
      "r183",
      "r396",
      "r397",
      "r462",
      "r466",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r151",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r175",
      "r177",
      "r178",
      "r179",
      "r183",
      "r396",
      "r397",
      "r462",
      "r466",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of foreign currency on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r77",
      "r127",
      "r147",
      "r148",
      "r149",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r172",
      "r185",
      "r218",
      "r264",
      "r365",
      "r366",
      "r367",
      "r375",
      "r376",
      "r395",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r424",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r398",
      "r399",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r417",
      "r423"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability.",
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r213",
      "r215",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r247",
      "r261",
      "r393",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r487",
      "r529",
      "r530",
      "r531",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r133",
      "r230"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2023 remainder of year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r65",
      "r458"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r65",
      "r457"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails",
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Effect of foreign currency on operations"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property, plant and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r132",
      "r227",
      "r459",
      "r488",
      "r501",
      "r534",
      "r535"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r58",
      "r214",
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Short-term investments, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesSoldAtPar": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), with interest rate reset through auction process, sold at par value.",
        "label": "Debt Securities, Held-to-Maturity, Sold at Par Value",
        "terseLabel": "Sale of short-term investments"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesSoldAtPar",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "auth_ref": [
      "r210",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale of investment in debt security measured at amortized cost (held-to-maturity), excluding other-than-temporary impairment (OTTI).",
        "label": "Debt Securities, Held-to-Maturity, Sold, Realized Gain (Loss), Excluding Other-than-temporary Impairment",
        "terseLabel": "Realized gains (losses) from sale of short-term investments"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r23",
      "r114",
      "r118",
      "r125",
      "r195",
      "r197",
      "r201",
      "r203",
      "r463",
      "r486"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r158",
      "r371",
      "r372",
      "r373",
      "r377",
      "r381",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r159",
      "r171",
      "r172",
      "r194",
      "r370",
      "r378",
      "r382",
      "r467"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.veracyte.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Supplies and inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r520",
      "r553"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r520"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r60",
      "r63"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Lab supplies and reagents consumed"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r140",
      "r482",
      "r501"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Supplies and inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Inventory, Work in Process and Raw Materials",
        "terseLabel": "Raw materials and finished diagnostic kits"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r216",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Expense and Measurement Of Lease Liabilities"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r157",
      "r217",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r390",
      "r391",
      "r392",
      "r404",
      "r485",
      "r541",
      "r556",
      "r557"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r116",
      "r122",
      "r501",
      "r522",
      "r532",
      "r548"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r130",
      "r157",
      "r217",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r390",
      "r391",
      "r392",
      "r404",
      "r501",
      "r541",
      "r556",
      "r557"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r34",
      "r35",
      "r38"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r38",
      "r119",
      "r124",
      "r128",
      "r142",
      "r145",
      "r149",
      "r157",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r176",
      "r195",
      "r197",
      "r201",
      "r203",
      "r217",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r397",
      "r404",
      "r486",
      "r541"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r195",
      "r197",
      "r201",
      "r203",
      "r486"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of future lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Less: short-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Long-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofOperatingLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, operating leases"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r422",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r421",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Change in currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r143",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r501"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Current portion of other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "terseLabel": "Components of Other Income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/ComponentsofOtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "totalLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payment of taxes on vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r30",
      "r57"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "Payments to Acquire Held-to-Maturity Securities",
        "negatedTerseLabel": "Purchase of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]",
        "terseLabel": "Pension Liability"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPensionsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r501"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r29",
      "r57"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities",
        "terseLabel": "Proceeds from maturity of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r29",
      "r57"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.",
        "label": "Proceeds from Sale of Held-to-Maturity Securities",
        "terseLabel": "Proceeds from sale of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r93"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options and employee stock purchases"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r536",
      "r552"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Payment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r94",
      "r126",
      "r564"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r39",
      "r44",
      "r476"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "periodEndLabel": "Restricted cash",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Long term deposit"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r84",
      "r121",
      "r472",
      "r474",
      "r501"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r127",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r172",
      "r218",
      "r365",
      "r366",
      "r367",
      "r375",
      "r376",
      "r395",
      "r469",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r191",
      "r192",
      "r196",
      "r199",
      "r200",
      "r204",
      "r205",
      "r206",
      "r275",
      "r276",
      "r456"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r278",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition and Cost of Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r206",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Common Stock Equivalents Excluded From Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r62",
      "r64",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other Income, net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/ComponentsofOtherIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r73",
      "r75",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r136",
      "r137",
      "r138",
      "r186",
      "r248",
      "r249",
      "r250",
      "r252",
      "r256",
      "r261",
      "r263",
      "r489",
      "r511",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r74",
      "r75",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Reserved Shares of Common Stock for Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Aggregate Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r47",
      "r49",
      "r50",
      "r51",
      "r110",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Third-party Payers as a Percentage of Total"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.veracyte.com/role/StockholdersEquityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "calculation": {
      "http://www.veracyte.com/role/StockholdersEquityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options issued and outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r15",
      "r77",
      "r127",
      "r147",
      "r148",
      "r149",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r172",
      "r185",
      "r218",
      "r264",
      "r365",
      "r366",
      "r367",
      "r375",
      "r376",
      "r395",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r424",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r185",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r1",
      "r2",
      "r77",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r1",
      "r2",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r56",
      "r501",
      "r522",
      "r532",
      "r548"
     ],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r156",
      "r249",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r264",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r213",
      "r215",
      "r247",
      "r261",
      "r393",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r529",
      "r530",
      "r531",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r187",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r174",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used to compute net loss per common share, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r173",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used to compute net loss per common share, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) resulting from ESPP stock-based compensation expense.",
        "label": "Adjustments To Additional Paid In Capital, Share Based Compensation, ESPP",
        "terseLabel": "Stock-based compensation expense (ESPP)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) resulting from employee stock-based compensation expense.",
        "label": "Adjustments To Additional Paid In Capital, Share Based Compensation, Employee",
        "terseLabel": "Stock-based compensation expense (employee)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase In additional paid-in capital (APIC) resulting from non-employee stock-based compensation expense.",
        "label": "Adjustments To Additional Paid In Capital, Share Based Compensation, Non Employee",
        "terseLabel": "Stock-based compensation expense (non-employee)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biopharmaceutical And Other - Biopharmaceutical Revenue",
        "label": "Biopharmaceutical And Other - Biopharmaceutical Revenue [Member]",
        "terseLabel": "Biopharmaceutical revenue"
       }
      }
     },
     "localname": "BiopharmaceuticalAndOtherBiopharmaceuticalRevenueMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_BiopharmaceuticalAndOtherContractManufacturingAndTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biopharmaceutical And Other - Contract Manufacturing And Testing",
        "label": "Biopharmaceutical And Other - Contract Manufacturing And Testing [Member]",
        "terseLabel": "Contract manufacturing and testing"
       }
      }
     },
     "localname": "BiopharmaceuticalAndOtherContractManufacturingAndTestingMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_BiopharmaceuticalAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents biopharmaceutical.",
        "label": "Biopharmaceutical And Other [Member]",
        "terseLabel": "Biopharmaceutical and other revenue"
       }
      }
     },
     "localname": "BiopharmaceuticalAndOtherMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofBiopharmaceuticalandOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_BusinessCombinationContingentConsiderationCashToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Cash To Be Paid",
        "label": "Business Combination, Contingent Consideration, Cash To Be Paid",
        "terseLabel": "Additional cash to be paid"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationCashToBePaid",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Fair Value Adjustment",
        "label": "Business Combination, Contingent Consideration, Liability, Fair Value Adjustment",
        "terseLabel": "Contingent consideration, changes in fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityFairValueAdjustment",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for concentrations of credit risk and other risks and uncertainties.",
        "label": "Concentrations Of Credit And Other Risks And Uncertainties [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationsOfCreditAndOtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vcyt_DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, End Of Term Payment Interest Amount And Prepayment Penalty",
        "label": "Debt Instrument, End Of Term Payment Interest Amount And Prepayment Penalty",
        "terseLabel": "Interest on end-of-term debt obligation"
       }
      }
     },
     "localname": "DebtInstrumentEndOfTermPaymentInterestAmountAndPrepaymentPenalty",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_DecipherBioSciencesProductTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decipher BioSciences Product Technology",
        "label": "Decipher BioSciences Product Technology [Member]",
        "terseLabel": "Decipher product technology"
       }
      }
     },
     "localname": "DecipherBioSciencesProductTechnologyMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DecipherBiosciencesTradeNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decipher Biosciences Trade Names",
        "label": "Decipher Biosciences Trade Names [Member]",
        "terseLabel": "Decipher trade names"
       }
      }
     },
     "localname": "DecipherBiosciencesTradeNamesMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_DevelopedProductTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed Product Technology",
        "label": "Developed Product Technology [Member]",
        "verboseLabel": "Prosigna product technology"
       }
      }
     },
     "localname": "DevelopedProductTechnologyMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_EmployeeAndNonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee or non-employee is entitled to receive in the future, subject to vesting and other restrictions, number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee And Non Employee Stock Option [Member]",
        "terseLabel": "Shares of common stock subject to outstanding options"
       }
      }
     },
     "localname": "EmployeeAndNonEmployeeStockOptionMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/NetLossPerCommonShareDetails",
      "http://www.veracyte.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_FacilitiesInMarseilleFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities In Marseille, France",
        "label": "Facilities In Marseille, France [Member]",
        "terseLabel": "Facilities in Marseille, France"
       }
      }
     },
     "localname": "FacilitiesInMarseilleFranceMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_HalioDXDevelopedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HalioDX Developed Technology",
        "label": "HalioDX Developed Technology [Member]",
        "terseLabel": "HalioDx developed technology"
       }
      }
     },
     "localname": "HalioDXDevelopedTechnologyMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_HalioDxCustomerBacklogMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HalioDx Customer Backlog",
        "label": "HalioDx Customer Backlog [Member]",
        "terseLabel": "HalioDx customer backlog"
       }
      }
     },
     "localname": "HalioDxCustomerBacklogMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_HalioDxCustomerRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HalioDx Customer Relationships",
        "label": "HalioDx Customer Relationships [Member]",
        "terseLabel": "HalioDx customer relationships"
       }
      }
     },
     "localname": "HalioDxCustomerRelationshipsMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters And Laboratory Facilities South San Francisco And San Diego, California, Austin, Texas, Marseille, France And Richmond, Virginia",
        "label": "Headquarters And Laboratory Facilities South San Francisco And San Diego, California, Austin, Texas, Marseille, France And Richmond, Virginia [Member]",
        "terseLabel": "Headquarters And Laboratory Facilities South San Francisco and San Diego, California, Austin, Texas, Marseille, France and Richmond, Virginia"
       }
      }
     },
     "localname": "HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoAndSanDiegoCaliforniaAustinTexasMarseilleFranceAndRichmondVirginiaMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters And Laboratory Facilities South San Francisco",
        "label": "Headquarters And Laboratory Facilities South San Francisco [Member]",
        "terseLabel": "Headquarters And Laboratory Facilities South San Francisco"
       }
      }
     },
     "localname": "HeadquartersAndLaboratoryFacilitiesSouthSanFranciscoMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Liabilities And Deferred Revenue",
        "label": "Increase (Decrease) In Accrued Liabilities And Deferred Revenue",
        "terseLabel": "Accrued liabilities and deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Annual Undiscounted Amount",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Annual Undiscounted Amount",
        "terseLabel": "Annual rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAnnualUndiscountedAmount",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_LymphmarkProductTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents LymphMark product technology.",
        "label": "LymphMark Product Technology [Member]",
        "verboseLabel": "LymphMark product technology"
       }
      }
     },
     "localname": "LymphmarkProductTechnologyMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_MajorCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Customers",
        "label": "Major Customers [Member]",
        "terseLabel": "Customers Representing >10% Of Total Revenue"
       }
      }
     },
     "localname": "MajorCustomersMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_MeasurementInputProbabilityOfAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using probability of achievement.",
        "label": "Measurement Input, Probability Of Achievement [Member]",
        "terseLabel": "Probability of achievement"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfAchievementMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsFairValueMeasurementInputDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Medicare.",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NCounterDxLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "nCounter Dx License [Member]",
        "label": "nCounter Dx License [Member]",
        "terseLabel": "nCounter Dx license"
       }
      }
     },
     "localname": "NCounterDxLicenseMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NanostringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents NanoString.",
        "label": "NanoString [Member]",
        "terseLabel": "NanoString"
       }
      }
     },
     "localname": "NanostringMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncash portion of lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Translation Gain (Loss), Nonoperating",
        "label": "Other Nonoperating Income (Expense), Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Gain (loss) on currency revaluation"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseForeignCurrencyTranslationGainLoss",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_OtherNonoperatingIncomeExpenseForeignTaxCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Tax Credit, Nonoperating",
        "label": "Other Nonoperating Income (Expense), Foreign Tax Credit",
        "terseLabel": "French research tax credits"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseForeignTaxCredit",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_OtherNonoperatingIncomeExpenseInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Expense, Nonoperating",
        "label": "Other Nonoperating Income (Expense), Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseInterestExpense",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_OtherNonoperatingIncomeExpenseInterestIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Nonoperating Income (Expense), Interest Income",
        "label": "Other Nonoperating Income (Expense), Interest Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseInterestIncome",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_OtherNonoperatingIncomeExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Nonoperating Income (Expense), Other",
        "label": "Other Nonoperating Income (Expense), Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseOther",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/ComponentsofOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_PerceptaProductTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percepta Technology [Member]",
        "label": "Percepta Product Technology [Member]",
        "terseLabel": "Percepta product technology"
       }
      }
     },
     "localname": "PerceptaProductTechnologyMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_ProsignaCustomerRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Prosigna customer relationships.",
        "label": "Prosigna Customer Relationships [Member]",
        "verboseLabel": "Prosigna customer relationships"
       }
      }
     },
     "localname": "ProsignaCustomerRelationshipsMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/BalanceSheetComponentsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Exercises In Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Non-Option Equity Instruments, Exercises In Period",
        "terseLabel": "Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstrumentsExercisesInPeriod",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "vcyt_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Value, Options And Non-Option Equity Instruments, Exercises In Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Value, Options And Non-Option Equity Instruments, Exercises In Period",
        "terseLabel": "Issuance of common stock on exercise of stock options and vesting of restricted stock units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquityInstrumentsExercisesInPeriod",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vcyt_TestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents testing.",
        "label": "Testing [Member]",
        "terseLabel": "Testing revenue"
       }
      }
     },
     "localname": "TestingMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "vcyt_UnitedHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents United Healthcare.",
        "label": "United Healthcare [Member]",
        "terseLabel": "UnitedHealthcare"
       }
      }
     },
     "localname": "UnitedHealthcareMember",
     "nsuri": "http://www.veracyte.com/20230331",
     "presentation": [
      "http://www.veracyte.com/role/OrganizationDescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofThirdpartyPayersAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(9))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r505": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r506": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r507": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r508": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r509": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001384101-23-000067-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001384101-23-000067-xbrl.zip
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M5LY+AFEDF-[1%B4X"^SFD\H\Q0)&)3,.,$=M;*%*C*9,&;IAPUY9;F+3N%"
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M;!;]KW^?_AVZ;K]CRJ^7+6++M$-_,QR%[C TPX\VC/RP 2D5OF$.>N6;87\
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M"*E/)+3I8:HC2JM<.AT%T%B8^(@GVG),E$S.\3QY/+,MO:<'U8BI8\'EF(O
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MERWWCB;Y&<8ZZ6/_UXSQY.DK;C5[3SD Z=UJ'F#SF>)[PCB MTXQ&  JAC;
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MPP[RO2K?(CT0?"EPC^!9^&49V&EC=9U^X9))XU0JWB]BVC<DD!) [!FV0KM
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M*0O3OFW(Z%Q*C2VI&P"R9RN6,G(9BE$ JA%\X5) *7WK>IU.*$?A7W,*\.G
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MG0;9[6QV=E??%HW6^EFS\RDVW^"3]ZVU06,+0W_@><=?L(E8\YPBQ[1#7+&
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MH)F]UY-)M9_G5-W$S5[8/Y]AFV<3#)C#7MJW7PMI6!1IV'T]9Q9Y#'Q/:HM
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M%'+YP6[^)2W+\+JN]UZ1EQN$CVX2LQOTO\RFHB[5D&Q"6S.'M]VJSLY;VPG
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MD?F3+1=7A:X 70&Z1@-=4():JBT'<L"9E)H8; +QGL48F/L.GRM ]Q1 )V:
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M(BD?EL.L</H^_HJ*([R^2!'."36PZ[VT;[^^K4N/;HY&@XX;CZSKQOW^6SL
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MPB!EL$1<A8"LQ!'QP'1R7)F42^I0W)9Z >F2!4(+A*X"A-X"04';DL*86RH
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M=GJVYQ\A/[SYR>&KFQE>FXW9"]?M]P[KB&>([FYNMU4(>2R<X[X[BVWLI?^
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MCVMET?-@0_[;VIH)-IS[*ZKKTZGXN%!9-?+<SIN.U;0!%V:VAX;'03W7.[T
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MB_QTX__/WI<VMW5D6?X5!+MGNAR!9.6^N"88(5N26QU%RI9H*Z@OBEQ)2"#
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MB7HS)^>DLZ8[<NDCA?TVAY&J$-&"#U*B647_SR6;YE3&8!I6JEOB%MR+"O-
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M:3DW=[S,;C)<'A=\/JSP^<4,GS/CY6UHEIK#\>,^>1MZK^T^C3>DF[W1"]^
MB_91+=R3XZ9=K?\;+%7];:O ?ML N2=^RVW;OO^\-Q;#[>;HN<UD.,4MIM:G
MX 17(E@ON5!!>18C$=Q=PV6'V"TG$<WF99:RE1B.[9>;A6W8;KK@%:'5QT-Z
M<OP)'WY\\^G]\<N/1Q__$(?O_A1']-7GHX_/Q.O?7GU]?_ZR>W+^XNLRH=7A
MU_=GKX__N#SZ[4WW\-TA/7K^Z<O[XT_LY.,S>OC\$SSOT?G)N[_@OD>9T(HL
M\]]A6$@>*1)21<15B$A+QA##2C.2(M4![QWP-N>KL\BVCPITD[R_#18V6+B
MA=A&PFFFZ$N.$VN,\3['3(-0TF@>EHCZ&BS<=BQD2UB(??!"!(T<"P3!5L-/
M3AB4G(@\:0Q:C^P=J#;F5\7 MPX+GP U\41TUG1^U(T>NVJ-/U&6U#56*#;&
M>4*]II0G1HR@FG'F0DI1<!$;*W2GD/=RQ0IUB3$?F4+:,+!",:;(F(@129P:
MAQ63*NP=D+;4WVV%;H99M2%#O@\#2PJNH_5*$,63\58&Z@P--)BDN+>-@;5C
M8KYL8%$>(VR:1RH& 6)>F#VX1")X&U-TABF6Q5RIJRK2?H28;RB064DKVVYC
MZK@_LMU=M9=N:&W7&6K8B5;HCW.^>[*LC4N_J?5Y+"H)C,T0M LR:0=N/W/:
MRD2XL(D'$81I+,]=4DE'OZY8GB*Q2+@1*!2^7!DY,EI9A&F(5%DNA51[![)-
M&-^LS[\!*=N- &D#MPW<WA1N(\/&6L=$#K4J+K4#0Q%3Q9V1'$O2>  [!K?+
M'D "1XY+IQ#F!B/.L$8.G#S$C PR4IIX HM.MS5]/'!;_(=_EB+)=<,-OW=6
M^_VUDEW9G7@%"WN_FE1Y]]G&/V+,VJ.D&9D.2)C.FI@-%_7U-JT.7![$5MU>
MFEO ZP$*>>I0F3(TF0Z6(7SVMWPG^-'._[J],,NG:BWO7]INQ?$;XL4 P+2>
MVU35;$^N-^V[SL-;9E-YYIYJ.,ZSAB>#1R9\&34[2K*^Z@0O7=>]"L?++(L\
MCP36_W3V6ONM7\MT(#L<]O/33 9LU$,MRA3G.*S[5NLOE7D1I::\T %/.41*
MI\.I'81N/=UC,CH@/T>9##>8#6*;'QJ7;U@W,U2]$7GH-5S[SHVJ6R<T:_"N
M&>\ZMV:F&>^Z!<_2C'=MQKMNQ0O=9;SK7<>U7CM^=:EQ*R@PTIU.$4L+'W/@
MJ7FXL71"1.YB^G'C6N]HJ-Y]X/QVZ]P=,50GV[ TM78R]#Y;5^!R#S*?4:$2
MK6<Y7HP'_LP.JUF7L['R99KCTLCZ,MIBNT:XC,XZ@_ CI[6@,O%HW;S4."B#
M1(?P*MW:.I_,S2Q#_L##MJ>SH:KU3,YZ6N 2A\A_E3&O<9#G)A7K?<[N7ABM
MYI<.P72 5^4QU-<OS9RU4Q%FUGRGD%(MCM%:GD<TF09:V?OKSEMAIOWV2:JD
M;-%X7YQ*-#_/;ZVQO]%!SZNK-F'F"M4291G*@8R*\6JJ$O-WIB.M[LYGLEN(
MMW5ZYQ['1F_=SGS3V]MF[;3>9KK>!IIL\DU:U*>:;D&_S0(0.?#Y=S54M9IQ
MM3!B>F',[=*,Z?HB]SA5>_JGE3A29NN+9[:;*K+*Z:3[U;.P0>/EBK#IMHC^
M/<^H^!U0'Q;T62\4%/D=SM(@CN!<Y)W]O0NO4G]B6%%][V;RXCO&5;P0KX]/
M/VAC8H0CE]?1Y'$5>5)%L"@1(65@'/Q\NNSU1*HE3ER D%-N6!Z;)85WFB;)
M#+5A>5Q%O="MZ=29:\=$[/Q4N?50>>W"+8SU[F<6ML*R.B'UJWE2%]X(GM"C
MSA=TU@GPVC\_L0/\Z8/G-#&9..*PMHA;39%)@L)_>BFB(39RO70(GOJ2!1<H
MYTHAG3BL&S$&&68#8B$% EK<,2/V#BYJJ;T K)S*8/E7UJ8^#D8VCRGM]]"?
M^V_W6_'\HMN_C-6P\^QI_@4VM;\<Q=;;9V];P[$;=L"#&%RNT7FMUK/R+0>F
MP*T''Y7<0R[1:TT>>'X4_2W'K1$5*#9).0IB2A1U#@LM&0$5Q"G3\:8SMYY7
M$OM+);!9V]0_OIX^6S-Y:_T1?2:.X(@28A,UQ".BL02U1"2R46-$'#&,>^^,
M4[?KEZ":2ZJDL5QR0@U ,%%.>!REHM'3FP[2:W;V.W<VA( M> <H:$<09PGP
MVC*,6 H\$;#OA  ]B/=7NQIN,%^OLQC\J%R+;F>.B.&;40%GNV5R__ LQK5\
M)E?;)?=KS()54@_W!+?B]T&_!S_ZRN>IK-?JGT]W]EI6;"<?P.,T2E.&L,(!
M<2KS<%?)D3$>6P*VK0\KQNDVN41Y<&MOU)IM=6MQK[>)_NO1Q=Y?]5JO_:@/
M)D:V+$AE6;Q\]O870)4AN#ZM9V__+']!VS<%_9?Q,%/1#+/OX#J]NOSC'Y.I
M[>*GG^</50ZH3EM$<YE?'>&=_N[?<XA9$@:3OPRK^HQ)K> /GK%>3>^OPSUY
MD.&H>N11?Q9D+B]6\]G, C1V]M+3W\VK">O+-8L2L2TW65T_6]WR%Y]I!HK&
M*,N2![Y33#C"ICWE&?SF^DVV2&+Y4\7[,K[(JJAB5I]G59S0 F3JE_R>,Z;%
M*F)^TQ<;U8P;4R+E*25 14LQI4ZHB1GKE8BMSOEY#)T)SWNAEIG^O:HP:94G
M']B:(<26<<C)=C*M6W=<\]KT8/,+7Y,=%'5=\=SDV?V%J^%BT)_,,:TX&LIA
M39UL-+4NHX4E<_&TTRN4\J7P8^H8M(B8^ 3E?>##\*@V]"M^E(M,09/)&A>)
MELK?<P+E+),YCSO5=L)"3QV/FF&BOLR9#>#SM#*=PR#GUFM*]GP@ZC6=6A-I
MFH"?RS8LDDX/?;=?F);V5T/$-^9_WDFF]6*?7%M:PK*1?_^1RV\J97KOXW1?
MU*P>O\?!VS,[V)X1NI>U&??QU9?WQ^'LY..?_.CCBR^''_]@[W][WSD\?O'Y
M\/D?7X]^.^J\?GX$?S_DRV;<X<>7W2/ZLG-T?$KA\Y='S\,GN.>7P^-GGX^>
M'^(3^HH?PM\/OYZEHX\GEQ]<--IP)E&0!",N%/@'(45$(I,6PS^37&'-91;<
M."V\(M)Q*\#'PS%Q3;$*5DABEVV^HP@ZK@^ #BN>D> <Q+>L_+<#DVMC>M?>
MNS'4-OSHOX!>\(6RMYOW$("]Y&DRY^99R0H##MNN'U<@"WH,WJM3B$"GW[&C
MT:#CQM5HWQS-JK\_ J$[ZW=#5LVU JP>)09D,Q'1*6BP<=$V)3\UNRNXEN-1
M46SY1J%*"LV2X95.ZH]G3%%3!L/Y>Y<B7]"6%9WF\TZNUPS7O"HHLO$#ONC\
M(RZ\\V2X=)W]GY*^A=9X.%F,T:!88I?UVYY'6)-P[_CZ-G./C;OQ=7H&TAOR
MJH)]\3;Z<471_*(FG*M:8O)RUG/-&V"> O/7#]$F)TA4R"2N<N!&(PW*&RD!
MJT]TH%&M +/7!'1\XGE8">?6PS^(PU0:K>!?QBT#\W$AP<U3QO.)F3]=5TD)
M&&395(RQM\0;&*X5'A>]S13D<# [@RIN5.+'4TI$"Z^")L?EFMGFZ\L0KWO]
MW;?C)H76U:3SW#$DUHUE?? YZHKL&VKN-$==[5/&GNP<=6+V*17W,4>=W&TZ
M^[4/>[/+-J.RFSGJS1SU+4>IQSX.O)FCWLQ1OYD<OZV=RB7_<#AV'^O.R'GK
MN I.#G=>[+\U[FTC,X9W9Q)$%558KD\)DD4? C8Q<E@/Q[3A@M-DHK'*D6MF
M[^ 5QLCO\X>?E53"S>H=\&[ZS/5TB!?B_;N_SH^^_@+W![_XZQ]?X=KB\/B7
M[M'SL[/#KR\[)U_AY]_^Q"O3(8Z[W??OX$U_._D,S_@5?&MXCT]?#N&SKW][
M\?7PW?]\S#^_/WZS;A@Y%2%*S@@2D1O$N6;(A<A0HH)%%1)+1.P=L+:2JHWU
MS@SAW="\G08X;@@<V'NBF8N"$<)]$#9*S;D36FCJK=?73)%I@&/K@6-YK(PW
MA,+>.H13KH7QS"!0$19YKXP4^?\P+<"!61O^:U> X_%X:B_J@MG:LJM[..-B
MO>UVF6=W,>0>.[)&;S36G H1,RNLMYH%@%&G39[%C5-CDNTVLJY.YF;149Y;
M#(BA#) U"62E=LBI/*89<Y<R63AC;6-N.;/W_BRK6QA0CUU@,8O""RD]=9P'
MPL"'BHQ08:2VTKC4F$*[+K K,[9=T. G!?"AA$,\&H,<#A8I@7,U>M"!.Q!8
MW);T*A+W>Q38)Q#,>A.'HT''5XWWV=C)$OHDHE6/'4PU&#S<2$:PY5R19!W7
MQ 5E,::":]58/SL-IFNF0^==IH11Y*+)/1:&(">Y03I35/@40J)\[X"V&3=M
M(LB&_,H=C3D]=O&/1N:^.J6Q9-QSZYQ2B5$,J."X(:ZQI79=_)=M*9:HPD&!
M!16E1ERPB&P TPI'3D0&_\ *+9$0IBTXWB+Q?SR1H\)(<F5%W&,RJ^YW7/Z.
M@^^=*F,;\-T9\'V[8GL%H:(B$2RN&!3BR1-D5/(H!>HLEZ!PF2O,' *W*1.W
M!-\?/A7^NT-7#5Y\"R^,]2JZF$)R*7=>:>6<]#1YEY(*[#HNN08OMAXO5MA[
M"1:2,(^"IQ9Q1S"RW"5$*?R3LB")%WL'HDT-:VMR6X*Y'XX7BRP2MYFM_NWY
M4C?K3>3XQ_<FLOOOG<GD J5WU79_J<9CO,W3,9[/>E>WI"L&'\ZF3HA\W:/G
M[\]>__;^_/7S/RZ/Z%_P,PCL\S^_'GY\V0%A$X?/WWQ<G3K1[;S^[14^.G_!
MWY^?\*/GK]C[=R_X"0CXT?'AY>&[5R!LGSZ#H*?\S(>G'S 7PBNMD"$L\[<X
MA;3R&'GBM91$"Q_D<E^,"TQIP4"!.\VY]U:(2.%_4EACF&#+?3'URK?*TI?>
MY8K*XCL&J:UM6+G^N1;?@W)NF?318"]XBD(KL$&23]P+I;C7MVIPN>]^R%L.
MX_BMWP^Y#7\C<T=W>)3=9!UN/4QK4R.7)@^P$W.5'AR%CH[]!XL=MQYK!)I*
M@I[7&!E8;Z2BUJ# B% .1%$:LV:JTNH0I1\Q,*W9XV_N\<<_P):+W*<4$-;!
M(XX%J!D2,6)&".EUBMRDO,=BWURWQZ6L_+9S]FI.'K#UNY?5" U_E@?O#J>3
MMNU@<%G&<M0#1N FIQ/LF&N('I6FG/.J*2<N-N54C_$Y#B)\HS0LYT$C (NM
M,@N\YR];HP%@636,?;^U,,KC#%ZLUQ_-1ICD7^;Y')U!H4V:C-V JTZ>:\W8
MC8:'9P+\!#=$/%OP+)LFXMGX3.FUEN2UEN%RI[BAPAOG'?&!,RFT=X!HU$AO
M+(F$[[(E^0J<I]YI)^],-6VK#?<:W7Y<_PX;D7-+4(^HJN<TYBE)G5%$F3HC
M3,D;9N1T[>FP] J_<YO36>=B."74JT8J@5: :V6;8E@SW96AR;,K _[4S'17
MCGM_P#D4L^6H#L2S7IA80$6"G[)+??3L@\*$>:ER90%CB%L5D)9>(!X"UTI$
M'*1=F0'D'&$V*>:BY#K!;D7L&791$$VD\LLN]>J)G Q$"Q."R-DDBG\4&Z<_
M!A$(Q; )>5[!8/C3-5,A;CK*_+KQ">L%>?T\HNO6X:$G,1B];Y2\RR0&:O8Q
MHQL?&J#WE;G;*()O_TTPO?%G-?M2WVT%'OY9U3ZF?$>>%2P$>K>K_H@SP+3:
MD6?=I3, Z&+,;6:'+'F"E!<4WN)RDNNS"#>9&4'$MDW_T#=ZK<6HP@W*8J[-
M-._J2DQ'I$[".9M8#/CHH/_Y6]TC6[\N[^J1=ZUG]<B[-_'<=LILV6?G?7C,
MBO0ICXG,(^W^<9('T/ZT;A3%,C2H;8>&FRW0C:?)[,*PD9N]\F^#/"SNUTDP
MLZI2:,:VW&$EGWD_/J^G<,Z+4[.8=UC,/++V]H?R22Y5(\&-!&_A8MY-@F^_
MCD^@GQ#L,1\O1G9-O'AC RNN+P?=ME7YSWMZ]]TL@5VM5<CL4LZ%)(**/!!A
ML:$Z"<T#-T9I>T4]"EL.X[\L>85_Y[3"<AR_J)Z;U3"PW0SMUR6M'JX3X%Z?
MOIY\_./+R?$?XO"K%R?TA+U^]R<]^?CB\^%O1Y].X/F62UJ/OH9SN/[YZ^,C
MN.?+LZ/GG[X>?>U^?/_1B_?'N93VV><3^N;LB+[/8VV^+/=R&Q48P10QKBWB
M*<^C%E8CR:W4"O[/:+5W0&0;3MU]S[39IJ[$!N<>-\[]8[N ;LXRG#<,&^C;
M(/1]7>[^4=$1X05RQB;$-25(1RP1(TXY1RCUDN\=Z+9@; 7Y?FI KP&]G0.]
M[<(\<. :?-L@OBUW-XIH&&P11T$J,.VLL4A[S!"),DK-J#6&[AVH-I=753$W
M(-> W&,&.1\ YH+ *6*=)] 9QQQG3$AC-+/<7%%MWWBP/Q+FEILRG5/6LTQ2
M+#Q%/ B2)P=J%"-SU%CM)":-!]O@W&/#N=MXL \ =(T'>__0)Y9GASGA$\,)
M$8,-XEA39)1AR&I%A53"1D^S!TO76'B-!]N WNZ!WG9A7N/!;C@Y =A6$A1'
M7U]].?QX^"%X'15) GF7.3*)]<@DIU&.SY7&)A=X=F'5FA#=(S;M;G.-&[_0
MMG!6?5/PU[826<IB#)PX%A7WV%AF$\&261:2M9;?H)7H:B'_<QC3N/OO3HH+
MH@ZOX7\.X\%EM(-&N&\FW)>+PHV5P$PJAB+UN2N)"J2-#HARZJ11)+H CINZ
MLB/H3L49J?QOIXHS!OTA/,--BC-N-$IUS0KL^'2N5=W/).;:$A>,%Z#S@V%2
MT"2#5<$[RU13FK!U '&Y4IJ0.'?>&H\"=:#\L='(,>90PI1$A3W3Q.P=\#:A
MWQW768\*]ZKBEVYYIZG(.RO*MXE=/( L7QF[: 3X-@*\G&!GWB;LG$<*]B_/
M-B;(1J61\3*%**0.#@38D-7!FC</3C22^Y25<.. ;U:"EU/(FAOI8G*(^5(=
MF"48NXB"24E(SW!(.I/>47S;X;B-(.^.('-'I1;,8"T]E\I:9V2DQG <I8!#
MT*1)MU"4E].DQ+FHB9=Y8BV(,I$4F605BE@ZE\?+:1P;:WHG1?DVUO0#R')C
M36]$@)>3?4%R@H4W2"86$:<A(<.P M6L$J<$S"HF]PXT_YY47R.Y3UD)-];T
MA@-:*^FL@&V42B)#> "'. 5DM6,H.L>"$(DD@8LYK;X[G;7%DOQ]X?G=2DUY
MDANHI#=).&XL-R00XS@F6F;:U/5\?DUJZL$%=2DUE5P@ :L$NI;&[/<:I!,'
MN34A:LLB5AJ,94(VFYO:P<;A26YJ_5#).^6G'A_5WYKN"DP]BUYA+B+/!+K4
M,2X\N&>)1QU<DY_:-I0X^G4E/Q5\B!$3BZSQ''%I/=).PSF.H-EY],Q&E9D[
M.=LFVKZ&M7/3W:'W+\M-;>W]2_=R\DH((P2. 47K$P(O*R(=!4:8*JJUPTJZ
MW%;0EFOB9;>NK6T$^TGJZ.)P-V)Z&S%=H<_&"FLG*4I,L2RF#)G$& J*2:\Q
M,Q:GO0--&A7\>"65"VZPCW "M.1<.T<,MX)Y OXV%:YIX]M&05[.3U&31])K
MT++&:L1M D'FTJ-@G#&9.XT&V5C3.RG*M\I/W;\L-];T_4OW<O+*"1IQI#9G
MJ\!7U@$C)V5$6%CKI#",,Y&M:6Y6V;8::WI;!7N[Y+JQIF\?TEK.4&$2J69)
MH$0H>+TN..0\%T@G;P5F)'!C]PX,(X]8!W]?B'ZW\E,A89R(H32DR%UDUC,G
M1+0AN[E,W82%J<E//8"8+N6GE->,>)N9D5W*M2 8V3S)+%&K#)4ATES,M>'T
MU.ZU3O5^S5.!XZ#U_,N$WJQIF;I"00>NA#&2V4@DEY*;)'$0FH6(":'"-RFI
MK0.&MRLI*>Q"<&!0(VJE0CQXCIS6N<-24N4-HY&PO0,NVUHW59X[)LNW\:(?
M0)@;+_K^Q7LY)Z44%EPI"N:X"XCGWFF3"U1R%[6+SNO$<>89;G.BFRK0G9'L
M[1+LI@ITLT*\G+$RP6!#C4="^8BXEQI9[BE2%FQY*Y2-/.T=,-GFDC8Z^M%*
MLK&<&ZNHLQ'S(.!("#@8X+YI(EDBODE:;:$L+R>MO DQ ?""0E8:<>8T*&3#
M$:CGI+D/5G#=V-N[*<NWL;<?0)@;>_O^Q7LY:^49YUY3B:(S+L]7E$B3"#)N
M&0Y.26,=V-NF+9ELS.V=$>SMDNO&W-YP2&PYI<4-"Y81CABVN?%9@[8F6*"8
MO,/1,FN4!'M;M2GGCUA'/Z6N*^HIC? Q14WD()^.&*R-QX)$3+$+359K.R1U
M.:NE@G4NQ[,82XA;EY 3X!X+SAFGR;+H0M-UM7?P[\OSB[-#._BTJ9& 3Z$
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MR$7.M'."8!'W#MA3;]CZ;WB$_O,OH&_^CMW^10Q-Q]8-%#F)U@3.I%*1>PT
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MOU"U@8,MAH/M0H/&_]^PY"_GVW2$'3-1(>JC0YPH@DRB"<P!(X1TDH&YL'=
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M(^?T[WP[\R&;XO:9C<YS4+UD=PSX&:P%4*PQY[@98QOZK!00<<*$*.!C-(]
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M1LTT]+_VUA+!+;+A-A2)_;+F.]EL1/F2"Z95636 3W'56\;+CV"E(-6/@!]
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M:98"2&5!*@,,_ $*4\,^8.FSOT'9Q=.*]YX1^6&09 3#K\\N\,-GH.^>$</
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M^\T!][70^F8/KU%>AB(__,DG:K^;.:X4O&@%9LCY&DCD*AD!,"UAI4AT=+F
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M6(]O#_R>Y6-@PY#%?%()HQIH<DRK4]D(#V(0MY(]65'@GBB[2N5U_XUV99,
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M*N3M+<CE]'NVL2E,:_<JY)3$;9/$F=8-^W8JB5,2=Y,*4W_[^Z>LE7B^M37
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M]@#23Y!H3PXZ>F4(1.%&*]SHQ[>>%#:OHJ:BYKI[Z1:0\FD5S"C0Z XEBRI
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M2'='+Z]N]/' 82;8,UD9/>DI([%+SL70F;3:3H9>&G2[T0&9ZJ[S18I5K/%
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M4Y]#"?GC+&3 K_,9M#ZW>Y5QX'RM#]Y(*O2#3MS!MV!&O<W[X]>\%8NF:R2
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M*=^Y<I_(T=LK?UBK1:6-F5"NAE[X-X41S'?=T9D ^^4BSPIAZAKG8+ 9)'M
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M;V9*<ZNMWJ7E:/!H-$I^(MRZKE,R7?[3_H/HCUQ:MS37[8+.J>X=2+L%G;Y
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MR/*!IX_I@&)0OZD,$@>A[B%Y29G1ND?QHOP;I,:GU:1KN,TP=UI'N^$+XQ!
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M 0:DLJD$"X-MN]W122'A]SR8F=@ ?,2S0#.%1(+X C*"_429'>JF97MCDQ5
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M_?;66W9=/37  5<\FX^-=D.#&@W"6?9)%Z^QMA=T,M<9RP7G7)P2 F _%QI
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MUY;(I<PZR6M=S[-S4-&9T.A9O7%QY, 8G15M786>#2JM:/"E]JCUBR4?RBW
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M=:2M4,,.&D%'+!URR=KZ:*2)' ID\9URUU8]9N=M_D@WYW;RJ\$W8 $XEST
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MZ] T]5MOAM_:PJYJ-TWP6MF!0-V*K[S%Y*.&',<!>["JK^+Z;77LM]2Q[SE
MD/4:\L)A3P1[*68^=V&8Z#94<S_IPZ$,(C#4?=CUR1[=\S0%PSK3O D568LR
MN$+F^UL9N5X9>1XT_U7_/PCEZ@EZN248GIEU+]BTX?0,ZW>J4@Y>CL^*]V!M
MX>7$8M27_B U[EN+[8:<2#W6!/=-J@.9?E<[>Y['/\#^P=G(T21!58<(ZC4<
MNW&A,C)^H-'5=HF_Y1)_<+V0+B@UX/9I-1F*%?0W2-9<S<%VO6YD2W*Y5P3+
M<%ZR)?=@+4O>BI/26JAF]7O6=GF[?C<6@-5DIEC+_8:#08_EH&OX7Z0K.8=
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MS4AJ4IF3>\S I:.))^MP__[NZ+V?W $V<IL\\;/=Y/."I@QU$Q XI\PG\[1
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M(3P_'+$@/68!U89?M/-T-0JX4\)"6GN4;\_DC%91[8+.XV?16S":#76VDOK
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MX"'^?F%D8]O0FY\AIQ,X,A18HM[_;Y@N#AG)@''"O<Y3')0[>3;+1Z]^._X
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MJ8K8#"HF!S9L%-VDZ<7^(#<!^)I<C87IRARIGBZ><L-C!(6\G)G.&N3X?2E
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ML\5Q^ZHXV1#0O!O:JY)6(F6[BQKRP]A<.Q(I"S:MV>5#EQ.XC&AK<-:'S48
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M^51+C!XZS<4+'*5=6/AA45C]W75)M<70*5E (K$X(S+WTZ51*U/W(/JHV!.
MAXN$%NM:EJ+\P"?T*G@)JW*= +.=PR9%$GI#\=,VH'=W1^_DB'>I<-_HECA]
M>=M2^MWIJB4+4_J,?4R-18/S&RNYNTPZ7_BT9"ECY!.$JC[5C4O7*Y=X:1MK
MGOFRR*^"):$5'UM%&ZJX+C956/@1(]';<-_"G._+E#P]>)@KQP5WT)K\B78B
M4WN0^E^42RV3 ,U/"RC;*8"SA1S6Z6&#8HD>*?I(FU'8Z>M3M\*I[LKK;I1&
M#"%0<U%KEQ0_K_0S^/2I=TU/G*O]-B\UW($]5'?Q.<>2DY$'.SUBBO(0#",]
MF[0KG5H#L>&SU.-E0\'/MZ7><GKP4R\XDJ4?OF% *%PY/ J18-+&>8(WN7U[
M#W:<! >91#/,V5PY4P9BS-&OLYJBFYMNROR?I:O_9NI_GVPFJD3+<$WN_[QM
M^B8,E7[@E[ 3UVU^'1[]C#0(4;!3I4J78*/%/;G8IN$,))5[,2(WMC2YE]$D
M)V<5<;QPW2:S 33ISYG7'<6C$7 RR=.DA6@Y#X1W+'Y-VZ:Y*,I+GW*)K]*L
M[KC-(K=49FF9C[7F,G1AN.SL(7Q56$;3"1U1O90;CKO3-+,\<:=H27TC@G\@
M(_[%HU??_?A4DN/VK%S.6=L*<VW R*<<RB'/307]'W2Y.:E\^_9[,)1#/Z#2
M S/')Y/ME7L_O#B[S\>:B$=-*"7NA45_/TF3)1LL$>?A=&0X'_\=XC]@S2@"
MV+!#6X%7"JMLDR3PC"7#<6,</E>M5D(/]N)^BI-82Z7":;%D0MNOO7D1[(P%
M$)5HVX((@*U.DX1"\"E\YH:=RO"J7>?%2NA]Y0 "K.>Z7CRC+<V8J/J=7O7>
MTZO'S^[[&[@$*J:*Z*4:<)YZ"M\7V)1J/V]^? T18@V&+A!K5]Z7!HP=:?"H
M#.R*+.LB7_.?$_M%?@%*URGNK?-=@EK"4QP6O^U9G)(7;DJNYG"__^OWYT]
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MPQUC;'*D)SAM+/"=,57EG*>;$A$<]_E[7PRD"L;8O3;875=FGE!!I$0T2+J
M[*^TWL 0'IP0LRK$Z(4SS+==*KXC,B0-=?FO(0JMB?=9#]0CFTD8@C"9@53N
MZ=)\:YI]]/38]&@MV.54XFKT0M.WR1E@Z 3^)$K=[GK%A)2H_E/X1PM_=KA
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MN=9]F9\$%^Y77_QD'%YCNTN&E-+RHESU'D;V@Y-*TJN?;<IVFUMPIN=EL$E
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M>!\+YV;2$4CKB/]-__7J-UZSBCOAPR&Q@@F1R4=F([I!= 6'T8AD.ZK:KH0
M1E3@*E\BQ.57)=8?%]0D?Q)O,+TX^]5]WEX0=PD?0U=4)UJ'51L6] H< )Q=
M9,<?50AY0\#*.*U-_?SL5].Y"^K[8M_($@;NN:G&30G*FLAO?O[LYZ>/3QY^
M%3SX&DJ!.'56-&XXVI7\)&'L@HE/MZB^#(R]W]'XK"AK=M.)66>']3IB?Z_2
M1%+ PM*SZGTP8 =RO!73H^2H#2 )^_OW^5OJ:K>?X^<7DW3%6E1-"*TQ%_4E
M%9*LEU:GR@35ILK'8Q\)*\K(NKA:%R[?]))GIQ(""PD[TI1#Y%1&$,&:(UJD
MZUS1@":^! <DZ4\J3:J( =&UK\)4H"8=!3<9QD3UDHG\ &XX=!9]^^LG1@.:
M;MC3? >N*,3ZG'UXZ-D;4G[&Z$V-^QP6!=V1S-JXIUEDTT?DBX!I(1\6XN^P
MZR['?D4DXV!/HD^$MZ</E$C6C!\&E/P?ROFX<5''<?QPH.S_\_\T*W1PNGX(
MOG!S)8*&!W,V<PRBBJ!2"YKXCH[7E&,< WDHS_CT,+A3\(*GCM-4#=W8W2QF
M#!E(F]JAUDP:F 2J?(GY$]S:E$WD+SA00H![4=8GDN7_E$H#QX:)/]PP 9ZI
M1 N<=$64VTXX=1W=UZ$SZG ?^W'>_AK2$9T;2X*YLWC$D8P3[CA#[W>&NC#V
M'.L[&KB(FE46U&T#M\Q P?,-9,<>L3]O8I9#6:U'@5FF #/0OEK6B0%E4S5&
M30&+.E3BBMQ"9,:S83XQH*4TE[@CAM+PF8NV0&$4,#;55."*HY"6[0EZROE7
MQ%8N+9O<0YCN)/XIN;\(2BB2%?CCK&9'^_=7;+/-'!AO)O@,?N6R;+"C*%W?
M 7JZ/YY6[[N_.2D&0;GPYJ0"2*=5@6D)5+IL8_!_^+]$U)'S*M_FKH1PY7@,
MOH?]"0B#C+UDB4J014M>)-4>3EF<)<1&9^?M._9^VN\X6YTM-N&*-VG$_%HP
M6:RVS#DZW9B&$L"<JJ2$BU$B?+3NPYCV!.OKI D/4'ANKEM4$+24#YXNSICV
M?=>4T!P2$MEEN$V8/_^ E*>WPS7$>&ND @%HF4>72U1X(%49'JK(!;>:/GR*
M<YFPQTK]2M&%@K=(R6L5>P'D3>X]JSG(1O \R'DP%5Q?%4=&L]P5K+KVE,;@
MT$)GUZ(;B<0J+!R=4@RZ7A<;XDU?A-'!L-L6X*L8MDE+^M&$XLOQTK.)4YH,
M6G^+U673,,&M3N<X(:8=L/R^*6LOJ4V/BNWIV_MDK'OU(R330S(?'B&9'\>S
MW!U(YMCV0$]!K'?>]B5#6NBT/012FLNYP];:,9WBUP[)JT\SP_))[F]B&TN7
M)2(J:C2DDVL3@F25-!X8!MH3E@,"I>0=WA$(XT0W=:(#'7[WNBC"+W+M>6OS
M7;EVP[FBG(27/!.%-[2Z"@"?3+QTX8"X3S3*Z[5-*T&^U/1&-".=#\5M%&%X
M:G(HR"YH0UW43PEA3-$2\D&(";G6Y-<P'VE,H>"P8YG;@'22>U09%0YIOJV'
M1&-<1PNEO6%VW[214ZK1C)76U<)E9WDVAD(1K6S3)L5J<I"BS.]T8164FD&)
M6)A_X+)0FYW(]MEW=7VL(.U"YS252H<:J-OKM&1>UG5SI8 4@/S6OH+L*N6,
MG*R&-><X8_68FSR%__^F79/4^9IVSDG3CM&D5\V^@_(VW,-UV1&$L\N\AAI>
M6Z 1F3F9'VX+?5SV[!S:%6A>HN5D.XC(B9CZ>-2=NV-0C>RA!*,">'.4-N$E
MG6J?)" _BFY<&DED-'@28JSERU/ARCF$[6ZA=7L6S3VZH%-R E[@T#'!V$J;
M:H:)"NNZ:G"D0)RC"?[!13W;7#T2=SG @,#&;+8Y6\KML!'8]IF"K*'(>Q2>
M^*#<>-](\_*W1=@FE\$75$*BYZ3[YQ3.SYB^1W]UQJ"ZAU]]]072!M\^?7YV
MIE&G[QZG/=H6E^DB=&?/]8A\1+3*KG+I.D;J48QXL 4] _ N^7''G,4)0$B]
M7.H_I!-.L'UZ:R@E%D0STS8UP1NH+92[ -3:A.NL^5KHQ,33-8XS#][")P\>
M?LIB1.B9XC>PX8S/]U,\N>G)G@03!Z> [G2NAZ!\[PRH71K5GYZ<?\L_\M"&
M,PY(Z*(&L8B>M>$'S,#\T+G2E1^AS,D*F9W$PUV5#4I?D.#N"UR_J-%L(?H$
MX':6Y#!8Z?(0V+=UL>]4UXG'L-Q20SV3&$UFA^+D\$XW<T$?*6D_O*4P(@;/
M A7)UAP31V3J )'06/>L++H_5:3DN#@^_.+PQ\A9\+I.7I>KUX1^7+QDEW!Q
M+RK>T(1?0=JZNZ\V+9CURW))S>W$-8H6%^&KKJK-0-&%1@\4=>WQWPZ<+CW^
M#4 X<8KPDMH.M?A$F?0"59R(K?6GC)G-A,\(T4#+<0EZ?41VE<DYPHU;[NO,
M:P=-S522=3.TU B(!V']/<EFZW-1TD34^O@:?;$%I0@+_W&X"#T03M'0YL$#
M7E\V52%DBZPWNJ2"J1ZA? 1B5PHCRG%[?*S;XPFUL-6<1_A.=@><AQ<%5[?5
MGPK.Q-^GVP+U!%[PLJZE-3DS(TQK6#8)K[-]LA-8&!:D-]P_0<L:AMQ(_T$3
M1+X0J#8:M!7(PUTVU(!BUCRX('G/B<1\):0Q38)JVL3UW3%U%..DE\'G3W2.
M@/$HKX1<:5:[Z+B&/XXUK"8^&/7V]6)WN>_">J3'*ZK-B=G)$ *^N[G/W650
MWMOFKWE1VO4@GRJ>NR-:%?]_;HTEQ%%B&;W/X9:IB)@*,9Y>+*.2'<(0>SB(
M8P=?EO*O]%H\\(LMDUE?H@G'TVZ*.W19[DSC<T')6B-W\6VQ\Z^4::(-A\S\
MM3<A-#<VE[SVWE<XW8J=:"EK81"C?O2Q_Q?LL?/@952+'YJZZ*E1[KD%9]]#
MQC?=1DD^A8B$Z@O.=+L3H>7PEGK!"(3G3P:8>MLP9+BQ<WDYGOA=M%B&R(ZJ
MU_1,ND=82)X<-^1BNTLDX^AG(0>MRM=4*(=[M:F&0OL3W<5$6[PC6U)8.T=2
MXU+6CW#BH56?/E2PCV7<;(1%4H/@O2FR"OX%\\.O:+L.:4G=0MA7-P&FC_OF
MX]@WWX""[YP)6%S6A+,0G:/N:YB84)9O6!1BGH/3[:*0'4%\D"FA8XB8K$RU
MG/]"'9TY,_]EP4KSPASX\YLV']9#Q2UR1%#C5/[4*JLS'WVBXR+[6!?9<W,'
MGBL;T,N!#N*ZX+46K#22D]3Y&RR7D0J?GXW785Z#\C?R<R>)D+ @PTL,I.(\
MM *RC#Z0> ?K=I"VTV7)!>(N<9821G8U_ATW>Q.(@#VEK:J_N09K9E1>EUW?
MELL!2 #46MC#:DG%H;3TH6J-Z]B #-904<L]$\)!?;ZG9!]]^++I=E1NDC2K
M/G$:T"K!J.,VOPX6'WX/8F+">6$K@1(F-MG&1T%(8S_)(7/(B^L6D,8R=RW.
M#5N&/W]?WDD0U2='$-7'\2Q_.8CJ>.S\\6.'7?JI;CA<"ZY1+0<IO$9M\#Q)
MPO+?7/B' R:)V@G.7)QTP<GM%3D4;+^6PL9?-6YDI7$R7$5.JH.0EJ"NC8'<
M(VX"B+G5)*;6U!.(\I'70C7:\RCGJTBWS<WA5([BGH0#KC[Y=0F=*B66DL-*
M,DX0M3SFG#[2M3]*6M#*HUHEY4L4\&Q!G?'_TCK)$H"".!<6S&%!%P B='+0
MWWA1Q,=$82XZ$.U?X0H<U\N?Y*(S0( V^1FW57CIDIAC_TQ-RHB11=CKDY0T
MZ]2P&^WIWY#C5F+HJ.O%[*?$7P$^T,CAJ+Y_6FD7-).[>X@=(XTI:TN&/W"X
MR:F_X_K[6-??CTT("=NP?&BBSZ1#!:S=*LS!QVLLF-\[))_RR21?#JV(H3]I
M-B=UT0/V:5RXR)Y;<3X>K-R2QQII8@5CEU;PG_5".*6[R[S55AP[7:6^6:PG
M2)U\02X ;J)6UEW1)]>D3,2R!S&@4]8Q]FD 'C//@\1461S,7BL*5'='Y>*/
M=@NT0P6?["('6Z4GRY^2R8Q=M_G:S7@;I$XD'\R6!)8Z4HM"TK!3/-FJB+V)
M42H[F.1::Y]MLRE@=M._;,#'FSPW\^;$:M--CR,"*;2;.N9R"_\F4!A_W;\+
MI1[73<%]?ICA!X]H2Q;HU:.D]ZK KQ\^BFD*TYCQSZ!W/QX4'^,N<>:.$U:Z
ML&7IL$]!F#R9],XT8IPDN 9[DP4@P,=""7%9&G+/BS9LIIQQ,JOFI%2P)[7]
MG$1QHS6+;(8]V7D--#Y&* _':U>-<2992#U\^/W&<CW<^L,[42$OQ VA_4'7
M\KO5)7$KKB."^8@+^'B7,FHO AXG%;]AUP<?7%>M882__-*OHZX,3Y>WDI@0
M6/ENQS5"Q_$M?'Q1[.RX!C[&-3#4")1AKZ@;H=\'I[9;!?^OOW^@HR"F<]*N
M)^"36 VY<24QB+$QX+@L3)N+;T6M/>@C" YG!;,TB%DE5 9ZO.(#;KCX&PUL
M&(5FK0(-1Z?RHUQ?C#M7[02R#="&'9A)@5=!2]=X"U/6<0X_(+7(#0U&#B.F
M5?%\&?;^+6S84H4#%88]($PIJ#!V@J3'[5UT,-'*#=P/A5Z42EB1@G<QEEK(
MI'D3C9DFJ$'B9<6U*2:,-3A[Z_#B-M'QWU% -K;OV8F>40I.C#P_ ?.*DPA$
MN.KDR475H;W(:^7.U@9-)RTQ]$13HA'?JQK"*81&+[BKW:0[<)88U0@5Q]'Y
M4IH4-EY$V)!MJ X*BOY"L*8*G/Y*(9XSHQ51F4-_>:)M6E72.JF(Q$@\-^K6
M60[]O")H"%61*0R[+$'77A0U'I,;),&VEC-1.BT.K1[?.=I;WQ*^>'7ZDHAS
MI'E)00+/B*4EW!3;-79)=:MV"(MCKRO+01:HOM7U+;-=XVOG37W18M'21Q\7
M5#O0(L,_:5A4+#K]D[2 T4KX=@BONW@IJ;CTV?01GM9(R(7I_P?W79E^9WK9
MQ\6FJ#MKU5PVX!9B<Q268-EU [W@L-PU19UWSE^G18ALS0:XB]C1YKB[&(Y1
M7LA.;S;&F;AE$<05$(WX70LL?+6@C."%;&$2X2$2"S>@$ 2HZ2&MCS["8+G3
M0O RV$<C,!_#1SR+H]MYF;6EA_]N&PDT8K@-/J=F-6PUY:YOL];>IRCM*]\)
M>Y_4::IB"78+&=E-24K<UB(=-G/8A5L8E0$ :'[O^=>..KC3 O 8Z-8QP-]3
M'4C7"/7O0X*1+G3MGY&(GU2,ET+S*!I,'XUVQ-"9U@_ 3X8,!-[C;EF0'Z@<
M*-#OCL\4(2A_\BH]WZT\A(K\1;GI8Y<\#+=J1[.Z>\(1IFL1[)9"^R'@K\6]
M6,M^^O/CQ0^/"5PO\RUXV:NR._G/__CDD\\>G5Q1IB7!5EFB4[:Y.TV[&45H
M,&9(,)7K*J,^5(1.T3K&LSZ1S#L 0)--"B?GX.,I,%,/6_!\AF%.AS\9=$L<
M2 K58_0ZRY\Z.)Z#>MFCDA0)Z1XGN+Q[S,0F;(8,X4-]+XR^)C7$@TV^)ZLC
M<4,RH/R2>4U!?W=K3]W 'Z!&D12?@'A)&0C@E.W:@@VUIN3)\96E%WXSXQ.!
M8<3[39Q/58^)%#4N=)=&2KPPD^(@"D3=7(%NW%K-%9#*E=N"5[I"(Y6)L:WS
M+35;L<CC;NBC/SMARJ.EVA*I123/\*T@G3KI9;MF,Y VVK*"\GHA$'BWW]U!
M[^S/!#]#=B&\K*CD+<-Q1K1T>GX-OFT\'B)=$2LBZD@GB2"B]A."O,A;SJQZ
MA:H:$YM?KW+G?)0-RB)#G"V.J#[,F4C#U9T>X^%P:UF^A\<@.='R'JY_(^U'
MF"4EU)@*U(D$X8AR8T,2'X(*OW%]8 2.:%"/!OWTB ;].)[E[E#J39/19MW=
MJ4(;UV5;&+,3?M5US:I$*<XJL+;AO;V="7<,]Y.)W6<#14!YS<@(EY0G7@W3
M,D2NA4[]=<ET<UQRZ+O!//9$.XJN ,IVI-:++;H<3I2ANVBX,%BSYN?*,@<T
MU$Q%-F$2M>R+;U$$[]Q=X,)BEC(ZDB[S?X?CGH(\S?3 [\OIU*FYQMEK!Q%E
M8'+N!^?>H[+^=6CWZ2*@5J6JD&YM&E H_/+"N9VIT9%CE_)589V!LDKJAHPS
M&3N+[.EI=^U 75F$149-F:X4+!_] [KAZO"'#X2CD]-_VDL3?M)Y#*['):E#
M:;1T3:267C>PD.9^#K&1E6,=1+#<(^4W.]_@50Y^;;,O"N:Q\]Y;]$CP%M-'
M9YBU/3G[&+;X+!=,+A820.^TZE!$<TN/>01&RX^<6^ZA80H\%='E#S-2(:(<
MFU9MG'XF=N'Q?0F55JS%#59.:;FY,\(&5^!>)/*<Q793_,=I8^#8\+*'LM>3
M)</&'QR'SI>,O']3OCDN7,ZQS>%%H\_K32E?4*A%^+U5A#EZ^;,$GG?!D*J\
M8!(%4&AW892.WX9+-8\Y!GQ,36@TD%^7#7A0:<7HD:1@6J:I3=OG63E7H[I(
M31?%4F^A;7T13%+').00KZ%U64N?M;DQ3<W'OPZZ1#!O'74A]3NL^";R''VS
M^^^OCMH<?THY]9=H]L(90.6 @6TM0ER<:RMQ V-OCN#7)0A71L[7A39!UT45
MSQS[?MQ4;Q5@.<[PGS[#Y%[<8!)G9@G-QQ7YG&N7)LYPF!=OH-02G(E]<&&V
MG=_K]S73:Z[ 4'L%:4E(B9ZR]8'-/(%7D< Q>%V&[[%V133)+&6-I#&C?FHI
ML6I;;Y=*&$P28DD0TASBO;;:+M'$(G=$+U"VVH,? KJBCP<"53C:-8LJ:PLW
MZ.C"6PKC;XSQPN@1VQ>Y)G(9NN-%TZR)N.RX7=[C=GDV2WS>^*B4*I4\@Q+M
MQQ7%:YICZGOE?6W\(DHK\52-")P#ZT-[S^TW3W&;Z15A7E%P;L8H1U>G-/<Q
M1<!):IKZZ%N.-]8Q?,A,U99>FN#EP<D,:R=XM2W>Q+8*+>L:#V7W2>*.1V$(
MPACLVN*D>%,RB)@A XRY2K/.IB@_'0S34&=?M^GYO(HF 9E'Z-CT32;0_-8'
M*-MF;;R@D8%8IH\\?>;U"U$0 4^IBCGBE\:[A)<9ZDU^U;!J3<X\M@@1C<?,
MJ:C?\$K_%<MR@)J%JU_=/X!(BVN(@C2J^!T-PGLT",_;LFF3K<KF.RS[6F(P
M]6SK\,%9S_::CD.?3]OF9/*9:LNP0-@;3371A,3JQ](W#?&$<#\<,,.R(O$&
M%/SW/GLXJ2#*FGR9M\L\K,639V^JPG$&/OCD=/%X0.\6=8XAI#=/89V6-;IW
M].I3+'9\S_B*TM3(?6UP$4Q#??RM,)AP+D@>NEB?+LZ\?D"A9;R+5A,]X;)M
M<U7\GB=7&106HHX/Z!]/GRKF#-)*'U>6DF^C/&AO,\+KQ?RQ90*2O&QX,G3#
MM\$2F>,CVN;($5]2O;&^4"1!Z1H&12TB$6F1QU1MQ*0&MBY87VHEN1<#GET7
M^6L[IS"R_PH62YBU95C_"U^9&]?_TLX_L'A'' [GSU950ZWTAP;H:/K>?^A
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MWV)C!#<Q<;*6A9LXK?Q$JI+P=3QE$UZD#HNODIY$J2.Z=A2 KG\\RW2TW>\
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MS2)^= -B1J/%YS<K*F^$Q076<<=GHM\ HE#Y&[@[;^'^&,M%F=<?\8,2]='
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MX;SAY^:<$P>6ZY+7K75D4C/@95,!D^@!#)Q)FUR!8\,UI]W1*2S%'W!2TLH
MBJA _G^E.; P\E2BZ@@S8R+'#=?$].8S38I\^/"N13IQV<\\"BF%-R&JOH:\
MEJ3ET.69B,PF7$3-6,Q$S[DD5>7%@>GFQ5JY(U">"K?7U)GU $_&:PP*B6W
MF_)-L382L"8$X!>)L IB0!KF^&5[ARM.&U+UQ/.*D1W+DS=T!HT5@C&(Y$&
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M=XB=$I&<O3_Z 9+3J;_MD=4(34"68$=$CS9I+EA@WAE&^F<2!YVHOVYQA//
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M1Q9U6Y*F6#P37XC7)@U$?7X2AY=)"L6[0L6)-YJ\WB_[^J<C.,GJ2)Q?NQ=
MA[T$]!VMSPZES:T$N"T"93R?6R)6R.KNRY!K#: 1#K1<[Q:>YH2>Y.7G<+[2
M*N$_:2#@(N):F@;>XES&.(X%UVI:RT5UWT^KW!>-!1$CD#,W9Y"9KUSWU30P
M')ES1O)^%(S\',WC&7R!!B^8I#F0FV+H&^X50+\&DZR\5)Q0+A<.NPM+_B&>
M]H,K*)M%"U*DLT,/^NZ_D< H@S6A&8A?<3TD>+=P:SK,MV]*-6#(ZPLOKPO:
M$ZX":#98)A[&UQ@[XS&J-US.5S2JEL@("SFAA8U'I\]8U*R3RNA3;>"0UX+2
M]I2E;["M&&]NENIUPA9G-6R\6Z?7IYG;#3G8?,(DY!*HDU3,>PS2;0Q9<JXA
M1[*8&S* <ZXWN[;1_@H 787FC#$![T6!%R@?+BEIHWC;B?A8['&\K/G=<6(;
MWU#63Z:#Y%OA5L-E4$G1<U^IT@R7K$J!IU-OO6V*X&KV(N]X5@1,? 9Z-[X/
M!T(D@MFH=BSP"B;C.B_2I503NOR(^)O.>V1SACO8!;",L(9OMM'7#6?-'ZG:
MVC1%K9E]MXUXBJ0N..Q1S'>9M21H\R >P>=JSK6/MHYVV27"W$(G5PA9.&?"
M0U#>$LQ6/(6:H[!N35NK<A19RQIN6$7 7'&6L=GNO):C6'OEDG!6>!.=Z5#Q
M"#97:[$O6Y6@KLZ=6F.J1 33+D"DZ<)2-L-=2<*3ORV:@[<G";D<IIZ#0I@Z
M)A(<=8-5"?9 2\"0,:$((]SW^E-0+*]K;YS,<,B:!@TMRB$L1!:V>I15Z!%A
M#.&?FQ<D.A^.0Y2["7P905MK+?*I^.Z.+P:+]@KI..8L.U.11.:(ATH\2UA,
M1],640AD.Q M4D$Y$0#6:46US_7P>\(J%4U'3]6BI/Q[DSR%1:3S!:Y'4=W>
M%52-9/#Q"O)>Y=ZA)7<]>>D\E_NC$C/BP!9F!2UT2]U&2OM%W48YID[C7=/H
M^25-0! 4-M6:"0 OP-H73DB'[*#/0,=BEK6]C^@8$+Y\DB.MSK3>G1F54+&'
MT['99)EV48 1,R2D*T1\)GTG ,V2>0P+LUD"-FRPL3'+7-(NWI[ -6)=%2*G
MQ6 T7 X0-Z3"'*PP$=]-PI_V:V7"]QUY6UZE'3G7%MO9[,V,P/[,*4C-9I]5
M5=&MW:W%J>%3E2H]94=X!S2MNSBA*AR*I'F:1V5.MH85Y+GK$6GI&.%7D7UU
M1DF+2MMD(\0+NFL@_L(-L L4]X0_R\'/+IS.R\-AK!!;!_Z-/?$*C'O0>SWH
MA)>:($,?/U13*5V&*_C((DVHPZAU$CDX))8W@@7(7$D;/#P.UD;;YA-.K+;1
MYVCE"DL)OYM$<Y(C9^O-ZKV9!V9:7K,F_J81AZ[TQAF!C?)QKE5GG#.S#/%K
MTCT-,]#QT2*;?2$6+(.#3=U!3.4K$M<MV$.#/?HMV.-IM.5AP![/[$[[D<HU
M'-=UFDG$1/*CB"6CI'!$,3?(JQ TC^J^FG+F! _)X)<4.D']<Y<ZL'SO8&.8
M@PP5%2@RM,%7DR+=>N+<*=\J_RVU[^1+,KU.O/;6_>TI]LQ5OMS6EF[PWB6%
M848!.T$7O;Q::O9PV%C#[LHA$NJ./T+V9,19,6PC0(=4V->VU#*]-H C2^>I
MJ"6@=&K=&SE0T;'5H3**<FH[!H-J.!RK=61A[6[0[#<EW 4U/L8]0;45SF/P
M-%M$;BY,E#+_UG!PQ3M6;ET<4Z'ED.>S,> >VJFK*VMGF.-?4RJ#<J(W6R![
MJ%3(=DOU0[U $4VH&%O%2TF7=DUA9BD9FV4MY"HN(,S&Z#2>1Q,/UV)?75>1
MUIW*7;L;&@MTFK"\R8-WKY6A9J>3-66]Y_H!#Q[V6LX \;_6F45Z#1H/SGDN
ME$&GX<3FH$)U4.=&H.O'8FZ+2*(@3JDX8' 7K05>,F;B(!2*R25(P;E!DT)^
M"&RAHVKF7!6V*Z180_]&D66V%N9\&T3C2"N\GNE3_-EBICF@ P=[*72'.YK;
M,=,02[E:-[B@5D'&CLQC&W;5A3T!;,4.H1>)LR0 DCS G DJRW7)TF^J)2$I
MS_#*^#%H.G":B-I(M4( HJN\LQL8[WJ"FQ#K:FN<+P[?;4NHL68:.T%U-?!,
M-T+T*NA#]54[=9)^HL0=Y^S67WTHMI"C!TY7GY?J2I'*?9L:&YPL'9<A7STU
M\R/<DLC&!9,79]&XT%[FMM>SQ3M*6Q&$P%EX?>DVW-!?]U8.W@A_9QT6:"G#
M)?ZD*,312U3(4>-$+C'!SR@K/X1%<%")<>U"&=-O]HAD:!DFEY2#KE1$UE26
MZ$@!C^@>2L_9."&<(O.5Q1C<HB];5XM/L^W$XK_Y0X1G0VKF@>)M3$D#4:VV
MNQES?ORSG\$VUWB<.PP\FRSF=U)L0^$[NKK5KK71/*%\0H8SV!\ 2C#_-Y<;
M@UIU.,>C"M0\.B[9&>88S%ZEI8WZX?T%P2D.P[' -]M <GLY174TEB!XC6&X
M]?TC["PV417>5@+:E8+(^A<T2D%=NI5Z2,L'I6'#*B_;V?A=' &Q<3%9PV1E
M60H&7*$,R'+WO)(%<CO!\#A51"RS1H%-#/]]CAB^88%R0@X'65+@0=JB>$"2
M;[>]#BSZQ@=P57:N&](-/D$,FDIZA>XD3C.G4N!]W-I=PEM-@!?44+:(!6,U
M(*6$)UJ/\8R:%])107IS\NYA+8/GIEB!4BXE1BCC!^Z=&9%/UKI[#[Z H-MN
MPZT@B0 "B'''$U,3W;- ?);H3;VVDL-.@ANR*S;+&RL":D3R'N2CD>8(/$J<
M.%&P4\.D'#UO2-FV@) -9[>X9PY;1'D\2'-U PYC@4/%]=S:7QJ)HFSN36A3
M)83B"P'#)$.X>"U)*P ^"8GO;L)V4V;(@;\:4%M5U(4KT"VJFQG1NQUG#,-7
MJS(D38_BN[=>) (A-65SZ1P;KPUP"^($W$5?FX+FW9Y>$'L Z)T@"$J%+] ?
MLFIMA +53 N:I8(O:R$$:J [<!$7N^;UBG5H1&-&KJCTS;K.Q-7@KGP\Y[)R
M60B>7SZ*I!2NQ(_]:16Y%,12ZD*2E8.!?'$H<B Q52F$6(OEVYC#:UH4L@ Z
M#.XFP]>Y2W17-;J$32G5ZIKI.,^&&VPM[E&938 H@HMXK/_2L95M"BC -A=5
M4JDUIR%G;L=XY"U;)NL0N9AS*AA&O,R$7DW2B> 7!$ 5B92W[ ]PX7E5C_?/
M. 3/^: [P=VP2#&=C[PIURZ.EDSJ5HH.V"-8K%R,L,I"K T->)4GH;]&4"*Z
M_>H WH95JVD#() '&"Q"2#,9)H:U0#R(VNZ]$DX4]R78EC=XE54(!ZAN& .H
MR$T#5ON*P&'HN8 E\MX/4;A&2TSUFH!GL<_A@PO4%]>> WTI52UCD'01JEK(
M ,JKIND\3ETHU.D(P=,JIQ'OI[E_5TEQ%S\4^&T)S">%+_:@D!W#GP0L/E1P
MSE*)YKNB8CE#/6X>GA[S!<J#019*)A9:XJ@MBH)0=0D?=V2$IIHF'&^S#.7(
M;,Q'>'<8%T!H6<Q$!2P6)=L<X(A5!+:SXN1(;S@6*Y6M[X2$79M&S><M"40K
M2Y_G0?0UT0QE.KPQ"TUR-$Y]4HI:;'06OHHQT,I^\D*X:$8*%:[>KGJ9>ILN
M++R=ZY*2M!\W8TV<U&GHHN^DR$DL5+%YJW"R.0P';<T65J%A%8,65O$TVK([
M\B1X-YH#\#)+KY$=G[,V-L/ZJ4;JHX\-QF81 (\=SG@-O='*:3<QR)6C>'X6
M=/-]2FZ[.[CI4M,69$/5F<*K$EMX1\2T@!R@0[A4H,E&Y&>'$BB, 85?HN>
M!<XUVA Y*G-QM555A.4+KC 95>Q8JM!P53<<4E*>MH4^(&^E@^4UXN 8.^$#
M$C_8^4.R=*FH=C94A:V)!S%.?C=NH!0[<G 1E/*FE9C\/!U_K@( V8OJ5)"
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M1I[',8STEN%X%D>$X9_&A96?.L'SQ$K##TD89M"APKM)PVSADG[W_N=.9=K
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M[5N[J:52R*66(=P9;3+\"1EMS$G^;X)(CH!E%E<3E[13B1BXJ!U$M@%MU93
M>')%,$$";F5&6W6"<HD27TYE7*%<X+2!,B=<*F:I,H]/&_I_A.F76D"B'T3Z
M#:)S1"P-$<^;";9FC,#I1G+TP-:'JV!2SL$2FL_Q+$@X'(UH?\C/1Y$MAT8(
MU KIM,"8@+ '.&SMQ#_HQ%,=QHJ%Q?QIRCW+U99WD+@ SW&:0&GX:LVIT1%C
M(P;;69 8(^*PEB#8+(ZF#+ZDTC$DSEB_$':R:N.@K=IX&FVY]ZJ-]IR[CW-.
M"55@+2]&&LP5%".34CJ.)E"*:H,F=-@1^?U52.7O4!F0I26D3)E1WC%SR,76
M<&#JF!=&07*D=$899<DX$$\3P1^PD(#OWN93M;TC'VOMV%KS!@,Y!GY'X<3&
M !=(^F 4!2(KIQA..;<_G*,1)/\X)[.:M,$I\@(,EBRC<'F)] 7 1]-._@-/
MOK#VV*EW,\X(_RQ:I%=B"DT16UCF+?;E,>?I*AR'5*TO&DWU_6IFKX.2=TMD
M $(4Q76<*PXK8];.P^L.S/$T]JS=D-).3-BKG.091D39AG6\/QA;QGJR,/BC
M3+.R314^YO) XJ1H@EFJ29P7&0B@08#3B@-4I/[R&1'MBA#KO!0.P')AB]H@
MP&R<"9%T34C.= [,5DA,G$D@CCA]I^)CAPP_=W(+2MF'^<KZKX9#)*CD.%N[
M?![134Y2STBD"M(%A#&P]FU<+@!D!Z5?2)9. 15KUGF6W,;T=#MQ7R^P!82G
M9I;V]+E-\P.T6;"I;)4MGP!8;;>WH Q2-%'1ZV>8J*CJ<5:U+V=>]-Z,D+#Y
M#'I#&3";-_J) 0"G*D?P<WAMV6 ]8A!)4N5=[YF<UD;VLW06CX#63 A*HN0R
MO+24Y59^T9RV(W:JR)@.'99 XLJ\9;5^$\\Z60+W-[U/*S_X&_-')A'F!T%(
MG)P7)N?&P!R7R'"6G)D1F;[  8RA[@(FPWU?J E3H.&/, 3"0F?/;^/<-I A
M*9O6QI- +U3EPI(8PGW*/)@KX7:,0@0!$^%_R1E^'__BU..9D@)CE>2'CD'@
MU4P8*,Q:D#%AAIV,!&JP7SJ)+$4M280$1!C(IA*F)AD/QQ1@(1$++A$'83SE
M^FK2F5X4?!6"U5"B'4O4PJVN(FJ%$%"R]08):3-2*O_?8.%;LFDB Y26-)3F
M=YI4V&6^-'-W1PXF?>Q8*?LU>NSK'1#3LFB!,LM7(>1<3QP1OGL_!*$@+F^A
M$TBXVU0/+8.$>;AT'K%&#<JXPZ(22W6;G?D%Q]JZ;1Q/_OK=[>'2?N_5=[63
MX0&)#%#7X;PP\S'H&O-?T49>A'/*6)X1@+<BO/DK6?,?((H83?*[G7$/?FIA
M-]\9B^:NA_&6L]@?/)%9'':-13(-L3[[UR40441);#: F[U=GZF73V2F]KO!
M+\"S?1%.([.]WCI&RF]CA@HE1G)?<W7T1.;J93=XCS?<N>/)_S9FZ=[VT:#_
M7<.]:1HZW@, K;$$7N?E8A%F]T^_MF;B/IW]$AQT_^L_^@>]X^#L7W\_?W/^
MZ6(K4B%.$#]:3 %:?%NHJTB7KZF-!5HT-MN?&5=OS[1U'B[SZ+7\< QHY'FX
M>ATG^$;\TK$?-H.<^!4$[,;AG(T?'!7Z,Z?+7[WJ'O8.(6->9.:_B;R8D^E=
M3*:_*"8-?QMT!_O#M7_N=?M?]+=^=Q_G^TN^N;ZQ^[WNP='15V]LK_MR^&5#
ML+&QW<.#E]](6P^ZP\-O95R_I;8>=0\'^]](6P^[1_N'6SWU!1XR=-"8HPR.
MQ+]^-_RN$BM^/5C>!'T_4@SQT-IIEBX?_DSO-9SIW.T-/>I!?[[;ZJ-;=IY.
M\6^^_\;NV&( "+;V2$-0LT=Z%&RVX5],LGX$Z"]4'+6K0O7_ZV[X1YWPLQN,
MX*.9_0X5\1YLII_@\G\;Y>,L7GJ>TU<9!K9XP1XVGPU0GRF0_GQ;8_2C\2VW
M&)RM>KQC(P=DE^_2;CMZ?^:D:@?ORY8>)%#>FGM]E\]WV(&3 "^[OQN[!E+1
M=[G8O];"^MIK\!%>N?5\/R]WIAV;=FS:L7F$L?&><Q\!E^:\.M*UK1_K^ZIS
MZFU;<^6E,B*RD(X?O8%<B#4KBF7^^L6+Z^OKKFEG]S*]>G&2C6<@[? BFER&
MV8M)6(0O^L.C_7ZO_\*TEW\<#''V#U]$-\,^\&B,5T6TQP#;,)ED4=Z=%<:*
M&'8'#75;CQ&CL*NH72Q/=;&<*"*$CT*$\(:($!@H^1&A)5F8%(^PK)[:87^T
M][^/["P\7M_-ZMH;'O1?'NSL" R[_9WM^^!%O_=BT!L,[V<$6F/FV[N?N#W#
M?K\WW!OV;V!UL W2AYW2&B'/>I)/+<L2 YL_9'$"*/MY<&;Y,=X3/T:P+#-@
MWL<BAH\E(%3[PW"OO_]]^,.+_LL)_40U8Y-TB1P[ZAM2:S'L#<0LN0BS49A$
M^=[[FWFTDLJS0:_W&-;O4SNL'SAMW7:_[7[;_2?2_7_=8UZ^-:7N^Y8=-)A2
M;3SGN4_R!E/J1UO_M<Z4:BVI]C)IN]]VO^W^_5M2+[#^XF_UZHZ'I'EL*M:I
MC^,C5<$<'#XH]^.F,7EX8W1K8LC'LE.>!EMD6P/5UD"U-5!M6]L:J#;T\F2\
M\D$]BS7PLUB/88/^=QOW><8K[(M3:/VCX-?N1?>T&X"/=G@<](<O>\'W$MUY
MU3NX/;KS0QO>V74/M^U^V_V=[7Z;*/N6[])ZHFS@)\I::ZU=85]WA7UQEJZU
MUMH+J^U^V_VV^X]OK:'U]72ZU>_UN^?O+AYL6I\6O=(Y)G2"?[WY^'-PGH!T
M\C@*WK+*;["'5V(LOQ?U7_.#:4%"1)91F GW\CDL6%"IN(J@JC\,D%QB%)&"
M!5"RXWN*\#)'QOAH,8HF4/P$->_V&;9!.[O3=OR@:;O?=G]GN_^,;]F+T[^W
MMVSP*;Q)DW2Q"LYNBB@!@93@8CR+%N'.+OD=W_%M]]ON[VSWG_%U=WKR<![,
M-W7=G8;S,0I[@<Y7G'P>A?EC$\"U^[_M?MO]MOOMY?>5+K^W9S^VEU_3Y?<V
MFL9)W-Y][?9ON]]V?W>[_XSOOI]/WK1W7]/=]W,XBN;MM;?C.[_M?MO]G>W^
M,[[V/GP\:Z^]IFOO ZAG)T4;\&P/@+;[;?=WN/M;W'Z#QG[U@F_A#MQOGM[F
M><(>];;LSXY=J*>I:4KP(;Q<ARG]_A;H*-+IC\U[0O.;">!36:DK,);*#SN[
M_W;\^&F[WW9_9[M_G\6V3TT+]Z%ORK;_;?_;_K?];_O_-/K/MYNTA#_.A(>-
M'7XX2=-;/GL?+!B/,2O__546Y%8=_[W,BWBZ>CI]/T^"<#PV*PJK)L%##<Z+
M:$$+]:#7_W[TP_?#P0_?Q_$/]+MT"B)OC(FE7UWL_2\ZL1=GI^9O\RC,4::;
M_CC<W]L_?'5TT$&_=ZQ9$?)@6F9)G,\\MS?G[PVZ?7PJ4'4$LRB+BA0K,2=1
MM#!?@'^9AB_,F*W,H^,\ &%U^FZ_M_</_.YU/)]C\>?(?N^__N-H,# C"DK&
M^'/_.)BF2,&P3/,(E>R8:X$?=B1\"V<WXUF8&$<?F18RU9(15)Z:45P"483Y
MU6@59-'4M!D&-4Z@K::54Q*11A*)Q@<BJ4,T+K.XB$U+X+?1S3A:(B\$_#&"
M0+WYURPL\-^9E=L+\F4TQI&=SU>Z,7D0%UY[NG<QKH5,-4F1E&/#!OESGVSY
MDF_;K<27?+2>+QGZ$$_^^MWM?+S]P?YW?[L_EN6G2Z3\Z&VY=\[DNE./OXE-
M"Y+B]0%.&*_=OZ&,N_^\+WO2_>V"F@H][H*+\Y_>G7SZ]>/9Q>;6/VQ;FW=L
MQ>+;,,IB&NBF\Q9[I+9_4*Q$=-O\4<99!+0*5O!575?^;38-^J^&^YWJ-34+
M\V!2FBL*B18F='-GD;FK"KY(<S,8Y@]I@BP,HV@6SJ=P@<&#<"?1!_#)653"
MY8H/#,MBEF:F>Y/N\U@6;3NW;^=;8^F\#GX)5]3@EYT F+B"I]_P;V6 ;VGG
M(W/UOP3*?7YQ,UF_Y[3Y?^SWY;O-?]_XY4U_?/FRV_O2[[8/;A^\+CC4WQ0=
M>@)1ET</!:[]Z,%3&J;M C3_//MX<OI_G\XZ-&#G[TZ[#SQHVT4!O[$U^OCQ
MZN<$@OEZX_3J673^V]P3W_B6>&(8NS>KUU]W0[ 5S7;Q^M3/D]\P+_(7P<=H
M%(W'87 Z"Q<CX]-OL7T&PW;[/(,;Y=$NE*WRIG?-(F^*=]_K)EJ[@<0UO[=F
MX1-?QX49B?$V -E9'$WKG.<-[.3-2:"MHM4/F2%Z,LF@5^N302]&Z61E_C<K
M%O.__3]02P,$%     @ [$"E5KB;_M0J#   *($  !$   !V8WET+3(P,C,P
M,S,Q+GAS9.U=65/CN!9^[U^AFY?;MVI""#M4PQ1+,T,52PK"+$]=BJTD&FPI
M+<E YM??(]DFBQ?9)C2>,?W0Q+'.IN_HZ!Q95K[\_.Q[Z)$(23D[;'77UEN(
M,(>[E(T.6_?]\_9>Z^>C3Y^^_*?=_N/D]A*=<2?P"5/H5!"LB(N>J!JCWUTB
M']!0<!_]SL4#?<3M]I$A.N63J:"CL4(;ZQN;RW?%P:Z+!RYVM]J#(?RW-=C;
M;N^3_=WV9G>'[.WO;G<W=P8_C0[<K0V\/=C<:&]W"6EO=;=WV_M[SEY[;W/7
M7<<[P_W='6*8/LL#Z8R)CQ$8QN3!LSQLC96:''0Z3T]/:T^;:UR,.AOKZ]W.
M'U>7=Z9I*VKK4?:PT/IY(+RX_69'WQY@2>+FC\Y4+32';L3P'5ESN-_1YJYO
M;G;CUIH7S>%.F528.2_<727::CHA,IT&;G?T;2UGO;W>;6^ )*R4H(- D7,N
M_#,RQ($'&@;L>X ].J3$!7 ]HN%;:#!W6V$Q(NH:^T1.L$,*F'?T"2'=Z]2?
M<*$02Y .L1P8E:50FFRCA4*$+KF#E7$[W5)"4V-=HGV'>$KJJ[:^6GN6;JM3
M7&H@VR.,)Z4DS].$TJ-ORF@PYV[=_?W]SK/VGW0-4AW"M&_KC^WN!HR'$F*S
M/*NX;+AJQW2KT&$V=LKI$-.]4H?4T9+E"S9*<RT+JF$82>*LC?ACQR6TB!\N
M-]<?4CP/,\:5H=??1-]-)I0->?@%?*7[[R#NQ%LRC(-1(M2E>*KY<X"%([AG
M<>O.1/ )$8H2.1\F#8.Q(,/#E@Z6[3AH?//P8 TTB9LD!"QZ@K[= 1+B7<XL
MB6DU&(<M"0!X).R;.AL^$:2LX4 B(6(;H/_Q]CO8*VL_D#B!]^\PWR7#LN8#
M"66T@O6:N@_W$74/6Z<<9N\>'H%V^OO[VXOLJ=V(G1'$7&.^,X6.ULV_+FK/
MTL(V,I1(DW[I+!,LL0HD<6_8D?F\[.81<=0DAW#)/PK3+79L*EGT9=R3N?W+
M7,* &#Y([E%7Y\8GV-/SY]V8$"4#A@.7*IUD%46@.$LK1AL S!UT+GD!*6*.
MYKFCB#T*^://+Q+^]X%E6L?WL  [QT11T/P-@%WD;T5Y\[4HH\\+$AN/^DMG
M2CZ\@4!O=)3W*QG*-MY6M+>*H3V3@_@0S22AS_<?HSL%BU/N@X5C:$,?R267
M;P!WC@@KZMM54%\0B+3$#_33H;E3W'D8<\\E0G[]'E U73W\>3*L^.]4P7]>
MXG]1*//# S(&)Y;C<X\_O<6X3[*VXKU;:;R#(&0D-13E&S'"C/YMM#@CTA%T
MHC_RX4D@*2-28N;>!;Z/Q13&(QTQ.H2$AZECQ^$!4Y2->M"U#M1U1<%?H42K
M3^SIBHM*Q^,R$ 0NYH7_A.;$:V>(%4"@ 8I4,$%AI@2::8%B-1KD+==$Z3FQ
M1P1,E#YG=V/(@HL"GTYLQ7!_&4/@$\[,P F%K)#AU2 @YJL@G;-PIB-:420R
MJ&U0=->7H5@HD-",58.0.,=4_(:]@%P1K'O%+P-$.K$5A^XR#IH/,HS0/*<&
MP:#C %7&:HC>,./K$$U8F8DICX45DHUE2.:XF?ED@5^#@$GF\$7Q2*&TPK"Y
M#$-:0M^@WI^%9#Z\46,B+ACT;XG%[71R*PY;*<,AXF065S0O%#)K$!JAP7W\
M7#PHS9-8>WU[N==#:F3(&]3/JRLQWJ^X*5SD='=^1)&#/L>?/JKC*G#V\<![
M#S>*Y%J=:#?/B=#JO"C4ITD^E%KVEG.'/!969!-K()GU<Q/122^%R\&3R\.*
M3V)](ZNH;B(\J05R.73R6-C V4BL>&14VDW$)J=>+H>0G9$5I\2*2&[YW42T
MDM5T.9 RZ:W8))9&TA^R-0^2C.JZ].#)86(%)[%@DEVH-Q&BU27BUUCH_22/
MY(PH3+UW* 42&EB=([&*\R:5)62DL6;H<Z3;AX]505B_I>,&'N'#_I@*=X*%
MFO;P%,+L,7/-4#X-I(*A+.2[>6$%':U^FECW>B,_C777K8WV;:,^"O5'8$ 4
M,%],^'#H%3G+">43J%%][)# ;+G$D;?<DD?" E('ARZLH]6A?\R2WJ)#)[0W
M[$)_C@UHI#NGKKZ4=+=<'E9W2"S.Y2SA-!"@]/67J@E706Y6T!+K;IGK.DU/
M@-)[?!97+\ R-J)0>QQ+25394%^5O17AXBMWBY%V)A"%$C]0+P[+M^X;X_ZM
M^X'\^R)_'BCHU6.?"Q6E/%^?)WHK[XH'OE6.S0\V"V^(6_*#4#*:%XTBV1\>
MD8(49*\B(.XEQ0/J4?T6Z8I=(5N U0<22\\%?2 2B>9D-A+[U.<S59.W8LRL
MF":6K+,>^S0]=4OM[[0O+]@D4*L T\K<"FYBR3L;W/0[R,AK)-XYC^JJ#MDR
M+*W8INT[S'D.V/3AF]/WRVG2%4CU _\2A@'IX:FA61W29:19G2"Q'&QS@I34
M+%( &0U0K,*'DU2&K7C=MC)Y'XY20T>)WJMG(]-AU0J[UPNRND9B!;Z,:[R(
MCKRBR:5=<M](2;"S&5A!3*R;I^\\:2 J&;M&RH_#/"Y6?!)+Y'F;3QJ(TMS+
M'R612:&THI%8U)Q_>^3?WO]?.HN' H;7"P<'ZF,#HU-!#3KZQ+)OB:>F\2Z&
MQ(WH&>H5\0=$M! >2 6HJ<.6$@%IF1,1#UN5V3'J>7IW5LS.G*)Z /,0Y6[?
M''[F!N%Y-BTD Y!-5:"O?A$\F!RVPN94$;^%PK/27HY5/7"YCRF[@'N:T>Q8
MQ41?](APR$3AGN!NX*@^<<:,>WPTS;?92E8'V\ZQ$RW27; K+"0!G<BYT M]
M^=85(*R#?=>G>GL $6?/E]31R4J^59G-ZV"+&3#7G/$X#0L#692%F;OS=@VQ
M)U\,*T1;QLCPWB!<$SYL.8*X5!6T/?S&AQE183$M8/FOV*/\[(\SB T>6. 6
M'8)VNCK@FAD<=2ZNC;K"+!C"WT  <'"S3Z2&L&+(+<BU#CUC]GZ<0*GAZ@P*
M/-7(.Q809D:FZ<ETUB2J48^?L'!OS"8BO?4.?#Z\"+/B"P9]94ZJE%^?(4!3
MJ0-8SUB5.7A^M!HK[_KP&ZEUE$4F!9UJD$OZ2-REA\DZ7CB*N/-/^(Z'$##_
M)%B<\R [ +V*I[U#PK.J52(NN63P=F'IV/TKD&'MW.?'KFOR,^SU, 4;3_&$
M*NRE^PZXPU=_XO$I(9D]MB+NM0WJ^5/2.1>$CA@DZ:>1%I5FMB2;VO9'H:A>
MPR!="(#30 C"G&D?8J8,ZY]?@+W>[/<Z9',9UQ;K>'B&,T-\999QPFDBWPL*
MD]?!/ZK'L:]WO=X;A,>0;6U]HW*V81[HUB3S>8TNM47F7J<P[J\$>VKL@-7Y
M@S2K=1W&9%@8/<?O<]R2,'+*,9W((B55/F4=+#PC S5SLZ]0^PS[1/B1CU[H
M(A^F4L@YH=X'!^T),@EO]0A$$7V:4\:0>#WC5_CWFZ:SUYAQL,N:@R3;U0'P
M5\P';Y>)_P/2\%,.0O2*@!G&-\,P3XX7"VZI?- !_!X:"05(J/@,GVF?/*L3
M#U*.S'Y;!>LW="T52RD43J(EI)*+P':Z.HR=RZD_&?M8/)2TSDY7!^M@"G:_
M!UBH\&7,2SS@()*+Z6P-^XX':GR'F5G IM+AT XNSR@9\5/]XVA<,(J/ UU\
M@7-BN;3D#<UOJ3.&8>?^1L6(0F/+-/JN.M4!E3/BT$GX!.C.H5#"P> O.[:*
M<ZB#Q?GU;)PY1)<5J^($E[HF&Y=$2D(6-[.8_ZZY^M-L9O<UHNXQ8P'V[IFK
M1X!^-N.&J55F_[R><?75QK>=J<&Y)1TQ7"%K+T1:AS&R5%Z<8.<!AG&IDF2)
MI@Y6P7!UL!S/[]C*]-_4MG4=Q?$KVC"J!I09!5XVD"G]^P34C7YN1O\B09^?
M$)TT9]I>E5UMD^LJT_SJ$X<Z#86Y25M&DW9?8)>8GYPM/-]GD];!QN57."#Z
M#L*7H:8WPV-G3*$HT#?SS2W+I0Z6ITZ^T8M@TWB\G@6DV#/#BMSJ.G]G/I&O
M^""_3L!?X;_X[(0;BV.GMJV#%9!*"^UD$&G,WPN6?($2>O^,#(D 5XGVJF7Z
M;U5V=9WMBY4>\5'LKZI?8B:UG=F+IRHO$>OE%;_9>N(*,J%\]G5UI2O QOX(
M9;G5#XT19JML^#O=1Y_^#U!+ P04    " #L0*56+S#.JM@=  "Q)P$ %0
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MTI.S?8DFEFD%$IN0;(Z@0E7/UGB0O/@DK7$FMLX&W4S1D(+RQB!I*(IF\*#
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M,$%A<,1D:K[U=,-^Y?:@?H<)QY_KY/Z.B].00'OMLS047J,AN7$#SB0&PJ5
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M]1)O1]1!:(KV3#W9HDCC@=,^0S%%,1Z$UY[O*][>O5KF3*&UX%Z6;.HNIF)
MMCO5#)\'Y,9+$W7 Y@7.UU,S)*=Z6^G?5BRSY=SW6>1N<M92\P3)"$W^'',4
M*7L.GADT.DF#K$=P#W"3N)7L=YSK^RS0'&G#A1<^@O%DOU6N-:48/"1FA29M
MS%1L[5=M0>:0//!6J.E;6@UW%5>AX<I@DYT^J^9P,4(N3-"E &9;ZMF%#,'0
M6\4"^F"4RK:U7KF%I"'YY:W@TE(*?9\@.6/\DHTZZ=H1H)8**L12"P\-"&FD
MY>3GL6);.QZW$34DC[N9_]%4$A< \M<G%V?J-;UOVH+H_8)>E[MPL[+FA7[[
M1_->1+>-TUM3HCLQV*@[$>F%;U'6B L9.),)1,R$@I@E.%<0C! 4X:$)T;0.
MA<\1L'O!V\F37M(R6MG*(T+\M]E\AF76X:F&Q/F+KXLNT(HF^]H=OZ+Y7_KE
M]4#>;$+#?#PICAAI1@NLB #1QE@;E2EP021 E9.3(>O"6[M!/;(SI !K>PQ>
M+L<;AOP;5G"N"5T7ES[#*99Q;9G@G?)2 48AR<M+ 9P2Y.KY*#2W%$VJUH4O
MUY!RQV@-'A22=IOXACL>\V7IR9J6.7ER#I,EUSZA)"J8%A#(O0?)<I#.$"W8
MNNCC(@T[9VG/=(9Z4RZV@!A9D\HR5>Q#( ZYJYL,HFXSVL(Q</)UFF_UWDC1
MD!3F3GBXE(%M)XBF@']3WN%GG![A*#'N:4@#RI;:68+<WTBZ&#0S!07C1=G6
M <(Y H:4D&HJ^NVGN5U[-M*K79C45G'Y<#P=SQ?54'_&-7\CYA(971D(>:E2
M)GC=80[ 9&8Y4U22<FO9WT+2D!)-3='04A3MJIUPZ8414;^%[D^LX>L)/3PD
M*TD]@0PQ4<A:,UW*$\/>&F%*E"&U[N9U/35#RB<U144C ;1L]X;TF'J^XA=2
M7)/9LDGE"4DNI)PP9S"8ZVY*3N2N\PQ8M.9<J:QU:\?H1H*&E$=J"HMV8FB?
M:3P3 DC&5?$L A-:DTU# RXGB@.""4YK:S(3?>46VZ4UUA;Z)*:]V"KHVWD.
M<MGH7ZX;Y?70?3 ^@)2)%B=)NG9E%, XYP*#(LW=OAKFSF0.R:O>%3^7ETB_
M4NLOO+129,,<@Y2+KUQK<!@BA)*=E4G)6%JOFIO#RWM.*[1&QDX3WCBWU$^R
MC#Q$;KS+H+6D6*)$1A.3U+(SC$99(B^M-_SVEBQM8YE88$J6S"$7\J%5-#1#
MWF9:Z3)S6NXRQ>;]:6ZS3/>K?X>"QVOWS;:47MM61\3@[#Q!ITZ708?2D/]F
M&)+318R&(CF@(M?.&>-,[J7CT;44#2EO,EAPM9/I_>[(GBO<K//<[\;L#</M
M97]V4W8;;=->419[6A);7!(B&@DBD+NHM">?D;Q(FM#,3"F9I>;%-3>0LZN2
M.[^%HP(:%QFQA9:6EG$"HC 6M&4YJBATE*V+4F_8D+[OK'\;#%Q40=O/>%O+
M=DWI]TO2RN./TU799#K^T(7IG$*IU?TBRW=KB>3_I<BJ+L_36>$Q9\65AY*+
M 25J1IML-6C),RE.GG1N?AE$+YP,R9+V!<,!8.">+6B8'[R<S+[T;3DO#[,?
MBWD+>^T*FNI(;[O9YS$][=GQ'_-:$7GJQ#\EV'Q>%=/QP(JVSH))U;G"F" D
M=&"=245YGJ)LO;>T.76[E^1^NXB)?I[@53<RT0I(JB@-B7Q54"%H<%+1HC6)
M)V\8=Z[U%LHF= W)ZO:$I\NUNXW%U3)-U-6"T5]P]?\9WL\7DHZ4BYDC12<\
MVMKNDQ=R'9B@&%FH6$CWJ]CZ'.[&Q W)@NX)4OT(KD=<G333JXPCAI1#** Q
MR=I84T/DF@&&;)1RY$K('A*(UQ-TQUW_WLO<[@= VTJH1]"LFV^>G'VXL@GG
MJ!3&N:ZAC%(UOUYW.J5CP',H- O.L-#Z[K_M*+UC&<%W"K/F,NT1?Y?; X^X
MY-JDZ"%XK&<IO(5@3:"5$6)(EF$*_>NNRW3=L1;A.\76CO)JAJ3K0]I?PWA:
M@]Y50KK&L,$+A1@+2%?]/DYS$22KYEHGR;((2;;>C[T#>7?L:_]=X*HOZ>U!
M4:U[](]<UD;4#B[",TNHYQ8<4QFT"EX)QV0L[>\VO(6H(=UH=^\::AM![8R?
MFE :U7TN8GT9)9SL1"DF,_&(@&)Y-_GR)D8KP?N(.AJ)YN+]]9=S4]<]?!.Q
MN^]#[$WFM[]SVQ=.N[A"SCUQ D4D4EW%90CHB2A9BM;)V=B\X=XM)&T"%?]]
M0*4/(;6KRSX('3X+RWSO825GE:'RQ2?BB('EI*:4L!$\N@(E8M&%C* *K?O,
M7TW)1BE$]GT!I8%,VMB/*VW:A7OJEH7#*V"?'$"QQ@5&$PP$6XKHF" @ZU2
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M\X*X P/1)A5Q3)Y2! .6>!>!*/R]MX \-;JRSJ\ V+^>*RFFJ275'E3\&5K
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M95UQY6@GT\%GC\YDMRJ:K(.VD9$0720R*'04D9#$95!9R:2LV:BK(#[UTL*
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MDV8XVTC\Z>#1N"U[RTC)+O10=\5/K%!>UU,-=SI+>ZF#(:B+P4]5VR%*M3^
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MQ_4D[MV2W"]D&@@<>PGD4:@&>QIZD ;4@W$8!VF8(J$FPB:#_:#EN0WPM7)
M:V<VJ@_A.C^2KP)AY-%K:+_QD#UIZY%A6@GVQ_OBVT_JGG:$JE\V _.PI4D&
MXTD#^@%X^H*!D[4LSVKQ(?LF^/N\5GV3T67K!?RE$G*U_)!)L0AIJN9<0D(B
ML!J/<1+#%'D!C$7*I9J<A8%O=5+$1.C<ANI!2<,O0G.>]JJWLU_I\*RLX."'
M_Q*DM VJ,^H,P[F08XC'GN(TZL)&7[!1N,^4U^H,M-(.)RP6$+F:AYB(G'9Z
M80'"P:S!YM[!:1-TC8'/9?$MXX*_>E8M*V'OFT5?/1%A=?:MF:4L<,@1QTQ
MCQ(.48(PI(2$,/(BFI @0H1RRYP*AJ*MJ&JBA M-C96G3G= G\$/JZH)*ONQ
M6S%OU@?6)EB?FC?M%3.V&@?KD3E+P]P41?F\#?-?>IC7RH/;RS /.7IOB9B[
M<_FF@J<^M&\)R)$3_;8MN#GNOUTZM]O09@D781A1B"A1'A>+]9$'1F'@TY2F
M:>"C^*IC_X<BY^9O75&@VP!?,UIRB]K(='1P^/]FM^KVY="+J], G,9GI'0
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M=4;4Q(FH+AM]F&_*X)ZA20YN.5</4-7(^%0VF8>5(8LT%3$CQ(>)%Q&(8E]
M$B4Q#-(@03R@Z@/C^B?G!,V-.KI3^YVR-\UA?:$@!;W"MFD.3N![GC5<HC8R
M8PP';$"B@_-H7)'HX$3#$R<Z.&_>8:*#"]<[3<GY]8$H62?3VU6+))(>2\(0
M8D^G14$Z"UV,&41A0,(PTBE]K2JT#-1C;H1BD)83_)"I#QN[+*NU#.TK4Y]E
M]!X8W9TYG::S->-\GDZ'*]-7@CENJLZ+6LPA6:<I5(;I.HV;&UA#<KOA+N5_
MZG/)/"(@(IXB1AI@2"D/H1?JY2PI?(*L O:.R)@;_:U'5TMZ3_WH>CJ7!=<8
M4#,>NQ*FL1VH7?YQ7R+AC/FN2D<>D3!MX<C3)AZ4C3QSZ15)8(YDZ]295?N,
MG2WEJ,]+O3KT1K0_-XLURF?R8NY!P5(.D<]CB(-40A(*[OL>#IA=!,[U*LV-
M1]HL [NI?K,NA:U.^?NCY9$#!YUF1C[3=L7(7-7V@F$BX5$6C=S!Z3(WSG4*
M39](QPF 1[/NN&EYX,Q5>W2O5'M<:Z%4: ]?E*5ZA)OULU?/FTNZA?G;WTG)
M/SVU:1!6=563G"L7L8V36$0(!2+P!,1)$$+UNX 4(0\2BF+,,0E];L7+SC6<
M'4VW>H*LG7(UJ4,V.E\QT77>M893X)?LL+$GQUIQV&@.MJT#6^;I>H+;UW4F
M@L9&O0_:6*E^V=BI7@&-I0ZGSF-U@JM)M7/]IIUNCP7OP41\-$'#WA=-VW?J
MWMOO6;6((B%C'X>0(*:SVR<8$A%SF 94^HQ)GGI6B5QW6I\;3S?* :V=\M*4
M?I8;HKO(F5'I8#Q&ID%S**R)ZZC)CDAGM^U)">.H6?N#_?A% QT[]B#X:BD^
MR6;6_NKY]9)457NH(DXQH23P8<QU_N40,TBIAV @)0ZBF/@46Q6E."-K;H.X
M5U7/M]K%(_6V;M0==GCE',R&[I(;\,9V?(;C9N^[7$;$E1=R1M*T_L1EDP\\
M X-;G%9O7T=K[51O9TD2"!]Z3<@#QCY,J12ZN$-*L,>56Q [J-Y^1+05L4Q9
MO;TKV+YUP,5QO?9C_6!&->.@.S+S7*C7O@DKG;!>^QG$QJW7?DSP'.JUGP'$
ML%[[N1:&QFGIM;3RJ6@S=C81'Z]U)M?R^77!Q8*$/,*10)"3A$(4! A2QCS(
M4R&"2.?'C*E=N-99>7/SA+H@I!V=MT*1.LV!5MTV?NL\[N>Y:@0TQ]Z,= #D
M@+@N(WBN".\ZW_[$45Y&QAX&>YG=-B"QXX?GQZ>'1U+^IFB,KUA])]A#7BR+
M^^=NEUU2G]$@2!2RJ8!(T%A-L<(8^CSP1,!"[E%_\4V4M##*\WA)GLUPV)8Z
MWJAH-/Y%:0R>6I5!O=;9(M'A1:#/LXES\$;FD@UJG:Y@H^SE,(<!\%DDC70)
MXT09)+_H+"%5DQGXW//H*HFD*4)G,TI>;&2Z])*F]NSDFC2^:6#DR/$S0YO2
M8C25.,60)$UF!19!0O41'HX"P1(B(VEUV/&\N+GY=,<JC*WG1VW>U.&UQLX#
MCP6.69)RZ"<Z&9>4'&(14?T/H1%1_TNEV0O//?03O?%$5?V\G2-^7,#-IOSN
M0!SYS7?N>*C[FF]&J+B*=CDO;-I(%B/##Z)4S.X:N*/8EE>I/A:UT.G8/Q0D
MK[X()K)O>BWS0Y:+][5XK!:,^I+&2%$*U27B9)3JS48,$Y92R23VJ%DU*%O!
M<R/Y7F]=&ZW6T?B-XDW<R+LL)SG3@VAC!_A56P(:4VRW+$V[QG W<P3 Q][H
M' -K^SU12^!<;9>:BIUV)]42C(--5MO[A]':*U)EU2=YNRX>U=8"VB^U19 ,
M_"!E, D%ARC@$M(4"2C#U,?2IS'%5B? S,3.C=(:K;6W^KF=K@W(7FJ(MQE3
MN4=Q9)Y: [A1^09T9>1LRLE94Y,=4HZ(R5#HI+1D!\0^*5G>/?!XE92"U9_D
MV^_L08>/?=%'8'.]&:/_>_O?*\6 RS;Q1E67&:L%UU\HCMS]8.O*!4EB'@9$
MPD#&$B(O1C#E000]X7,_5FJH2;?5\2SW.LZ-[%H3]6"512FR^QRTU5;5$%53
M=KV'?-/N)(N-#8W'4:XM;+ZW/ HV0N>;D>D+=^G8NS_KWNSM U^:G9^\V;6^
M:?>NMW37&8[6_=A>HCMW[\/=.W1&L2Q?:6>SFXL5+L_9CMA#KD[+C:#AM*?M
MQH/XX+3>B*(&;)7M'UQYGZNW7+D2?*NRO)+]1DBA6)!W^7<74OAAQ$()8Y:H
M%TM(/$@3%D&9!JG/(\$(,R^3-DR'N;TX.IVW5Q0;ZN"=VNH%T>AML3\TL',,
M-MW&AWQD8N\- #_T)OP(WN>@[X0M,YH2SKTA?4KO\3O!8NMN_,Z8:$-OK$ZQ
MV^>[#LZSNW\#FYYN3_ ZVW=V"J]LRL7^89]J<$$\ZM&8)Q!%%$$4T!!B&GB0
M!>HUA&4@&;$[37Y4S-S>*(VG^40RWI0T)X_-PI@^([Y<\3:*M7X0X%&9L"K7
M*>Z<;FNM.V#(=M806*?>QNIU'&OS:A^#43:MUD)><+-JW]#SFU0'5[M@B^K=
MJE8#X9<LSQY7C[V(-ZM-?H,D3-.880)#%"@:X9&$F/D4>AZ//4J1KO<PG$8N
MRI\;O^R-!C63;2T G0GKT0&4$3?;V7[!NFCWT 2DMETWA("<=LBTS#167UQ)
M9\:(CL)SEZ6_( $:0W.>&<V;&5JZ3V:YX*]$KGZI=5HP?:+Q[?=:Y[=H-MBJ
M>A$0S-(@1##R] E$GH8P#3&"A' ?212%<6!5 ,=$Z-S(L=,9=$HWR?-NND.U
M&\V!5MVVHI9)%YCQG6M@1R8Y0TS?YFJRVBZCNJRY98&5LZ)^!B(G+NIG#L)A
M43^+>X>QTQ?QU#'>)_FAR.^; AV"UHN0<D(805"FB0^1CSE,4RX5(Q&$28+B
M@(I%KLN$"7YG3DRGY!F-F;0=,P=2QQL_?:X2/<U3VK9QC%SI:T= )U$V(YVK
M0)N&:#8J:JRTDK"INO/F'%;6C'()"$<L<E+,I,QQR=A]MKAX_76)$PKY3KE(
MM2*=;_I\8JUZ7W/0;56)NO.AMHN-OOVNL[.T=0,WX28R(93B,(9,2C4?%'X"
MJ53_<($3Y(<X9LBNHH1#Y>;F#VVG&.BF)K==94:Q4X87=.8,R]3@I%_->.RE
M>FMD[MOIJ,8PV%@&-J:!UK;U'/-8]W6)(\:)2QH#>L=))YRH]B)9*ER">BJM
MA5,9UZ;0N<WKC&?+5:V4Z0K=9Z)Z^[U=)W^G@-+9N59U5T/V+2ES-=VN/HNR
M2<[59=U!& <TIOJ\N7H7>#Z#1))4_1GX5/#0I]3HO/DXZLWY;;!M']@8"'H+
M@7Y4P9:-33A.9Z5.7M_FX[LVPX^3I\#NS3%]WT[X[IBJ6Z](0.02?><YBYPH
M]T)ICEP">SHSDE,IPUXBAYO<3<[?CPJP]OA4^T9;4,2)+PF#:EX0J[<##6 J
M@Q FF$A&N @1#_OU![/W@Z'D 2L18^\:-1FS2:.='5>;@FU&PBX!?+F8I2P'
M+: ;O3OOW!UA6B+EB E-I4Y*<990['.7[>W#2*G?];DK;ME_K[)2_%DL^5W1
M[_-MJ'*1,I'$H1]!E H/HB2.( FC!,K02UG :>KYT8!E46,%YKI.VM=D41[)
MUHGO+/\FJOI\O,>5'6)&76[QG8:\UOO/=0$ZK8%6&]8%7.] ;S1WQU[68#GB
M+W.YDS*8-1S['&;?P("P\EO^MU4WU)0<SC/MPI&EKB']/G]-GK*:+(\GSU9<
MVA>T620L]I ?^E $(88(Z]S5OIJB^ZF:K5,<!YP'QE'F3E2:W3Q<)Q>%M,ED
MS[8SWHMN%>^'O,BAZ+0W+%'@L ?/\^'+],O(1+EE#[@KP,:BIH*ZCH?NC.H*
M]H'#>@7Z/'N^+N,W>:=9A*Y/WGD31;+?-L&VVG_(>J===1S9]*4.RX69/A#8
MV A^N/W\_O6/^A#@:MF$<36K(]N#KZT7=V:LNLISY;1/SH;#NY$T772\4V1V
M@N7=MGQ%U3;5W#JG5%NLJ%M[7P2)[PDL&911G.I >AU"X3$8I2BA& >A+ZVJ
M09P7-[<793O);NNKW8!<6(9,7,0V$ BS6($IU&1,(@35U"R  8YX2!)?3=,"
MFT3;#K&=(+GVN-B:3:G<(3:R>[!>[=FD?NOKS77*GO;2AM66NXB*R[IQIX5-
M7Q/NHN%'Z[U=OFOH4O,W]7HHRN>_%N5O[_//9<%$I4]0?2&_J\F7*#.RK!8>
M\2CF 851@CR(PC"!J4@8] -"%(GP.$:>#4L;29T;62O=P&.O7'.(5F9Y5CTH
MQXEGY#XOJCICX+?,?@':I M,EY\= SOZXG.G[PW0&NN%YT[G-L&!@GRMMLNE
M9PN4G"T\F\B<>-G9 H;#16>;FR==K%E/&;7[$W*40AKZ:9O]CV*40(&)[\4>
MIDEJ%$GG2)^Y$=KE99IIEVBF69_YOW5Q9M*%F6E79?Z^EF2R 4LR?T?+,1.M
MQ?Q=+<2,M KC: E&-?FH2UFH)ZN14]VNZH>BS/Y'\ 5#/B8DC=0[46]F>#Z'
M.(@$#&2D8P\)":G19H:!K+F]_EI5VQ%WTY5+!F2M[O BRN?P-G/C':$X\FNK
M _!K"V"K*-AHZLY?-X##D9=^3M*DOKF!R?L>N<DM _SP/Y-E5KSYSS?BFU@6
M3SI48J\<2.(S(@7SH? )AXCR"!+))&2"XX1%/H^)N9=]2=K<2*35]SO@O<+#
M2M9<!-G )78)W<C,T:D*UKI>6;+F(GP6;JI+&"=R0L_!Z<A?-$7EK#=XL9'I
M?#U3>W8\.>.;AOEI6RFL%ICSQ,<,01KK(JD"QS#%F$,:$AJ'4D9^FMCLW6RU
M/;>-FCLM8WANJ&W4S+RK@5B,S(D?# "P]IR.F.K(4]IN>5+/Z(A)^Y[0L4M<
MY'+ZJ\CN'VK!;[^I3^_%%_%(LKS_4A\E]A<!1:GG^8$:J+$'D4\P)+&0:O!*
M023U$NZ1X<F<+BLP-_^HUQB05F50]CIW.>%T#.PU29H,^L1PKW9$I,?>O=U/
M(+=&O5,?K/5OKP!WYU"_,AV3.72CY&,R$/^""9G,P3F?D<FBG8$'677E4^V[
M?I+M?O-MWJQ-E>)!9U;Y)KI/[5*A6;8ZHS&VUERO]>ZHW$=*C)'H;"!>KHX-
M6DJ?]ES@,&@.#OX-;,9N5%5EO?B%?-?9T[H9J6!>X*,(0]\/(HCTZFN:TA@*
M'*7,%S&C@=&JR4'+<_, .N7,WO&'.)WGE:NL'YDQ.KTNKV<8L\)):\^-=W73
MUEA7?VW&^6%[DXS@DV;T8_/T!8/+!:X>5TM]T*L)ICHROC\45?51*!*X(]\7
M2(2A[\<I)#S2X4Y49^!)" P]Z;$X2'WD"\NJ@3;RYS:"M]0'11,HR';>?TNE
MNW610*L.,7,N1H1Y9*K81K@-Q3SJ8?R@U?_Q!B@+M!>B;'!:+W (>.[*!EI)
MG[IZX!!HCA01'-3,@#T;7598B!,E6.^*5T)O/NOTK5+QAT[7^TX]R@O)$:<I
M%C#FH80HC1BD1 @8!AY/N,>P'X;&&SF#5)@;\]VI;A)$:VBQ&3$,?(,-GM$A
M'7N%L]'_!APL5VR5;;XKP"O1A#W=Z)S2H+&ES2BMK1F]&RPVBD;OCHEVC\;L
M%KM-IJL0/;OS-*SEZ;:CKK)\9X_JNI9<K)+S-MW$AW6EYY A3_HBA9Y,U%0W
M8!CB)*60QSP@@>HJ]5P.7Q/?%S>W=\A^#OUK%KL/H!VRM'T-8-,N9/,NZ<Q(
M);+-8!EED?I V LN29\R_/P"],F[["B$BVSQ-J\5-QV$+WU:U55-<JXD+A@-
M(A[%^BAC$$-$B0<)"S$,N1?Y8>JQB!FYIF;BYD8AK<;@:+S=EMKV$8N&Z)]G
M&?>8CLPRAG!>3S1VR!PAFDJP/]X7WWY2#;4<HW[94(MA\Y-0BYVI/;58WC4T
M??]>R=*]0J6;/%D+*HD7Q,*'C L.$8D%Q%X@(<6,<TXH)\+J-+JYZ+E1SI=K
MZD9;(!Z@ ,<X9) *RB"* A^26%%\F)(T%"+R98(7ZL63%?QM;IC$<!S4=Y7X
M^T?>DTA&% F8^ &&*,013"4.8!RE/)2Q3SB*%]]$28N7?=JW51AQ$ERH]V=7
MN>*IJ#+KXA7&N)NY[.-@.?*+=;\>N3[">UB8?*.ZRZ(7MG Y*X-A+'CBPABV
M@!R6RK!N8>#QI*/-W]:O25D^J]?_?Y#E2BQHZ$M&@@ F84@@2B*]7\X)E!*)
MP,<"4YE8'50RD3JWM_)Z5.DW Q ;O2T/*!DA'C*N8=6%C:1"/$P03'DB8<)9
M(H)4>4HLL'TU.T=]JK?RI,B;O2*<8SGRV^',*X'4H-<:-&H[/#MF@Y*K4V1&
M,J<]3V8#P\'),JN;!^Q7?A:E-H)\+@N^8O7!\1W)91QC'BGNP12BP!.0!$+"
MV/,#2:,XIM3\B-D%87/C_%Y=\-3J.^R V26$#;8?'>(V,M.L(>M4O?)TV27L
M+/8,'6(XT>[@&DL;#.VV_0Q!.;O!=ZF-Z;;R#*W9V;0SO6=@^%NS4O^ZFW^F
M82R1/J$2^3&#B*0AQ![F,"9IY#.2(DY#FY-E.ZU;D>=D9\OZ$@9#RD/L@F?F
MF0V&9&1>[ NLO78]_3YJL*O0L)VVIPW\.F;605C7T8N&+E5_$_E*M$5F\B;@
M_*]9_?!Z5=7%HR@_%\N,/6\J"L:$"RJ]"'J4!A#%:01Q)##DD1]B(A.!XLAN
MN=I&_-P<I4Y[\$6PXCYOLJRTTXVB:L(EN^]M%_:L>L1T<6\LG$=?X&LA[HIL
MM:J#WY7NH%<>_-JJ/TZ)QF'(.5OKLQ(^\7K?$& .U_P&M3*PH(SJ%:%8DV_M
M^KVOJI7@BRB,4C^)8^A+&D*44@13$OLP02B6+$T2%%AE)3HM:FXDMM9T+R]1
MUF@[/"?1&;#-.,L-A&-/_-;H[>[JMXHZK/YR$0Q7Y5Y."YJVOLM%@P\*NER^
MPSY2Z$TWY[U3MRY2ZD4R\! ,8HPABG0=EBCR(?4H9I+Z+,1&887[#<^-$GK=
M@%;./*YG!ZOS8_P:!$8>T6;&6T7D'+-T4.S-3D.31=D<4W\[GN;H]T.#\KX^
MDN7RU:K*<E%5BYC*,,8)@9'4.T+(PS 500"9+B>0A C[,;:+PMMI?VX#KXL3
M:W0$O9*V@76["%X>AU?B,O)PM(-D0*#<4<.OB(S;;6_B4+BCQAS&OAV_;&BN
M3Z6;]MSU]/=+5OWV2N3LX9&4O[TI=(J(11"% ?&(>DWB4+G6PD\A)83#V/=B
M$1$6![8)/\\+G-N@WM$7:(7!6F/P:ZNS9;7OBYB;>=@ND1R9!JX#<4#^3S-D
MG"4!O2!NXDR@9L8?I@,UO&]@?IB#*'$>!LA/$@:QQQ.]L9"JWR("B=3UJ'TA
M/1QW\2)?:U+69OQR52#YOK3Q1L0KHOYD0D<R4'&?Y4VNI4*"5H/A\_9C,+/0
MBU@(DR2-(9($09IX F+!)0YXD":8VX;E. !Y_!"<+8A%SL<!UXRIYWRXH=7M
MQNU!AHN&NTHX]#*'%RZ:=Y TR-$1A6;SM\_R?IOSK;)[S;+)IR=-WEV8 ?-9
M0F3DPS#!BE]]Y;YA221,8A0*7<V->*EQ$(RAT+EY;]UZGAK[;"M[.ZA6]&]"
MA\84H-@Z#U4TEAA.V:SZXCQ/C(7PV).[O@B%4GFGUFN[F@I:M8=$T)C":A%)
M,P*\4Y4,R0$I2_5)FT[N=YUC@CX#DF^J@!3E;I'6K%*O/#557.K\X@4H!1,Z
M+8QZ[]4/ LA5O2K%S?8HT"7E]0C0^Y]MRIZR"^?6 ^(&Y"L-3EN)OMU?:)L2
M[?Q>O6()J)X$RV2F1#ZI&U7[I )<2#5+Y?WEY+X4C16NRI)8]NK9D"#3MJ8+
M#;*T;B=$R/;>H5D?57L/Q5+=4>E0S_KY8U&+-UG%ED6E'K+-3C>+,4D"PF#$
M:03UOARD-!'0YT2D*2,)"1.[XT/&LFW&]#2GA[95_V?0*F_IBAH#;^BBC@'F
MV*[K$12!5AML] :_CA)78 V7LPR;IG(GSJUI"<=A5DW;!JX*F*K6:6@YI12G
M)(02"P$1X3'$/@UAJ!A)!CYF/#**%#\E8&X.<:??SX.BFBK+[+W7@#$R=_2J
MC9*%]Y3=;N.*JI?)HWO*N!.Q08?7#1NY[[(\J\4'Y<;R]\KESN\SNA1M+.5'
M42\8D2$5W(.4R%B-8UV7+,42!LB+8I92SPLBFRCE\^*L1O548<MV0_H"GF8#
MW!U*(P_W5E'8: HVJH(^POGCF7+OUL/?#!5'9'!!V*348&;X/E$8WN6<-GXA
M?RO*UTM251_5D]-MO2$B>9(2#CG6N<=D'$!,TQ@FV"?J(4,BL*M<;BE_;N["
MI7'3V  :(X"V8N".J&TO7<U.UV+_PG1E#[M+$CL'WOBL=E3Z7&CN'#06O'>V
MF0%;!FU[751VU2V>!AXFF,0$XL2/== T@P2%@9KZ<!1[-/9"8A0/>5+"W,AL
MK1[X(IY4PWKQ,K\'_W1?_\GW_E_P28+V^)?5P8_3^!JL^5^+VL@TU-',&K8!
M*_E'D;%8MK\6H8G6Z/>0<K2Z?<[XLTO91V^<;MWZG-X[B]1G+[2OF-(=AZUN
M<_Y5E-\R)JK.84@9"W"LIH<)CWR(F(]@*GT&>1R+))8I]R.C*+:S4N;&=_UI
M=KVITVEJZ9^=!_4\P3F#:F22&X2250F6BRA<48[E=-N3E6:Y:-YVF9;+%P^;
MYZF9HDXWHIK_EG'!7SW_I=)NU3H'[2VKLV]-A4=]4"W+5^JS[LLBWZQK1I@A
M+\0!Y#Q@$(6AA"0E#*9QC'@4,(*%U?3/C5IS(Y9-VF6RUM]NPN>HN\SF@=-W
MPLB4I>NY-$F1>I, ?08_:*M EO^XE9A_8]D-V-@&-L:-LOSM%F]',TI'2DTZ
MT70+Y/[\TW'K@X\,/8CE4M>V(?GS@B4^(WZ4J.DHUJG_/02)%!X4<8R3."(B
MM3XQM-7\W'BT/QVC502=CM;GA;;A.\^'UX,R,J]9X3'DL- 1LZ\Y*[3=W-1'
MA8Z8<N2DT+&KACE8;[KCN6WAJ3OR_>WW)Y%7XI7(A<SJ!291Z/,$P1#K(_A^
M&D,:$P(3XF$UZ?(28I=;Y(*\N0WE3JTVTT76EE^KR7=;O^@2RF8.CT/L1A[Q
MO:9]Q3JE*^B4!3]TZIX.TK?V3 R!<>1R7)(VJ2]A:/J^DV!ZV\#P0?8@^&HI
MJD]RY_C1)]D<0'K6_[Y33D91;N+9?$F#,.8!C)F:F"'!(HA9BF'@ARB*98!C
M8D4T W28&_GT)C1%'A^RDL,G4JH7Z6?RK)=MB?H_:%+&Y;4N[EYT"]V6$8<#
M^LJ,KD;N@9$I;*U]6^A[^Z"C3B*E=+_1T[/FT&-K!?CUCNC=O'$B$X>#Z2I&
M<8 &TT8K#H?H(&[QBJ:&4>;9>FUJP.O-CNK-2GQ4\NY^%\MOXA<U>WNH%BGA
MB>).##%6E(G21$ <^!PF,A!Q&&%&!+/AS:&*S(T\U?.+[)AP<!>8T>$4P([,
MB28E(NL"T+Y$9%,8\E/N,(WWM2 ZXL+!:DQ*B->"M<^*5[<W-$%<H40J">I9
MK&]SK@/)G_K4-MV>52P8#2EE, H9ABA.,"11P&$:>H%/XS@0TJIBDX',N1&>
M+EW3A1;=[006#0S>,H'=C/D<@SDVR0W'<4 ".6-DG&62NRQQXI1RQA <YI8S
MOW5PF"G)64:6[_.J+IN(D]OO6;5 84 3YC.(18H@"JD/TYB',$Q]QCS?)TEH
MM)Y]0<[<*&:M)MCH"7[5FMH'AA[%U8Q/'* U,H<, 6I(*.<Y&-R%;!Z5,G5H
MYCE3CX1@GKU\&!F\SUFI79XWHOWY/K]EK%@IG^=+<Q!;3_X7,4Z#D! /4C^E
M$+%40DR)#WV)2<I(X'MAM,C%/:F%85(6$[%&CW[:/OK;PL<; ;V.W2%UK:0=
M11BA;<87SA"<ACQZ=<$/O<(_ZH/V:T2_7$;4FDML(')$+$8B)V49&Q#V*<?J
M7OL]]:^"K4HUR_(#>J?S/RQH&ON<( %#P7V( D$@C3TUX='5:N.0A5@:5\+>
M;WQN;D>CE%YU]8,?Z(^@5]=\2_T O<L;ZM=@,C(_V,)AM:-^RNY!^^D'C4VV
MFW[*C.V]])/7##B)\6=!^'^O2*F'PVV3 JTH-<K/[PC3RR.9J+X6J_KA*\G?
ME=HWJ5BA8R5)_B83]\5KLLQD4>89N5WIC"UWXCNI?B%J:&7+I6CNT!D_OF3L
MX;'(^7]DY7VF+N[B[F./<1H)-1$1GL[E&28PE8A"YB.2!@&FE)B717M)2^9&
M/-M8--F0-FB #1R@P0,H!, :D3;L6'W2@'(#-K#<@!:8&]! HP]]=>#<M+>+
MYMX>H!O00V1Q.N-%G\;SW/KB^LV(R*]XO&ZO>+QNCSY>0TX!O>AS9G':Z._E
M>9OH5-.LGCM'9ZKFT,5GSVZ]J(+3G1&;0S_LG$6;A4+7K#Z+W7VVKXH=FEQ[
MG^1ZF>MS435USMY^KT5>Z1V+#UE5+QA'J><Q"KDOE%^(?0YI$DF8X#!A421%
MG!IE"G6DS]R\N\Z<(WO8:YOT+&NSEMN;!7[=& :T98-6OX?WJ\TJ^22]-<EJ
M^K4=]397[]8VC,?Y(OS5*#M=K!^NS0LLZE\-W?'%_^N;'1CZ2I:BZC(-?!1U
MGY.!>#)"0D#&DA0BZC-(XH!!7Z1Q[(><H)!;!;<>DS(W?AU4:/,X?F:,=S4J
M(_-87S9SJT:&LPK:1ABXB@0]*F/:6,]S9AY$<YZ]>*+5ONY)3D7"*0D$Q)1R
MB (B(!6"P)@(/_1X2EE,1UVKFR=7#)^2CKQ<,>ZBUNPHZHJE@8G6CZ99_?F_
M<.WF!1=:1EXF^;M8Y'"\1''52VR[/N3GOFS/&^4A+Q*NEPE\#T8,"8B$>CUA
M0A(H>"(3).*84*,XVI,2YO;B61<6;;54LT0.M)[V!59W@;R\PWPU/"._"JR1
M&51]]:CU5Y5AW6UQ\GJL1PTZ5ICU^(5#RSU63>Z=[A1GM0C])!#"QS"-6* 3
M8Q%(?1+!R(]]$:FQ[ ?<)F_RO@"K83Q5IF10K,^EB$Y/VPJ.>S":S3NO 6?D
M0=RHUFPHO[V$R(!RC,?-=E9^<:_YB<LM'C?NL+SBB>L&#F2='/23;.HF?,AR
M\;X6C]4"Q5Z" C^"!'%/YU#AD#".H"!Q('V._!0;!7N=E3*W-W.;!K>07=6I
M7[6BH-'4MB[K44P-A_:U2(T]O@> 9#_0SX'@:K0?E3'MD#]GYL&X/WOQL,%_
MXF3=0J9Q'(0TA#PF/D1>Z$.<8 01#7'@!T&8BMCF97Y"SMS>Z9_;7+[@&UFN
MFGC'ML 96#;!T4_=>4,[+C@%L1D;. !N9#XX?3+7'1U<0,$1(9R2,BDE7#!U
MGQ0N73Z,%MK<X8L$BP0ACT,>:)<^4K_AB,0P]$+/2X.48A3:L$#;[-P&?>O(
MDT8WNZ'=P60VDNV-'WG@WIZWV'J0[AKH:$QVC4XZ!'<-V1]Q>]\.&V!O2:GK
M=%=J1MX4EK7,0WKJ]AD]7;V*>BT'-$J.DB'T$A*.'L.38B9],"\9N_^H7KS^
MNEQ;G^1^M0DU*_WWHN"_9\MEDYAHD[]),)(& A.(0L$@2A(*T]@GD*<\0D'
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MYX ]SR5.X1J90WJD>CU!I^B@S'OG(+/)K><(NJFRYYV T%5N/ ,TSF>_.]?
MA/GM#.S8S6!G<L/@S=.FC-IG\JS7E7H7(4[]@"0LA8%VPQ#A$J8H#F J4H:2
M($+,%Y8[IT?$S(TLUS4 GUHUK7?VCD%IO*UW)4#C[^FUV'0:CK.A=P8#=[MY
MQX1,O95WQM C^WCGKAY<;551R8>BJMJ Z+S.\E66WW<Y-HJ\>B5D48KVNCOR
M74=0UR51,K*<E,]-0IZ/REQUIS)=2;I_GZLQ*JIZX<DHPD@0B!D/=/'$$%(_
M3&!$8L:]A%&)K5)IC*CKW-:8M9& -M: K#$'U-H>Z^*NHW6NZ2K1++IL]$6G
MIH=^T';^"/0X!QM3P<;6OD>[ZQMS;\"N>:"WSVG5V;$[P5VQVM$TG;K&[=B0
M'RF-.[K(@;DSS@0-<Q;RQ NA"$FL_$N4PA2' 4RHQQ.$.*>IU4+]WT^8\+&P
M8-%H_+-E'HQK(X'_+F)_MY7\YS[R][:NRXRNZB:+15THEU1[1*,$!$\6 CR7
MH%_[,-_1 GL_E^*)9'WNU]N<?ZH?1-F&3O2S*RH#2G 00^(C'R+J"4@"CB'A
MW(LY"KV08ALB,9 Y-T;I5%YO%S0;@H56&[!6XT$)WTS0-R,:QYB.S#@]G)VZ
M#9J-PETJG1$FOA8 .6(;$XF3THX%!/O\8W/K4"(JF!"\<;!TM:-/\L]BR>^*
M7TC=E#C?'!)>$$*)%[%808XH1"$7D":^A$1$<111$ON,V?&1J>CYT5*K>3LO
MJDB;F:IZ*,H:*OF/3<Q"50_(,FO1':8$-0;(H_/4-KY?.WRUXK N8*_Z5CH%
MEWQEBY<SVC(6/#%[V0)R2&+6+;C)QKE)DD>D>N8\Y4!A21!$,M9)9_P IEP1
M%\:4AF9[I!<ES8VI=.QAL_"FTW>^+AX?B[S-XFD9>'$263,6<H+7R*1S+-/I
M*&D$+X(Q4K+3%TH)>-'<2^E.KTWO5Y7UXA?RMZ+L-QG;+$4\Q$FB:]Q@D3*(
M./$@ICR$,<>212(,.39:ISG>_-R(8+UO;9,LZ@1RY\?\]7B,/-!-H3 >V.<M
M/C>:U9U;(UG]M1G%)QJ=9.B>-Z@?KQ>N&A#GU,QN/A;YNAI3N[#;37_>%:7(
M[O,[\OUU*7A6+U(:$.93 B.:1&I"$B9Z+"=0X#BA?N0IB\TCG^QDSVUXORMU
M96"@ZUXHR!_TSAI@C::&$Y A^)_G@9%1'9DDVF61;<W[+:X?.N5_O &=_GK7
M"[06C >V16C5>*!/E?SG ->;G:YP%'0U#*>S85B634X7F#7,UIU0K8%-#-Q@
MTT= 1/.L+5\1]70P\?5!B/I-5K%EH0\35EM9Z4,_Y)2$D*&00.0A-;,+? P3
M(2.6"B$)CZRVW"R$S^U-T.D+&H7UE.^IR.W7H:S@-]R3&PG4L7?IMM0&N^!N
M:3[25'$(9JXV[6Q$3[N--P"4@XV](6T,#D<K=5&G-Z+]^3X_54H,A\Q+,,>0
M!51 )/T0XB# T MB*=(P1 F6BV^BI(7Y(3]#V38#;EN#$1VPM=_55FT;G)7&
M''\S'AL%TY%)K-<9_-!K_2/(<K!7\VV,DF_6:+D+NS*4.W40E1T<1T*B+!NP
M+_#^-J]5 ^^RI2A?DUK<%^7S(HT"1&,_43X5YFJNG0I(:>)#YN-(1GX@)38*
M1CC1_MR\J%9%T.@(>B7-*[L?0_ \NSC 9>SU<2M(K$JZGS%\4$'W8^U-5L[]
MC#';Q=S/73;,T?BKFG\]Z+2IZ@5-[L7'E3Y#\TDV:^C5IU5=U23G7:H5M@AH
M$ 9)*&$D=((JPA%,(REA&/MAR.(886X5IF@E?6[#O=42K'1.CKIHCBJO:@%R
MY>0O]>[9DPXX:G?/*GWI#:#:#/!#UGU0_6CGE-CUE9EC,EH/C$PLO=Z@4QRT
MFC>UJ=M^V5+^!C3JNW-0!J'FR$FQDSVIHS((EGUG95@C Q>,F@('R@/BK[<2
M#=R6I7K4FHE>]>IY<\WGM@;T[>^DY,T_=TKJ;<X_JR?SHWI6WQ2/),L7B'O2
M(PF#+ D01#[Q%4DF,2088Q(F<4QBH^($8RHY-RYM- 5:5?!KJZ%EUKY1>M)P
MC>J%^V=DIK7I&ONUJA&Q<[6F-8:*TZY]C0CRP1K9F+*&D?P;0>M-N-AN&%E;
M!:?)O]4DG.E/^C25 VZ7R^)WO<KWKBC;_0D=%;5@D2 )]Q@, [UQP&0**8IC
MR%)/'P:7*$:^#;\[UF]NU/[5082KZRXT(_87[)B1.5U;MA4)>W,0)JN+I70&
M@CX74V_B#6@J#(&UE4 69;?EVL0-NGL]C-0#CMX,KK6;]*4P$K3[[X.QQ%R9
M'%'7D:D>1%,2N%H(%(F(>@GTF)00Q32 A(02TB!B"?>#6$@K1C\N9F[$K)H'
MU7;2Q%*H^99.::$>H6KU*/C Y(F[X)IND%P+V>B[(>N$BKV*30%Q19[_7CHE
MO?-0N$ZVN"OD9=(N'C7T9 +&XU</(P0=W9ZU'HER.]O#XFH,,'U6)HG#,/8B
M 4.FX_^I%\-4TA#*Q%/6(IF$PNKHTAE9<Z.&+54;9F#;RMJQPCF$S:C!$6XC
M\\,^9*^-(+,F!P,P'#'$.4F3TH2!R?M<87++V)GBCV6>6&<DH"1)0B\.81H2
M-8<45$#B)S[T \H$)IB0P&HCQ8U:<Z.A=Q,FDS_;769$-7TGC,QI Y+0WYS(
M^#-&+@JW>$^>POZL4C--;V\"Y/#4]T:MVX>F=/-//=]\T,N0>F5QD8HH5IV7
M0@]Y$41,;V6',8&!'\B(!H)QL_#?4P+FQJ6]CJ!7$F@MS:-3CH)X.3SE6FA&
M9CA+5*P"5,Z9/BA"Y6B#DX6HG#-G.T;E['5#X\J^B/M,\T!>-\\=PT(&OL]@
MC+&:FL5I"#$B'*HA':5Q&(N8&RW8G!(PM\';A5%ME+0<O$=!O#QXKX5FY,%K
MB<J Z++CIE\17K;7X,3Q9<?-.0PP.W&=\\.9S;>+V(N#,(DY)#(*(/)Y G&<
MI! ':9IX(J(8&:VSF J<V^!NE')V!K#%]/S8'@.ID<>ZT='*,9!T=H32&M&)
MSDTZ0-;E"<H=F*XX-MFV,Y>SDCM661R0W+W/.0'W.V[MAPLO$KXGO03Z*59S
M(LY3Q<FI!T.<8ISP-(B)T:J4M>2Y47*O79=SVAFE[.%]-4L/1W$.=+U&^?VH
M*#MC\.%HSXG*35%W2>K'D;N"W?<:G O-'[?3@N]/-# X7ZP492EXDY&VJ;.[
MH$&0QI&:*B>(,X@(\V'J13%,J'JZ$NK%U+?,QW@@8VYDOE815%K'&_"_O#]Z
MG@^>2 F^:87_!*(;S_/T?]W!#$!6]4-19O\C^ W(B_[3K*IT(%233W83B Y(
MI8\=_*)SJ/S3/_JQ]Z?0OP'ZB6ZN?"-84YAFYZO .O?L04^:[4E<V3\COR8V
M7?.U[9JN9OC[!FBG"65/H> N@>R!A*D3QIXR\4B"V).7#G QU0.>/2E2>Y45
M7UDFE+;5Y[+@*U;?"?:0%\OB_KDK]25QFM(PX3"*,(6(>1&D*9<04T8039D,
M(O/D2^9RY\9(O>:Z<K;6%]1KA2V<( O<#1S-<= <F3_60&YI#3JUP4;O(27K
M+-"U<##'07DB]](0;4<>I3U49_U)B^:F\R;M;=SQ)0?<[OX(Q?% W5.QO0N*
MTC (PQ!R]2[0^?<$Q+%(("-4\BA*=$",J],3=JK-[2UQ_.#$#2 [<?>ZR@'3
M!V';S'W-T6/;*!F'W6OFE;Y,IXW^,KIXJ.+DD8ESYRVF.4XQ#/8)3E)8*C:;
M0Q3# +4Y/S%0PK!7P!?Q3>0KT=?4TB$Y?\WJASZ-ZT:JII]*\#OR?1$1&OEQ
MA&$2(@F5@Q]#$E&][" (YMA')+8J1C- A[F1^ITNF@C*UA [EA[2 V9T/#*N
M(_-NI_VFWJ#6'_RN#%@77MZAU\X(G2C4';5> :$C#AVBP:1D>05$^ZQX35-#
M0Y!N.5=/;?5:_?JIO"M^SQ?,\Y/$YRGT$A9 E&"J8Q803%'H\SB(HX!PNRBD
M QESHZ\NY*;3\P9H316.0.MJ&XYT".AYMG($T\AL- BA :%))S&X(CKIL,V)
M Y1.&G48HW3ZTH&I8-B#X"M=:&8W-QYO"V?=Z=J*BQB%5 2QK\_Z$XC\((2I
M)#X,& \2Z8>13ZTFKR9"YT8!O<YZSV,O%R3O2L*!7QO-;5.XF/2 F4/C&M>1
M.<,%I/:I5RPP<I5*Q43DM*E1+$ X2'5B<^\P4GJUJK)<LUSQ2+.\6=Y5_DZ5
M\>YTQ%U)\JK=RVDKC?:3O:K=0;O-N?ZE&3E^FD22AAB&:1KJ P^)\E9\]9N(
M4.KQ) E]RT3!#K6S&8S3I!)NML7:"GW;>[]9#@A3QE29MM".X%SVIAD/OE /
MC4R7O55@RZSFW-G&,+!EV4U?)GEM7+>_W&S/]_:Y(]810'?$ORXUFY2F1X!T
MG\W'$#$\)T&1-WOSK\E35I-EF_OPBZA$^4WP=T7Y;E6O2M'(4_@M4D8QX5(J
M9U1OJV,20ZR3+;.01PD2<2"8MZCURI,9L5MK8.6CKO48>Y4M7Z<$[3B\[/1O
M5M^S3O?A^5CM.\J,M4>%?V1N[LM%MN$\G?I]2M8OV_BW)H#>!K<I$@;!YS!Q
M@IW\R=,I#(+G6)*%80T-"#*ZF%?P5%K!3T_M,>*<?RSR]H^>OZNZ;,(FJK??
M1<FR2E3O\\^BS J^"'PI$A]'VD6.=: 24XRJ:)7PU$<)(G$LJ7&@TK2ZSVV]
MH.]]S<-].FS]S #UB^B4;SBZ_; UN7'-])ZWG@BK+_6+MLR:?>[VNE6>*3_.
MFKI?XEDZ3_HS?T+&7OG05L'&++!M.MBR';QZ!MO7=?:#!H ;T$$ % 8Z]!VV
M?V]\_C4.>A.H0T)]#%HLYOO86$25S??QF2@R;;Z/D5W,V\MTY-FXN8E5FB[V
M[F6PWHG?>R$5ADU+UXN<W5&5K616..8)"T.81L2'*.04$AHD,$22^3'S8BFD
MS:[(24ES<VTV:_6BT_1GNQGD:4S-9HI.D!KY%;\!J5=RE&10%Z%P-+L[+6?2
M6=Q%<_=G:Y=OL ^,>%U\$^7ZD97(0\3W/.BE80!13 3$'B.0DS0@'I(1]5/3
M<(B=EN<V[!OE3![B"X!=#G<8#,/HJSR&"%@%-ARU=E XPVY+DP4Q'#5@.W3A
M^ 4#ED..KU:W62[KG75KG7KMKG@E/I.,+P*.8JS>TC *U#\H#1%,$S5..15^
ME'+.2908+VL,TV%N@_F6\V8KCRP!TZD.ZP)0 9Z4IA93PX'=8; R,#[(+[59
MU]FPNV]WT^:;O"O *P$^3]()%O/L\3MCHOGR6)UB-]N]#LZSL]:!34\W^[S.
M]IU9Y)5-V;U]JK)>_)+EV>/JL3O]B(3O!3RED";$@RA@"20Q\J$DTF,^"8F,
M8Y-WRD'+_Z>[+^UQ'&?2_+Z_0L  .]U <J"#E,@=8("LJZ>PU96Y5=D[&/0'
M@V>5W]=IY]C.ZLKY]4OJL.5#$BE12KT+=&?E(9$1#\U@D(QX8FXK12F<G46Z
MQ*G=V _2?F037LK5G45K/?T;M6W;I.F7:ALT_=/1Y[ML;Y*9W*A&-3^;'^AW
M!G.:_W/,"_I E]N"%4*&$<:()D )4W(Y#@4@)D2=<2'#-.%1!JUBTJU[G-LL
M;<J:5%K@@N[#[8BF&W*[HQJO0(X\X2TR&8W8!5N'OR,<:X@\'>5T]S?ID8ZU
M^N='._8O]MAIWHJ_/9>3Z&%SW"P9%^+CNG[O?W&._?[K_?TB,H'Q2'$@0P(!
MI"$&))301)UF442P8FELO>,<)LOL+)6YR 8LOXSB]4NK\C Y^,5([7*Q/7"L
M++:CTXW R":NIHC9V-1. 8PNYF*OU.:FN#0,+B\7;P*CTW3#X[!1G6Z8)MJP
MWCYNGO6V=*,,(^/61-GGD=C'43,'-D#_BI<19[_<WG]\^ZN)&WE>Y9</>7:H
MT:X((&F9=__B:7OK9Q!:M[D#NYANN^L'BY-MKZ<F>V:+Z0]\?D-[I\HZ%KKG
M39$4<#C?1YAS$B,%) U3 '$6 @8Q!PA'+*48)B&WNA!QZ71^BUPILYF[!ZF#
M2FSG6Q2G ;#SS'W#.O+*Y0%1]UPQ!XA\Y8K9=#EMKI@#"!>Y8B[O]LU0?_\H
MM]_T6O?;=O/7_KNQ>'3]LH"2<ZQ,HA>%IEQU!@%FC #!61+',*,TMB+AZ.AG
M;H:GS,.N9 T*88-26M=<]>O0=E_@>@)L9)/2$ZL>6>NM2 S(7+_>[L39ZZW*
M76:PMS\^.'?HGF[OMKG=$?DAP+W<YN[0 B*.6,HD('IC;KAX8H!Q2("241I%
MBL5$.85K6?0Y-^/PMA:'?G,D L[CR?_X^BYXDMLBKKQ_1E C_'9.B6=01S8@
MIUD_6F##>%&(7!P2FC#98B,]2IY/%T3^,WL:>WRM7)XN"%JR=SI?]5Y;^=UR
MQU>;W?-6.OKJ3FW.;((T5@<.CJ*/XKWW FW\*L)7^IY+7>%F6!PJ#;<TTN,<
M_O-;<P(FM^]^?EIR<TQ5D0^G*2<QY( QI'W\1%) *(D PAG!2J_K1$KK _:&
M3N:V?*]+,8-W/X-5(:C#,6P3DA;'WQ[P&=G0U*$I9>S#?MWX:;,_@_: U42'
MR[TP<SL+[@"C]9"WZ=WI3F\[I#\YENUZMI\O<;C*/!K5W8/\N7^C9?S[0J$T
M(3!#@*J\;E4< 6RJJ=,PC"*]J:$HMBHK8-7;W(SA\28^^%U2(VN^&KEM7-KQ
MM?/-O*$VLHFL 5:3-/C3R!KDPGKTO:Q \>1KM?<UJ6]EI?:Y+V7WTK *);N2
M)_]A2T5>FGA7KFR4*TQ4G "5R4S[45A[5#+E(!)12I7(!+0+8[3M<&YFY%#<
M86\$#?)'^Y7+:(38PL'R#-S(EJ1>$*,2-\CES2L1[P;6'6D$LE_!$1^ OD*E
MD6O ^B\QT@6.;6V1QG9>I:A(EU9-U40ZW^M9D*Y(8=Y]D2MSV/2P>: _#6_S
M]\W*L#5_V&RO7]@OI(H85QP!@F4$8*1=/48) 2FGDJ42)S&+%VOYS;1JY^+U
M%<5JLI!BLM0%&F^N5#P&&Q7LZ4\]3S;KG#E%B@;6%,?2<WW'S,YI''4<)BIB
M5ZAP8PCE@YKL-]?I)H[9_1[KVPU$T5<1O+YB3%LI;R!8%^7TAK;7SYA^6E*V
M7.6!OK?KHI2?Z5&[B@45Q(*)+$S3- &A-,F>L20 8Z9 G' 5LAA3G*4NK(!=
M'3IYM).1 *Z.4N<G[[N:W/_SGW <9?\:R%Q^-[O8";^=_?,)ZLAV[M,9DN_;
M47,V8K90>#)6G=U-:I1LE3\W/M;ON0<5&>=/VZ^O+X]LLUJ$/(NP$A"@--3[
MXTP1P!*< 0PE8CP)H6#6840G+<]M(UP*%Q32V0<*G<+5/OL'@3#R-+?4WRGX
MYZJNO<)]3EN:+,#GJ@+UD)[K#_2-Y/NP7,G/.7OM@L<A2R)!00KC$$!A;OH2
MP]V.:*9PG,9Z_KF%[QT;G]O4*^/0C(!!(:%KG%X-N.X9. 2.D2>A Q(]HO N
M51X0>E=K;.)XNTLU+H/LKCS3ZP"9[8_4:N_7XDX]R.UCZ?E73.!%DHI>AN^W
M\JGXT[U<TY5V!A.!((EI"CCD!$#&." 0AP AQ&(5(@*AU2SV(LW<IGTE<<X(
MNQ9@HXK\76'24#=LM?R6[Y><#E$'CI?54?5THS#Z.;8&^JC+3:"U">Y48/0Y
M'%P<1JG,Q3)$F4>E@E*K*0?)Z1A\NL&:[(Q\_$%S/4[W W+'6?O 3J8\B/>#
MQ]DIO:=&>RR#=_OO<OMYL]Y47((?UWSS*$M&P0^;K5Q^6[]]WF[EFK_D!3-6
M^23XC2[7IC3M@J<R)!)K9S86"$ 2QH"8E/ P(CA!281#N^+?7J29VS)HY I^
M,?6[?S4K(2\E-\5BZ>K9=0D</%862^"4(S#R$IBK$M1U"0IE@E]*=7Z]"4J-
M@DJEH*934 R?4<LE97_P,#DL@E,.UT2+H.V(W)P,K:?USA>>K>O=X$ZF6^]\
MX7&RWGEKM&?@X7*]W,M/RQ]Y(77]T5NRE2P*_.DU=KM?_G>14EZ(\Y^2;C_H
M#_="14FH.$P XQD%4,41H!%/0*2@4HJP..56]4.&B3&W%4Y_NC/'N,1^\-O=
MO8P/ZLB+5J$ R#4(CBH4)4-O<K[M_/*_KLU-8!0)C"8>HQP'(>DK_+&?$-/&
M10X"ZB)@<EAK_2RB*>^D7_JN-Q?OY ^YVCSE&Y&BCX6 &5*<2I"25&C#AT+
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M(Y=Y8J*.=IQ&HNIHZ/15R3K:@>BBZ^AXNY])JE>1O%/G72X0(ZE(N 2"Q"F
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MD:<=%3]7KEP-CIO@ (C^=7#OX ._VN?((7YVYI^GB:)T9_^Y<@L-?L5!;0U
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MZ/$8D%@[>C2+48A34[4:]:: :>UZ;@;PC&3$R![4A!_ Z-(^ G;F<!Q<1[:
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M >3"5'X@,8@%C\(0T9!(*YO0TL?<S,&A;DFMME*02^I>U^4<SG8SX FDD2U
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MG'[^LOY),"%O_NWRGVT.,8>L(!;ZCXI.@T=O07*#SEO-I8G_S^=_SDH$':4
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MT<,C9(V=#AL89ZT5TQ?6;IWS)B<M@^"08IUA')4$)XJ%K -YE=%SR5LW8'^
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ML099*N),&N%BZ_;M3Z5QW 9-XR-V4)UV@-FW^-N51,1R,:<OTYG\[DY+(*K
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M%W5+624465D0R9&4!*N5M"E 88+SF!5+O/7#Z%UI&[<.=8S,W2!:ZP"-MT+
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M88KD%$DO7% V"!-;1TN/T31RO4,OX-D)U'MJ<NQ$SR_DD2Z^(YX-Y#W_;M/
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M%W;PEBF_S9.V3JH@(J3*B<H,P65R)X00TAK/5'!^8,C=15>WMTK# .Y@U70
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MPOW:Z;6^A9>&0Q%,1\YU[=]Y!,3U<*2VT?8.$-I#]&,7 OP50_[':5BNS\X
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MP(RL_<T*/"='P)BWW-@@K6[=$/(,*=,^B7A*P+7010?V[QDV=J^41N%TT$Q
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M/V)8XC_^]G]02P$"% ,4    " #L0*56:!&B-&0(  #"-@  &
M    @ $     97AH:6)I=#,Q,3 S+3,Q>#(P,C,N:'1M4$L! A0#%     @
M[$"E5HI)*AIN"   /#<  !@              ( !F@@  &5X:&EB:70S,3(P
M,RTS,7@R,#(S+FAT;5!+ 0(4 Q0    ( .Q I5;:W_VB)04  *@B   8
M          "  3X1  !E>&AI8FET,S(Q,#,M,S%X,C R,RYH=&U02P$"% ,4
M    " #L0*56 H((2S$%  "S(@  &               @ &9%@  97AH:6)I
M=#,R,C S+3,Q>#(P,C,N:'1M4$L! A0#%     @ [$"E5IV"$J8=? ( 0U07
M !$              ( ! !P  '9C>70M,C R,S S,S$N:'1M4$L! A0#%
M  @ [$"E5KB;_M0J#   *($  !$              ( !3)@" '9C>70M,C R
M,S S,S$N>'-D4$L! A0#%     @ [$"E5B\PSJK8'0  L2<! !4
M     ( !I:0" '9C>70M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( .Q
MI5;K>C7.^RL  -B[ 0 5              "  ;#" @!V8WET+3(P,C,P,S,Q
M7V1E9BYX;6Q02P$"% ,4    " #L0*56#Z#\SH29   4408 %0
M    @ '>[@( =F-Y="TR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ [$"E
M5M&A"ABV5P  0,\# !4              ( !E8@# '9C>70M,C R,S S,S%?
=<')E+GAM;%!+!08     "@ * *("  !^X ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
